
PMID- 35905570
OWN - NLM
STAT- Publisher
LR  - 20220803
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
VI  - 165
DP  - 2022 Jul 22
TI  - Factors affecting climacteric women with SARS-CoV-2 infection: A multinational
      Latin America study (REDLINC XI).
PG  - 33-37
LID - S0378-5122(22)00147-5 [pii]
LID - 10.1016/j.maturitas.2022.07.006 [doi]
AB  - OBJECTIVE: To evaluate the association between factors, especially those linked
      to the climacteric, and a history of COVID-19 infection. METHODS: This was an
      observational, cross-sectional, and analytical study in which women from ten
      Latin American countries, aged 40-64, who attended a routine health check-up were
      invited to participate. A positive history for COVID-19 was based on reverse
      transcription-polymerase chain reaction reports. We evaluated sociodemographic,
      clinical, lifestyle, anthropometric variables, and menopausal symptoms using the 
      Menopause Rating Scale (MRS). RESULTS: A total of 1238 women were included for
      analysis, of whom 304 (24.6 %) had a positive history for COVID-19. The median
      [interquartile range: IQR] age of participants was 53 [IQR 12] years, duration of
      formal education was 16 [6] years, body mass index 25.6 [5.1] kg/m(2), and total 
      MRS score 10 [13]. In a logistic regression model, factors positively associated 
      with COVID-19 included postmenopausal status and having a family history of
      dementia (OR: 1.53; 95 % CI: 1.13-2.07, and 2.40; 1.65-3.48, respectively),
      whereas negatively associated were use of menopausal hormone therapy (current or 
      past), being a housewife, and being nulliparous (OR: 0.47; 95 % CI: 0.30-0.73;
      0.72; 0.53-0.97 and 0.56; 0.34-0.92, respectively). Smoking, being sexually
      active, and use of hypnotics were also factors positively associated with
      COVID-19. CONCLUSION: Postmenopausal status and a family history of dementia were
      more frequent among women who had had COVID-19, and the infection was less
      frequent among current or past menopause hormone therapy users and in those with 
      less physical contact.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Vallejo, Maria S
AU  - Vallejo MS
AD  - Clinica Quilin, Facultad de Medicina, Universidad de Chile, Santiago de Chile,
      Chile.
FAU - Blumel, Juan E
AU  - Blumel JE
AD  - Departamento de Medicina Interna Sur, Facultad de Medicina, Universidad de Chile,
      Santiago de Chile, Chile. Electronic address: juan.blumel@redsalud.gov.cl.
FAU - Bencosme, Ascanio
AU  - Bencosme A
AD  - Ginecologia Obstetricia, Hospital Metropolitano de Santiago, Santiago de los
      Caballeros, Dominican Republic.
FAU - Calle, Andres
AU  - Calle A
AD  - Centro Integral de Salud Obstetrica y Femenina-CISOF, Quito, Ecuador.
FAU - Dextre, Maribel
AU  - Dextre M
AD  - Ginecologia Obstetricia, Clinica Internacional-Clinica Javier Prado, Lima, Peru.
FAU - Diaz, Karen
AU  - Diaz K
AD  - Centro Ciudad Mujer, Ministerio de Salud, Asuncion, Paraguay.
FAU - Lopez, Marcela
AU  - Lopez M
AD  - Clinica Alemana y Hospital Militar, Santiago de Chile, Chile.
FAU - Miranda, Carlos
AU  - Miranda C
AD  - Hospital Central FAP-Instituto Medico Miraflores, Lima, Peru.
FAU - Nanez, Monica
AU  - Nanez M
AD  - II Catedra de Ginecologia, Universidad Nacional de Cordoba, Cordoba, Argentina.
FAU - Ojeda, Eliana
AU  - Ojeda E
AD  - Departamento Academico de Medicina Humana, Universidad Andina del Cusco, Cusco,
      Peru.
FAU - Rey, Claudia
AU  - Rey C
AD  - Medicina Ginecologica Consultorios Medicos, Buenos Aires, Argentina.
FAU - Rodrigues, Marcio A
AU  - Rodrigues MA
AD  - Department Gynecology and Obstetrics, Federal University of Minas Gerais, Belo
      Horizonte, Brazil.
FAU - Salinas, Carlos
AU  - Salinas C
AD  - Hospital Los Angeles, Puebla, Mexico.
FAU - Tserotas, Konstantinos
AU  - Tserotas K
AD  - Clinica Tserotas, Ciudad de Panama, Panama.
FAU - Perez-Lopez, Faustino R
AU  - Perez-Lopez FR
AD  - Instituto Aragones de Ciencias de la Salud, Facultad de Medicina, Universidad de 
      Zaragoza, Zaragoza, Spain.
LA  - eng
PT  - Journal Article
DEP - 20220722
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
SB  - IM
PMC - PMC9303064
OTO - NOTNLM
OT  - COVID risk factors
OT  - COVID-19
OT  - Climacteric
OT  - Menopause
OT  - Menopause Rating Scale
OT  - SARS-CoV-2
EDAT- 2022/07/30 06:00
MHDA- 2022/07/30 06:00
CRDT- 2022/07/29 18:17
PHST- 2022/03/01 00:00 [received]
PHST- 2022/07/02 00:00 [revised]
PHST- 2022/07/09 00:00 [accepted]
PHST- 2022/07/30 06:00 [pubmed]
PHST- 2022/07/30 06:00 [medline]
PHST- 2022/07/29 18:17 [entrez]
AID - S0378-5122(22)00147-5 [pii]
AID - 10.1016/j.maturitas.2022.07.006 [doi]
PST - aheadofprint
SO  - Maturitas. 2022 Jul 22;165:33-37. doi: 10.1016/j.maturitas.2022.07.006.

PMID- 35891211
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220731
IS  - 2076-393X (Print)
IS  - 2076-393X (Linking)
VI  - 10
IP  - 7
DP  - 2022 Jun 30
TI  - A Comparative Analysis of a Self-Reported Adverse Events Analysis after Receiving
      One of the Available SARS-CoV-2 Vaccine Schemes in Ecuador.
LID - 1047 [pii]
LID - 10.3390/vaccines10071047 [doi]
AB  - The COVID-19 pandemic has put a lot of pressure on health systems worldwide. Mass
      vaccination against SARS-CoV-2 has reduced morbidity and mortality worldwide.
      Despite their safety profiles, vaccines, as with any other medical product, can
      cause adverse events. Yet, in countries with poor epidemiological surveillance
      and monitoring systems, reporting vaccine-related adverse events is a challenge. 
      The objective of this study was to describe self-reported vaccine adverse events 
      after receiving one of the available COVID-19 vaccine schemes in Ecuador. A
      cross-sectional analysis based on an online, self-reported, 32-item questionnaire
      was conducted in Ecuador from 1 April to 15 July 2021. Participants were invited 
      by social media, radio, and TV to voluntarily participate in our study. A total
      of 6654 participants were included in this study. Furthermore, 38.2% of the
      participants reported having at least one comorbidity. Patients received
      AstraZeneca, Pfizer, and Sinovac vaccines, and these were distributed 38.4%,
      31.1%, and 30.5%, respectively. Overall, pain or swelling at the injection site
      17.2% (n = 4500) and headache 13.3% (n = 3502) were the most reported adverse
      events. Women addressed events supposedly attributable to vaccination or
      immunization [ESAVIs] (66.7%), more often than men (33.2%). After receiving the
      first dose of any available COVID-19 vaccine, a total of 19,501 self-reported
      ESAVIs were informed (87.0% were mild, 11.5% moderate, and 1.5% severe). In terms
      of the vaccine type and brand, the most reactogenic vaccine was AstraZeneca with 
      57.8%, followed by Pfizer (24.9%) and Sinovac (17.3%). After the second dose,
      6776 self-reported ESAVIs were reported (87.1% mild, 10.9% moderate, and 2.1%
      severe). AstraZeneca vaccine users reported a higher proportion of ESAVIs (72.2%)
      in comparison to Pfizer/BioNTech (15.9%) and Sinovac Vaccine (11.9%). Swelling at
      the injection site, headache, muscle pain, and fatigue were the most common
      ESAVIs for the first as well as second doses. In conclusion, most ESAVIs were
      mild. AstraZeneca users were more likely to report adverse events. Participants
      without a history of COVID-19 infection, as well as those who received the first 
      dose, were more prone to report ESAVIs.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
FAU - Izquierdo-Condoy, Juan S
AU  - Izquierdo-Condoy JS
AUID- ORCID: 0000-0002-1178-0546
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
AD  - Health Management and Research Area, Universidad Internacional Iberoamericana,
      Campeche 24560, Mexico.
FAU - Fernandez-Naranjo, Raul
AU  - Fernandez-Naranjo R
AUID- ORCID: 0000-0002-4875-9652
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
FAU - Simbana-Rivera, Katherine
AU  - Simbana-Rivera K
AUID- ORCID: 0000-0002-8130-5361
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
FAU - Vasconez-Gonzalez, Jorge
AU  - Vasconez-Gonzalez J
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
FAU - Naranjo, Eddy P Lincango
AU  - Naranjo EPL
AUID- ORCID: 0000-0003-4668-7429
AD  - Facultad de Ciencias Medicas, Universidad Central del Ecuador, Quito 100201,
      Ecuador.
FAU - Cordovez, Simone
AU  - Cordovez S
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
FAU - Coronel, Barbara
AU  - Coronel B
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
FAU - Delgado-Moreira, Karen
AU  - Delgado-Moreira K
AD  - One Health Research Group, Faculty of Health Science, Universidad de Las
      Americas, Quito 170507, Ecuador.
FAU - Jimbo-Sotomayor, Ruth
AU  - Jimbo-Sotomayor R
AD  - Centro de Investigacion para la Salud en America Latina (CISeAL), Pontificia
      Universidad Catolica del Ecuador, Quito 17012184, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20220630
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC9323750
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - adverse events
OT  - pandemic
OT  - self-reporting
OT  - vaccines
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
CRDT- 2022/07/27 01:43
PHST- 2022/05/13 00:00 [received]
PHST- 2022/06/15 00:00 [revised]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/07/27 01:43 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
AID - vaccines10071047 [pii]
AID - 10.3390/vaccines10071047 [doi]
PST - epublish
SO  - Vaccines (Basel). 2022 Jun 30;10(7). pii: vaccines10071047. doi:
      10.3390/vaccines10071047.

PMID- 35865818
OWN - NLM
STAT- MEDLINE
LR  - 20220803
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 12
DP  - 2022
TI  - Clinical Performance of Three Commercial SARS-CoV-2 Rapid Antigen Tests for
      Community-Dwelling Individuals in a Tropical Setting.
PG  - 832235
LID - 10.3389/fcimb.2022.832235 [doi]
AB  - During the second year of the COVID-19 pandemic, the use of Rapid Diagnosis
      Antigen Tests (RDAgTs) for SARS-CoV-2 detection has substantially increased as
      some of the brands available in the market were certified for clinical use by
      international regulatory agencies. RDAgTs are a fast and cheap tool for
      SARS-CoV-2 surveillance with great potential to improve testing capacities in
      middle- and low-income countries compared to the gold standard RT-qPCR. However, 
      as the clinical performance of RDAgTs has been shown to vary greatly between the 
      commercial brands available, evaluation studies are necessary. Moreover, the
      available evaluation has been done in high-income countries while SARS-CoV-2
      transmission is also actively happening in developing countries, many of which
      are located in tropical latitudes where cross-reactivity with other infectious
      agents is highly prevalent, which could compromise RDAgT specificity. Moreover,
      unreported mutations and/or new SARS-CoV-2 variants may compromise RDAgT
      sensitivity as genomic surveillance is limited in these settings. Here we
      describe a multicenter and manufacturer-independent evaluation of the clinical
      performance and analytical sensitivity of three different RDAgTs brands available
      in South America from three companies, Rapigen (South Korea), SD-Biosensor (South
      Korea), and Certest (Spain), compared to the gold standard RT-qPCR. A total
      number of 1,646 nasopharyngeal swabs from community-dwelling individuals were
      included in the study, and 379 of them were SARS-CoV-2 positive by RT-qPCR. The
      overall sensitivity for each RDAgT was 79% (IC95%: 72 - 86.2), 64.2% (IC95%: 56.7
      - 71.6), and 45.8% (IC95%: 35.8 - 55.8) for SD-Biosensor, Certest, and Rapigen,
      respectively. The overall specificity for each RDAgT was 100%, 97.7% (IC95%: 96.8
      - 98.6), and 100% for SD-Biosensor, Certest, and Rapigen, respectively. However, 
      the limit of detection (LoD) to achieve a sensitivity over 90% was substantially 
      lower for Certest RDAgT (10(2) copies/uL) compared to SD-Biosensor (10(3)
      copies/uL) or Rapigen (10(6) copies/uL) RDAgTs, considering that the gold
      standard RT-qPCR method used in this study has a high sensitivity of 97.7% and
      low LoD of 5 copies/uL. Additionally, the Certest RDAgT also showed an improved
      sensitivity up to 79.7% (IC95%: 70.2 - 89.2) for symptomatic individuals.
      Finally, the slight reduction in specificity for Certest RDAgTs was only
      associated with one of the laboratories performing this study, pointing out the
      need for locally assessed evaluation for RDAgTs like this one carried out in
      Ecuador. In conclusion, two of the three the RDAgTs tested in this study are a
      fast, cheap, and point of care tool for SARS-CoV-2 surveillance and reliable
      enough to detect SARS-CoV-2 infectious individuals.
CI  - Copyright (c) 2022 Morales-Jadan, Viteri-Davila, Castro-Rodriguez,
      Vallejo-Janeta, Rivera-Olivero, Perez and Garcia-Bereguiain.
FAU - Morales-Jadan, Diana
AU  - Morales-Jadan D
AD  - One Health Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Viteri-Davila, Carolina
AU  - Viteri-Davila C
AD  - One Health Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Castro-Rodriguez, Bernardo
AU  - Castro-Rodriguez B
AD  - One Health Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Vallejo-Janeta, Alexander Paolo
AU  - Vallejo-Janeta AP
AD  - One Health Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Rivera-Olivero, Ismar A
AU  - Rivera-Olivero IA
AD  - One Health Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Perez, Franklin
AU  - Perez F
AD  - OneLabt, Santa Elena, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220705
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - SARS-CoV-2 variants
SB  - IM
MH  - *COVID-19/diagnosis
MH  - Humans
MH  - Independent Living
MH  - Pandemics
MH  - *SARS-CoV-2/genetics
MH  - Sensitivity and Specificity
PMC - PMC9294138
OTO - NOTNLM
OT  - *Certest
OT  - *RapiGEN(R) Ag test kit
OT  - *SARS-CoV-2
OT  - *SD-Biosensor
OT  - *antigen test
OT  - *clinical performance
COIS- 'Author FP is employed by OneLabt. The remaining authors declare that the
      research was conducted in the absence of any commercial or financial
      relationships that could be construed as a potential conflict of interest.
EDAT- 2022/07/23 06:00
MHDA- 2022/07/26 06:00
CRDT- 2022/07/22 02:34
PHST- 2021/12/09 00:00 [received]
PHST- 2022/05/24 00:00 [accepted]
PHST- 2022/07/22 02:34 [entrez]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
AID - 10.3389/fcimb.2022.832235 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2022 Jul 5;12:832235. doi:
      10.3389/fcimb.2022.832235. eCollection 2022.

PMID- 35864727
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220805
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 23
DP  - 2022 Jul 22
TI  - Multidrug-Resistant Klebsiella pneumoniae in a Patient with SARS-Cov-2 Pneumonia 
      in an Intensive Care Unit in Guayaquil, Ecuador: A Case Report.
PG  - e936498
LID - 10.12659/AJCR.936498 [doi]
AB  - BACKGROUND Multi-resistant microorganisms are a public health problem. Their
      incidence has risen due to COVID-19, indiscriminate antibiotics use,
      corticosteroid treatments, and higher admissions to intensive care units (ICUs)
      of patients requiring invasive mechanical ventilation. These are risk factors for
      bacterial over-infection. The present case study that is relevant because of the 
      multiple isolated strains with a resistance pattern: Klebsiella pneumoniae
      carbapenemases (KPC), extended-spectrum beta lactamases (ESBL) and New Delhi
      metallo-ss-lactamase (NDM) in a patient without comorbidities. CASE REPORT A
      53-year-old Ecuadorian man with no past medical history arrived at the Emergency 
      Department (ED) with dyspnea, nasopharyngeal swab with a positive reverse
      transcription polymerase chain reaction (RT-PCR) test for SARS-CoV2, and a chest 
      computed tomography (CT) scan showing bilateral ground-glass pulmonary
      infiltrates with 40% involvement. On day 10 in the ICU, the presence of
      Klebsiella pneumoniae KPC strain was reported in an axillary swab culture.
      Consequently, the antibiotic was rotated to vancomycin 1 g intravenously (i.v.)
      every 12 h and meropenem 1 g i.v. every 8 h. On day 15 in the ICU, a tracheal
      secretion culture was reported with the presence of Klebsiella pneumoniae ESBL
      and a blood culture with Klebsiella pneumoniae NDM. CONCLUSIONS The COVID-19
      pandemic is a perfect scenario for superinfection with multi-resistant pathogens 
      such as carbapenem-resistant Klebsiella pneumoniae (CRKP), due to the increase in
      patients admitted to ICUs requiring invasive mechanical ventilation, the use of
      corticosteroids, and empirical broad-spectrum antibiotic management based on
      guidelines. The emergence of combined multidrug-resistant strains is a challenge 
      for laboratory detection and the selection of antimicrobial treatment.
FAU - Pazmino Gomez, Betty J
AU  - Pazmino Gomez BJ
AD  - Department of Teaching and Research, State University of Milagro, Milagro,
      Ecuador.
FAU - Rodas Pazmino, Jennifer P
AU  - Rodas Pazmino JP
AUID- ORCID: 0000-0003-4046-3344
AD  - Department of Emergency, Leon Becerra Hospital, Milagro, Ecuador.
FAU - Gonzalez Quinde, Gabriel S
AU  - Gonzalez Quinde GS
AUID- ORCID: 0000-0001-7900-3092
AD  - Department of Emergency, Leon Becerra Hospital, Milagro, Ecuador.
FAU - Guevara Viejo, Jorge F
AU  - Guevara Viejo JF
AUID- ORCID: 0000-0003-2615-9872
AD  - Department of Teaching and Research, State University of Milagro, Milagro,
      Ecuador.
FAU - Merejildo Amaguana, Miguel J
AU  - Merejildo Amaguana MJ
AUID- ORCID: 0000-0001-5187-8372
AD  - Department of Laboratory, General Hospital of the North of Guayaquil Los Ceibos
      IESS, Guayaquil, Ecuador.
FAU - Rodas Neira, Edgar I
AU  - Rodas Neira EI
AUID- ORCID: 0000-0001-6376-2940
AD  - Department of Microbiology, "Pazmino" Clinical and Microbiological Laboratory,
      Milagro, Ecuador.
FAU - Rizzo Rodriguez, Francisco A
AU  - Rizzo Rodriguez FA
AUID- ORCID: 0000-0003-0631-7570
AD  - Department of Emergency, Ambato General Teaching Hospital, Ambato, Ecuador.
FAU - Cagua Montano, Luis E
AU  - Cagua Montano LE
AUID- ORCID: 0000-0002-5084-1460
AD  - Department of Teaching and Research, State University of Milagro, Milagro,
      Ecuador.
FAU - Rodas Pazmino, Karen A
AU  - Rodas Pazmino KA
AUID- ORCID: 0000-0002-6461-1068
AD  - Department of Teaching and Research, State University of Milagro, Milagro,
      Ecuador.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220722
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *COVID-19
MH  - Ecuador
MH  - Humans
MH  - Intensive Care Units
MH  - *Klebsiella Infections/diagnosis/drug therapy
MH  - Klebsiella pneumoniae
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Pandemics
MH  - *Pneumonia
MH  - RNA, Viral
MH  - SARS-CoV-2
PMC - PMC9319302
EDAT- 2022/07/23 06:00
MHDA- 2022/07/26 06:00
CRDT- 2022/07/22 01:36
PHST- 2022/07/22 01:36 [entrez]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
AID - 936498 [pii]
AID - 10.12659/AJCR.936498 [doi]
PST - epublish
SO  - Am J Case Rep. 2022 Jul 22;23:e936498. doi: 10.12659/AJCR.936498.

PMID- 35853454
OWN - NLM
STAT- Publisher
LR  - 20220724
IS  - 1934-6069 (Electronic)
IS  - 1931-3128 (Linking)
DP  - 2022 Jun 20
TI  - Emergence and widespread circulation of a recombinant SARS-CoV-2 lineage in North
      America.
LID - S1931-3128(22)00315-8 [pii]
LID - 10.1016/j.chom.2022.06.010 [doi]
AB  - Although recombination is a feature of coronavirus evolution, previously detected
      recombinant lineages of SARS-CoV-2 have shown limited circulation thus far. Here,
      we present a detailed phylogenetic analysis of four SARS-CoV-2 lineages to
      investigate the possibility of virus recombination among them. Our analyses
      reveal well-supported phylogenetic differences between the Orf1ab region encoding
      viral non-structural proteins and the rest of the genome, including Spike (S)
      protein and remaining reading frames. By accounting for several deletions in
      NSP6, Orf3a, and S, we conclude that the B.1.628 major cluster, now designated as
      lineage XB, originated from a recombination event between viruses of B.1.631 and 
      B.1.634 lineages. This scenario is supported by the spatiotemporal distribution
      of these lineages across the USA and Mexico during 2021, suggesting that the
      recombination event originated in this geographical region. This event raises
      important questions regarding the role and potential effects of recombination on 
      SARS-CoV-2 evolution.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Gutierrez, Bernardo
AU  - Gutierrez B
AD  - Department of Zoology, University of Oxford, Oxford, UK; Consorcio Mexicano de
      Vigilancia Genomica (CoViGen-Mex), Mexico; Colegio de Ciencias Biologicas y
      Ambientales, Universidad San Francisco de Quito USFQ, Quito, Ecuador. Electronic 
      address: bernardo.gutierrez@zoo.ox.ac.uk.
FAU - Castelan Sanchez, Hugo G
AU  - Castelan Sanchez HG
AD  - Consorcio Mexicano de Vigilancia Genomica (CoViGen-Mex), Mexico; Consejo Nacional
      de Ciencia y Tecnologia, Ciudad de Mexico, Mexico.
FAU - Candido, Darlan da Silva
AU  - Candido DDS
AD  - Department of Zoology, University of Oxford, Oxford, UK; Instituto de Medicina
      Tropical, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Jackson, Ben
AU  - Jackson B
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Fleishon, Shay
AU  - Fleishon S
AD  - Hertzl 52, Jerusalem, Israel.
FAU - Houzet, Renaud
AU  - Houzet R
AD  - 10 rue de Dunkerque, 75010, Paris, France.
FAU - Ruis, Christopher
AU  - Ruis C
AD  - Molecular Immunity Unit, Department of Medicine, University of Cambridge,
      Cambridge, UK; Department of Veterinary Medicine, University of Cambridge,
      Cambridge, UK.
FAU - Delaye, Luis
AU  - Delaye L
AD  - Consorcio Mexicano de Vigilancia Genomica (CoViGen-Mex), Mexico; Departamento de 
      Ingenieria Genetica, Unidad Irapuato, CINVESTAV, Irapuato, Mexico.
FAU - Faria, Nuno R
AU  - Faria NR
AD  - Department of Zoology, University of Oxford, Oxford, UK; Instituto de Medicina
      Tropical, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; 
      MRC Centre for Global Infectious Disease Analysis, School of Public Health,
      Imperial College London, London, UK; The Abdul Latif Jameel Institute for Disease
      and Emergency Analytics, School of Public Health, Imperial College London,
      London, UK.
FAU - Rambaut, Andrew
AU  - Rambaut A
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Pybus, Oliver G
AU  - Pybus OG
AD  - Department of Zoology, University of Oxford, Oxford, UK; Department of
      Pathobiology, Royal Veterinary College, London, UK. Electronic address:
      oliver.pybus@zoo.ox.ac.uk.
FAU - Escalera-Zamudio, Marina
AU  - Escalera-Zamudio M
AD  - Department of Zoology, University of Oxford, Oxford, UK; Consorcio Mexicano de
      Vigilancia Genomica (CoViGen-Mex), Mexico. Electronic address:
      marina.escalerazamudio@zoo.ox.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20220620
PL  - United States
TA  - Cell Host Microbe
JT  - Cell host & microbe
JID - 101302316
SB  - IM
PMC - PMC9212848
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - molecular epidemiology
OT  - phylogenetics
OT  - recombination
COIS- Declaration of interests The authors declare no competing interests.
EDAT- 2022/07/20 06:00
MHDA- 2022/07/20 06:00
CRDT- 2022/07/19 18:42
PHST- 2021/12/14 00:00 [received]
PHST- 2022/03/18 00:00 [revised]
PHST- 2022/06/16 00:00 [accepted]
PHST- 2022/07/19 18:42 [entrez]
PHST- 2022/07/20 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
AID - S1931-3128(22)00315-8 [pii]
AID - 10.1016/j.chom.2022.06.010 [doi]
PST - aheadofprint
SO  - Cell Host Microbe. 2022 Jun 20. pii: S1931-3128(22)00315-8. doi:
      10.1016/j.chom.2022.06.010.

PMID- 35818397
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220801
IS  - 2052-2975 (Print)
IS  - 2052-2975 (Linking)
VI  - 48
DP  - 2022 Jul
TI  - First case of within-host co-infection of different SARS-CoV-2 variants in
      Ecuador.
PG  - 101001
LID - 10.1016/j.nmni.2022.101001 [doi]
AB  - Background: COVID-19 infection caused by severe acute respiratory syndrome
      coronavirus 2 (SARS-CoV-2) can cause mild symptoms to severe illness and death.
      Co-infections of SARS-CoV-2 with other respiratory viruses have been described.
      However, two SARS-CoV-2 lineage co-infection have been rarely reported.
      Methodology: A genotyping analysis and two different types of whole genome
      sequencing were performed (Illumina MiniSeq and ONT MinION). When examining the
      phylogenetic analysis in NextClade and Pangolin webservers, and considering the
      genotyping findings, conflicting results were obtained. Results: The raw data of 
      the sequencing was analyzed, and nucleotide variants were identified between
      different reads of the virus genome. B.1 and P.1 lineages were identified within 
      the same sample. Conclusions: We concluded that this is a co-infection case with 
      two SARS-CoV-2 lineages, the first one reported in Ecuador.
CI  - (c) 2022 The Author(s).
FAU - Fernandez-Cadena, J C
AU  - Fernandez-Cadena JC
AD  - Laboratorio INTERLAB, Ecuador.
FAU - Carvajal, M
AU  - Carvajal M
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Munoz, E
AU  - Munoz E
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Prado-Vivar, B
AU  - Prado-Vivar B
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Marquez, S
AU  - Marquez S
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Proano, S
AU  - Proano S
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Bayas, R
AU  - Bayas R
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Guadalupe, J J
AU  - Guadalupe JJ
AD  - Universidad San Francisco de Quito, COCIBA, Laboratorio de Biotecnologia Vegetal,
      Ecuador.
FAU - Becerra-Wong, M
AU  - Becerra-Wong M
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Gutierrez, B
AU  - Gutierrez B
AD  - Universidad San Francisco de Quito, COCIBA, Laboratorio de Biotecnologia Vegetal,
      Ecuador.
AD  - Departament of Zoology, University of Oxford, UK.
FAU - Morey-Leon, G
AU  - Morey-Leon G
AD  - Universidad de Guayaquil, Ecuador.
FAU - Trueba, G
AU  - Trueba G
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Grunauer, M
AU  - Grunauer M
AD  - Universidad San Francisco de Quito, COCSA, Escuela de Medicina, Ecuador.
AD  - Unidad de Cuidados Intensivos, Hospital de los Valles, Quito, Ecuador.
FAU - Barragan, V
AU  - Barragan V
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Rojas-Silva, P
AU  - Rojas-Silva P
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
FAU - Andrade-Molina, D
AU  - Andrade-Molina D
AD  - Universidad Espiritu Santo, Laboratorio de Omicas, Ecuador.
FAU - Cardenas, P
AU  - Cardenas P
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20220706
PL  - England
TA  - New Microbes New Infect
JT  - New microbes and new infections
JID - 101624750
PMC - PMC9259011
OTO - NOTNLM
OT  - COVID19
OT  - NGS
OT  - SARS-CoV-2
OT  - co-infection
OT  - genome sequencing
EDAT- 2022/07/13 06:00
MHDA- 2022/07/13 06:01
CRDT- 2022/07/12 01:44
PHST- 2022/01/29 00:00 [received]
PHST- 2022/06/24 00:00 [accepted]
PHST- 2022/07/13 06:00 [pubmed]
PHST- 2022/07/13 06:01 [medline]
PHST- 2022/07/12 01:44 [entrez]
AID - 10.1016/j.nmni.2022.101001 [doi]
AID - S2052-2975(22)00053-1 [pii]
PST - ppublish
SO  - New Microbes New Infect. 2022 Jul;48:101001. doi: 10.1016/j.nmni.2022.101001.
      Epub 2022 Jul 6.

PMID- 35805606
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20220716
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 19
IP  - 13
DP  - 2022 Jun 28
TI  - SARS-CoV-2 Viral Load Analysis at Low and High Altitude: A Case Study from
      Ecuador.
LID - 7945 [pii]
LID - 10.3390/ijerph19137945 [doi]
AB  - SARS-CoV-2 has spread throughout the world, including remote areas such as those 
      located at high altitudes. There is a debate about the role of hypobaric hypoxia 
      on viral transmission and COVID-19 incidence. A descriptive cross-sectional
      analysis of SARS-CoV-2 infection and viral load among patients living at low (230
      m) and high altitude (3800 m) in Ecuador was completed. Within these two
      communities, the total number of infected people at the time of the study was 108
      cases (40.3%). The COVID-19 incidence proportion at low altitude was 64% while at
      high altitude was 30.3%. The mean viral load from those patients who tested
      positive was 3,499,184 copies/mL (SD = 23,931,479 copies/mL). At low altitude
      (Limoncocha), the average viral load was 140,223.8 copies/mL (SD = 990,840.9
      copies/mL), while for the high altitude group (Oyacachi), the mean viral load was
      6,394,789 copies/mL (SD = 32,493,469 copies/mL). We found no statistically
      significant differences when both results were compared (p = 0.056). We found no 
      significant differences across people living at low or high altitude; however,
      men and younger populations had higher viral load than women older populations,
      respectively.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AUID- ORCID: 0000-0002-1895-7498
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito 170124, Ecuador.
AD  - Department of Cell Biology, Physiology and Immunology, Faculty of Biology,
      Universitat de Barcelona, 08028 Barcelona, Spain.
FAU - Simbana-Rivera, Katherine
AU  - Simbana-Rivera K
AUID- ORCID: 0000-0002-8130-5361
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito 170124, Ecuador.
FAU - Fernandez-Naranjo, Raul
AU  - Fernandez-Naranjo R
AUID- ORCID: 0000-0002-4875-9652
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito 170124, Ecuador.
FAU - Vasconez, Jorge Eduardo
AU  - Vasconez JE
AUID- ORCID: 0000-0003-4573-6217
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito 170124, Ecuador.
FAU - Henriquez-Trujillo, Aquiles R
AU  - Henriquez-Trujillo AR
AUID- ORCID: 0000-0002-3094-4438
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito 170124, Ecuador.
FAU - Vallejo-Janeta, Alexander Paolo
AU  - Vallejo-Janeta AP
AD  - Laboratorio de Investigacion, Universidad de las Americas, Quito 170124, Ecuador.
FAU - Rivera-Olivero, Ismar A
AU  - Rivera-Olivero IA
AUID- ORCID: 0000-0001-8345-8217
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito 170124, Ecuador.
FAU - Lozada, Tannya
AU  - Lozada T
AD  - Laboratorio de Investigacion, Universidad de las Americas, Quito 170124, Ecuador.
FAU - Viscor, Gines
AU  - Viscor G
AUID- ORCID: 0000-0003-4942-2346
AD  - Department of Cell Biology, Physiology and Immunology, Faculty of Biology,
      Universitat de Barcelona, 08028 Barcelona, Spain.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito 170124, Ecuador.
CN  - UDLA-COVID-19 Team
LA  - eng
PT  - Journal Article
DEP - 20220628
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Altitude
MH  - *COVID-19/epidemiology
MH  - Cross-Sectional Studies
MH  - Ecuador/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - *SARS-CoV-2
MH  - Viral Load
PMC - PMC9265329
OTO - NOTNLM
OT  - COVID-19
OT  - RT-PCR
OT  - SARS-CoV-2
OT  - cycle threshold (Ct)
OT  - high altitude
OT  - hypoxia
OT  - viral load
EDAT- 2022/07/10 06:00
MHDA- 2022/07/14 06:00
CRDT- 2022/07/09 01:08
PHST- 2022/03/16 00:00 [received]
PHST- 2022/05/03 00:00 [revised]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/07/09 01:08 [entrez]
PHST- 2022/07/10 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
AID - ijerph19137945 [pii]
AID - 10.3390/ijerph19137945 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2022 Jun 28;19(13). pii: ijerph19137945. doi:
      10.3390/ijerph19137945.

PMID- 35694627
OWN - NLM
STAT- MEDLINE
DCOM- 20220614
LR  - 20220716
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 100
IP  - 6
DP  - 2022 Jun 1
TI  - Equitable distribution of SARS-CoV-2 tests.
PG  - 411-412
LID - 10.2471/BLT.21.287398 [doi]
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Via a Nayon S/N, 170125
      Quito, Ecuador.
FAU - Bruno, Alfredo
AU  - Bruno A
AD  - Centro Nacional de Referencia para Influenza y Otros Virus Respiratorios,
      Instituto Nacional de Salud Publica en Investigacion Leopoldo Izquieta Perez,
      Guayaquil, Ecuador.
FAU - Morales-Jadan, Diana
AU  - Morales-Jadan D
AD  - One Health Research Group, Universidad de Las Americas, Via a Nayon S/N, 170125
      Quito, Ecuador.
FAU - Vidal, Jorge E
AU  - Vidal JE
AD  - Department of Microbiology and Immunology, University of Mississippi Medical
      Center, Jackson, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20220502
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - *COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques
MH  - Humans
MH  - *SARS-CoV-2
PMC - PMC9178421
EDAT- 2022/06/14 06:00
MHDA- 2022/06/15 06:00
CRDT- 2022/06/13 03:34
PHST- 2021/10/07 00:00 [received]
PHST- 2022/04/08 00:00 [revised]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/06/13 03:34 [entrez]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/06/15 06:00 [medline]
AID - 10.2471/BLT.21.287398 [doi]
AID - BLT.21.287398 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2022 Jun 1;100(6):411-412. doi: 10.2471/BLT.21.287398.
      Epub 2022 May 2.

PMID- 35690364
OWN - NLM
STAT- Publisher
LR  - 20220805
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
DP  - 2022 Jun 8
TI  - Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from
      Venezuela, 6 months after vaccination with Sputnik V.
LID - S1201-9712(22)00341-1 [pii]
LID - 10.1016/j.ijid.2022.06.008 [doi]
AB  - BACKGROUND: . Scarce information is available regarding the long-term
      immunogenicity of the Sputnik V vaccine. Here Sputnik V vaccinated subjects were 
      evaluated 6 months after receiving the 2-dose prime-boost schedule. METHODS: .
      Eighty-four hospital workers from Venezuela, 32 with a previous COVID-19
      infection and 54 SARS-CoV-2 naive subjects, were enrolled. IgG antibodies levels 
      against the Receptor Binding Domain (RBD) were measured in an ELISA and with an
      in vitro ACE2-RBD neutralization assay at day 42 and day 180 after receiving the 
      second dose. IgG levels were expressed in BAU/ml. Neutralizing antibodies were
      expressed in IU/ml. RESULTS: . On average, RBD-IgG levels decreased by
      approximately 50% between the two time-points in the COVID-19 naive cohort
      (geometric mean titer (GMT) 675 BAU/mL vs. 327 BAU/ml) and decreased by
      approximately 25% in the previously infected cohort (GMT 1209 BAU/mL vs 910
      BAU/ml). Within our cohort, 94% showed a "good to excellent" neutralizing
      activity measured with the in vitro test 6 months after vaccination. CONCLUSIONS:
      . The Sputnik V vaccine provided long-term and durable humoral immunity in our
      cohort specially if a person has been both vaccinated and had a previous
      infection with SARS-CoV-2. These individuals with hybrid immunity are no priority
      for a third booster vaccine dose.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - Claro, Franklin
AU  - Claro F
AD  - Servicio Autonomo Instituto de Biomedicina, Universidad Central de Venezuela,
      Caracas, Venezuela; Servicio Autonomo Instituto de Biomedicina, Ministerio del
      Poder Popular para la Salud, Venezuela.
FAU - Silva, Douglas
AU  - Silva D
AD  - Servicio Autonomo Instituto de Biomedicina, Ministerio del Poder Popular para la 
      Salud, Venezuela.
FAU - Bogado, Jesus A Perez
AU  - Bogado JAP
AD  - Servicio Autonomo Instituto de Biomedicina, Ministerio del Poder Popular para la 
      Salud, Venezuela.
FAU - Rangel, Hector Rafael
AU  - Rangel HR
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Altos de Pipe,
      Miranda, Venezuela.
FAU - de Waard, Jacobus H
AU  - de Waard JH
AD  - Servicio Autonomo Instituto de Biomedicina, Universidad Central de Venezuela,
      Caracas, Venezuela; One Health Research Group, Universidad de Las Americas
      (UDLA), Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20220608
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
PMC - PMC9176181
OTO - NOTNLM
OT  - IgG antibodies
OT  - Receptor Binding Domain (RBD)
OT  - Sputnik V vaccine
OT  - binding antibody units or BAU/ml
OT  - hybrid COVID-19 immunity
OT  - international units or IU/ml
OT  - neutralization assay
OT  - nucleocapsid protein (NP)
EDAT- 2022/06/12 06:00
MHDA- 2022/06/12 06:00
CRDT- 2022/06/11 19:28
PHST- 2022/04/05 00:00 [received]
PHST- 2022/06/05 00:00 [revised]
PHST- 2022/06/06 00:00 [accepted]
PHST- 2022/06/11 19:28 [entrez]
PHST- 2022/06/12 06:00 [pubmed]
PHST- 2022/06/12 06:00 [medline]
AID - S1201-9712(22)00341-1 [pii]
AID - 10.1016/j.ijid.2022.06.008 [doi]
PST - aheadofprint
SO  - Int J Infect Dis. 2022 Jun 8. pii: S1201-9712(22)00341-1. doi:
      10.1016/j.ijid.2022.06.008.

PMID- 35643308
OWN - NLM
STAT- Publisher
LR  - 20220726
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 122
DP  - 2022 May 26
TI  - SARS-CoV-2 transmission from infected owner to household dogs and cats is
      associated with food sharing.
PG  - 295-299
LID - S1201-9712(22)00313-7 [pii]
LID - 10.1016/j.ijid.2022.05.049 [doi]
AB  - OBJECTIVES: Several cases of reverse transmission of SARS-CoV-2 from human to
      pets were reported during the first year of the COVID-19 pandemic. Accordingly,
      the World Organization for Animal Health has recommended to improve SARS-CoV-2
      surveillance on household animals to assess the risk of transmission between
      species. After such recommendation, we studied the potential SARS-CoV-2 infection
      in household dogs and cats in the city of Guayaquil, the most populated city in
      Ecuador. METHODS: Oral and nasal swab samples were collected from dogs and cats
      within 10 days of a positive SARS-CoV-2 test result of their owners. Total
      ribonucleic acid was extracted and detection of viral gene targets N and ORF1ab
      was performed by quantitative reverse transcription polymerase chain reaction.
      RESULTS: From the 50 cats and dogs tested, 12 were SARS-CoV-2 positive, giving a 
      total positivity rate of 24%. A total of 1 of 8 cats tested positive, whereas 11 
      of 42 dogs were positive, yielding a positivity rate of 12.5% and 26.2%,
      respectively. SARS-CoV-2 was confirmed by whole genome sequencing. In addition,
      we also found a statistically significant association between SARS-CoV-2 pet
      positivity and food sharing with infected owners. CONCLUSION: This study is the
      second active surveillance of SARS-CoV-2 in household dogs and cats in Latin
      America. Moreover, it is the first study to address the risk factors associated
      with potential anthropogenic SARS-CoV-2 transmission to domestic cats and dogs.
      Given the high presence of free-roaming dogs and cats in rural and urban areas in
      Latin American countries and the high capacity shown by coronaviruses for
      interspecies transmission, our findings support the view that SARS-CoV-2
      surveillance in pets is necessary to better understand the role that pet-human
      interaction plays in the COVID-19 spread.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Alberto-Orlando, Solon
AU  - Alberto-Orlando S
AD  - Instituto Nacional de Investigacion y Salud Publica, Direccion Investigacion
      Desarrollo e Innovacion, Guayaquil, Ecuador; Universidad Espiritu Santo,
      Guayaquil, Ecuador. Electronic address: aorlando@inspi.gob.ec.
FAU - Calderon, Joselyn L
AU  - Calderon JL
AD  - Instituto Nacional de Investigacion y Salud Publica, Direccion Investigacion
      Desarrollo e Innovacion, Guayaquil, Ecuador.
FAU - Leon-Sosa, Ariana
AU  - Leon-Sosa A
AD  - Instituto Nacional de Investigacion y Salud Publica, Direccion Investigacion
      Desarrollo e Innovacion, Guayaquil, Ecuador.
FAU - Patino, Leandro
AU  - Patino L
AD  - Instituto Nacional de Investigacion y Salud Publica, Direccion Investigacion
      Desarrollo e Innovacion, Guayaquil, Ecuador.
FAU - Zambrano-Alvarado, Melissa N
AU  - Zambrano-Alvarado MN
AD  - Instituto Nacional de Investigacion y Salud Publica, Direccion Investigacion
      Desarrollo e Innovacion, Guayaquil, Ecuador.
FAU - Pasquel-Villa, Lisette D
AU  - Pasquel-Villa LD
AD  - Ministerio de Salud Publica del Ecuador, Distrito Pascuales 2, Guayaquil,
      Ecuador.
FAU - Rugel-Gonzalez, David O
AU  - Rugel-Gonzalez DO
AD  - Facultad de Medicina Veterinaria y Zootecnia, Universidad Agraria del Ecuador,
      Guayaquil, Ecuador.
FAU - Flores, Dayana
AU  - Flores D
AD  - Facultad de Medicina Veterinaria y Zootecnia, Universidad Agraria del Ecuador,
      Guayaquil, Ecuador.
FAU - Mera, Maria Daniela
AU  - Mera MD
AD  - Facultad de Medicina Veterinaria y Zootecnia, Universidad Agraria del Ecuador,
      Guayaquil, Ecuador.
FAU - Valencia, Pamela
AU  - Valencia P
AD  - Facultad de Medicina Veterinaria y Zootecnia, Universidad Agraria del Ecuador,
      Guayaquil, Ecuador.
FAU - Zuniga-Velarde, Jose Julian
AU  - Zuniga-Velarde JJ
AD  - Clinica Veterinaria Dr. Pet, Guayaquil, Ecuador.
FAU - Tello-Cabrera, Clara
AU  - Tello-Cabrera C
AD  - Instituto Nacional de Investigacion y Salud Publica, Direccion Investigacion
      Desarrollo e Innovacion, Guayaquil, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
      Electronic address: magbereguiain@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220526
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
PMC - PMC9132679
OTO - NOTNLM
OT  - Cats
OT  - Dogs
OT  - Food sharing
OT  - Pets
OT  - Risk factors
OT  - SARS-CoV-2
COIS- Declaration of Competing Interest The authors have no competing interests to
      declare.
EDAT- 2022/06/02 06:00
MHDA- 2022/06/02 06:00
CRDT- 2022/06/01 09:24
PHST- 2022/03/23 00:00 [received]
PHST- 2022/05/19 00:00 [revised]
PHST- 2022/05/21 00:00 [accepted]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/02 06:00 [medline]
PHST- 2022/06/01 09:24 [entrez]
AID - S1201-9712(22)00313-7 [pii]
AID - 10.1016/j.ijid.2022.05.049 [doi]
PST - aheadofprint
SO  - Int J Infect Dis. 2022 May 26;122:295-299. doi: 10.1016/j.ijid.2022.05.049.

PMID- 35640480
OWN - NLM
STAT- Publisher
LR  - 20220805
IS  - 1476-928X (Electronic)
IS  - 1476-9271 (Linking)
VI  - 99
DP  - 2022 Aug
TI  - Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the
      monomer of the main protease SARS-CoV-2: A volumetric study based on molecular
      dynamics, elastic networks, classical thermodynamics and SPT.
PG  - 107692
LID - S1476-9271(22)00072-X [pii]
LID - 10.1016/j.compbiolchem.2022.107692 [doi]
AB  - The COVID-19 pandemic has accelerated the study of drugs, most notably ivermectin
      and more recently Paxlovid (PF-07321332) which is in phase III clinical trials
      with experimental data showing covalent binding to the viral protease M(pro).
      Theoretical developments of catalytic site-directed docking support
      thermodynamically feasible non-covalent binding to M(pro). Here we show that
      Paxlovid binds non-covalently at regions other than the catalytic sites with
      energies stronger than reported and at the same binding site as the ivermectin
      B1a homologue, all through theoretical methodologies, including blind docking. We
      volumetrically characterize the non-covalent interaction of the ivermectin
      homologues (avermectins B1a and B1b) and Paxlovid with the mM(pro) monomer,
      through molecular dynamics and scaled particle theory (SPT). Using the
      fluctuation-dissipation theorem (FDT), we estimated the electric dipole moment
      fluctuations at the surface of each of complex involved in this study, with
      similar trends to that observed in the interaction volume. Using fluctuations of 
      the intrinsic volume and the number of flexible fragments of proteins using
      anisotropic and Gaussian elastic networks (ANM+GNM) suggests the complexes with
      ivermectin are more dynamic and flexible than the unbound monomer. In contrast,
      the binding of Paxlovid to mM(pro) shows that the mM(pro)-PF complex is the least
      structurally dynamic of all the species measured in this investigation. The
      results support a differential molecular mechanism of the ivermectin and PF
      homologues in the mM(pro) monomer. Finally, the results showed that Paxlovid
      despite beingbound in different sites through covalent or non-covalent forms
      behaves similarly in terms of its structural flexibility and volumetric
      behaviour.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Alvarado, Ysaias Jose
AU  - Alvarado YJ
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Centro de
      Investigacion y Tecnologia de Materiales (CITeMA), Laboratorio de Caracterizacion
      Molecular y Biomolecular, 4001 Maracaibo, Bolivarian Republic of Venezuela.
      Electronic address: alvaradoysaias@gmail.com.
FAU - Olivarez, Yosmari
AU  - Olivarez Y
AD  - Universidad del Zulia (LUZ). Facultad Experimental de Ciencias (FEC),
      Departamento de Quimica, Laboratorio de Electronica Molecular, 4001 Maracaibo,
      Bolivarian Republic of Venezuela.
FAU - Lossada, Carla
AU  - Lossada C
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Centro de
      Investigacion y Tecnologia de Materiales (CITeMA), Laboratorio de Caracterizacion
      Molecular y Biomolecular, 4001 Maracaibo, Bolivarian Republic of Venezuela.
FAU - Vera-Villalobos, Joan
AU  - Vera-Villalobos J
AD  - Facultad de Ciencias Naturales y Matematicas, Departamento de Quimica y Ciencias 
      Ambientales, Laboratorio de Analisis Quimico Instrumental (LAQUINS), Escuela
      Superior Politecnica del Litoral, Guayaquil, Ecuador.
FAU - Paz, Jose Luis
AU  - Paz JL
AD  - Departamento Academico de Quimica Inorganica, Facultad de Quimica e Ingenieria
      Quimica, Universidad Nacional Mayor de San Marcos, Lima, Peru.
FAU - Vera, Eddy
AU  - Vera E
AD  - Universidad del Zulia (LUZ). Facultad Experimental de Ciencias (FEC),
      Departamento de Quimica, Laboratorio de Electronica Molecular, 4001 Maracaibo,
      Bolivarian Republic of Venezuela.
FAU - Lorono, Marcos
AU  - Lorono M
AD  - Departamento Academico de Quimica Analitica e Instrumental, Facultad de Quimica e
      Ingenieria Quimica, Universidad Nacional Mayor de San Marcos, Lima, Peru.
FAU - Vivas, Alejandro
AU  - Vivas A
AD  - Universidad del Zulia (LUZ). Facultad Experimental de Ciencias (FEC),
      Departamento de Quimica, Laboratorio de Electronica Molecular, 4001 Maracaibo,
      Bolivarian Republic of Venezuela.
FAU - Torres, Fernando Javier
AU  - Torres FJ
AD  - Grupo de Quimica Computacional y Teorica (QCT-UR), Facultad de Ciencias
      Naturales, Universidad del Rosario, Bogota, Colombia; Grupo de Quimica
      Computacional y Teorica (QCT-USFQ), Instituto de Simulacion Computacional
      (ISC-USFQ), Departamento de Ingenieria Quimica, Universidad San Francisco de
      Quito (USFQ), Quito, Ecuador.
FAU - Jeffreys, Laura N
AU  - Jeffreys LN
AD  - Centre for Drugs and Diagnostics, Department of Tropical Disease Biology,
      Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
FAU - Hurtado-Leon, Maria Laura
AU  - Hurtado-Leon ML
AD  - Universidad del Zulia (LUZ), Facultad Experimental de Ciencias (FEC),
      Departamento de Biologia, Laboratorio de Genetica y Biologia Molecular (LGBM),
      Maracaibo 4001, Zulia, Bolivarian Republic of Venezuela.
FAU - Gonzalez-Paz, Lenin
AU  - Gonzalez-Paz L
AD  - Universidad del Zulia (LUZ), Facultad Experimental de Ciencias (FEC),
      Departamento de Biologia, Laboratorio de Genetica y Biologia Molecular (LGBM),
      Maracaibo 4001, Zulia, Bolivarian Republic of Venezuela; Instituto Venezolano de 
      Investigaciones Cientificas (IVIC), Centro de Estudios Botanicos y
      Agroforestales, (CEBA), Laboratorio de Proteccion Vegetal, 4001 Maracaibo,
      Bolivarian Republic of Venezuela. Electronic address: lgonzalezpaz@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220514
PL  - England
TA  - Comput Biol Chem
JT  - Computational biology and chemistry
JID - 101157394
SB  - IM
PMC - PMC9107165
OTO - NOTNLM
OT  - ANM
OT  - COVID-19
OT  - GNM
OT  - Volume Molar
OT  - Volume fluctuation
OT  - Voronoi
EDAT- 2022/06/01 06:00
MHDA- 2022/06/01 06:00
CRDT- 2022/05/31 18:26
PHST- 2022/01/04 00:00 [received]
PHST- 2022/04/28 00:00 [revised]
PHST- 2022/05/02 00:00 [accepted]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/05/31 18:26 [entrez]
AID - S1476-9271(22)00072-X [pii]
AID - 10.1016/j.compbiolchem.2022.107692 [doi]
PST - ppublish
SO  - Comput Biol Chem. 2022 Aug;99:107692. doi: 10.1016/j.compbiolchem.2022.107692.
      Epub 2022 May 14.

PMID- 35592728
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220521
IS  - 2214-7144 (Electronic)
IS  - 2214-7144 (Linking)
VI  - 40
DP  - 2021 Apr
TI  - Approaches applied to detect SARS-CoV-2 in wastewater and perspectives
      post-COVID-19.
PG  - 101947
LID - 10.1016/j.jwpe.2021.101947 [doi]
AB  - Currently, SARS-CoV-2 has been detected in the influent of wastewater treatment
      plants (WWTP), pumping stations, manholes, sewer networks and sludge of WWTP and 
      facilities of countries as France, Spain, Italy, Netherlands, United States,
      Australia, Ecuador, Brazil and Japan. Although this virus has been detected in
      the wastewater streams, there is no robust method for its detection and
      quantification in wastewater. This review compiled and analyzed the virus
      concentration approaches applied to detect the SARS-CoV-2, besides to provide
      insights about the methodology for viral concentration, limit of detection,
      occurrence, persistence, and perspectives post-COVID-19 related with the
      implications of the virus presence in wastewater. The SARS-COV-2 detection in
      wastewater has been related to virus concentration methods, which present
      different recovery rates of the virus. The most used viral concentration methods 
      have been the polyethylene glycol (PEG) for precipitation of viral material and
      the ultrafiltration at molecular weight level. After viral concentration, the
      detection and quantification of SARS-COV-2 in wastewater are mainly via
      quantitative reverse transcription polymerase chain reaction (RT-qPCR), which is 
      the clinical assay adapted for environmental purposes. Although in some
      experiments the positive control during RT-qPCR is running a surrogated virus
      (e.g., Mengovirus or Dengue virus), RT-qPCR or reverse transcription droplet
      digital PCR (RT-ddPCR) targeting the gene encoding nucleocapsid (N1, N2 and N3)
      of SARS-COV-2 are highly recommended to calculate the limit of detection in
      wastewater samples. Current results suggest that a rigorous methodology to
      elucidate the positive cases in a region from genomic copies in wastewater is
      needed.
CI  - (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Cervantes-Aviles, Pabel
AU  - Cervantes-Aviles P
AD  - Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Via Atlixcayotl 5718,
      Reserva Territorial Atlixcayotl, Puebla, Pue, CP 72453, Mexico.
FAU - Moreno-Andrade, Ivan
AU  - Moreno-Andrade I
AD  - Laboratory for Research on Advanced Processes for Water Treatment, Instituto de
      Ingenieria, Unidad Academica Juriquilla, Universidad Nacional Autonoma de Mexico,
      Blvd. Juriquilla 3001, Queretaro, CP 76230, Mexico.
FAU - Carrillo-Reyes, Julian
AU  - Carrillo-Reyes J
AD  - Laboratory for Research on Advanced Processes for Water Treatment, Instituto de
      Ingenieria, Unidad Academica Juriquilla, Universidad Nacional Autonoma de Mexico,
      Blvd. Juriquilla 3001, Queretaro, CP 76230, Mexico.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210129
PL  - Netherlands
TA  - J Water Process Eng
JT  - Journal of water process engineering
JID - 9918401088206676
PMC - PMC7846222
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Detection
OT  - Virus concentration
OT  - Wastewater treatment plant
OT  - Wastewater-based epidemiology
COIS- The authors report no declarations of interest.
EDAT- 2022/05/21 06:00
MHDA- 2022/05/21 06:01
CRDT- 2022/05/20 02:29
PHST- 2020/08/24 00:00 [received]
PHST- 2020/12/16 00:00 [revised]
PHST- 2021/01/26 00:00 [accepted]
PHST- 2022/05/20 02:29 [entrez]
PHST- 2022/05/21 06:00 [pubmed]
PHST- 2022/05/21 06:01 [medline]
AID - 10.1016/j.jwpe.2021.101947 [doi]
AID - S2214-7144(21)00034-9 [pii]
PST - ppublish
SO  - J Water Process Eng. 2021 Apr;40:101947. doi: 10.1016/j.jwpe.2021.101947. Epub
      2021 Jan 29.

PMID- 35585654
OWN - NLM
STAT- MEDLINE
DCOM- 20220715
LR  - 20220805
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 94
IP  - 9
DP  - 2022 Sep
TI  - Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma
      samples of COVID-19: A transversal surrogate in vitro study performed in
      Quito-Ecuador.
PG  - 4246-4252
LID - 10.1002/jmv.27866 [doi]
AB  - Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) infection, was first reported in Wuhan,
      China, in December 2019. Diagnostic methods for the detection of the virus and
      seroconversion of neutralizing antibodies (NAbs) in plasma have been developed
      specifically, but some of them require a BSL3 facility. In this study, we used
      the SARS-CoV-2 Surrogate Virus Neutralization Test Kit to determine the presence 
      or absence of NAbs anti-receptor binding domain of the viral spike (S)
      glycoprotein in a BSL2 facility. The sample population was chosen in Quito,
      Ecuador, with a total of 88 COVID-19 positive convalescent patients. We
      determined that 97.7% of the analyzed convalescent sera maintained the presence
      of NAbs with neutralizing activity, and this activity remained until 10 months
      after the infection in some cases. In addition, the relationship between the
      presence of NAbs and immunoglobulin G was significant compared to immunoglobulin 
      M, which tended to be absent over time.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Villacres-Granda, Boris
AU  - Villacres-Granda B
AUID- ORCID: http://orcid.org/0000-0001-8913-6366
AD  - Universidad Hemisferios, Quito, Ecuador.
FAU - Paz, Elius
AU  - Paz E
AUID- ORCID: http://orcid.org/0000-0003-0062-6030
AD  - Centro de Investigacion Genetica y Genomica - UTE, Quito, Ecuador.
FAU - Burbano, Maria Jose
AU  - Burbano MJ
AUID- ORCID: http://orcid.org/0000-0003-0497-6791
AD  - Universidad Hemisferios, Quito, Ecuador.
FAU - Villacres-Granda, Irina
AU  - Villacres-Granda I
AUID- ORCID: http://orcid.org/0000-0002-4503-6600
AD  - Escuela Internacional de Doctorado, Universidad de Sevilla, Sevilla, Espana.
FAU - Armijos, Daniela
AU  - Armijos D
AUID- ORCID: http://orcid.org/0000-0001-6869-3227
AD  - Universidad Hemisferios, Quito, Ecuador.
FAU - Aguirre, Mauricio
AU  - Aguirre M
AUID- ORCID: http://orcid.org/0000-0001-6597-9844
AD  - Universidad Hemisferios, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20220526
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - COVID-19 serotherapy
SB  - IM
MH  - Antibodies, Neutralizing
MH  - Antibodies, Viral
MH  - *COVID-19/diagnosis/therapy
MH  - Ecuador
MH  - Humans
MH  - Immunization, Passive
MH  - *SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus
PMC - PMC9347805
OTO - NOTNLM
OT  - IgG
OT  - IgM
OT  - SARS-CoV-2
OT  - convalescence
OT  - neutralizing antibodies
OT  - plasma
EDAT- 2022/05/19 06:00
MHDA- 2022/07/16 06:00
CRDT- 2022/05/18 23:47
PHST- 2022/04/26 00:00 [revised]
PHST- 2022/01/05 00:00 [received]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/05/19 06:00 [pubmed]
PHST- 2022/07/16 06:00 [medline]
PHST- 2022/05/18 23:47 [entrez]
AID - 10.1002/jmv.27866 [doi]
PST - ppublish
SO  - J Med Virol. 2022 Sep;94(9):4246-4252. doi: 10.1002/jmv.27866. Epub 2022 May 26.

PMID- 35550308
OWN - NLM
STAT- Publisher
LR  - 20220716
IS  - 1579-2129 (Electronic)
IS  - 0300-2896 (Linking)
DP  - 2022 Apr 27
TI  - Tuberculosis Reactivation After Severe SARS-COV-2 Pneumonia.
LID - S0300-2896(22)00323-4 [pii]
LID - 10.1016/j.arbres.2022.03.024 [doi]
FAU - Cardoso-Landivar, Jose
AU  - Cardoso-Landivar J
AD  - Universidad Catolica de Cuenca, Ecuador.
FAU - Jimenez-Fuentes, Maria-Angeles
AU  - Jimenez-Fuentes MA
AD  - Pneumology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
FAU - De Souza-Galvao, Maria-Luiza
AU  - De Souza-Galvao ML
AD  - Pneumology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
      Electronic address: msouza@vhebron.net.
LA  - eng
LA  - spa
PT  - Case Reports
DEP - 20220427
PL  - Spain
TA  - Arch Bronconeumol
JT  - Archivos de bronconeumologia
JID - 0354720
SB  - IM
PMC - PMC9045861
EDAT- 2022/05/14 06:00
MHDA- 2022/05/14 06:00
CRDT- 2022/05/13 12:35
PHST- 2022/03/09 00:00 [received]
PHST- 2022/03/14 00:00 [revised]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/05/13 12:35 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/14 06:00 [medline]
AID - S0300-2896(22)00323-4 [pii]
AID - 10.1016/j.arbres.2022.03.024 [doi]
PST - aheadofprint
SO  - Arch Bronconeumol. 2022 Apr 27. pii: S0300-2896(22)00323-4. doi:
      10.1016/j.arbres.2022.03.024.

PMID- 35544541
OWN - NLM
STAT- MEDLINE
LR  - 20220716
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 5
DP  - 2022
TI  - Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of
      care clinical application.
PG  - e0268340
LID - 10.1371/journal.pone.0268340 [doi]
AB  - Continued waves, new variants, and limited vaccine deployment mean that
      SARS-CoV-2 tests remain vital to constrain the coronavirus disease 2019
      (COVID-19) pandemic. Affordable, point-of-care (PoC) tests allow rapid screening 
      in non-medical settings. Reverse-transcription loop-mediated isothermal
      amplification (RT-LAMP) is an appealing approach. A crucial step is to optimize
      testing in low/medium resource settings. Here, we optimized RT-LAMP for
      SARS-CoV-2 and human beta-actin, and tested clinical samples in multiple
      countries. "TTTT" linker primers did not improve performance, and while guanidine
      hydrochloride, betaine and/or Igepal-CA-630 enhanced detection of synthetic RNA, 
      only the latter two improved direct assays on nasopharygeal samples. With
      extracted clinical RNA, a 20 min RT-LAMP assay was essentially as sensitive as
      RT-PCR. With raw Canadian nasopharygeal samples, sensitivity was 100% (95% CI:
      67.6% - 100%) for those with RT-qPCR Ct values </= 25, and 80% (95% CI: 58.4% -
      91.9%) for those with 25 < Ct </= 27.2. Highly infectious, high titer cases were 
      also detected in Colombian and Ecuadorian labs. We further demonstrate the
      utility of replacing thermocyclers with a portable PoC device (FluoroPLUM). These
      combined PoC molecular and hardware tools may help to limit community
      transmission of SARS-CoV-2.
FAU - Lu, Suying
AU  - Lu S
AD  - Lunenfeld Tanenbaum Research Institute, Mt Sinai Hospital, Sinai Health System,
      Toronto, ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON, Canada.
AD  - Department of Ophthalmology and Vision Science, University of Toronto, Toronto,
      ON, Canada.
FAU - Duplat, David
AU  - Duplat D
AUID- ORCID: 0000-0003-1054-5664
AD  - Centro de Investigaciones en Microbiologia y Parasitologia Tropical (CIMPAT),
      Department of Biological Sciences, Universidad de los Andes, Bogota, Colombia.
FAU - Benitez-Bolivar, Paula
AU  - Benitez-Bolivar P
AUID- ORCID: 0000-0002-1576-0403
AD  - Centro de Investigaciones en Microbiologia y Parasitologia Tropical (CIMPAT),
      Department of Biological Sciences, Universidad de los Andes, Bogota, Colombia.
FAU - Leon, Cielo
AU  - Leon C
AD  - Centro de Investigaciones en Microbiologia y Parasitologia Tropical (CIMPAT),
      Department of Biological Sciences, Universidad de los Andes, Bogota, Colombia.
FAU - Villota, Stephany D
AU  - Villota SD
AUID- ORCID: 0000-0002-3250-6589
AD  - Centro de Investigacion en Enfermedades Infecciosas y Vectoriales (CIREV),
      Instituto Nacional de Investigacion en Salud Publica, Quito, Ecuador.
FAU - Veloz-Villavicencio, Eliana
AU  - Veloz-Villavicencio E
AUID- ORCID: 0000-0003-2234-2055
AD  - Centro de Investigacion en Enfermedades Infecciosas y Vectoriales (CIREV),
      Instituto Nacional de Investigacion en Salud Publica, Quito, Ecuador.
FAU - Arevalo, Valentina
AU  - Arevalo V
AUID- ORCID: 0000-0002-0088-4200
AD  - Centro de Investigacion en Enfermedades Infecciosas y Vectoriales (CIREV),
      Instituto Nacional de Investigacion en Salud Publica, Quito, Ecuador.
FAU - Jaenes, Katariina
AU  - Jaenes K
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
FAU - Guo, Yuxiu
AU  - Guo Y
AD  - LSK Technologies Inc., Kitchener, Canada.
FAU - Cicek, Seray
AU  - Cicek S
AD  - LSK Technologies Inc., Kitchener, Canada.
FAU - Robinson, Lucas
AU  - Robinson L
AD  - Velocity, University of Waterloo, Kitchener, ON, Canada.
FAU - Peidis, Philippos
AU  - Peidis P
AD  - Lunenfeld Tanenbaum Research Institute, Mt Sinai Hospital, Sinai Health System,
      Toronto, ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON, Canada.
AD  - Department of Ophthalmology and Vision Science, University of Toronto, Toronto,
      ON, Canada.
FAU - Pearson, Joel D
AU  - Pearson JD
AD  - Lunenfeld Tanenbaum Research Institute, Mt Sinai Hospital, Sinai Health System,
      Toronto, ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON, Canada.
AD  - Department of Ophthalmology and Vision Science, University of Toronto, Toronto,
      ON, Canada.
FAU - Woodgett, Jim
AU  - Woodgett J
AUID- ORCID: 0000-0003-3731-5797
AD  - Lunenfeld Tanenbaum Research Institute, Mt Sinai Hospital, Sinai Health System,
      Toronto, ON, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, Canada.
FAU - Mazzulli, Tony
AU  - Mazzulli T
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON, Canada.
AD  - Department of Microbiology, Sinai Health System/University Health Network,
      Toronto, Canada.
FAU - Ponce, Patricio
AU  - Ponce P
AD  - Centro de Investigacion en Enfermedades Infecciosas y Vectoriales (CIREV),
      Instituto Nacional de Investigacion en Salud Publica, Quito, Ecuador.
FAU - Restrepo, Silvia
AU  - Restrepo S
AD  - Department of Food and Chemical Engineering, Universidad de los Andes, Bogota,
      Colombia.
FAU - Gonzalez, John M
AU  - Gonzalez JM
AD  - Grupo de Ciencias Basicas Medicas, School of Medicine, Universidad de los Andes, 
      Bogota, Colombia.
FAU - Bernal, Adriana
AU  - Bernal A
AD  - Laboratory of Molecular Interactions of Agricultural Microbes (LIMMA), Department
      of Biological Sciences, Universidad de Los Andes, Bogota, Colombia.
FAU - Guevara-Suarez, Marcela
AU  - Guevara-Suarez M
AD  - Applied genomics research group, Vicerrectoria de Investigacion y Creacion,
      Universidad de los Andes, Bogota, Colombia.
FAU - Pardee, Keith
AU  - Pardee K
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
AD  - LSK Technologies Inc., Kitchener, Canada.
AD  - Department of Mechanical and Industrial Engineering, University of Toronto,
      Toronto, ON, Canada.
FAU - Cevallos, Varsovia E
AU  - Cevallos VE
AD  - Centro de Investigacion en Enfermedades Infecciosas y Vectoriales (CIREV),
      Instituto Nacional de Investigacion en Salud Publica, Quito, Ecuador.
FAU - Gonzalez, Camila
AU  - Gonzalez C
AUID- ORCID: 0000-0001-8089-4056
AD  - Centro de Investigaciones en Microbiologia y Parasitologia Tropical (CIMPAT),
      Department of Biological Sciences, Universidad de los Andes, Bogota, Colombia.
FAU - Bremner, Rod
AU  - Bremner R
AUID- ORCID: 0000-0001-9184-7212
AD  - Lunenfeld Tanenbaum Research Institute, Mt Sinai Hospital, Sinai Health System,
      Toronto, ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON, Canada.
AD  - Department of Ophthalmology and Vision Science, University of Toronto, Toronto,
      ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220511
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (RNA, Viral)
RN  - LAMP assay
SB  - IM
MH  - *COVID-19/diagnosis
MH  - Canada
MH  - Humans
MH  - Molecular Diagnostic Techniques
MH  - Nucleic Acid Amplification Techniques
MH  - Point-of-Care Systems
MH  - RNA, Viral/analysis/genetics
MH  - *SARS-CoV-2/genetics
MH  - Sensitivity and Specificity
PMC - PMC9094544
COIS- I have read the journal's policy and the authors of this manuscript have the
      following competing interests: Y.G., S.C., and K.P. are co-inventors of the PLUM 
      reader and co-founders of LSK Technologies, Inc. No other commercial declarations
      are relevant to this study. This does not alter our adherence to PLOS ONE
      policies on sharing data and materials.
EDAT- 2022/05/12 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/05/11 13:45
PHST- 2022/02/22 00:00 [received]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2022/05/11 13:45 [entrez]
PHST- 2022/05/12 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
AID - 10.1371/journal.pone.0268340 [doi]
AID - PONE-D-22-05378 [pii]
PST - epublish
SO  - PLoS One. 2022 May 11;17(5):e0268340. doi: 10.1371/journal.pone.0268340.
      eCollection 2022.

PMID- 35502127
OWN - NLM
STAT- Publisher
LR  - 20220523
IS  - 2578-5826 (Electronic)
IS  - 2578-5826 (Linking)
DP  - 2022 May 2
TI  - Immunouniverse of SARS-CoV-2.
PG  - 1-39
LID - 10.1080/25785826.2022.2066251 [doi]
AB  - SARS-CoV-2 virus has become a global health problem that has caused millions of
      deaths worldwide. The infection can present with multiple clinical features
      ranging from asymptomatic or mildly symptomatic patients to patients with severe 
      or critical illness that can even lead to death. Although the immune system plays
      an important role in pathogen control, SARS-CoV-2 can drive dysregulation of this
      response and trigger severe immunopathology. Exploring the mechanisms of the
      immune response involved in host defense against SARS-CoV-2 allows us to
      understand its immunopathogenesis and possibly detect features that can be used
      as potential therapies to eliminate the virus. The main objective of this review 
      on SARS-CoV-2 is to highlight the interaction between the virus and the immune
      response. We explore the function and action of the immune system, the expression
      of molecules at the site of infection that cause hyperinflammation and
      hypercoagulation disorders, the factors leading to the development of pneumonia
      and subsequent severe acute respiratory distress syndrome which is the leading
      cause of death in patients with COVID-19.
FAU - Jimenez, Dennis
AU  - Jimenez D
AUID- ORCID: 0000-0001-8807-1695
AD  - Departamento de Ciencias de la Vida y Agricultura, Carrera de Ingenieria en
      Biotecnologia, Universidad de las Fuerzas Armadas ESPE, Sangolqui, Pichincha,
      Ecuador.
FAU - Torres Arias, Marbel
AU  - Torres Arias M
AUID- ORCID: 0000-0002-3902-5083
AD  - Departamento de Ciencias de la Vida y Agricultura, Carrera de Ingenieria en
      Biotecnologia, Universidad de las Fuerzas Armadas ESPE, Sangolqui, Pichincha,
      Ecuador.
AD  - Laboratorio de Inmunologia y Virologia, CENCINAT, GISAH, Universidad de las
      Fuerzas Armadas, Sangolqui, Pichincha, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220502
PL  - England
TA  - Immunol Med
JT  - Immunological medicine
JID - 101736847
SB  - IM
OTO - NOTNLM
OT  - Hyperinflammation
OT  - cytokines
OT  - hypercoagulation
OT  - immune response
EDAT- 2022/05/04 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/05/03 01:22
PHST- 2022/05/04 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
PHST- 2022/05/03 01:22 [entrez]
AID - 10.1080/25785826.2022.2066251 [doi]
PST - aheadofprint
SO  - Immunol Med. 2022 May 2:1-39. doi: 10.1080/25785826.2022.2066251.

PMID- 35417456
OWN - NLM
STAT- MEDLINE
DCOM- 20220427
LR  - 20220716
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Linking)
VI  - 16
IP  - 4
DP  - 2022 Apr
TI  - Analytical sensitivity and clinical performance of "COVID-19 RT-PCR Real TM FAST 
      (CY5) (ATGen, Uruguay) and "ECUGEN SARS-CoV-2 RT-qPCR" (UDLA-STARNEWCORP,
      Ecuador)": High quality-low cost local SARS-CoV-2 tests for South America.
PG  - e0010082
LID - 10.1371/journal.pntd.0010082 [doi]
AB  - BACKGROUND: Dozens of commercial RT-qPCR kits for SARS-CoV-2 detection are
      available with or without Emergency Use Authorization (EUA) by FDA or other
      regulatory agencies. OBJECTIVE: We evaluated the clinical performance of two
      SARS-CoV-2 RT-PCR kits designed and produced in South America, "COVID-19 RT-PCR
      Real TM FAST (CY5)" (ATGen, Uruguay) and "ECUGEN SARS-CoV-2 RT-qPCR"
      (UDLA-STARNEWCORP, Ecuador), for RT-qPCR SARS-CoV2 detection using "TaqMan
      2019-nCoV Assay Kit v1" (Thermofisher, USA) as a gold standard technique.
      RESULTS: We report a great clinical performance and analytical sensitivity for
      the two South American kits with sensitivity values of 96.4 and 100%, specificity
      of 100% and limit of detection in the range of 10 copies/uL of RNA extraction.
      CONCLUSIONS: "COVID-19 RT-PCR Real TM FAST (CY5)" and "ECUGEN SARS-CoV-2 RT-qPCR"
      kits are reliable SARS-CoV-2 tests made in South America that have been
      extensively used in Uruguay, Argentina, Brazil, Bolivia and Ecuador. These
      locally produced SARS-CoV-2 tests have contributed to overcome supply shortages
      and reduce diagnosis cost, while maintaining the high quality standards of FDA
      EUA commercially available kits. This approach could be extended for other
      diagnostic products to improve infectious diseases surveillance at middle and low
      income countries beyond COVID-19 pandemic.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AUID- ORCID: 0000-0003-2839-9941
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Morales-Jadan, Diana
AU  - Morales-Jadan D
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Zambrano-Mila, Marlon
AU  - Zambrano-Mila M
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Perez, Franklin
AU  - Perez F
AD  - OneLabt, Santa Elena, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AUID- ORCID: 0000-0003-0025-3609
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20220413
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Carbocyanines)
RN  - 0 (RNA, Viral)
RN  - 0 (cyanine dye 5)
SB  - IM
MH  - Brazil
MH  - *COVID-19/diagnosis
MH  - Carbocyanines
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Pandemics
MH  - RNA, Viral/analysis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *SARS-CoV-2/genetics
MH  - Sensitivity and Specificity
MH  - Uruguay
PMC - PMC9037941
COIS- I have read the journal's policy and the authors of this manuscript have the
      following competing interests: The authors of this study are employees of
      "Universidad de Las Americas". This institution is enrolled in the
      commercialization "ECUGEN SARS-CoV-2 RT-PCR kit", one of the kits evaluated on
      this study.
EDAT- 2022/04/14 06:00
MHDA- 2022/04/28 06:00
CRDT- 2022/04/13 17:12
PHST- 2021/06/07 00:00 [received]
PHST- 2021/12/07 00:00 [accepted]
PHST- 2022/04/25 00:00 [revised]
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2022/04/28 06:00 [medline]
PHST- 2022/04/13 17:12 [entrez]
AID - 10.1371/journal.pntd.0010082 [doi]
AID - PNTD-D-21-00840 [pii]
PST - epublish
SO  - PLoS Negl Trop Dis. 2022 Apr 13;16(4):e0010082. doi:
      10.1371/journal.pntd.0010082. eCollection 2022 Apr.

PMID- 35411129
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 0960-0779 (Print)
IS  - 0960-0779 (Linking)
VI  - 158
DP  - 2022 May
TI  - Forecasting of a complex phenomenon using stochastic data-based techniques under 
      non-conventional schemes: The SARS-CoV-2 virus spread case.
PG  - 112097
LID - 10.1016/j.chaos.2022.112097 [doi]
AB  - Epidemics are complex dynamical processes that are difficult to model. As
      revealed by the SARS-CoV-2 pandemic, the social behavior and policy decisions
      contribute to the rapidly changing behavior of the virus' spread during outbreaks
      and recessions. In practice, reliable forecasting estimations are needed,
      especially during early contagion stages when knowledge and data are insipient.
      When stochastic models are used to address the problem, it is necessary to
      consider new modeling strategies. Such strategies should aim to predict the
      different contagious phases and fast changes between recessions and outbreaks. At
      the same time, it is desirable to take advantage of existing modeling frameworks,
      knowledge and tools. In that line, we take Autoregressive models with exogenous
      variables (ARX) and Vector autoregressive (VAR) techniques as a basis. We then
      consider analogies with epidemic's differential equations to define the structure
      of the models. To predict recessions and outbreaks, the possibility of updating
      the model's parameters and stochastic structures is considered, providing
      non-stationarity properties and flexibility for accommodating the incoming data
      to the models. The Generalized-Random-Walk (GRW) and the
      State-Dependent-Parameter (SDP) techniques shape the parameters' variability. The
      stochastic structures are identified following the Akaike (AIC) criterion. The
      models use the daily rates of infected, death, and healed individuals, which are 
      the most common and accurate data retrieved in the early stages. Additionally,
      different experiments aim to explore the individual and complementary role of
      these variables. The results show that although both the ARX-based and VAR-based 
      techniques have good statistical accuracy for seven-day ahead predictions, some
      ARX models can anticipate outbreaks and recessions. We argue that short-time
      predictions for complex problems could be attained through stochastic models that
      mimic the fundamentals of dynamic equations, updating their parameters and
      structures according to incoming data.
CI  - (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Mendoza, Daniel E
AU  - Mendoza DE
AD  - Department of Civil Engineering, University of Cuenca, Av. 12 de Abril sn, CP:
      010112 Cuenca, Ecuador.
AD  - Faculty of Engineering, University of Cuenca, Av.12 de Abril sn, CP: 010112
      Cuenca, Ecuador.
FAU - Ochoa-Sanchez, Ana
AU  - Ochoa-Sanchez A
AD  - School of Environmental Engineering, Faculty of Science and Technology,
      University of Azuay, Cuenca, Ecuador.
AD  - TRACES, University of Azuay, Cuenca, Ecuador.
FAU - Samaniego, Esteban P
AU  - Samaniego EP
AD  - Faculty of Engineering, University of Cuenca, Av.12 de Abril sn, CP: 010112
      Cuenca, Ecuador.
AD  - Department of Water Resources and Environmental Sciences, University of Cuenca,
      Av. 12 de Abril sn, CP: 010151 Cuenca, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20220407
PL  - England
TA  - Chaos Solitons Fractals
JT  - Chaos, solitons, and fractals
JID - 100971564
PMC - PMC8986496
OTO - NOTNLM
OT  - Autoregressive-with-exogenous-variables
OT  - Differential-equations
OT  - Non-stationary
OT  - Outbreaks recessions
OT  - Vector-autoregressive
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/13 06:01
CRDT- 2022/04/12 05:30
PHST- 2021/10/12 00:00 [received]
PHST- 2022/03/31 00:00 [revised]
PHST- 2022/04/04 00:00 [accepted]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/13 06:01 [medline]
PHST- 2022/04/12 05:30 [entrez]
AID - 10.1016/j.chaos.2022.112097 [doi]
AID - S0960-0779(22)00307-1 [pii]
PST - ppublish
SO  - Chaos Solitons Fractals. 2022 May;158:112097. doi: 10.1016/j.chaos.2022.112097.
      Epub 2022 Apr 7.

PMID- 35402682
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2352-7714 (Print)
IS  - 2352-7714 (Linking)
VI  - 14
DP  - 2022 Jun
TI  - SARS-CoV-2 infection in free roaming dogs from the Amazonian jungle.
PG  - 100387
LID - 10.1016/j.onehlt.2022.100387 [doi]
AB  - During the ongoing COVID-19 pandemic, there were several reports of SARS-CoV-2
      transmission from human to animals, mostly to companion cats and dogs but also to
      free ranging wild species like minks and deers. Under this scenario, SARS-CoV-2
      surveillance in domestic animals to assess the risk of transmission between
      species have been suggested by the OIE. Here we present a case report of
      SARS-CoV-2 infection in free roaming dogs, found at a rural indigenous community 
      from the Ecuadorian Amazonia. Oral and nasal swabs samples were collected from
      three dogs found during a COVID-19 surveillance intervention in Amazonian
      indigenous communities where severe COVID-19 outbreaks were suspected. Total RNA 
      was extracted from dog samples and detection of SARS-CoV-2 gene targets N, ORF1ab
      and S was performed. The three dogs tested positive for at least two SARS-CoV-2
      viral targets. Moreover, there was a high SARS-CoV-2 infection rate of 87.2%
      within this community. Given that 17.1% of SARS-CoV-2 positive individuals had an
      ultra high load greater than 10(8) copies/ml, transmission from humans to dogs
      likely occurred. To our knowledge, this study is the first report of SARS-CoV-2
      positive free roaming dogs. Also, as those animals were found in the Amazonian
      forest, SARS-CoV-2 transmission to wild mammals is a potential concern. Given the
      high presence of free roaming dogs associated to rural and indigenous communities
      in South America, the potential role of these domestic animals on COVID-19 spread
      would deserve further surveillance studies involving SARS-CoV-2 detection by PCR 
      and molecular epidemiology based on genome sequencing to confirm human to dog
      transmission.
CI  - (c) 2022 The Authors.
FAU - Zambrano-Mila, Marlon Steven
AU  - Zambrano-Mila MS
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Orlando, Solon Alberto
AU  - Orlando SA
AD  - Instituto Nacional de Salud Publica e Investigacion Leopoldo Izquieta Perez,
      Guayaquil, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20220405
PL  - Netherlands
TA  - One Health
JT  - One health (Amsterdam, Netherlands)
JID - 101660501
PMC - PMC8979833
OTO - NOTNLM
OT  - Amazonia
OT  - Ecuador
OT  - Free roaming dogs
OT  - Reverse zoonosis
OT  - SARS-CoV-2
OT  - Zooanthroponosis
COIS- None.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
CRDT- 2022/04/11 05:32
PHST- 2021/11/02 00:00 [received]
PHST- 2022/03/23 00:00 [revised]
PHST- 2022/04/01 00:00 [accepted]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/04/11 05:32 [entrez]
AID - 10.1016/j.onehlt.2022.100387 [doi]
AID - S2352-7714(22)00019-2 [pii]
PST - ppublish
SO  - One Health. 2022 Jun;14:100387. doi: 10.1016/j.onehlt.2022.100387. Epub 2022 Apr 
      5.

PMID- 35308807
OWN - NLM
STAT- Publisher
LR  - 20220716
IS  - 1885-1398 (Electronic)
IS  - 1699-258X (Linking)
DP  - 2022 Mar 14
TI  - [Use Of Anakinra In The Treatment Of SARS-CoV-2 Severe Respiratory Infection].
LID - 10.1016/j.reuma.2022.02.003 [doi]
FAU - Figuero-Perez, Luis
AU  - Figuero-Perez L
AD  - Servicio de Oncologia Medica. Complejo Asitencial Universitario de Salamanca,
      Salamanca, Espana.
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Espana.
FAU - Olivares-Hernandez, Alejandro
AU  - Olivares-Hernandez A
AD  - Servicio de Oncologia Medica. Complejo Asitencial Universitario de Salamanca,
      Salamanca, Espana.
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Espana.
FAU - Escala-Cornejo, Roberto A
AU  - Escala-Cornejo RA
AD  - Instituto de Investigacion Nacional (SOLCA) de Guayaquil, Guayaquil, Ecuador.
FAU - Cruz-Hernandez, Juan J
AU  - Cruz-Hernandez JJ
AD  - Servicio de Oncologia Medica. Complejo Asitencial Universitario de Salamanca,
      Salamanca, Espana.
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Espana.
LA  - spa
PT  - Journal Article
TT  - Uso De Anakinra En El Tratamiento De La Infeccion Respiratoria Grave Por
      SARS-CoV-2.
DEP - 20220314
PL  - Spain
TA  - Reumatol Clin
JT  - Reumatologia clinica
JID - 101293923
PMC - PMC8919784
EDAT- 2022/03/22 06:00
MHDA- 2022/03/22 06:00
CRDT- 2022/03/21 08:43
PHST- 2022/02/01 00:00 [received]
PHST- 2022/03/21 08:43 [entrez]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
AID - 10.1016/j.reuma.2022.02.003 [doi]
AID - S1699-258X(22)00069-9 [pii]
PST - aheadofprint
SO  - Reumatol Clin. 2022 Mar 14. pii: S1699-258X(22)00069-9. doi:
      10.1016/j.reuma.2022.02.003.

PMID- 35295184
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220319
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - High SARS-CoV-2 Infection Rates Among Special Forces Police Units During the
      Early Phase of the COVID-19 Pandemic in Ecuador.
PG  - 735821
LID - 10.3389/fmed.2021.735821 [doi]
AB  - Background: At the beginning of the COVID-19 pandemic, health workers and
      first-responders, such as police officers, were in charge of trying to contain a 
      disease that was unknown at that time. The lack of information and the tremendous
      need to contain new outbreaks put police officers at higher risk. Methodology: A 
      cross-sectional study was conducted to describe SARS-CoV-2 infection rates among 
      Police Special Forces Officers in Quito, Ecuador. In this study, 163
      community-dwelling police officers from elite divisions voluntarily participated 
      in our SARS-CoV-2 detection program using reverse transcription quantitative
      real-time PCR (RT-qPCR). Results: A total of 20 out of 163 police officers tested
      positive for SARS-CoV-2, yielding an infection rate of 12.3%. Within this cohort,
      10% (2/20) of SARS-CoV-2 positive individuals were potentially super spreaders
      with viral loads over 10(8) copies/ul. About 85% of the SARS-CoV-2 positive
      individuals were asymptomatic and 15% reported mild symptoms related to COVID-19.
      Conclusions: We found a high SARS-CoV-2 infection rate within the special forces 
      police officers that, beyond a high health risk for themselves, their families,
      and coworkers. Our results point out the need for permanent SARS-CoV-2 testing
      among asymptomatic essential workers and first-responders to avoid local
      outbreaks and to prevent work-place absenteeism among police special units.
CI  - Copyright (c) 2022 Ortiz-Prado, Andrade, Vasconez, Escobar-Espinosa,
      Vallejo-Janeta, Freire-Paspuel, Coronel, Galvis, Morales-Jadan, Rivera-Olivero,
      Lozada, Henriquez-Trujillo, Garcia-Bereguiain and the UDLA-COVID-19 Team.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Andrade, Felipe
AU  - Andrade F
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Vasconez, Eduardo
AU  - Vasconez E
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Escobar-Espinosa, Cristina
AU  - Escobar-Espinosa C
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Vallejo-Janeta, Alexander Paolo
AU  - Vallejo-Janeta AP
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
AD  - Direccion General de Investigacion, Universidad de Las Americas, Quito, Ecuador.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - Direccion General de Investigacion, Universidad de Las Americas, Quito, Ecuador.
FAU - Coronel, Barbara
AU  - Coronel B
AD  - Direccion General de Investigacion, Universidad de Las Americas, Quito, Ecuador.
FAU - Galvis, Heberson
AU  - Galvis H
AD  - Direccion General de Investigacion, Universidad de Las Americas, Quito, Ecuador.
FAU - Morales-Jadan, Diana
AU  - Morales-Jadan D
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
AD  - Direccion General de Investigacion, Universidad de Las Americas, Quito, Ecuador.
FAU - Rivera-Olivero, Ismar A
AU  - Rivera-Olivero IA
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Lozada, Tannya
AU  - Lozada T
AD  - Direccion General de Investigacion, Universidad de Las Americas, Quito, Ecuador.
FAU - Henriquez-Trujillo, Aquiles R
AU  - Henriquez-Trujillo AR
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
CN  - UDLA-COVID-19 Team
LA  - eng
PT  - Journal Article
DEP - 20220228
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8918664
OTO - NOTNLM
OT  - Ecuador
OT  - RT-PCR
OT  - SARS-CoV-2
OT  - police
OT  - surveillance
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
IR  - Jaramillo T
FIR - Jaramillo, Tatiana
IR  - Gordon DS
FIR - Gordon, Daniela Santander
IR  - Iturralde GA
FIR - Iturralde, Gabriel Alfredo
IR  - Teran JA
FIR - Teran, Julio Alejandro
IR  - Vasquez KM
FIR - Vasquez, Karen Marcela
IR  - Rondal JD
FIR - Rondal, Jonathan Dario
IR  - Granda G
FIR - Granda, Genoveva
IR  - Santamaria AC
FIR - Santamaria, Ana Cecilia
IR  - Pino CL
FIR - Pino, Cynthia Lorena
IR  - Espinosa OL
FIR - Espinosa, Oscar Lenin
IR  - Buitron A
FIR - Buitron, Angie
IR  - Grisales DS
FIR - Grisales, David Sanchez
IR  - Jimenez KB
FIR - Jimenez, Karina Beatriz
IR  - Bastidas V
FIR - Bastidas, Vanessa
IR  - Aguilar DM
FIR - Aguilar, Dayana Marcela
IR  - Paredes IM
FIR - Paredes, Ines Maria
IR  - Bilvao CD
FIR - Bilvao, Christian David
IR  - Paredes-Espinosa MB
FIR - Paredes-Espinosa, Maria Belen
IR  - Rodriguez AS
FIR - Rodriguez, Angel S
IR  - Laglaguano JC
FIR - Laglaguano, Juan Carlos
IR  - Herrera H
FIR - Herrera, Henry
IR  - Espinosa PM
FIR - Espinosa, Pablo Marcelo
IR  - Galarraga EA
FIR - Galarraga, Edison Andres
IR  - Zambrano-Mila MS
FIR - Zambrano-Mila, Marlon Steven
IR  - Tito AM
FIR - Tito, Ana Maria
IR  - Zapata ND
FIR - Zapata, Nelson David
EDAT- 2022/03/18 06:00
MHDA- 2022/03/18 06:01
CRDT- 2022/03/17 05:06
PHST- 2021/07/03 00:00 [received]
PHST- 2021/12/15 00:00 [accepted]
PHST- 2022/03/17 05:06 [entrez]
PHST- 2022/03/18 06:00 [pubmed]
PHST- 2022/03/18 06:01 [medline]
AID - 10.3389/fmed.2021.735821 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Feb 28;8:735821. doi: 10.3389/fmed.2021.735821.
      eCollection 2021.

PMID- 35176774
OWN - NLM
STAT- Publisher
LR  - 20220401
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
DP  - 2022 Feb 18
TI  - Characterization of the immune resistance of SARS-CoV-2 Mu variant and the robust
      immunity induced by Mu infection.
LID - jiac053 [pii]
LID - 10.1093/infdis/jiac053 [doi]
AB  - We have recently revealed that the SARS-CoV-2 Mu variant shows a pronounced
      resistance to antibodies elicited by natural SARS-CoV-2 infection and
      vaccination. However, it remains unclear which mutations determine the resistance
      of SARS-CoV-2 Mu to antiviral sera. Also, it is unclear how SARS-CoV-2 Mu
      infection induces antiviral immunity. Here we reveal that the two mutations in
      the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the 
      resistance to COVID-19 convalescent sera during early 2020 and vaccine sera.
      Notably, the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly 
      antiviral against Mu as well as other SARS-CoV-2 variants of concern/interest.
CI  - (c) The Author(s) 2022. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Uriu, Keiya
AU  - Uriu K
AD  - Division of Systems Virology, Department of Infectious Disease Control,
      International Research Center for Infectious Diseases, The Institute of Medical
      Science, The University of Tokyo, Tokyo, Japan.
FAU - Cardenas, Paul
AU  - Cardenas P
AD  - Institute of Microbiology, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Munoz, Erika
AU  - Munoz E
AD  - Institute of Microbiology, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Barragan, Veronica
AU  - Barragan V
AD  - Institute of Microbiology, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Kosugi, Yusuke
AU  - Kosugi Y
AD  - Division of Systems Virology, Department of Infectious Disease Control,
      International Research Center for Infectious Diseases, The Institute of Medical
      Science, The University of Tokyo, Tokyo, Japan.
FAU - Shirakawa, Kotaro
AU  - Shirakawa K
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto
      University, Kyoto, Japan.
FAU - Takaori-Kondo, Akifumi
AU  - Takaori-Kondo A
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto
      University, Kyoto, Japan.
FAU - Sato, Kei
AU  - Sato K
AUID- ORCID: 0000-0003-4431-1380
AD  - Division of Systems Virology, Department of Infectious Disease Control,
      International Research Center for Infectious Diseases, The Institute of Medical
      Science, The University of Tokyo, Tokyo, Japan.
AD  - CREST, Japan Science and Technology Agency, Saitama, Japan.
CN  - Ecuador-COVID19 Consortium, The Genotype to Phenotype Japan (G2P-Japan)
      Consortium
LA  - eng
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20220218
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
SB  - IM
PMC - PMC8903444
OTO - NOTNLM
OT  - COVID-19
OT  - Mu variant
OT  - SARS-CoV-2
OT  - immune resistance
EDAT- 2022/02/18 06:00
MHDA- 2022/02/18 06:00
CRDT- 2022/02/17 20:18
PHST- 2021/12/20 00:00 [received]
PHST- 2022/02/17 20:18 [entrez]
PHST- 2022/02/18 06:00 [pubmed]
PHST- 2022/02/18 06:00 [medline]
AID - 6530359 [pii]
AID - 10.1093/infdis/jiac053 [doi]
PST - aheadofprint
SO  - J Infect Dis. 2022 Feb 18. pii: 6530359. doi: 10.1093/infdis/jiac053.

PMID- 35104837
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220715
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 603
IP  - 7902
DP  - 2022 Mar
TI  - Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
PG  - 706-714
LID - 10.1038/s41586-022-04474-x [doi]
AB  - The SARS-CoV-2 Omicron BA.1 variant emerged in 2021(1) and has multiple mutations
      in its spike protein(2). Here we show that the spike protein of Omicron has a
      higher affinity for ACE2 compared with Delta, and a marked change in its
      antigenicity increases Omicron's evasion of therapeutic monoclonal and
      vaccine-elicited polyclonal neutralizing antibodies after two doses. mRNA
      vaccination as a third vaccine dose rescues and broadens neutralization.
      Importantly, the antiviral drugs remdesivir and molnupiravir retain efficacy
      against Omicron BA.1. Replication was similar for Omicron and Delta virus
      isolates in human nasal epithelial cultures. However, in lung cells and gut
      cells, Omicron demonstrated lower replication. Omicron spike protein was less
      efficiently cleaved compared with Delta. The differences in replication were
      mapped to the entry efficiency of the virus on the basis of spike-pseudotyped
      virus assays. The defect in entry of Omicron pseudotyped virus to specific cell
      types effectively correlated with higher cellular RNA expression of TMPRSS2, and 
      deletion of TMPRSS2 affected Delta entry to a greater extent than Omicron.
      Furthermore, drug inhibitors targeting specific entry pathways(3) demonstrated
      that the Omicron spike inefficiently uses the cellular protease TMPRSS2, which
      promotes cell entry through plasma membrane fusion, with greater dependency on
      cell entry through the endocytic pathway. Consistent with suboptimal S1/S2
      cleavage and inability to use TMPRSS2, syncytium formation by the Omicron spike
      was substantially impaired compared with the Delta spike. The less efficient
      spike cleavage of Omicron at S1/S2 is associated with a shift in cellular tropism
      away from TMPRSS2-expressing cells, with implications for altered pathogenesis.
CI  - (c) 2022. The Author(s).
FAU - Meng, Bo
AU  - Meng B
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Abdullahi, Adam
AU  - Abdullahi A
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Ferreira, Isabella A T M
AU  - Ferreira IATM
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Goonawardane, Niluka
AU  - Goonawardane N
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Saito, Akatsuki
AU  - Saito A
AD  - Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki,
      Miyazaki, Japan.
FAU - Kimura, Izumi
AU  - Kimura I
AD  - Division of Systems Virology, Department of Infectious Disease Control,
      International Research Center for Infectious Diseases, The Institute of Medical
      Science, The University of Tokyo, Tokyo, Japan.
FAU - Yamasoba, Daichi
AU  - Yamasoba D
AD  - Division of Systems Virology, Department of Infectious Disease Control,
      International Research Center for Infectious Diseases, The Institute of Medical
      Science, The University of Tokyo, Tokyo, Japan.
FAU - Gerber, Pehuen Pereyra
AU  - Gerber PP
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Fatihi, Saman
AU  - Fatihi S
AD  - CSIR Institute of Genomics and Integrative Biology, Delhi, India.
FAU - Rathore, Surabhi
AU  - Rathore S
AD  - CSIR Institute of Genomics and Integrative Biology, Delhi, India.
FAU - Zepeda, Samantha K
AU  - Zepeda SK
AD  - Department of Biochemistry, University of Washington, Seattle, WA, USA.
FAU - Papa, Guido
AU  - Papa G
AD  - MRC-Laboratory of Molecular Biology, Cambridge, UK.
FAU - Kemp, Steven A
AU  - Kemp SA
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Ikeda, Terumasa
AU  - Ikeda T
AD  - Division of Molecular Virology and Genetics, Joint Research Center for Human
      Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
FAU - Toyoda, Mako
AU  - Toyoda M
AD  - Division of Infection and Immunity, Joint Research Center for Human Retrovirus
      Infection, Kumamoto University, Kumamoto, Japan.
FAU - Tan, Toong Seng
AU  - Tan TS
AD  - Division of Infection and Immunity, Joint Research Center for Human Retrovirus
      Infection, Kumamoto University, Kumamoto, Japan.
FAU - Kuramochi, Jin
AU  - Kuramochi J
AD  - Kuramochi Clinic Interpark, Utsunomiya, Japan.
FAU - Mitsunaga, Shigeki
AU  - Mitsunaga S
AD  - Human Genetics Laboratory, National Institute of Genetics, Mishima, Japan.
FAU - Ueno, Takamasa
AU  - Ueno T
AD  - Division of Infection and Immunity, Joint Research Center for Human Retrovirus
      Infection, Kumamoto University, Kumamoto, Japan.
FAU - Shirakawa, Kotaro
AU  - Shirakawa K
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto
      University, Kyoto, Japan.
FAU - Takaori-Kondo, Akifumi
AU  - Takaori-Kondo A
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto
      University, Kyoto, Japan.
FAU - Brevini, Teresa
AU  - Brevini T
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Mallery, Donna L
AU  - Mallery DL
AD  - MRC-Laboratory of Molecular Biology, Cambridge, UK.
FAU - Charles, Oscar J
AU  - Charles OJ
AD  - Division of Infection and Immunity, UCL, London, UK.
CN  - CITIID-NIHR BioResource COVID-19 Collaboration
CN  - Genotype to Phenotype Japan (G2P-Japan) Consortium
CN  - Ecuador-COVID19 Consortium
FAU - Bowen, John E
AU  - Bowen JE
AD  - Department of Biochemistry, University of Washington, Seattle, WA, USA.
FAU - Joshi, Anshu
AU  - Joshi A
AD  - Department of Biochemistry, University of Washington, Seattle, WA, USA.
FAU - Walls, Alexandra C
AU  - Walls AC
AD  - Department of Biochemistry, University of Washington, Seattle, WA, USA.
AD  - Department of Virology, University of Cambridge, Cambridge, UK.
FAU - Jackson, Laurelle
AU  - Jackson L
AD  - Africa Health Research Institute, Durban, South Africa.
FAU - Martin, Darren
AU  - Martin D
AD  - University of Cape Town, Cape Town, South Africa.
FAU - Smith, Kenneth G C
AU  - Smith KGC
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Bradley, John
AU  - Bradley J
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Briggs, John A G
AU  - Briggs JAG
AD  - Max Planck Institute of Biochemistry, Martinsried, Germany.
FAU - Choi, Jinwook
AU  - Choi J
AD  - Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
FAU - Madissoon, Elo
AU  - Madissoon E
AD  - Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute,
      EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, UK.
FAU - Meyer, Kerstin B
AU  - Meyer KB
AD  - Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
FAU - Mlcochova, Petra
AU  - Mlcochova P
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Ceron-Gutierrez, Lourdes
AU  - Ceron-Gutierrez L
AD  - Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge Biomedical Campus, Cambridge, UK.
FAU - Doffinger, Rainer
AU  - Doffinger R
AD  - Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge Biomedical Campus, Cambridge, UK.
FAU - Teichmann, Sarah A
AU  - Teichmann SA
AD  - Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
AD  - Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, 
      UK.
FAU - Fisher, Andrew J
AU  - Fisher AJ
AD  - Transplant and Regenerative Medicine Laboratory, Translational and Clinical
      Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle 
      Upon Tyne, UK.
FAU - Pizzuto, Matteo S
AU  - Pizzuto MS
AD  - Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
FAU - de Marco, Anna
AU  - de Marco A
AD  - Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
FAU - Corti, Davide
AU  - Corti D
AD  - Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
FAU - Hosmillo, Myra
AU  - Hosmillo M
AD  - Department of Virology, University of Cambridge, Cambridge, UK.
FAU - Lee, Joo Hyeon
AU  - Lee JH
AD  - Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge, UK.
FAU - James, Leo C
AU  - James LC
AD  - MRC-Laboratory of Molecular Biology, Cambridge, UK.
FAU - Thukral, Lipi
AU  - Thukral L
AD  - CSIR Institute of Genomics and Integrative Biology, Delhi, India.
FAU - Veesler, David
AU  - Veesler D
AD  - Department of Biochemistry, University of Washington, Seattle, WA, USA.
AD  - Howard Hughes Medical Institute, Seattle, WA, USA.
FAU - Sigal, Alex
AU  - Sigal A
AD  - Africa Health Research Institute, Durban, South Africa.
AD  - Max Planck Institute for Infection Biology, Berlin, Germany.
AD  - School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, 
      Durban, South Africa.
FAU - Sampaziotis, Fotios
AU  - Sampaziotis F
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
AD  - Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
AD  - Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge Biomedical Campus, Cambridge, UK.
FAU - Goodfellow, Ian G
AU  - Goodfellow IG
AD  - Department of Virology, University of Cambridge, Cambridge, UK.
FAU - Matheson, Nicholas J
AU  - Matheson NJ
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
AD  - Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge Biomedical Campus, Cambridge, UK.
AD  - NHS Blood and Transplant, Cambridge, UK.
FAU - Sato, Kei
AU  - Sato K
AD  - Division of Systems Virology, Department of Infectious Disease Control,
      International Research Center for Infectious Diseases, The Institute of Medical
      Science, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.
AD  - CREST, Japan Science and Technology Agency, Saitama, Japan.
      keisato@g.ecc.u-tokyo.ac.jp.
FAU - Gupta, Ravindra K
AU  - Gupta RK
AUID- ORCID: http://orcid.org/0000-0001-9751-1808
AD  - Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
      Cambridge, UK. rkg20@cam.ac.uk.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.
AD  - Africa Health Research Institute, Durban, South Africa. rkg20@cam.ac.uk.
LA  - eng
GR  - MC_PC_17230/MRC_/Medical Research Council/United Kingdom
GR  - DP1 AI158186/AI/NIAID NIH HHS/United States
GR  - 200594/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - MC_UP_1201/16/MRC_/Medical Research Council/United Kingdom
GR  - MR/P008801/1/MRC_/Medical Research Council/United Kingdom
GR  - HHSN272201700059C/AI/NIAID NIH HHS/United States
GR  - WT108082AIA/WT_/Wellcome Trust/United Kingdom
GR  - T32 GM008268/GM/NIGMS NIH HHS/United States
GR  - MC_U105181010/MRC_/Medical Research Council/United Kingdom
GR  - R01 AI138546/AI/NIAID NIH HHS/United States
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220201
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Immune Sera)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - EC 3.4.17.23 (ACE2 protein, human)
RN  - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
RN  - SARS-CoV-2 variants
SB  - IM
CIN - Signal Transduct Target Ther. 2022 May 7;7(1):151. PMID: 35525870
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme 2/metabolism
MH  - Animals
MH  - Antibodies, Neutralizing/immunology
MH  - Antibodies, Viral/immunology
MH  - COVID-19/immunology/*pathology/*virology
MH  - COVID-19 Vaccines/immunology
MH  - Cell Line
MH  - Cell Membrane/metabolism/virology
MH  - Chlorocebus aethiops
MH  - Convalescence
MH  - Female
MH  - Humans
MH  - Immune Sera/immunology
MH  - Intestines/pathology/virology
MH  - Lung/pathology/virology
MH  - Male
MH  - *Membrane Fusion
MH  - Middle Aged
MH  - Mutation
MH  - Nasal Mucosa/pathology/virology
MH  - SARS-CoV-2/drug effects/immunology/*metabolism/*pathogenicity
MH  - Serine Endopeptidases/*metabolism
MH  - Spike Glycoprotein, Coronavirus/genetics/metabolism
MH  - Tissue Culture Techniques
MH  - Virulence
MH  - *Virus Internalization
MH  - Virus Replication
PMC - PMC8942856
IR  - Baker S
FIR - Baker, Stephen
IR  - Dougan G
FIR - Dougan, Gordon
IR  - Hess C
FIR - Hess, Christoph
IR  - Kingston N
FIR - Kingston, Nathalie
IR  - Lehner PJ
FIR - Lehner, Paul J
IR  - Lyons PA
FIR - Lyons, Paul A
IR  - Matheson NJ
FIR - Matheson, Nicholas J
IR  - Ouwehand WH
FIR - Ouwehand, Willem H
IR  - Saunders C
FIR - Saunders, Caroline
IR  - Summers C
FIR - Summers, Charlotte
IR  - Thaventhiran JED
FIR - Thaventhiran, James E D
IR  - Toshner M
FIR - Toshner, Mark
IR  - Weekes MP
FIR - Weekes, Michael P
IR  - Maxwell P
FIR - Maxwell, Patrick
IR  - Shaw A
FIR - Shaw, Ashley
IR  - Bucke A
FIR - Bucke, Ashlea
IR  - Calder J
FIR - Calder, Jo
IR  - Canna L
FIR - Canna, Laura
IR  - Domingo J
FIR - Domingo, Jason
IR  - Elmer A
FIR - Elmer, Anne
IR  - Fuller S
FIR - Fuller, Stewart
IR  - Harris J
FIR - Harris, Julie
IR  - Hewitt S
FIR - Hewitt, Sarah
IR  - Kennet J
FIR - Kennet, Jane
IR  - Jose S
FIR - Jose, Sherly
IR  - Kourampa J
FIR - Kourampa, Jenny
IR  - Meadows A
FIR - Meadows, Anne
IR  - O'Brien C
FIR - O'Brien, Criona
IR  - Price J
FIR - Price, Jane
IR  - Publico C
FIR - Publico, Cherry
IR  - Rastall R
FIR - Rastall, Rebecca
IR  - Ribeiro C
FIR - Ribeiro, Carla
IR  - Rowlands J
FIR - Rowlands, Jane
IR  - Ruffolo V
FIR - Ruffolo, Valentina
IR  - Tordesillas H
FIR - Tordesillas, Hugo
IR  - Bullman B
FIR - Bullman, Ben
IR  - Dunmore BJ
FIR - Dunmore, Benjamin J
IR  - Graf S
FIR - Graf, Stefan
IR  - Hodgson J
FIR - Hodgson, Josh
IR  - Huang C
FIR - Huang, Christopher
IR  - Hunter K
FIR - Hunter, Kelvin
IR  - Jones E
FIR - Jones, Emma
IR  - Legchenko E
FIR - Legchenko, Ekaterina
IR  - Matara C
FIR - Matara, Cecilia
IR  - Martin J
FIR - Martin, Jennifer
IR  - Mescia F
FIR - Mescia, Federica
IR  - O'Donnell C
FIR - O'Donnell, Ciara
IR  - Pointon L
FIR - Pointon, Linda
IR  - Shih J
FIR - Shih, Joy
IR  - Sutcliffe R
FIR - Sutcliffe, Rachel
IR  - Tilly T
FIR - Tilly, Tobias
IR  - Treacy C
FIR - Treacy, Carmen
IR  - Tong Z
FIR - Tong, Zhen
IR  - Wood J
FIR - Wood, Jennifer
IR  - Wylot M
FIR - Wylot, Marta
IR  - Betancourt A
FIR - Betancourt, Ariana
IR  - Bower G
FIR - Bower, Georgie
IR  - Cossetti C
FIR - Cossetti, Chiara
IR  - De Sa A
FIR - De Sa, Aloka
IR  - Epping M
FIR - Epping, Madeline
IR  - Fawke S
FIR - Fawke, Stuart
IR  - Gleadall N
FIR - Gleadall, Nick
IR  - Grenfell R
FIR - Grenfell, Richard
IR  - Hinch A
FIR - Hinch, Andrew
IR  - Jackson S
FIR - Jackson, Sarah
IR  - Jarvis I
FIR - Jarvis, Isobel
IR  - Krishna B
FIR - Krishna, Ben
IR  - Nice F
FIR - Nice, Francesca
IR  - Omarjee O
FIR - Omarjee, Ommar
IR  - Perera M
FIR - Perera, Marianne
IR  - Potts M
FIR - Potts, Martin
IR  - Richoz N
FIR - Richoz, Nathan
IR  - Romashova V
FIR - Romashova, Veronika
IR  - Stefanucci L
FIR - Stefanucci, Luca
IR  - Strezlecki M
FIR - Strezlecki, Mateusz
IR  - Turner L
FIR - Turner, Lori
IR  - De Bie EMDD
FIR - De Bie, Eckart M D D
IR  - Bunclark K
FIR - Bunclark, Katherine
IR  - Josipovic M
FIR - Josipovic, Masa
IR  - Mackay M
FIR - Mackay, Michael
IR  - Butcher H
FIR - Butcher, Helen
IR  - Caputo D
FIR - Caputo, Daniela
IR  - Chandler M
FIR - Chandler, Matt
IR  - Chinnery P
FIR - Chinnery, Patrick
IR  - Clapham-Riley D
FIR - Clapham-Riley, Debbie
IR  - Dewhurst E
FIR - Dewhurst, Eleanor
IR  - Fernandez C
FIR - Fernandez, Christian
IR  - Furlong A
FIR - Furlong, Anita
IR  - Graves B
FIR - Graves, Barbara
IR  - Gray J
FIR - Gray, Jennifer
IR  - Hein S
FIR - Hein, Sabine
IR  - Ivers T
FIR - Ivers, Tasmin
IR  - Le Gresley E
FIR - Le Gresley, Emma
IR  - Linger R
FIR - Linger, Rachel
IR  - Kasanicki M
FIR - Kasanicki, Mary
IR  - King R
FIR - King, Rebecca
IR  - Kingston N
FIR - Kingston, Nathalie
IR  - Meloy S
FIR - Meloy, Sarah
IR  - Moulton A
FIR - Moulton, Alexei
IR  - Muldoon F
FIR - Muldoon, Francesca
IR  - Ovington N
FIR - Ovington, Nigel
IR  - Papadia S
FIR - Papadia, Sofia
IR  - Penkett CJ
FIR - Penkett, Christopher J
IR  - Phelan I
FIR - Phelan, Isabel
IR  - Ranganath V
FIR - Ranganath, Venkatesh
IR  - Paraschiv R
FIR - Paraschiv, Roxana
IR  - Sage A
FIR - Sage, Abigail
IR  - Sambrook J
FIR - Sambrook, Jennifer
IR  - Scholtes I
FIR - Scholtes, Ingrid
IR  - Schon K
FIR - Schon, Katherine
IR  - Stark H
FIR - Stark, Hannah
IR  - Stirrups KE
FIR - Stirrups, Kathleen E
IR  - Townsend P
FIR - Townsend, Paul
IR  - Walker N
FIR - Walker, Neil
IR  - Webster J
FIR - Webster, Jennifer
IR  - Butlertanaka EP
FIR - Butlertanaka, Erika P
IR  - Tanaka YL
FIR - Tanaka, Yuri L
IR  - Ito J
FIR - Ito, Jumpei
IR  - Uriu K
FIR - Uriu, Keiya
IR  - Kosugi Y
FIR - Kosugi, Yusuke
IR  - Suganami M
FIR - Suganami, Mai
IR  - Oide A
FIR - Oide, Akiko
IR  - Yokoyama M
FIR - Yokoyama, Miyabishara
IR  - Chiba M
FIR - Chiba, Mika
IR  - Motozono C
FIR - Motozono, Chihiro
IR  - Nasser H
FIR - Nasser, Hesham
IR  - Shimizu R
FIR - Shimizu, Ryo
IR  - Kitazato K
FIR - Kitazato, Kazuko
IR  - Hasebe H
FIR - Hasebe, Haruyo
IR  - Irie T
FIR - Irie, Takashi
IR  - Nakagawa S
FIR - Nakagawa, So
IR  - Wu J
FIR - Wu, Jiaqi
IR  - Takahashi M
FIR - Takahashi, Miyoko
IR  - Fukuhara T
FIR - Fukuhara, Takasuke
IR  - Shimizu K
FIR - Shimizu, Kenta
IR  - Tsushima K
FIR - Tsushima, Kana
IR  - Kubo H
FIR - Kubo, Haruko
IR  - Kazuma Y
FIR - Kazuma, Yasuhiro
IR  - Nomura R
FIR - Nomura, Ryosuke
IR  - Horisawa Y
FIR - Horisawa, Yoshihito
IR  - Nagata K
FIR - Nagata, Kayoko
IR  - Kawai Y
FIR - Kawai, Yugo
IR  - Yanagida Y
FIR - Yanagida, Yohei
IR  - Tashiro Y
FIR - Tashiro, Yusuke
IR  - Tokunaga K
FIR - Tokunaga, Kenzo
IR  - Ozono S
FIR - Ozono, Seiya
IR  - Kawabata R
FIR - Kawabata, Ryoko
IR  - Morizako N
FIR - Morizako, Nanami
IR  - Sadamasu K
FIR - Sadamasu, Kenji
IR  - Asakura H
FIR - Asakura, Hiroyuki
IR  - Nagashima M
FIR - Nagashima, Mami
IR  - Yoshimura K
FIR - Yoshimura, Kazuhisa
IR  - Cardenas P
FIR - Cardenas, Paul
IR  - Munoz E
FIR - Munoz, Erika
IR  - Barragan V
FIR - Barragan, Veronica
IR  - Marquez S
FIR - Marquez, Sully
IR  - Prado-Vivar B
FIR - Prado-Vivar, Belen
IR  - Becerra-Wong M
FIR - Becerra-Wong, Monica
IR  - Caravajal M
FIR - Caravajal, Mateo
IR  - Trueba G
FIR - Trueba, Gabriel
IR  - Rojas-Silva P
FIR - Rojas-Silva, Patricio
IR  - Grunauer M
FIR - Grunauer, Michelle
IR  - Gutierrez B
FIR - Gutierrez, Bernardo
IR  - Guadalupe JJ
FIR - Guadalupe, Juan Jose
IR  - Fernandez-Cadena JC
FIR - Fernandez-Cadena, Juan Carlos
IR  - Andrade-Molina D
FIR - Andrade-Molina, Derly
IR  - Baldeon M
FIR - Baldeon, Manuel
IR  - Pinos A
FIR - Pinos, Andrea
EDAT- 2022/02/02 06:00
MHDA- 2022/04/01 06:00
CRDT- 2022/02/01 20:12
PHST- 2021/12/21 00:00 [received]
PHST- 2022/01/26 00:00 [accepted]
PHST- 2022/02/02 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2022/02/01 20:12 [entrez]
AID - 10.1038/s41586-022-04474-x [doi]
AID - 10.1038/s41586-022-04474-x [pii]
PST - ppublish
SO  - Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022
      Feb 1.

PMID- 35077937
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20220218
IS  - 1879-0534 (Electronic)
IS  - 0010-4825 (Linking)
VI  - 142
DP  - 2022 Mar
TI  - Comparative study of SARS-CoV-2 infection in different cell types:
      Biophysical-computational approach to the role of potential receptors.
PG  - 105245
LID - S0010-4825(22)00037-3 [pii]
LID - 10.1016/j.compbiomed.2022.105245 [doi]
AB  - Cellular susceptibility to SARS-CoV-2 infection in the respiratory tract has been
      associated with the ability of the virus to interact with potential receptors on 
      the host membrane. We have modeled viral dynamics by simulating various cellular 
      systems and artificial conditions, including macromolecular crowding, based on
      experimental and transcriptomic data to infer parameters associated with viral
      growth and predict cell susceptibility. We have accomplished this based on the
      type, number and level of expression of the angiotensin-converting enzyme 2
      (ACE2), transmembrane serine 2 (TMPRSS2), basigin2 (CD147), FURIN protease,
      neuropilin 1 (NRP1) or other less studied candidate receptors such as heat shock 
      protein A5 (HSPA5) and angiotensin II receptor type 2 (AGTR2). In parallel, we
      studied the effect of simulated artificial environments on the accessibility to
      said proposed receptors. In addition, viral kinetic behavior dependent on the
      degree of cellular susceptibility was predicted. The latter was observed to be
      more influenced by the type of proteins and expression level, than by the number 
      of potential proteins associated with the SARS CoV-2 infection. We predict a
      greater theoretical propensity to susceptibility in cell lines such as NTERA-2,
      SCLC-21H, HepG2 and Vero6, and a lower theoretical propensity in lines such as
      CaLu3, RT4, HEK293, A549 and U-251MG. An important relationship was observed
      between expression levels, protein diffusivity, and thermodynamically favorable
      interactions between host proteins and the viral spike, suggesting potential
      sites of early infection other than the lungs. This research is expected to
      stimulate future quantitative experiments and promote systematic investigation of
      the effect of crowding presented here.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Gonzalez-Paz, Lenin
AU  - Gonzalez-Paz L
AD  - Universidad del Zulia (LUZ), Facultad Experimental de Ciencias (FEC),
      Departamento de Biologia, Laboratorio de Genetica y Biologia Molecular (LGBM),
      4001, Maracaibo, Venezuela; Instituto Venezolano de Investigaciones Cientificas
      (IVIC), Centro de Estudios Botanicos y Agroforestales (CEBA), Laboratorio de
      Proteccion Vegetal (LPV), 4001, Maracaibo, Venezuela. Electronic address:
      lgonzalezpaz@gmail.com.
FAU - Alvarado, Maria Jose
AU  - Alvarado MJ
AD  - Universidad del Zulia (LUZ), Facultad Experimental de Ciencias (FEC),
      Departamento de Biologia, Laboratorio de Genetica y Biologia Molecular (LGBM),
      4001, Maracaibo, Venezuela.
FAU - Hurtado-Leon, Maria Laura
AU  - Hurtado-Leon ML
AD  - Universidad del Zulia (LUZ), Facultad Experimental de Ciencias (FEC),
      Departamento de Biologia, Laboratorio de Genetica y Biologia Molecular (LGBM),
      4001, Maracaibo, Venezuela.
FAU - Lossada, Carla
AU  - Lossada C
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Centro de
      Investigacion y Tecnologia de Materiales (CITeMA), Laboratorio de Caracterizacion
      Molecular y Biomolecular, 4001, Maracaibo, Venezuela.
FAU - Vera-Villalobos, Joan
AU  - Vera-Villalobos J
AD  - Facultad de Ciencias Naturales y Matematicas, Departamento de Quimica y Ciencias 
      Ambientales, Laboratorio de Analisis Quimico Instrumental (LAQUINS), Escuela
      Superior Politecnica del Litoral, Guayaquil, Ecuador.
FAU - Lorono, Marcos
AU  - Lorono M
AD  - Departamento Academico de Quimica Analitica e Instrumental, Facultad de Quimica e
      Ingenieria Quimica, Universidad Nacional Mayor de San Marcos, Lima, Peru.
FAU - Paz, J L
AU  - Paz JL
AD  - Departamento Academico de Quimica Inorganica, Facultad de Quimica e Ingenieria
      Quimica, Universidad Nacional Mayor de San Marcos, Lima, Peru.
FAU - Jeffreys, Laura N
AU  - Jeffreys LN
AD  - Centre for Drugs and Diagnostics, Department of Tropical Disease Biology,
      Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
FAU - Torres, F Javier
AU  - Torres FJ
AD  - Grupo de Quimica Computacional y Teorica (QCT-UR), Facultad de Ciencias Natuales,
      Universidad del Rosario, Bogota, Colombia; Grupo de Quimica Computacional y
      Teorica (QCT-USFQ), Instituto de Simulacion Computacional (ISC-USFQ),
      Departamento de Ingenieria Quimica, Universidad San Francisco de Quito (USFQ),
      Qutio, Ecuador.
FAU - Alvarado, Ysaias J
AU  - Alvarado YJ
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Centro de
      Investigacion y Tecnologia de Materiales (CITeMA), Laboratorio de Caracterizacion
      Molecular y Biomolecular, 4001, Maracaibo, Venezuela. Electronic address:
      alvaradoysaias@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220120
PL  - United States
TA  - Comput Biol Med
JT  - Computers in biology and medicine
JID - 1250250
SB  - IM
MH  - *COVID-19
MH  - HEK293 Cells
MH  - Humans
MH  - SARS-CoV-2
MH  - Virus Internalization
PMC - PMC8770263
OTO - NOTNLM
OT  - *Cell lines
OT  - *Cell susceptibility
OT  - *Docking
OT  - *Macromolecular crowding
OT  - *Viral spike
EDAT- 2022/01/26 06:00
MHDA- 2022/02/17 06:00
CRDT- 2022/01/25 20:13
PHST- 2021/12/14 00:00 [received]
PHST- 2022/01/07 00:00 [revised]
PHST- 2022/01/16 00:00 [accepted]
PHST- 2022/01/26 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
PHST- 2022/01/25 20:13 [entrez]
AID - S0010-4825(22)00037-3 [pii]
AID - 10.1016/j.compbiomed.2022.105245 [doi]
PST - ppublish
SO  - Comput Biol Med. 2022 Mar;142:105245. doi: 10.1016/j.compbiomed.2022.105245. Epub
      2022 Jan 20.

PMID- 35068245
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220130
IS  - 2150-1327 (Electronic)
IS  - 2150-1319 (Linking)
VI  - 13
DP  - 2022 Jan-Dec
TI  - Risk for Subsequent SARS-CoV-2 Infection and Severe COVID-19 Among
      Community-Dwellers With Pre-Existing Cervicocephalic Atherosclerosis: A
      Population-Based Study.
PG  - 21501319211070685
LID - 10.1177/21501319211070685 [doi]
AB  - BACKGROUND: COVID-19 patients may develop atherosclerosis-related complications. 
      Whether a proportion of these patients already had asymptomatic cervicocephalic
      atherosclerosis before SARS-CoV-2 infection is not known. This study assessed
      whether pre-existing cervicocephalic atherosclerosis increased the susceptibility
      to SARS-CoV-2 infection or resulted in more severe or fatal COVID-19. METHODS:
      Individuals enrolled in the Atahualpa Project cohort who received head CT (for
      assessing carotid siphon calcifications) and B-mode ultrasounds (for measurement 
      of the carotid intima-media thickness) prior to the pandemic were eligible for
      this study. Among this cohort, those who also received serological tests for
      detection of SARS-CoV-2 antibodies and clinical evaluations for assessment of
      COVID-19 severity were enrolled. Multivariate logistic regression and
      exposure-effect models were fitted to assess the association between pre-existing
      atherosclerosis biomarkers, and SARS-CoV-2 seropositivity and COVID-19 severity. 
      RESULTS: Overall, 154 of 519 study participants (30%) had evidence of
      cervicocephalic atherosclerosis. A total of 325 (63%) individuals became
      SARS-CoV-2 positive, and 65 (23.5%) of seropositive individuals had severe or
      fatal COVID-19. The risk of SARS-CoV-2 seropositive status did not differ across 
      individuals with and without atherosclerosis biomarkers (P = .360). Likewise,
      seropositive individuals with pre-existing atherosclerosis were not more prone to
      develop severe or fatal COVID-19 than those without evidence of atherosclerosis
      (P = .274). Average estimated exposure effects of pre-existing cervicocephalic
      atherosclerosis versus no atherosclerosis over SARS-CoV-2 seropositivity and
      COVID-19 severity were not significant. CONCLUSIONS: Pre-existing cervicocephalic
      atherosclerosis does not increase the risk of acquiring SARS-CoV-2 infection nor 
      the severity of COVID-19 among seropositive individuals.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - Universidad Espiritu Santo-Ecuador, Samborondon, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Freenome, Inc., South San Francisco, CA, USA.
FAU - Del Brutto, Victor J
AU  - Del Brutto VJ
AD  - University of Miami Miller School of Medicine, Miami, FL, USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - The Atahualpa Project, Atahualpa, Ecuador.
FAU - Rumbea, Denisse A
AU  - Rumbea DA
AUID- ORCID: 0000-0001-8257-7572
AD  - The Atahualpa Project, Atahualpa, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Hospital Universitario Reina Sofia, Cordoba, Spain.
FAU - Sedler, Mark J
AU  - Sedler MJ
AD  - Stony Brook University, New York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Prim Care Community Health
JT  - Journal of primary care & community health
JID - 101518419
SB  - IM
MH  - *Atherosclerosis/epidemiology/etiology
MH  - *COVID-19
MH  - Carotid Intima-Media Thickness
MH  - Cohort Studies
MH  - Humans
MH  - SARS-CoV-2
PMC - PMC8796101
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *cervicocephalic atherosclerosis
OT  - *population-based study
OT  - *risk factors
EDAT- 2022/01/25 06:00
MHDA- 2022/01/28 06:00
CRDT- 2022/01/24 08:45
PHST- 2022/01/24 08:45 [entrez]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
AID - 10.1177/21501319211070685 [doi]
PST - ppublish
SO  - J Prim Care Community Health. 2022 Jan-Dec;13:21501319211070685. doi:
      10.1177/21501319211070685.

PMID- 35066369
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20220503
IS  - 1873-5150 (Electronic)
IS  - 0887-8994 (Linking)
VI  - 128
DP  - 2022 Mar
TI  - Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children
      Diagnosed with Acute SARS-CoV-2 or MIS-C.
PG  - 33-44
LID - S0887-8994(21)00276-9 [pii]
LID - 10.1016/j.pediatrneurol.2021.12.010 [doi]
AB  - BACKGROUND: Our objective was to characterize the frequency, early impact, and
      risk factors for neurological manifestations in hospitalized children with acute 
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or
      multisystem inflammatory syndrome in children (MIS-C). METHODS: Multicenter,
      cross-sectional study of neurological manifestations in children aged <18 years
      hospitalized with positive SARS-CoV-2 test or clinical diagnosis of a
      SARS-CoV-2-related condition between January 2020 and April 2021. Multivariable
      logistic regression to identify risk factors for neurological manifestations was 
      performed. RESULTS: Of 1493 children, 1278 (86%) were diagnosed with acute
      SARS-CoV-2 and 215 (14%) with MIS-C. Overall, 44% of the cohort (40% acute
      SARS-CoV-2 and 66% MIS-C) had at least one neurological manifestation. The most
      common neurological findings in children with acute SARS-CoV-2 and MIS-C
      diagnosis were headache (16% and 47%) and acute encephalopathy (15% and 22%),
      both P < 0.05. Children with neurological manifestations were more likely to
      require intensive care unit (ICU) care (51% vs 22%), P < 0.001. In multivariable 
      logistic regression, children with neurological manifestations were older (odds
      ratio [OR] 1.1 and 95% confidence interval [CI] 1.07 to 1.13) and more likely to 
      have MIS-C versus acute SARS-CoV-2 (OR 2.16, 95% CI 1.45 to 3.24), pre-existing
      neurological and metabolic conditions (OR 3.48, 95% CI 2.37 to 5.15; and OR 1.65,
      95% CI 1.04 to 2.66, respectively), and pharyngeal (OR 1.74, 95% CI 1.16 to 2.64)
      or abdominal pain (OR 1.43, 95% CI 1.03 to 2.00); all P < 0.05. CONCLUSIONS: In
      this multicenter study, 44% of children hospitalized with SARS-CoV-2-related
      conditions experienced neurological manifestations, which were associated with
      ICU admission and pre-existing neurological condition. Posthospital assessment
      for, and support of, functional impairment and neuroprotective strategies are
      vitally needed.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Fink, Ericka L
AU  - Fink EL
AD  - Division of Pediatric Critical Care Medicine, Department of Critical Care
      Medicine, Pittsburgh, Pennsylvania; Safar Center for Resuscitation Research, UPMC
      Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: 
      finkel@ccm.upmc.edu.
FAU - Robertson, Courtney L
AU  - Robertson CL
AD  - Departments of Anesthesiology and Critical Care Medicine, and Pediatrics of The
      Johns Hopkins University SOM, Baltimore, Maryland.
FAU - Wainwright, Mark S
AU  - Wainwright MS
AD  - Division of Pediatric Neurology, University of Washington, Seattle Children's
      Hospital, Seattle, Washington.
FAU - Roa, Juan D
AU  - Roa JD
AD  - Department of Pediatrics, Universidad Nacional de Colombia and Fundacion
      Universitaria de Ciencias de la Salud, Bogota, Colombia.
FAU - Lovett, Marlina E
AU  - Lovett ME
AD  - Division of Critical Care Medicine, Department of Pediatrics, Nationwide
      Children's Hospital, The Ohio State University, Columbus, Ohio.
FAU - Stulce, Casey
AU  - Stulce C
AD  - Department of Pediatrics, University of Chicago, Chicago, Illinois.
FAU - Yacoub, Mais
AU  - Yacoub M
AD  - Division of Critical Care, Department of Pediatrics, UMC Children's Hospital, Las
      Vegas, Nevada.
FAU - Potera, Renee M
AU  - Potera RM
AD  - Department of Pediatrics, University of Texas Southwestern Medical Center,
      Dallas, Texas.
FAU - Zivick, Elizabeth
AU  - Zivick E
AD  - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Medical
      University of South Carolina, Charleston, South Carolina.
FAU - Holloway, Adrian
AU  - Holloway A
AD  - Division of Critical Care, Department of Pediatrics, University of Maryland
      Medical Center, Baltimore, Maryland.
FAU - Nagpal, Ashish
AU  - Nagpal A
AD  - Department of Pediatrics, Section of Critical Care Medicine, Oklahoma Children's 
      Hospital at OU health, Oklahoma University College of Medicine, Oklahoma City,
      Oklahoma.
FAU - Wellnitz, Kari
AU  - Wellnitz K
AD  - Division of Pediatric Critical Care, Department of Pediatrics, University of Iowa
      Carver College of Medicine, Iowa City, Iowa.
FAU - Czech, Theresa
AU  - Czech T
AD  - Division of Pediatric Neurology, Department of Pediatrics, University of Iowa
      Carver College of Medicine, Iowa City, Iowa.
FAU - Even, Katelyn M
AU  - Even KM
AD  - Division of Pediatric Critical Care Medicine, Penn State College of Medicine,
      Hershey, Pennsylvania.
FAU - Brunow de Carvalho, Werther
AU  - Brunow de Carvalho W
AD  - Department of Pediatrics, University of Sao Paulo, Sao Paulo, Brazil.
FAU - Rodriguez, Isadora Souza
AU  - Rodriguez IS
AD  - Department of Pediatrics, University of Sao Paulo, Sao Paulo, Brazil.
FAU - Schwartz, Stephanie P
AU  - Schwartz SP
AD  - Department of Pediatrics, University of North Carolina at Chapel Hill Hospitals, 
      Chapel Hill, North Carolina.
FAU - Walker, Tracie C
AU  - Walker TC
AD  - Department of Pediatrics, University of North Carolina at Chapel Hill Hospitals, 
      Chapel Hill, North Carolina.
FAU - Campos-Mino, Santiago
AU  - Campos-Mino S
AD  - Pediatric Intensive Care Unit, Hospital Metropolitano, Quito, Ecuador.
FAU - Dervan, Leslie A
AU  - Dervan LA
AD  - Division of Pediatric Critical Care Medicine, Department of Pediatrics,
      University of Washington School of Medicine, Seattle, Washington.
FAU - Geneslaw, Andrew S
AU  - Geneslaw AS
AD  - Division of Pediatric Critical Care and Hospital Medicine, Department of
      Pediatrics, Columbia University Irving Medical Center, New York, New York.
FAU - Sewell, Taylor B
AU  - Sewell TB
AD  - Division of Pediatric Critical Care and Hospital Medicine, Department of
      Pediatrics, Columbia University Irving Medical Center, New York, New York.
FAU - Pryce, Patrice
AU  - Pryce P
AD  - Division of Pediatric Critical Care and Hospital Medicine, Department of
      Pediatrics, Columbia University Irving Medical Center, Morgan Stanley Children's 
      Hospital New York-Presbyterian Hospital, New York, New York.
FAU - Silver, Wendy G
AU  - Silver WG
AD  - Division of Child Neurology, Department of Neurology, Columbia University Irving 
      Medical Center, New York, New York.
FAU - Lin, Jieru Egeria
AU  - Lin JE
AD  - Division of Child Neurology, Department of Neurology, Columbia University Irving 
      Medical Center, New York, New York.
FAU - Vargas, Wendy S
AU  - Vargas WS
AD  - Division of Child Neurology, Department of Neurology, Columbia University Irving 
      Medical Center, New York, New York.
FAU - Topjian, Alexis
AU  - Topjian A
AD  - Division of Critical Care Medicine at The Children's Hospital of Philadelphia,
      Philadelphia, Pennsylvania; Departments of Anesthesiology and Critical Care
      Medicine and Pediatrics, University of Pennsylvania Perelman School of Medicine, 
      Philadelphia, Pennsylvania.
FAU - Alcamo, Alicia M
AU  - Alcamo AM
AD  - Division of Critical Care Medicine at The Children's Hospital of Philadelphia,
      Philadelphia, Pennsylvania; Departments of Anesthesiology and Critical Care
      Medicine and Pediatrics, University of Pennsylvania Perelman School of Medicine, 
      Philadelphia, Pennsylvania.
FAU - McGuire, Jennifer L
AU  - McGuire JL
AD  - Division of Neurology at The Children's Hospital of Philadelphia, Philadelphia,
      Pennsylvania; Departments of Neurology and Pediatrics, Perelman School of
      Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Dominguez Rojas, Jesus Angel
AU  - Dominguez Rojas JA
AD  - Division of Pediatric Critical Care, Department of Pediatrics, Hospital de
      Emergencia Villa El Salvador, Lima, Peru.
FAU - Munoz, Jaime Tasayco
AU  - Munoz JT
AD  - Division of Pediatric Critical Care, Department of Pediatrics, Hospital de
      Emergencia Villa El Salvador, Lima, Peru.
FAU - Hong, Sue J
AU  - Hong SJ
AD  - Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago
      and Northwestern University Feinberg School of Medicine, Chicago, Illinois.
FAU - Muller, William J
AU  - Muller WJ
AD  - Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago
      and Northwestern University Feinberg School of Medicine, Chicago, Illinois.
FAU - Doerfler, Matthew
AU  - Doerfler M
AD  - Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago
      and Northwestern University Feinberg School of Medicine, Chicago, Illinois.
FAU - Williams, Cydni N
AU  - Williams CN
AD  - Division of Pediatric Critical Care, Department of Pediatrics Pediatric Critical 
      Care and Neurotrauma Recovery Program Portland, Oregon Health & Science
      University, Oregon.
FAU - Drury, Kurt
AU  - Drury K
AD  - Division of Pediatric Critical Care, Department of Pediatrics, Oregon Health &
      Science University, Portland, Oregon.
FAU - Bhagat, Dhristie
AU  - Bhagat D
AD  - Department of Neurology, NYU Langone Health, New York, New York.
FAU - Nelson, Aaron
AU  - Nelson A
AD  - Department of Neurology, NYU Langone Health, New York, New York.
FAU - Price, Dana
AU  - Price D
AD  - Department of Neurology, NYU Langone Health, New York, New York.
FAU - Dapul, Heda
AU  - Dapul H
AD  - Division of Pediatric Critical Care, Department of Pediatrics, Hassenfeld
      Children's Hospital at NYU Langone Health, New York, New York.
FAU - Santos, Laura
AU  - Santos L
AD  - Division of Pediatric Critical Care, Department of Pediatrics, Hassenfeld
      Children's Hospital at NYU Langone Health, New York, New York.
FAU - Kahoud, Robert
AU  - Kahoud R
AD  - Division of Pediatric Critical Care Medicine, Department of Pediatric and
      Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
FAU - Francoeur, Conall
AU  - Francoeur C
AD  - Department of Pediatrics, CHU de Quebec - Universite Laval Research Center,
      Quebec City, Quebec, Canada.
FAU - Appavu, Brian
AU  - Appavu B
AD  - Division of Neurology, Barrow Neurological Institute at Phoenix Children's
      Hospital, University of Arizona, College of Medicine, Phoenix, Arizona.
FAU - Guilliams, Kristin P
AU  - Guilliams KP
AD  - Departments of Neurology, Pediatrics, and Radiology, Washington University in St.
      Louis, St. Louis, Missouri.
FAU - Agner, Shannon C
AU  - Agner SC
AD  - Departments of Neurology, Pediatrics, and Radiology, Washington University in St.
      Louis, St. Louis, Missouri.
FAU - Walson, Karen H
AU  - Walson KH
AD  - Department of Pediatric Critical Care Medicine, Children's Healthcare of Atlanta,
      Atlanta, Georgia.
FAU - Rasmussen, Lindsey
AU  - Rasmussen L
AD  - Pediatric Critical Care Medicine, Lucile Packard Children's Hospital, Stanford
      University, Stanford, California.
FAU - Janas, Anna
AU  - Janas A
AD  - Pediatric Critical Care Medicine, Lucile Packard Children's Hospital, Stanford
      University, Stanford, California.
FAU - Ferrazzano, Peter
AU  - Ferrazzano P
AD  - Department of Pediatrics, University of Wisconsin, Madison, Wisconsin.
FAU - Farias-Moeller, Raquel
AU  - Farias-Moeller R
AD  - Division Child Neurology, Department of Neurology, Medical College of Wisconsin, 
      Children's Wisconsin, Milwaukee, Wisconsin.
FAU - Snooks, Kellie C
AU  - Snooks KC
AD  - Department of Pediatrics, Medical College of Wisconsin, Children's Wisconsin,
      Milwaukee, Wisconsin.
FAU - Chang, Chung-Chou H
AU  - Chang CH
AD  - Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh,
      Pennsylvania.
FAU - Yun, James
AU  - Yun J
AD  - Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh,
      Pennsylvania.
FAU - Schober, Michelle E
AU  - Schober ME
AD  - Division of Critical Care of the University of Utah, Department of Pediatrics,
      Salt Lake City, Utah.
CN  - Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID)
      Investigators
LA  - eng
GR  - K23 HL150229/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
DEP - 20211228
PL  - United States
TA  - Pediatr Neurol
JT  - Pediatric neurology
JID - 8508183
RN  - pediatric multisystem inflammatory disease, COVID-19 related
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Brain Diseases/epidemiology/etiology
MH  - COVID-19/*complications/epidemiology
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Headache/epidemiology/etiology
MH  - Humans
MH  - Infant
MH  - Intensive Care Units, Pediatric/statistics & numerical data
MH  - Logistic Models
MH  - Male
MH  - Nervous System Diseases/*epidemiology/etiology
MH  - Prevalence
MH  - Risk Factors
MH  - *SARS-CoV-2
MH  - South America/epidemiology
MH  - Systemic Inflammatory Response Syndrome/*epidemiology
MH  - United States/epidemiology
PMC - PMC8713420
OTO - NOTNLM
OT  - *Child development
OT  - *Neurological manifestations
OT  - *Pediatrics
OT  - *SARS-CoV-2
EDAT- 2022/01/24 06:00
MHDA- 2022/03/01 06:00
CRDT- 2022/01/23 20:34
PHST- 2021/11/19 00:00 [received]
PHST- 2021/12/20 00:00 [revised]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2022/01/24 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
PHST- 2022/01/23 20:34 [entrez]
AID - S0887-8994(21)00276-9 [pii]
AID - 10.1016/j.pediatrneurol.2021.12.010 [doi]
PST - ppublish
SO  - Pediatr Neurol. 2022 Mar;128:33-44. doi: 10.1016/j.pediatrneurol.2021.12.010.
      Epub 2021 Dec 28.

PMID- 35062223
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR  - 20220203
IS  - 1999-4915 (Electronic)
IS  - 1999-4915 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Dec 23
TI  - Presence of SARS-CoV-2 RNA on Surfaces of Public Places and a Transportation
      System Located in a Densely Populated Urban Area in South America.
LID - 19 [pii]
LID - 10.3390/v14010019 [doi]
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly
      transmissible RNA virus that causes COVID-19. Being aware of the presence of the 
      virus on different types of surfaces and in different environments, and having a 
      protocol for its detection, is important to understand the dynamics of the virus 
      and its shedding patterns. In Ecuador, the detection of viral RNA in urban
      environmental samples has not been a priority. The present study analyzed samples
      from two densely populated neighborhoods and one public transportation system in 
      Quito, Ecuador. Viral RNA presence was assessed using RT-LAMP. Twenty-eight out
      of 300 surfaces tested positive for SARS-CoV-2 RNA (9.33%). Frequently touched
      surfaces, especially in indoor spaces and on public transportation, were most
      likely to be positive for viral RNA. Positivity rate association for the two
      neighborhoods and for the surface type was not found. This study found viral RNA 
      presence on urban surfaces; this information provides an insight into viral
      dissemination dynamics. Monitoring environmental SARS-CoV-2 could support the
      public health prevention strategies in Quito, Ecuador.
FAU - Guadalupe, Juan Jose
AU  - Guadalupe JJ
AUID- ORCID: 0000-0003-1228-3688
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito (USFQ), 
      Diego de Robles y Via Interoceanica s/n, Quito 170157, Ecuador.
FAU - Rojas, Maria I
AU  - Rojas MI
AUID- ORCID: 0000-0003-4685-1487
AD  - Biology Department, San Diego State University, San Diego, CA 92182, USA.
AD  - Viral Information Institute, San Diego State University, San Diego, CA 92182,
      USA.
FAU - Pozo, Gabriela
AU  - Pozo G
AUID- ORCID: 0000-0001-8760-2060
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito (USFQ), 
      Diego de Robles y Via Interoceanica s/n, Quito 170157, Ecuador.
FAU - Erazo-Garcia, Maria P
AU  - Erazo-Garcia MP
AUID- ORCID: 0000-0002-0626-7166
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito (USFQ), 
      Diego de Robles y Via Interoceanica s/n, Quito 170157, Ecuador.
FAU - Vega-Polo, Pamela
AU  - Vega-Polo P
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito (USFQ), 
      Diego de Robles y Via Interoceanica s/n, Quito 170157, Ecuador.
FAU - Teran-Velastegui, Martin
AU  - Teran-Velastegui M
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito (USFQ), 
      Diego de Robles y Via Interoceanica s/n, Quito 170157, Ecuador.
FAU - Rohwer, Forest
AU  - Rohwer F
AD  - Biology Department, San Diego State University, San Diego, CA 92182, USA.
AD  - Viral Information Institute, San Diego State University, San Diego, CA 92182,
      USA.
FAU - Torres, Maria de Lourdes
AU  - Torres ML
AUID- ORCID: 0000-0001-7207-4568
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito (USFQ), 
      Diego de Robles y Via Interoceanica s/n, Quito 170157, Ecuador.
LA  - eng
GR  - Fondos COCIBA/Universidad San Francisco de Quito
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211223
PL  - Switzerland
TA  - Viruses
JT  - Viruses
JID - 101509722
RN  - 0 (RNA, Viral)
RN  - LAMP assay
SB  - IM
MH  - COVID-19/transmission
MH  - Cities
MH  - Ecuador
MH  - *Environmental Microbiology
MH  - Humans
MH  - Molecular Diagnostic Techniques
MH  - Nucleic Acid Amplification Techniques
MH  - RNA, Viral/genetics/*isolation & purification
MH  - SARS-CoV-2/genetics/*isolation & purification
MH  - *Transportation
PMC - PMC8780916
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2 RNA
OT  - *coronavirus
OT  - *environmental virus
EDAT- 2022/01/23 06:00
MHDA- 2022/02/04 06:00
CRDT- 2022/01/22 01:01
PHST- 2021/11/22 00:00 [received]
PHST- 2021/12/12 00:00 [revised]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2022/01/22 01:01 [entrez]
PHST- 2022/01/23 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
AID - v14010019 [pii]
AID - 10.3390/v14010019 [doi]
PST - epublish
SO  - Viruses. 2021 Dec 23;14(1). pii: v14010019. doi: 10.3390/v14010019.

PMID- 35039802
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 2590-0498 (Electronic)
IS  - 2590-0498 (Linking)
VI  - 13
DP  - 2022 Mar
TI  - Potentialities of graphene and its allied derivatives to combat against
      SARS-CoV-2 infection.
PG  - 100208
LID - 10.1016/j.mtadv.2022.100208 [doi]
AB  - Graphene is a two-dimensional material with sp2 hybridization that has found its 
      broad-spectrum potentialities in various domains like electronics, robotics,
      aeronautics, etc.; it has recently gained its utilities in the biomedical domain.
      The unique properties of graphene and its derivatives of graphene have helped
      them find their utilities in the biomedical domain. Additionally, the sudden
      outbreak of SARS-CoV-2 has immensely expanded the research field, which has also 
      benefitted graphene and its derivatives. Currently, the world is facing a global 
      pandemic due to the sudden outbreak of Severe Acute Respiratory Syndrome
      Coronavirus-2 (SARS-CoV-2), also known as COVID-19, from its major onset in Wuhan
      city, China, in December 2019. Presently, many new variants and mutants appear,
      which is more harmful than previous strains. However, researchers and scientists 
      are focused on understanding the target structure of coronavirus, mechanism,
      causes and transmission mode, treatment, and alternatives to cure these diseases 
      in this critical pandemic situation; many findings are achieved, but much more is
      unknown and pending to be explored. This review paper is dedicated to exploring
      the utilities of graphene and its derivatives in combating the SARS-CoV-2 by
      highlighting their mechanism and applications in the fabrication of biosensors,
      personal protection equipment (PPE) kits, 3-D printing, and antiviral coatings.
      Further, the paper also covers the cytotoxicity caused by graphene and its
      derivatives and highlights the graphene-based derivatives market aspects in
      biomedical domains. Thus, graphene and graphene-derived materials are our new
      hope in this pandemic time, and this review helps acquire broad knowledge about
      them.
CI  - (c) 2022 The Authors.
FAU - Hashmi, Ayesha
AU  - Hashmi A
AD  - Department of Chemistry, Govt. V. Y. T. PG. Autonomous College, Durg,
      Chhattisgarh, 491001, India.
FAU - Nayak, Vanya
AU  - Nayak V
AD  - Department of Chemistry, Institute of Science, Banaras Hindu University,
      Varanasi, Uttar Pradesh, 221005, India.
AD  - Department of Biotechnology, Indira Gandhi National Tribal University,
      Amarkantak, Madhya Pradesh, 484887, India.
FAU - Singh, Kshitij Rb
AU  - Singh KR
AD  - Department of Chemistry, Govt. V. Y. T. PG. Autonomous College, Durg,
      Chhattisgarh, 491001, India.
AD  - Department of Chemistry, Institute of Science, Banaras Hindu University,
      Varanasi, Uttar Pradesh, 221005, India.
FAU - Jain, Bhawana
AU  - Jain B
AD  - Department of Chemistry, Govt. V. Y. T. PG. Autonomous College, Durg,
      Chhattisgarh, 491001, India.
FAU - Baid, Mitisha
AU  - Baid M
AD  - Department of Chemistry, Govt. V. Y. T. PG. Autonomous College, Durg,
      Chhattisgarh, 491001, India.
FAU - Alexis, Frank
AU  - Alexis F
AD  - Department of Chemical Engineering, Universidad de San Francisco de Quito, Quito,
      107910, Ecuador.
FAU - Singh, Ajaya Kumar
AU  - Singh AK
AD  - Department of Chemistry, Govt. V. Y. T. PG. Autonomous College, Durg,
      Chhattisgarh, 491001, India.
LA  - eng
PT  - Journal Article
DEP - 20220113
PL  - England
TA  - Mater Today Adv
JT  - Materials today. Advances
JID - 101771735
PMC - PMC8755454
OTO - NOTNLM
OT  - Applications
OT  - COVID-19 pandemic
OT  - Cytotoxicity
OT  - Graphene oxide (GO)
OT  - Graphene-based derivatives
OT  - Nanotechnology
OT  - SARS-CoV-2
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2022/01/19 06:00
MHDA- 2022/01/19 06:01
CRDT- 2022/01/18 06:02
PHST- 2021/09/09 00:00 [received]
PHST- 2021/12/05 00:00 [revised]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/01/19 06:00 [pubmed]
PHST- 2022/01/19 06:01 [medline]
PHST- 2022/01/18 06:02 [entrez]
AID - 10.1016/j.mtadv.2022.100208 [doi]
AID - S2590-0498(22)00004-2 [pii]
PST - ppublish
SO  - Mater Today Adv. 2022 Mar;13:100208. doi: 10.1016/j.mtadv.2022.100208. Epub 2022 
      Jan 13.

PMID- 35018222
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220405
IS  - 2052-2975 (Print)
IS  - 2052-2975 (Linking)
VI  - 45
DP  - 2022 Jan
TI  - First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador.
PG  - 100951
LID - 10.1016/j.nmni.2022.100951 [doi]
AB  - The National Institute of Research and Public Health reported the first local
      record of the Omicron variant detected in Ecuador. A fully vaccinated subject
      returned from South Africa with a negative RT-PCR. We present the cumulative
      frequency of the variants in Ecuador and a phylogenetic analysis of this new
      Omicron.
CI  - (c) 2022 The Authors.
FAU - Carrazco-Montalvo, A
AU  - Carrazco-Montalvo A
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
FAU - Armendariz-Castillo, I
AU  - Armendariz-Castillo I
AD  - Coordinacion Zonal 9, Instituto Nacional de Investigacion en Salud Publica
      "Leopoldo Izquieta Perez", Quito, Ecuador.
FAU - Tello, C L
AU  - Tello CL
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
FAU - Morales, D
AU  - Morales D
AD  - Centro de Referencia Nacional de Influenza y Otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
FAU - Armas-Gonzalez, R
AU  - Armas-Gonzalez R
AD  - Centro de Referencia Nacional de Influenza y Otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
FAU - Guizado-Herrera, D
AU  - Guizado-Herrera D
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
FAU - Leon-Sosa, A
AU  - Leon-Sosa A
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
FAU - Ramos-Sarmiento, D
AU  - Ramos-Sarmiento D
AD  - Centro de Referencia Nacional de Influenza y Otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
FAU - Fuertes, B
AU  - Fuertes B
AD  - Centro de Referencia Nacional de Influenza y Otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
CN  - USFQ-Consortium
FAU - Patino, L
AU  - Patino L
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
LA  - eng
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
PT  - Case Reports
DEP - 20220107
PL  - England
TA  - New Microbes New Infect
JT  - New microbes and new infections
JID - 101624750
PMC - PMC8739794
OTO - NOTNLM
OT  - COVID-19
OT  - Omicron
OT  - SARS-CoV-2
OT  - genomics
OT  - variant of concern
IR  - Cardenas P
FIR - Cardenas, P
IR  - Marquez S
FIR - Marquez, S
IR  - Prado-Vivar B
FIR - Prado-Vivar, B
IR  - Guadalupe JJ
FIR - Guadalupe, J J
IR  - Gutierrez B
FIR - Gutierrez, B
IR  - Wong MB
FIR - Wong, M B
IR  - Grunauer M
FIR - Grunauer, M
IR  - Trueba G
FIR - Trueba, G
IR  - Rojas-Silva P
FIR - Rojas-Silva, P
IR  - Barragan V
FIR - Barragan, V
EDAT- 2022/01/13 06:00
MHDA- 2022/01/13 06:01
CRDT- 2022/01/12 06:32
PHST- 2021/12/29 00:00 [received]
PHST- 2022/01/04 00:00 [accepted]
PHST- 2022/01/13 06:00 [pubmed]
PHST- 2022/01/13 06:01 [medline]
PHST- 2022/01/12 06:32 [entrez]
AID - 10.1016/j.nmni.2022.100951 [doi]
AID - S2052-2975(22)00003-8 [pii]
PST - ppublish
SO  - New Microbes New Infect. 2022 Jan;45:100951. doi: 10.1016/j.nmni.2022.100951.
      Epub 2022 Jan 7.

PMID- 34960145
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211231
IS  - 2076-393X (Print)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 12
DP  - 2021 Nov 26
TI  - Major Complex Trait for Early De Novo Programming 'CoV-MAC-TED' Detected in Human
      Nasal Epithelial Cells Infected by Two SARS-CoV-2 Variants Is Promising to Help
      in Designing Therapeutic Strategies.
LID - 1399 [pii]
LID - 10.3390/vaccines9121399 [doi]
AB  - BACKGROUND: Early metabolic reorganization was only recently recognized as an
      essentially integrated part of immunology. In this context, unbalanced ROS/RNS
      levels connected to increased aerobic fermentation, which is linked to
      alpha-tubulin-based cell restructuring and control of cell cycle progression,
      were identified as a major complex trait for early de novo programming
      ('CoV-MAC-TED') during SARS-CoV-2 infection. This trait was highlighted as a
      critical target for developing early anti-viral/anti-SARS-CoV-2 strategies. To
      obtain this result, analyses had been performed on transcriptome data from
      diverse experimental cell systems. A call was released for wide data collection
      of the defined set of genes for transcriptome analyses, named 'ReprogVirus',
      which should be based on strictly standardized protocols and data entry from
      diverse virus types and variants into the 'ReprogVirus Platform'. This platform
      is currently under development. However, so far, an in vitro cell system from
      primary target cells for virus attacks that could ideally serve for standardizing
      the data collection of early SARS-CoV-2 infection responses has not been defined.
      RESULTS: Here, we demonstrate transcriptome-level profiles of the most critical
      'ReprogVirus' gene sets for identifying 'CoV-MAC-TED' in cultured human nasal
      epithelial cells infected by two SARS-CoV-2 variants differing in disease
      severity. Our results (a) validate 'Cov-MAC-TED' as a crucial trait for early
      SARS-CoV-2 reprogramming for the tested virus variants and (b) demonstrate its
      relevance in cultured human nasal epithelial cells. CONCLUSION: In vitro-cultured
      human nasal epithelial cells proved to be appropriate for standardized
      transcriptome data collection in the 'ReprogVirus Platform'. Thus, this cell
      system is highly promising to advance integrative data analyses with the help of 
      artificial intelligence methodologies for designing anti-SARS-CoV-2 strategies.
FAU - Costa, Jose Helio
AU  - Costa JH
AUID- ORCID: 0000-0001-7914-0150
AD  - Functional Genomics and Bioinformatics Group, Department of Biochemistry and
      Molecular Biology, Federal University of Ceara, Fortaleza 60451-970, Brazil.
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), Coordinated from Foros de Vale de Figueira,
      7050-704 Montemor-o-Novo, Portugal.
FAU - Aziz, Shahid
AU  - Aziz S
AUID- ORCID: 0000-0002-4657-1066
AD  - Functional Genomics and Bioinformatics Group, Department of Biochemistry and
      Molecular Biology, Federal University of Ceara, Fortaleza 60451-970, Brazil.
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), Coordinated from Foros de Vale de Figueira,
      7050-704 Montemor-o-Novo, Portugal.
FAU - Noceda, Carlos
AU  - Noceda C
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), Coordinated from Foros de Vale de Figueira,
      7050-704 Montemor-o-Novo, Portugal.
AD  - Plant Molecular and Cellular Biotechnology/Industrial Biotechnology and
      Bioproducts, Department of Life and Agricultural Sciences, Universidad de las
      Fuerzas Armadas-ESPE, Quito 171103, Ecuador.
FAU - Arnholdt-Schmitt, Birgit
AU  - Arnholdt-Schmitt B
AD  - Functional Genomics and Bioinformatics Group, Department of Biochemistry and
      Molecular Biology, Federal University of Ceara, Fortaleza 60451-970, Brazil.
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), Coordinated from Foros de Vale de Figueira,
      7050-704 Montemor-o-Novo, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20211126
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8708361
OTO - NOTNLM
OT  - ADH5
OT  - E2F1
OT  - SARS-CoV-2 RdRp
OT  - SARS-CoV-2 helicase
OT  - SARS-CoV-2 Delta382
OT  - anti-viral diagnosis and strategies
OT  - cell cycle
OT  - immunology paradigm shift
OT  - melatonin
OT  - microbiota
OT  - repurposing drugs
EDAT- 2021/12/29 06:00
MHDA- 2021/12/29 06:01
CRDT- 2021/12/28 01:05
PHST- 2021/09/15 00:00 [received]
PHST- 2021/11/15 00:00 [revised]
PHST- 2021/11/22 00:00 [accepted]
PHST- 2021/12/28 01:05 [entrez]
PHST- 2021/12/29 06:00 [pubmed]
PHST- 2021/12/29 06:01 [medline]
AID - vaccines9121399 [pii]
AID - 10.3390/vaccines9121399 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 Nov 26;9(12). pii: vaccines9121399. doi:
      10.3390/vaccines9121399.

PMID- 34913151
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220716
IS  - 1672-0415 (Print)
IS  - 1672-0415 (Linking)
VI  - 28
IP  - 3
DP  - 2022 Mar
TI  - In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2
      Using Molecular Docking Simulation.
PG  - 249-256
LID - 10.1007/s11655-021-3504-5 [doi]
AB  - OBJECTIVE: To explore potential natural products against severe acute respiratory
      syndrome coronavirus (SARS-CoV-2) via the study of structural and non-structural 
      proteins of human coronaviruses. METHODS: In this study, we performed an
      in-silico survey of 25 potential natural compounds acting against SARS-CoV-2.
      Molecular docking studies were carried out using compounds against
      3-chymotrypsin-like protease (3CL(PRO)), papain-like protease (PL(PRO)),
      RNA-dependent RNA polymerase (RdRp), non-structural protein (nsp), human
      angiotensin converting enzyme 2 receptor (hACE2R), spike glycoprotein (S
      protein), abelson murine leukemia viral oncogene homolog 1 (ABL1),
      calcineurin-nuclear factor of activated T-cells (NFAT) and transmembrane protease
      serine 2. RESULTS: Among the screened compounds, amentoflavone showed the best
      binding affinity with the 3CL(PRO), RdRp, nsp13, nsp15, hACE2R. ABL1 and
      calcineurin-NFAT; berbamine with hACE2R and ABL1; cepharanthine with nsp10,
      nsp14, nsp16, S protein and ABL1; glucogallin with nsp15; and papyriflavonol A
      with PL(PRO) protein. Other good interacting compounds were juglanin, betulinic
      acid, betulonic acid, broussooflavan A, tomentin A, B and E,
      7-methoxycryptopleurine, aloe emodin, quercetin, tanshinone I, tylophorine and
      furruginol, which also showed excellent binding affinity towards a number of
      target proteins. Most of these compounds showed better binding affinities towards
      the target proteins than the standard drugs used in this study. CONCLUSION:
      Natural products or their derivatives may be one of the potential targets to
      fight against SARS-CoV-2.
CI  - (c) 2021. The Chinese Journal of Integrated Traditional and Western Medicine
      Press and Springer-Verlag GmbH Germany, part of Springer Nature.
FAU - Hossain, Rajib
AU  - Hossain R
AD  - Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman
      Science and Technology University, Gopalganj, 8100, Bangladesh.
FAU - Sarkar, Chandan
AU  - Sarkar C
AD  - Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman
      Science and Technology University, Gopalganj, 8100, Bangladesh.
FAU - Hassan, Shardar Mohammad Hafiz
AU  - Hassan SMH
AD  - Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman
      Science and Technology University, Gopalganj, 8100, Bangladesh.
FAU - Khan, Rasel Ahmed
AU  - Khan RA
AD  - Harmacy Discipline, Life Science School, Khulna University, Khulna, 9280,
      Bangladesh.
FAU - Arman, Mohammad
AU  - Arman M
AD  - Department of Pharmacy, International Islamic University, Chittagong, Bangladesh.
FAU - Ray, Pranta
AU  - Ray P
AD  - Department of Biomedical Engineering, Huazhong University of Science and
      Technology, Wuhan, 430074, China.
FAU - Islam, Muhammad Torequl
AU  - Islam MT
AD  - Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman
      Science and Technology University, Gopalganj, 8100, Bangladesh.
FAU - Dastan, Sevgi Durna
AU  - Dastan SD
AD  - Department of Biology, Faculty of Science, Sivas Cumhuriyet University, Sivas,
      58140, Turkey.
AD  - Beekeeping Development Application and Research Center, Sivas Cumhuriyet
      University, Sivas, 58140, Turkey.
FAU - Sharifi-Rad, Javad
AU  - Sharifi-Rad J
AD  - School of Medicine, University of Azuay, Cuenca, Ecuador.
      javad.sharifirad@gmail.com.
FAU - Almarhoon, Zainab M
AU  - Almarhoon ZM
AD  - Department of Chemistry, College of Science, King Saud University, Riyadh, 11451,
      Saudi Arabia.
FAU - Martorell, Miquel
AU  - Martorell M
AD  - Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for
      Healthy Living, University of Concepcion, Concepcion, 4070386, Chile.
FAU - Setzer, William N
AU  - Setzer WN
AD  - Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL,
      35899, USA.
AD  - Aromatic Plant Research Center, 230 N 1200 E, Suite 100, Lehi, UT, 84043, USA.
FAU - Calina, Daniela
AU  - Calina D
AD  - Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 
      Craiova, 200349, Romania.
LA  - eng
PT  - Journal Article
DEP - 20211215
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - 0 (Antiviral Agents)
RN  - 0 (Biological Products)
SB  - IM
MH  - Animals
MH  - Antiviral Agents/pharmacology/therapeutic use
MH  - *Biological Products/pharmacology
MH  - *COVID-19/drug therapy
MH  - Humans
MH  - Mice
MH  - Molecular Docking Simulation
MH  - SARS-CoV-2
PMC - PMC8672856
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - molecular docking
OT  - natural products-derived anti-SARS-CoV-2 candidates
OT  - nonstructural proteins
OT  - structural proteins
EDAT- 2021/12/17 06:00
MHDA- 2022/03/04 06:00
CRDT- 2021/12/16 06:42
PHST- 2021/01/13 00:00 [accepted]
PHST- 2021/12/17 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2021/12/16 06:42 [entrez]
AID - 10.1007/s11655-021-3504-5 [doi]
AID - 10.1007/s11655-021-3504-5 [pii]
PST - ppublish
SO  - Chin J Integr Med. 2022 Mar;28(3):249-256. doi: 10.1007/s11655-021-3504-5. Epub
      2021 Dec 15.

PMID- 34908852
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211216
IS  - 1178-6973 (Print)
IS  - 1178-6973 (Linking)
VI  - 14
DP  - 2021
TI  - First Report of SARS-CoV-2 Lineage B.1.1.7 (Alpha Variant) in Ecuador, January
      2021.
PG  - 5183-5188
LID - 10.2147/IDR.S319439 [doi]
AB  - On January 5 2021, Ecuadorian COVID-19 genomic surveillance program detected a
      suspicious case of the B.1.1.7 lineage (alpha variant) of SARS-CoV-2 in Los Rios 
      province, later confirmed by genome sequencing. The patient travelled from the UK
      by the end of December 2020. By contact tracing, several new cases were detected 
      confirming B.1.1.7 transmission and spreading in Ecuador.
CI  - (c) 2021 Carrazco-Montalvo et al.
FAU - Carrazco-Montalvo, Andres
AU  - Carrazco-Montalvo A
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
FAU - Bruno, Alfredo
AU  - Bruno A
AD  - Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
AD  - Universidad Agraria del Ecuador, Guayaquil, Ecuador.
FAU - de Mora, Domenica
AU  - de Mora D
AD  - Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
FAU - Olmedo, Maritza
AU  - Olmedo M
AD  - Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
FAU - Garces, Jimmy
AU  - Garces J
AD  - Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
FAU - Paez, Michelle
AU  - Paez M
AD  - Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Instituto
      Nacional de Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, 
      Ecuador.
FAU - Regato-Arrata, Mary
AU  - Regato-Arrata M
AD  - Centro de Referencia Nacional de Virus Exantematicos, Gastroentericos y
      Transmitidos por Vectores, Instituto Nacional de Investigacion en Salud Publica
      "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
FAU - Gonzalez, Manuel
AU  - Gonzalez M
AD  - Centro de Referencia Nacional de Virus Exantematicos, Gastroentericos y
      Transmitidos por Vectores, Instituto Nacional de Investigacion en Salud Publica
      "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
AD  - Universidad de Guayaquil, Guayaquil, Ecuador.
FAU - Romero, Jorge
AU  - Romero J
AD  - Ministerio de Salud Publica, Zonal 5, Guayaquil, Ecuador.
FAU - Mestanza, Orson
AU  - Mestanza O
AD  - Instituto Nacional del Nino San Borja, Lima, Peru.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Gaviria, Anibal
AU  - Gaviria A
AD  - Laboratorio Cruz Vida, Cruz Roja Ecuatoriana, Quito, Ecuador.
FAU - Orlando, Solon-Alberto
AU  - Orlando SA
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
AD  - Universidad Agraria del Ecuador, Guayaquil, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AUID- ORCID: 0000-0003-0025-3609
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Patino, Leandro
AU  - Patino L
AD  - Direccion de Investigacion, Desarrollo e Innovacion, Instituto Nacional de
      Investigacion en Salud Publica "Leopoldo Izquieta Perez", Guayaquil, Ecuador.
LA  - eng
PT  - Case Reports
DEP - 20211206
PL  - New Zealand
TA  - Infect Drug Resist
JT  - Infection and drug resistance
JID - 101550216
PMC - PMC8664343
OTO - NOTNLM
OT  - Ecuador B.1.1.7 lineage
OT  - SARS-CoV-2
OT  - alpha variant
COIS- The authors declare no conflicts of interest in this work.
EDAT- 2021/12/16 06:00
MHDA- 2021/12/16 06:01
CRDT- 2021/12/15 12:25
PHST- 2021/05/12 00:00 [received]
PHST- 2021/10/16 00:00 [accepted]
PHST- 2021/12/15 12:25 [entrez]
PHST- 2021/12/16 06:00 [pubmed]
PHST- 2021/12/16 06:01 [medline]
AID - 10.2147/IDR.S319439 [doi]
AID - 319439 [pii]
PST - epublish
SO  - Infect Drug Resist. 2021 Dec 6;14:5183-5188. doi: 10.2147/IDR.S319439.
      eCollection 2021.

PMID- 34829328
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211130
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Linking)
VI  - 11
IP  - 11
DP  - 2021 Oct 26
TI  - Tracking SARS-CoV-2: Novel Trends and Diagnostic Strategies.
LID - 1981 [pii]
LID - 10.3390/diagnostics11111981 [doi]
AB  - The COVID-19 pandemic has had an enormous impact on economies and health systems 
      globally, therefore a top priority is the development of increasingly better
      diagnostic and surveillance alternatives to slow down the spread of the severe
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In order to establish
      massive testing and contact tracing policies, it is crucial to have a clear view 
      of the diagnostic options available and their principal advantages and drawbacks.
      Although classical molecular methods such as RT-qPCR are broadly used, diagnostic
      alternatives based on technologies such as LAMP, antigen, serological testing, or
      the application of novel technologies such as CRISPR-Cas for diagnostics, are
      also discussed. The present review also discusses the most important automation
      strategies employed to increase testing capability. Several serological-based
      diagnostic kits are presented, as well as novel nanotechnology-based diagnostic
      methods. In summary, this review provides a clear diagnostic landscape of the
      most relevant tools to track COVID-19.
FAU - Guaman-Bautista, Linda P
AU  - Guaman-Bautista LP
AD  - Centro de Investigacion Biomedica, Facultad de Ciencias de la Salud Eugenio
      Espejo, Universidad UTE, Quito 170147, Ecuador.
FAU - Moreta-Urbano, Erick
AU  - Moreta-Urbano E
AUID- ORCID: 0000-0002-9778-5611
AD  - Centro de Investigacion Biomedica, Facultad de Ciencias de la Salud Eugenio
      Espejo, Universidad UTE, Quito 170147, Ecuador.
FAU - Ona-Arias, Claudia G
AU  - Ona-Arias CG
AUID- ORCID: 0000-0001-7347-6032
AD  - Centro de Investigacion Biomedica, Facultad de Ciencias de la Salud Eugenio
      Espejo, Universidad UTE, Quito 170147, Ecuador.
FAU - Torres-Arias, Marbel
AU  - Torres-Arias M
AUID- ORCID: 0000-0002-3902-5083
AD  - Immunology and Virology Laboratory, Department of Life Science and Agriculture,
      Universidad de las Fuerzas Armadas, Quito 171103, Ecuador.
FAU - Kyriakidis, Nikolaos C
AU  - Kyriakidis NC
AUID- ORCID: 0000-0003-1382-5661
AD  - Grupo de Investigacion en Biotecnologia Aplicada a Biomedicina (BIOMED),
      Universidad de Las Americas, Quito 170125, Ecuador.
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas
      (UDLA), Quito 170125, Ecuador.
FAU - Malci, Koray
AU  - Malci K
AUID- ORCID: 0000-0002-2942-1146
AD  - Institute for Bioengineering, School of Engineering, University of Edinburgh,
      Edinburgh EH8 9LE, UK.
AD  - Centre for Synthetic and Systems Biology (SynthSys), University of Edinburgh,
      Edinburgh EH8 9LE, UK.
FAU - Jonguitud-Borrego, Nestor
AU  - Jonguitud-Borrego N
AD  - Institute for Bioengineering, School of Engineering, University of Edinburgh,
      Edinburgh EH8 9LE, UK.
AD  - Centre for Synthetic and Systems Biology (SynthSys), University of Edinburgh,
      Edinburgh EH8 9LE, UK.
FAU - Rios-Solis, Leonardo
AU  - Rios-Solis L
AUID- ORCID: 0000-0002-4387-984X
AD  - Institute for Bioengineering, School of Engineering, University of Edinburgh,
      Edinburgh EH8 9LE, UK.
AD  - Centre for Synthetic and Systems Biology (SynthSys), University of Edinburgh,
      Edinburgh EH8 9LE, UK.
FAU - Ramos-Martinez, Espiridion
AU  - Ramos-Martinez E
AUID- ORCID: 0000-0002-4361-821X
AD  - Experimental Medicine Research Unit, Facultad de Medicina, Universidad Nacional
      Autonoma de Mexico, Mexico City 4510, Mexico.
FAU - Lopez-Cortes, Andres
AU  - Lopez-Cortes A
AD  - Centro de Investigacion Genetica y Genomica, Facultad de Ciencias de la Salud
      Eugenio Espejo, Universidad UTE, Quito 170147, Ecuador.
FAU - Barba-Ostria, Carlos
AU  - Barba-Ostria C
AD  - Escuela de Medicina, Colegio de Ciencias de la Salud Quito, Universidad San
      Francisco de Quito USFQ, Quito 170901, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211026
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC8621220
OTO - NOTNLM
OT  - COVID-19
OT  - CRISPR-based diagnostics
OT  - antigen testing
OT  - automation
OT  - nanotechnology-based diagnostics
OT  - nucleic acid amplification test
EDAT- 2021/11/28 06:00
MHDA- 2021/11/28 06:01
CRDT- 2021/11/27 01:08
PHST- 2021/07/14 00:00 [received]
PHST- 2021/09/18 00:00 [revised]
PHST- 2021/09/23 00:00 [accepted]
PHST- 2021/11/27 01:08 [entrez]
PHST- 2021/11/28 06:00 [pubmed]
PHST- 2021/11/28 06:01 [medline]
AID - diagnostics11111981 [pii]
AID - 10.3390/diagnostics11111981 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2021 Oct 26;11(11). pii: diagnostics11111981. doi:
      10.3390/diagnostics11111981.

PMID- 34805199
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211123
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the
      International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score.
PG  - 728102
LID - 10.3389/fmed.2021.728102 [doi]
AB  - Background: Patients with sepsis with a concomitant coronavirus (COVID-19)
      infection are related to a high morbidity and mortality rate. We investigated a
      large cohort of patients with sepsis with a concomitant COVID-19, and we
      developed a risk score for the estimation of sepsis risk in COVID-19. Methods: We
      conducted a sub-analysis from the international Health Outcome Predictive
      Evaluation Registry for COVID-19 (HOPE-COVID-19-Registry, NCT04334291). Out of
      5,837 patients with COVID-19, 624 patients were diagnosed with sepsis according
      to the Sepsis-3 International Consensus. Results: In multivariable analysis, the 
      following risk factors were identified as independent predictors for developing
      sepsis: current smoking, tachypnoea (>22 breath per minute), hemoptysis,
      peripheral oxygen saturation (SpO2) <92%, blood pressure (BP) (systolic BP <90
      mmHg and diastolic BP <60 mmHg), Glasgow Coma Scale (GCS) <15, elevated
      procalcitonin (PCT), elevated troponin I (TnI), and elevated creatinine >1.5
      mg/dl. By assigning odds ratio (OR) weighted points to these variables, the
      following three risk categories were defined to develop sepsis during admission: 
      low-risk group (probability of sepsis 3.1-11.8%); intermediate-risk group
      (24.8-53.8%); and high-risk-group (58.3-100%). A score of 1 was assigned to
      current smoking, tachypnoea, decreased SpO2, decreased BP, decreased GCS,
      elevated PCT, TnI, and creatinine, whereas a score of 2 was assigned to
      hemoptysis. Conclusions: The HOPE Sepsis Score including nine parameters is
      useful in identifying high-risk COVID-19 patients to develop sepsis. Sepsis in
      COVID-19 is associated with a high mortality rate.
CI  - Copyright (c) 2021 Abumayyaleh, Nunez-Gil, El-Battrawy, Estrada, Becerra-Munoz,
      Uribarri, Fernandez-Rozas, Feltes, Arroyo-Espliguero, Trabattoni, Lopez Pais,
      Pepe, Romero, Ortega-Armas, Bianco, Astrua, D'Ascenzo, Fabregat-Andres,
      Ballester, Marin, Buonsenso, Sanchez-Gimenez, Weiss, Fernandez Perez,
      Fernandez-Ortiz, Macaya, Akin and HOPE COVID-19 Investigators.
FAU - Abumayyaleh, Mohammad
AU  - Abumayyaleh M
AD  - University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Nunez-Gil, Ivan J
AU  - Nunez-Gil IJ
AD  - Hospital Clinico San Carlos, Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain.
FAU - El-Battrawy, Ibrahim
AU  - El-Battrawy I
AD  - University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Estrada, Vicente
AU  - Estrada V
AD  - Hospital Clinico San Carlos, Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain.
FAU - Becerra-Munoz, Victor Manuel
AU  - Becerra-Munoz VM
AD  - Hospital Clinico Universitario Virgen de la Vic, Malaga, Spain.
FAU - Uribarri, Aitor
AU  - Uribarri A
AD  - Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
FAU - Fernandez-Rozas, Inmaculada
AU  - Fernandez-Rozas I
AD  - Hospital Severo Ochoa, Leganes, Spain.
FAU - Feltes, Gisela
AU  - Feltes G
AD  - Hospital Nuestra Senora de America, Madrid, Spain.
FAU - Arroyo-Espliguero, Ramon
AU  - Arroyo-Espliguero R
AD  - Hospital Universitario Guadalajara, Guadalajara, Spain.
FAU - Trabattoni, Daniela
AU  - Trabattoni D
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Lopez Pais, Javier
AU  - Lopez Pais J
AD  - Complexo Hospitalario Universitario de Ourense, Spain.
FAU - Pepe, Martino
AU  - Pepe M
AD  - Azienda ospedaliero-universitaria consorziale policlinico di Bari, Bari, Italy.
FAU - Romero, Rodolfo
AU  - Romero R
AD  - Hospital Universitario de Getafe, Universidad Europea, Madrid, Spain.
FAU - Ortega-Armas, Maria Elizabeth
AU  - Ortega-Armas ME
AD  - Hospital General del norte de Guayaquil IESS Los Ceibos, Guayaquil, Ecuador.
FAU - Bianco, Matteo
AU  - Bianco M
AD  - San Luigi Gonzaga University Hospital, Orbassano and Rivoli Infermi Hospital,
      Turin, Italy.
FAU - Astrua, Thamar Capel
AU  - Astrua TC
AD  - Hospital Virgen del Mar, Madrid, Spain.
FAU - D'Ascenzo, Fabrizio
AU  - D'Ascenzo F
AD  - San Giovanni Battista, Turin, Italy.
FAU - Fabregat-Andres, Oscar
AU  - Fabregat-Andres O
AD  - Hospital IMED, Valencia, Spain.
FAU - Ballester, Andrea
AU  - Ballester A
AD  - Hospital Clinico de Valencia, INCLIVA, Valencia, Spain.
FAU - Marin, Francisco
AU  - Marin F
AD  - Hospital Clinico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBERCV,
      Murcia, Spain.
FAU - Buonsenso, Danilo
AU  - Buonsenso D
AD  - Department of Woman and Child Health and Public Health, Fondazione Policlinico
      Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Sanchez-Gimenez, Raul
AU  - Sanchez-Gimenez R
AD  - University Hospital Joan XXIII, Tarragona, Spain.
FAU - Weiss, Christel
AU  - Weiss C
AD  - Department for Statistical Analysis, University Heidelberg, Mannheim, Germany.
FAU - Fernandez Perez, Cristina
AU  - Fernandez Perez C
AD  - Complejo Hospitalario Universitario de Santiago de Compostela Instituto para la
      Mejora de la Asistencia Sanitaria (IMAS Fundacion), Spain.
FAU - Fernandez-Ortiz, Antonio
AU  - Fernandez-Ortiz A
AD  - Hospital Clinico San Carlos, Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain.
FAU - Macaya, Carlos
AU  - Macaya C
AD  - Hospital Clinico San Carlos, Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain.
FAU - Akin, Ibrahim
AU  - Akin I
AD  - University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
LA  - eng
PT  - Journal Article
DEP - 20211014
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8603931
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *outcome
OT  - *score
OT  - *sepsis
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/11/23 06:00
MHDA- 2021/11/23 06:01
CRDT- 2021/11/22 06:53
PHST- 2021/06/20 00:00 [received]
PHST- 2021/09/06 00:00 [accepted]
PHST- 2021/11/22 06:53 [entrez]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2021/11/23 06:01 [medline]
AID - 10.3389/fmed.2021.728102 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Oct 14;8:728102. doi: 10.3389/fmed.2021.728102.
      eCollection 2021.

PMID- 34778508
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211216
IS  - 2352-7714 (Print)
IS  - 2352-7714 (Linking)
VI  - 13
DP  - 2021 Dec
TI  - Corrigendum to: "One health" inspired SARS-CoV-2 surveillance: The Galapagos
      Islands experience [One Health 11 (2020) 100185].
PG  - 100345
LID - 10.1016/j.onehlt.2021.100345 [doi]
AB  - [This corrects the article DOI: 10.1016/j.onehlt.2020.100185.].
CI  - (c) 2021 The Author(s).
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Vega-Marino, Patricio
AU  - Vega-Marino P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Velez, Alberto
AU  - Velez A
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Castillo, Paulina
AU  - Castillo P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Masaquiza, Carlos
AU  - Masaquiza C
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Cedeno-Vega, Ronald
AU  - Cedeno-Vega R
AD  - Pan American Health Organization, Quito, Ecuador.
FAU - Lozada, Tannya
AU  - Lozada T
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Cruz, Marilyn
AU  - Cruz M
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Published Erratum
DEP - 20211105
PL  - Netherlands
TA  - One Health
JT  - One health (Amsterdam, Netherlands)
JID - 101660501
EFR - One Health. 2020 Dec 20;11:100185. PMID: 33102678
PMC - PMC8570441
EDAT- 2021/11/16 06:00
MHDA- 2021/11/16 06:01
CRDT- 2021/11/15 07:11
PHST- 2021/11/16 06:00 [pubmed]
PHST- 2021/11/16 06:01 [medline]
PHST- 2021/11/15 07:11 [entrez]
AID - 10.1016/j.onehlt.2021.100345 [doi]
AID - S2352-7714(21)00135-X [pii]
PST - ppublish
SO  - One Health. 2021 Dec;13:100345. doi: 10.1016/j.onehlt.2021.100345. Epub 2021 Nov 
      5.

PMID- 34737323
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20211119
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Nov 4
TI  - High sensitivity-low cost detection of SARS-CoV-2 by two steps end point RT-PCR
      with agarose gel electrophoresis visualization.
PG  - 21658
LID - 10.1038/s41598-021-00900-8 [doi]
AB  - More than one year since Coronavirus disease 2019 (COVID-19) pandemic outbreak,
      the gold standard technique for severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) detection is still the RT-qPCR. This is a limitation to increase
      testing capacities, particularly at developing countries, as expensive reagents
      and equipment are required. We developed a two steps end point RT-PCR reaction
      with SARS-CoV-2 Nucleocapsid (N) gene and Ribonuclease P (RNase P) specific
      primers where viral amplicons were verified by agarose gel electrophoresis. We
      carried out a clinical performance and analytical sensitivity evaluation for this
      two-steps end point RT-PCR method with 242 nasopharyngeal samples using the CDC
      RT-qPCR protocol as a gold standard technique. With a specificity of 95.8%, a
      sensitivity of 95.1%, and a limit of detection of 20 viral RNA copies/uL, this
      two steps end point RT-PCR assay is an affordable and reliable method for
      SARS-CoV-2 detection. This protocol would allow to extend COVID-19 diagnosis to
      basic molecular biology laboratories with a potential positive impact in
      surveillance programs at developing countries.
CI  - (c) 2021. The Author(s).
FAU - Figueroa, Solange
AU  - Figueroa S
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Vega-Marino, Patricio
AU  - Vega-Marino P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Velez, Alberto
AU  - Velez A
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Cruz, Marilyn
AU  - Cruz M
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Cardenas, Washington B
AU  - Cardenas WB
AD  - Laboratorio para Investigaciones Biomedicas, Escuela Superior Politecnica del
      Litoral, Guayaquil, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
      magbereguiain@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211104
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Coronavirus Nucleocapsid Proteins)
RN  - 0 (DNA Primers)
RN  - 0 (RNA, Viral)
RN  - EC 3.1.26.5 (Ribonuclease P)
SB  - IM
MH  - COVID-19/*diagnosis/genetics
MH  - COVID-19 Nucleic Acid Testing/economics/*methods
MH  - COVID-19 Testing/methods
MH  - Coronavirus Nucleocapsid Proteins/genetics
MH  - DNA Primers
MH  - Electrophoresis, Agar Gel/methods
MH  - Humans
MH  - Laboratories
MH  - Nasopharynx/virology
MH  - RNA, Viral/genetics
MH  - Ribonuclease P/genetics/metabolism
MH  - SARS-CoV-2/*genetics/pathogenicity
MH  - Sensitivity and Specificity
PMC - PMC8568942
EDAT- 2021/11/06 06:00
MHDA- 2021/11/20 06:00
CRDT- 2021/11/05 06:16
PHST- 2021/05/14 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/11/05 06:16 [entrez]
PHST- 2021/11/06 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
AID - 10.1038/s41598-021-00900-8 [doi]
AID - 10.1038/s41598-021-00900-8 [pii]
PST - epublish
SO  - Sci Rep. 2021 Nov 4;11(1):21658. doi: 10.1038/s41598-021-00900-8.

PMID- 34715744
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20211103
IS  - 2150-1327 (Electronic)
IS  - 2150-1319 (Linking)
VI  - 12
DP  - 2021 Jan-Dec
TI  - Factors Associated With a Persistent Seronegative Status 1 Year After a
      SARS-CoV-2 Massive Infection Outbreak in Community Dwellers Living in Rural
      Ecuador: A Prospective Population-based Study.
PG  - 21501327211054989
LID - 10.1177/21501327211054989 [doi]
AB  - BACKGROUND: The SARS-CoV-2 pandemic is affecting millions of people living in
      rural areas of Low- and Middle-Income Countries and is causing an already
      anticipated devastating effect on the health and economics of these populations. 
      More information is needed to modify behaviors that may counterbalance the
      consequences of mass spread of the virus in these underserved communities. This
      study aimed to identify factors associated with a persistent SARS-CoV-2
      seronegative status 1 year after a massive infection outbreak in middle-aged and 
      older adults living in rural Ecuador. METHODS: Individuals enrolled in the
      Atahualpa Project Cohort as of March 2020 received 5 rounds of tests for
      determination of SARS-CoV-2 antibodies in blood. Individuals who remained
      seronegative up to April 2021 were considered "persistently seronegative." An
      adjusted Poisson regression model was fitted to estimate the incidence risk ratio
      of factors directly or inversely associated with a persistent seronegative
      status. RESULTS: A total of 673 individuals received baseline tests. Thirty-one
      declined consent or died and 429 seroconverted, leaving 213 seronegative
      subjects. Average SARS-CoV-2 incidence rate was 9.87 events (95% C.I.:
      8.91-10.83) per 100 person-months of observation. The use of flushing toilet
      systems (instead of open latrines) increased 1.5 times the possibility of
      remaining seronegative. Likewise, every additional bedroom in the house increased
      by 15% the possibility of remaining seronegative. In contrast, every additional
      person in the house and having high cholesterol levels significantly reduced the 
      possibility of remaining seronegative. CONCLUSIONS: The use of flushing toilet
      systems and the number of bedrooms in the house directly influenced the
      possibility of remaining seronegative among individuals living in this rural
      setting. Study results also demonstrated a sustained transmission of the virus
      even after a significant proportion of the population has been infected. Our
      findings reinforce the mass spread of SARS-CoV-2 in rural communities.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - Universidad Espiritu Santo - Ecuador, Samborondon, Guayaquil, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Universidad Espiritu Santo - Ecuador, Samborondon, Guayaquil, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Freenome, Inc., South San Francisco, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Prim Care Community Health
JT  - Journal of primary care & community health
JID - 101518419
SB  - IM
MH  - Aged
MH  - *COVID-19
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Middle Aged
MH  - Pandemics
MH  - Prospective Studies
MH  - Rural Population
MH  - *SARS-CoV-2
PMC - PMC8558583
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ecuador
OT  - *SARS-CoV-2
OT  - *cohort study
OT  - *incidence
OT  - *rural setting
EDAT- 2021/10/31 06:00
MHDA- 2021/11/04 06:00
CRDT- 2021/10/30 05:19
PHST- 2021/10/30 05:19 [entrez]
PHST- 2021/10/31 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
AID - 10.1177/21501327211054989 [doi]
PST - ppublish
SO  - J Prim Care Community Health. 2021 Jan-Dec;12:21501327211054989. doi:
      10.1177/21501327211054989.

PMID- 34626893
OWN - NLM
STAT- MEDLINE
DCOM- 20211122
LR  - 20220327
IS  - 1532-3102 (Electronic)
IS  - 0143-4004 (Linking)
VI  - 115
DP  - 2021 Nov
TI  - Seroprevalence of SARS-CoV-2 immunoglobulins in pregnant women and neonatal cord 
      blood from a highly impacted region.
PG  - 146-150
LID - S0143-4004(21)00610-X [pii]
LID - 10.1016/j.placenta.2021.10.001 [doi]
AB  - There is inadequate screening for SARS-COV-2 during pregnancy. We aimed to
      determine the impact of maternal and neonatal cord blood SARS-COV-2 antibodies
      and placental transfer ratios in a region with a low screening plan. We performed
      a blind study in one of the SARS-CoV-2 epicenters in South America. 32% of
      pregnant women were serological positive. Importantly, there is an efficient
      passive immunization of the fetus to SARS-CoV-2. We report high incidence of
      SARS-CoV-2 infection during pregnancy, which is higher than officially reported. 
      Therefore the need of active immunization to enhance maternal protection and
      fetal passive immunization.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Zambrano, Hector
AU  - Zambrano H
AD  - ECUAGENOMA, SA, Guayaquil, Ecuador.
FAU - Anchundia, Ketty
AU  - Anchundia K
AD  - ECUAGENOMA, SA, Guayaquil, Ecuador.
FAU - Aviles, Dalila
AU  - Aviles D
AD  - ECUAGENOMA, SA, Guayaquil, Ecuador.
FAU - Andaluz, Ruffo
AU  - Andaluz R
AD  - CGORA WOMEN CLINIC, Babahoyo, Ecuador.
FAU - Calderon, Nathaly
AU  - Calderon N
AD  - ECUAGENOMA, SA, Guayaquil, Ecuador.
FAU - Torres, Estefanie
AU  - Torres E
AD  - ECUAGENOMA, SA, Guayaquil, Ecuador.
FAU - Gonzalez-Granda, Nicolas
AU  - Gonzalez-Granda N
AD  - ECUAGENOMA, SA, Guayaquil, Ecuador.
FAU - Maxwell, Anthony
AU  - Maxwell A
AD  - C.S. Mott Center for Human Growth and Development, Department of Obstetrics and
      Gynecology, Wayne State University, Detroit, MI, USA.
FAU - Chen, Kang
AU  - Chen K
AD  - C.S. Mott Center for Human Growth and Development, Department of Obstetrics and
      Gynecology, Wayne State University, Detroit, MI, USA.
FAU - Gonik, Bernard
AU  - Gonik B
AD  - C.S. Mott Center for Human Growth and Development, Department of Obstetrics and
      Gynecology, Wayne State University, Detroit, MI, USA.
FAU - Mor, Gil
AU  - Mor G
AD  - C.S. Mott Center for Human Growth and Development, Department of Obstetrics and
      Gynecology, Wayne State University, Detroit, MI, USA. Electronic address:
      gmor@med.wayne.edu.
LA  - eng
GR  - R01 AI145829/AI/NIAID NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20211006
PL  - Netherlands
TA  - Placenta
JT  - Placenta
JID - 8006349
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Viral/blood
MH  - COVID-19/blood/*epidemiology/immunology
MH  - Ecuador/epidemiology
MH  - Female
MH  - Fetal Blood/*immunology/metabolism
MH  - Humans
MH  - Immunization, Passive/statistics & numerical data
MH  - Immunoglobulin G/blood
MH  - Immunoglobulin M/blood
MH  - Incidence
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/blood/*epidemiology/immunology
MH  - SARS-CoV-2/*immunology
MH  - Seroepidemiologic Studies
MH  - Young Adult
PMC - PMC8492380
OTO - NOTNLM
OT  - *IgG
OT  - *IgM
OT  - *Placenta
OT  - *Pregnancy
OT  - *SARS-COV-2
EDAT- 2021/10/10 06:00
MHDA- 2021/11/23 06:00
CRDT- 2021/10/09 20:19
PHST- 2021/08/19 00:00 [received]
PHST- 2021/09/27 00:00 [revised]
PHST- 2021/10/01 00:00 [accepted]
PHST- 2021/10/10 06:00 [pubmed]
PHST- 2021/11/23 06:00 [medline]
PHST- 2021/10/09 20:19 [entrez]
AID - S0143-4004(21)00610-X [pii]
AID - 10.1016/j.placenta.2021.10.001 [doi]
PST - ppublish
SO  - Placenta. 2021 Nov;115:146-150. doi: 10.1016/j.placenta.2021.10.001. Epub 2021
      Oct 6.

PMID- 34600119
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220131
IS  - 1469-0691 (Electronic)
IS  - 1198-743X (Linking)
VI  - 28
IP  - 2
DP  - 2022 Feb
TI  - Predictors of poor prognosis in healthy, young, individuals with SARS-CoV-2
      infections.
PG  - 273-278
LID - S1198-743X(21)00545-0 [pii]
LID - 10.1016/j.cmi.2021.09.021 [doi]
AB  - OBJECTIVES: To identify predictors of poor prognosis in previously healthy young 
      individuals admitted to hospital with coronavirus disease 2019 (COVID-19).
      METHODS: We studied a cohort of patients hospitalized with COVID-19. All patients
      without co-morbidities, without usual treatments and </=65 years old were
      selected from an international registry (HOPE-COVID-19, NCT04334291). We focused 
      on baseline variables-symptoms and signs at admission-to analyse risk factors for
      poor prognosis. The primary end point was a composite of major adverse clinical
      events during hospitalization including mortality, mechanical ventilation,
      high-flow nasal oxygen therapy, prone, sepsis, systemic inflammatory response
      syndrome and embolic events. RESULTS: Overall, 773 healthy young patients were
      included. The primary composite end point was observed in 29% (225/773) and the
      overall mortality rate was 3.6% (28/773). In the combined event group, 75%
      (168/225) of patients were men and the mean age was 49 (+/-11) years, whereas in 
      the non-combined event group, the prevalence of male gender was 43% (238/548) and
      the mean age was 42 (+/-13) years (p < 0.001 for both). On admission, respiratory
      insufficiency and cough were described in 51.4% (114/222) and 76% (170/223) of
      patients, respectively, in the combined event group, versus 7.9% (42/533) and 56%
      (302/543) of patients in the other group (p < 0.001 for both). The strongest
      independent predictor for the combined end point was desaturation (Spo2 <92%) (OR
      5.40; 95% CI 3.34-8.75; p < 0.001), followed by tachypnoea (OR 3.17; 95% CI
      1.93-5.21; p < 0.001), male gender (OR 3.01; 95% CI 1.96-4.61; p < 0.001) and
      pulmonary infiltrates on chest X-ray at admission (OR 2.21; 95% CI 1.18-4.16; p
      0.014). CONCLUSIONS: Major adverse clinical events were unexpectedly high
      considering the baseline characteristics of the cohort. Signs of respiratory
      compromise at admission and male gender, were predictive for poor prognosis among
      young healthy patients hospitalized with COVID-19.
CI  - Copyright (c) 2021 European Society of Clinical Microbiology and Infectious
      Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Espejo-Paeres, Carolina
AU  - Espejo-Paeres C
AD  - Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain.
      Electronic address: carolina.espejo.paeres@gmail.com.
FAU - Espliguero, Ramon Arroyo
AU  - Espliguero RA
AD  - Hospital Universitario Guadalajara, Guadalajara, Spain.
FAU - Uribarri, Aitor
AU  - Uribarri A
AD  - Hospital Clinico Universitario de Valladolid, Centro de Investigacion Biomedica
      en Red de Enfermedades Cardiovasculares (CIBERCV), Valladolid, Spain.
FAU - Anton-Huguet, Berta
AU  - Anton-Huguet B
AD  - Hospital Universitario La Paz, Madrid, Spain.
FAU - Romero, Rodolfo
AU  - Romero R
AD  - Hospital Universitario Getafe, Universidad Europea Madrid, Spain.
FAU - Fernandez-Rozas, Inmaculada
AU  - Fernandez-Rozas I
AD  - Hospital Severo Ochoa, Leganes, Spain.
FAU - Becerra-Munoz, Victor Manuel
AU  - Becerra-Munoz VM
AD  - Hospital Universitario Virgen de la Victoria, Universidad de Malaga (UMA), Centro
      de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV),
      Malaga, Spain.
FAU - Alfonso-Rodriguez, Emilio
AU  - Alfonso-Rodriguez E
AD  - Instituto de Cardiologia y Cirugia Cardiovascular, Havana, Cuba.
FAU - Huang, Jia
AU  - Huang J
AD  - The Second Affiliated Hospital of Southern University of Science and Technology, 
      Shenzhen, China.
FAU - Ortega-Armas, Maria Elizabeth
AU  - Ortega-Armas ME
AD  - Hospital General del norte de Guayaquil IESS Los Ceibos, Guayaquil, Ecuador.
FAU - Pepe, Martino
AU  - Pepe M
AD  - Azienda Ospedaliero-universitaria Consorziale Policlinico di Bari, Italy.
FAU - Gonzalez, Adelina
AU  - Gonzalez A
AD  - Hospital Universitario Infanta Sofia, San Sebastian de los Reyes, Madrid, Spain.
FAU - Bertolazzi, Marzia
AU  - Bertolazzi M
AD  - Sant'Andrea Hospital, Verdelli, Italy.
FAU - Cerrato, Enrico
AU  - Cerrato E
AD  - San Luigi Gonzaga University Hospital, Rivoli, Turin, Italy.
FAU - Quezada, Antonio
AU  - Quezada A
AD  - Hospital Clinico Universitario, Incliva, Universidad de Valencia, Valencia,
      Spain.
FAU - Raposeiras-Roubin, Sergio
AU  - Raposeiras-Roubin S
AD  - University Hospital Alvaro Cunqueiro, Vigo, Spain.
FAU - Vedia, Oscar
AU  - Vedia O
AD  - Hospital Clinico San Carlos. Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC). Madrid, Spain.
FAU - Feltes-Guzman, Gisela
AU  - Feltes-Guzman G
AD  - Hospital Nuestra Senora de America, Madrid, Spain.
FAU - Akin, Ibrahim
AU  - Akin I
AD  - First Department of Medicine, Medical Faculty Mannheim, University Heidelberg,
      Mannheim, Germany, DZHK (German Centre for Cardiovascular Research), Partner
      Site, Heidelberg-Mannheim, Mannheim, 68167, Germany.
FAU - Carrero-Fernandez, Ana
AU  - Carrero-Fernandez A
AD  - Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain.
FAU - Macaya, Carlos
AU  - Macaya C
AD  - Hospital Clinico San Carlos. Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC). Madrid, Spain.
FAU - Estrada, Vicente
AU  - Estrada V
AD  - Hospital Clinico San Carlos. Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC). Madrid, Spain.
FAU - Nunez-Gil, Ivan J
AU  - Nunez-Gil IJ
AD  - Hospital Clinico San Carlos. Universidad Complutense de Madrid, Instituto de
      Investigacion, Sanitaria del Hospital Clinico San Carlos (IdISSC). Madrid, Spain.
CN  - HOPE COVID-19 investigators
LA  - eng
PT  - Journal Article
DEP - 20210930
PL  - England
TA  - Clin Microbiol Infect
JT  - Clinical microbiology and infection : the official publication of the European
      Society of Clinical Microbiology and Infectious Diseases
JID - 9516420
SB  - IM
MH  - Adult
MH  - Aged
MH  - *COVID-19
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Respiration, Artificial
MH  - *Respiratory Insufficiency
MH  - Retrospective Studies
MH  - SARS-CoV-2
PMC - PMC8481119
OTO - NOTNLM
OT  - *COVID-19
OT  - *Healthy
OT  - *Lung disease
OT  - *Mortality
OT  - *Prognosis
OT  - *Young
EDAT- 2021/10/03 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/10/02 20:12
PHST- 2021/02/01 00:00 [received]
PHST- 2021/09/16 00:00 [revised]
PHST- 2021/09/19 00:00 [accepted]
PHST- 2021/10/03 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/10/02 20:12 [entrez]
AID - S1198-743X(21)00545-0 [pii]
AID - 10.1016/j.cmi.2021.09.021 [doi]
PST - ppublish
SO  - Clin Microbiol Infect. 2022 Feb;28(2):273-278. doi: 10.1016/j.cmi.2021.09.021.
      Epub 2021 Sep 30.

PMID- 34583573
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211003
IS  - 2150-1327 (Electronic)
IS  - 2150-1319 (Linking)
VI  - 12
DP  - 2021 Jan-Dec
TI  - Body Composition in Community-Dwelling Older Adults Before and After SARS-CoV-2
      Infection: A Longitudinal Prospective Study in a Rural Village Struck by the
      Pandemic.
PG  - 21501327211047781
LID - 10.1177/21501327211047781 [doi]
AB  - BACKGROUND: Information on the body composition of inhabitants of remote
      communities during the SARS-CoV-2 pandemic is limited. Using a longitudinal
      population-based study design, we assessed the association between SARS-CoV-2
      infection and changes in body composition. METHODS: Community-dwelling older
      adults living in a rural Ecuadorian village received body composition
      determinations before and 1 year after the pandemic as well as serological tests 
      for detection of SARS-CoV-2 antibodies. The independent association between
      SARS-CoV-2 infection and abnormalities in body composition at follow-up was
      assessed by fitting linear mixed models for longitudinal data. RESULTS: Of 327
      enrolled individuals, 277 (85%) received baseline and follow-up body composition 
      determinations, and 175 (63%) of them became SARS-CoV-2 seropositive. Overall,
      diet and physical activity deteriorated during the follow-up. Multivariate
      random-effects generalized least squares regression models that included the
      impact of time and seropositivity on follow-up body composition, showed that
      neither variable contributed to a worsening in body composition. Multivariate
      logistic regression models disclosed that the serological status at follow-up
      cannot be predicted by differences in body composition and other baseline
      covariates. CONCLUSIONS: Study results suggest no increased susceptibility to
      SARS-CoV-2 infection among older adults with abnormal body composition and no
      significant changes as a result of worse physical activity and dietary habits or 
      seropositivity during the length of the study. Together with a previous study in 
      the same population that showed decrease in hand-grip strength after SARS-CoV-2, 
      results confirm that dynapenia (and not sarcopenia) is associated with SARS-CoV-2
      infection in older adults.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - Universidad Espiritu Santo - Ecuador, Samborondon, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Biostatistics/Epidemiology, Freenome, Inc., South San Francisco, CA, USA.
FAU - Rumbea, Denisse A
AU  - Rumbea DA
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Perez, Pedro
AU  - Perez P
AD  - Department of Psychiatry, Mount Sinai Morningside, New York, NY, USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Sedler, Mark J
AU  - Sedler MJ
AD  - Renaissance School of Medicine, Stony Brook University, New York, NY, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Prim Care Community Health
JT  - Journal of primary care & community health
JID - 101518419
SB  - IM
MH  - Aged
MH  - Body Composition
MH  - *COVID-19
MH  - Humans
MH  - Independent Living
MH  - Pandemics
MH  - Prospective Studies
MH  - *SARS-CoV-2
PMC - PMC8485270
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *body composition
OT  - *older adults
OT  - *population study
OT  - *rural communities
EDAT- 2021/09/30 06:00
MHDA- 2021/10/02 06:00
CRDT- 2021/09/29 05:32
PHST- 2021/09/29 05:32 [entrez]
PHST- 2021/09/30 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
AID - 10.1177/21501327211047781 [doi]
PST - ppublish
SO  - J Prim Care Community Health. 2021 Jan-Dec;12:21501327211047781. doi:
      10.1177/21501327211047781.

PMID- 34563582
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20220301
IS  - 1879-0984 (Electronic)
IS  - 0166-0934 (Linking)
VI  - 298
DP  - 2021 Dec
TI  - Alternative RNA extraction-free techniques for the real-time RT-PCR detection of 
      SARS-CoV-2 in nasopharyngeal swab and sputum samples.
PG  - 114302
LID - S0166-0934(21)00241-X [pii]
LID - 10.1016/j.jviromet.2021.114302 [doi]
AB  - Standard diagnoses of SARS-CoV-2 infections are done by RNA extraction and
      real-time RT-PCR (rRT-PCR). However, the need for RNA extraction complicates
      testing due to increased processing time, high cost, and limited availability of 
      commercial kits. Therefore, alternative methods for rRT-PCR detection of
      SARS-CoV-2 without RNA extraction were investigated. Nasopharyngeal and sputum
      samples were used to compare the sensitivity of three techniques: Trizol RNA
      extraction, thermal shock, and the direct use of samples with an RNase inhibitor.
      Direct, extraction-free use of primary samples plus the RNase inhibitor produced 
      diagnostic values of 100 % sensitivity and specificity compared to standard
      protocols, and these findings were validated in a second, independent laboratory.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Villota, Stephany D
AU  - Villota SD
AD  - Instituto Nacional de Investigacion en Salud Publica (INSPI), Ecuador.
FAU - Nipaz, Victoria E
AU  - Nipaz VE
AD  - Instituto Nacional de Investigacion en Salud Publica (INSPI), Ecuador.
FAU - Carrazco-Montalvo, Andres
AU  - Carrazco-Montalvo A
AD  - Instituto Nacional de Investigacion en Salud Publica (INSPI), Ecuador.
FAU - Hernandez, Sarah
AU  - Hernandez S
AD  - Emory University, Department of Medicine, Division if Infectious Diseases,
      Atlanta, GA, USA.
FAU - Waggoner, Jesse J
AU  - Waggoner JJ
AD  - Emory University, Department of Medicine, Division if Infectious Diseases,
      Atlanta, GA, USA.
FAU - Ponce, Patricio
AU  - Ponce P
AD  - Instituto Nacional de Investigacion en Salud Publica (INSPI), Ecuador.
FAU - Coloma, Josefina
AU  - Coloma J
AD  - University of California Berkeley, Division of Infectious Diseases and
      Vaccinology, School of Public Health, CA, USA.
FAU - Orlando, Alberto
AU  - Orlando A
AD  - Instituto Nacional de Investigacion en Salud Publica (INSPI), Ecuador.
FAU - Cevallos, Varsovia
AU  - Cevallos V
AD  - Instituto Nacional de Investigacion en Salud Publica (INSPI), Ecuador. Electronic
      address: vcevallos@inspi.gob.ec.
LA  - eng
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20210923
PL  - Netherlands
TA  - J Virol Methods
JT  - Journal of virological methods
JID - 8005839
RN  - 0 (RNA, Viral)
SB  - IM
MH  - *COVID-19
MH  - COVID-19 Testing
MH  - Humans
MH  - Nasopharynx
MH  - RNA, Viral/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *SARS-CoV-2
MH  - Sensitivity and Specificity
MH  - Sputum
PMC - PMC8459549
OTO - NOTNLM
OT  - *RNA extraction
OT  - *Real-time RT-PCR
OT  - *SARS-CoV-2
EDAT- 2021/09/27 06:00
MHDA- 2021/11/25 06:00
CRDT- 2021/09/26 20:41
PHST- 2020/09/24 00:00 [received]
PHST- 2021/09/21 00:00 [revised]
PHST- 2021/09/22 00:00 [accepted]
PHST- 2021/09/27 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2021/09/26 20:41 [entrez]
AID - S0166-0934(21)00241-X [pii]
AID - 10.1016/j.jviromet.2021.114302 [doi]
PST - ppublish
SO  - J Virol Methods. 2021 Dec;298:114302. doi: 10.1016/j.jviromet.2021.114302. Epub
      2021 Sep 23.

PMID- 34549260
OWN - NLM
STAT- Publisher
LR  - 20220317
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
DP  - 2021 Sep 21
TI  - Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2
      Transmission and Disease Burden: A Modelling Analysis.
LID - ciab837 [pii]
LID - 10.1093/cid/ciab837 [doi]
AB  - BACKGROUND: The public health impact of the COVID-19 pandemic has motivated a
      rapid search for potential therapeutics, with some key successes. However, the
      potential impact of different treatments, and consequently research and
      procurement priorities, have not been clear. METHODS: Using a mathematical model 
      of SARS-CoV-2 transmission, COVID-19 disease and clinical care, we explore the
      public-health impact of different potential therapeutics, under a range of
      scenarios varying healthcare capacity, epidemic trajectories; and drug efficacy
      in the absence of supportive care. RESULTS: The impact of drugs like
      dexamethasone (delivered to the most critically-ill in hospital and whose
      therapeutic benefit is expected to depend on the availability of supportive care 
      such as oxygen and mechanical ventilation) is likely to be limited in settings
      where healthcare capacity is lowest or where uncontrolled epidemics result in
      hospitals being overwhelmed. As such, it may avert 22% of deaths in high-income
      countries but only 8% in low-income countries (assuming R=1.35). Therapeutics for
      different patient populations (those not in hospital, early in the course of
      infection) and types of benefit (reducing disease severity or infectiousness,
      preventing hospitalisation) could have much greater benefits, particularly in
      resource-poor settings facing large epidemics. CONCLUSIONS: Advances in the
      treatment of COVID-19 to date have been focussed on hospitalised-patients and
      predicated on an assumption of adequate access to supportive care. Therapeutics
      delivered earlier in the course of infection that reduce the need for healthcare 
      or reduce infectiousness could have significant impact, and research into their
      efficacy and means of delivery should be a priority.
CI  - (c) The Author(s) 2021. Published by Oxford University Press for the Infectious
      Diseases Society of America.
FAU - Whittaker, Charles
AU  - Whittaker C
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Watson, Oliver J
AU  - Watson OJ
AUID- ORCID: 0000-0003-2374-0741
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Alvarez-Moreno, Carlos
AU  - Alvarez-Moreno C
AD  - Clinica Universitaria Colombia, Clinica Colsanitas. Facultad de Medicina,
      Universidad Nacional de Colombia, Bogota, Colombia.
FAU - Angkasekwinai, Nasikarn
AU  - Angkasekwinai N
AUID- ORCID: 0000-0001-5723-4877
AD  - Division of Infectious Diseases and Tropical Medicine, Department of Medicine,
      Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Boonyasiri, Adhiratha
AU  - Boonyasiri A
AD  - Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Carlos Triana, Luis
AU  - Carlos Triana L
AD  - Hospital Universitario San Ignacio -Pontificia Universidad Javeriana, Bogota,
      Colombia.
FAU - Chanda, Duncan
AU  - Chanda D
AUID- ORCID: 0000-0001-5477-9054
AD  - Adult Infectious Diseases Centre, University Teaching Hospital, Lusaka, Zambia.
AD  - Department of Internal Medicine, University of Zambia School of Medicine, Lusaka,
      Zambia.
FAU - Charoenpong, Lantharita
AU  - Charoenpong L
AD  - Bamrasnaradura Infectious Diseases Institute, Department of Diseases Control,
      Ministry of Public Health, Nonthaburi, Thailand.
FAU - Chayakulkeeree, Methee
AU  - Chayakulkeeree M
AD  - Division of Infectious Diseases and Tropical Medicine, Department of Medicine,
      Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Cooke, Graham S
AU  - Cooke GS
AD  - Department of Infectious Diseases, Imperial College London, London, United
      Kingdom.
AD  - NIHR Biomedical Research Centre, Imperial College NHS Trust, London, United
      Kingdom.
FAU - Croda, Julio
AU  - Croda J
AD  - Oswaldo Cruz Foudantion, Mato Grosso do Sul, Campo Grande, Brazil.
AD  - School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande,
      Brazil.
AD  - Yale School of Public Health, New Haven, USA.
FAU - Cucunuba, Zulma M
AU  - Cucunuba ZM
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
AD  - Departamento de Epidemiologia Clinica y Bioestadistica. Facultad de Medicina,
      Pontificia Universidad Javeriana, Bogota, Colombia.
FAU - Djaafara, Bimandra A
AU  - Djaafara BA
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
AD  - Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
FAU - Estofolete, Cassia F
AU  - Estofolete CF
AD  - Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP), Sao Jose do Rio Preto,
      Brazil.
FAU - Grillet, Maria-Eugenia
AU  - Grillet ME
AD  - Instituto de Zoologia y Ecologia Tropical, Facultad de Ciencias, Universidad
      Central de Venezuela, Caracas, Venezuela.
FAU - Faria, Nuno R
AU  - Faria NR
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
AD  - Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina
      Tropical da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo,
      Brazil.
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Figueiredo Costa, Silvia
AU  - Figueiredo Costa S
AD  - Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao 
      Paulo, Brazil.
FAU - Forero-Pena, David A
AU  - Forero-Pena DA
AD  - Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar,
      Venezuela.
FAU - Gibb, Diana M
AU  - Gibb DM
AD  - MRC Clinical Trials Unit at University College London, London, United Kingdom.
FAU - Gordon, Anthony C
AU  - Gordon AC
AD  - Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College
      London, London, United Kingdom.
FAU - Hamers, Raph L
AU  - Hamers RL
AD  - Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Dept of Medicine,
      University of Oxford, Oxford, UK.
FAU - Hamlet, Arran
AU  - Hamlet A
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Irawany, Vera
AU  - Irawany V
AD  - Fatmawati General Hospital, Faculty of Medicine University of Indonesia.
FAU - Jitmuang, Anupop
AU  - Jitmuang A
AD  - Division of Infectious Diseases and Tropical Medicine, Department of Medicine,
      Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Keurueangkul, Nukool
AU  - Keurueangkul N
AD  - Samutprakan Hospital, Bangkok, Thailand.
FAU - Kimani, Teresia Njoki
AU  - Kimani TN
AD  - Kenyan Ministry of Health, Nairobi, Kenya.
FAU - Lampo, Margarita
AU  - Lampo M
AD  - Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela.
FAU - Levin, Anna S
AU  - Levin AS
AD  - Department of Infectious Diseases, Faculdade de Medicina, Universidade de Sao
      Paulo, Sao Paulo, Brazil.
FAU - Lopardo, Gustavo
AU  - Lopardo G
AD  - Hospital Bernardo Houssay, Buenos Aires, Argentina.
FAU - Mustafa, Rima
AU  - Mustafa R
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      United Kingdom.
FAU - Nayagam, Shevanthi
AU  - Nayagam S
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Ngamprasertchai, Thundon
AU  - Ngamprasertchai T
AD  - Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
      University, Bangkok, Thailand.
FAU - Njeri, Ng'ang'a Irene Hannah
AU  - Njeri NIH
AD  - Kenyan Ministry of Health, Kiambu County, Kenya.
FAU - Nogueira, Mauricio L
AU  - Nogueira ML
AD  - Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP), Sao Jose do Rio Preto,
      Brazil.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - OneHealth Global Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Perroud, Mauricio W Jr
AU  - Perroud MW Jr
AD  - School of Medical Sciences; University of Campinas, Campinas, Brazil.
FAU - Phillips, Andrew N
AU  - Phillips AN
AD  - Institute for Global Health, University College London, London, United Kingdom.
FAU - Promsin, Panuwat
AU  - Promsin P
AD  - Critical Care Division, Department of Medicine, Faculty of Medicine Siriraj
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Qavi, Ambar
AU  - Qavi A
AD  - School of Public Health, Imperial College London, London, United Kingdom.
FAU - Rodger, Alison J
AU  - Rodger AJ
AD  - Institute for Global Health, University College London, London, United Kingdom.
FAU - Sabino, Ester C
AU  - Sabino EC
AD  - Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de Sao
      Paulo, Sao Paulo, Brazil.
FAU - Sangkaew, Sorawat
AU  - Sangkaew S
AD  - Section of Adult Infectious Disease, Department of Infectious Disease, Faculty of
      Medicine, Imperial College London, London, UK.
FAU - Sari, Djayanti
AU  - Sari D
AD  - Department of Anesthesiology and Intensive Theraphy, Faculty of Medicine, Public 
      Health and Nursing Universitas Gadjah Mada. Public Hospital Dr. Sardjito,
      Yogyakarta.
FAU - Sirijatuphat, Rujipas
AU  - Sirijatuphat R
AD  - Division of Infectious Diseases and Tropical Medicine, Department of Medicine,
      Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Sposito, Andrei C
AU  - Sposito AC
AD  - Atherosclerosis and Vascular Biology Laboratory, State University of Campinas,
      Campinas, Brazil.
FAU - Srisangthong, Pratthana
AU  - Srisangthong P
AD  - Bangkok Christian Hospital, Bangkok, Thailand.
FAU - Thompson, Hayley A
AU  - Thompson HA
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Udwadia, Zarir
AU  - Udwadia Z
AD  - Hinduja Hospital and Research Centre, Mumbai, India.
FAU - Valderrama-Beltran, Sandra
AU  - Valderrama-Beltran S
AD  - Division of Infectious Diseases. School of Medicine. Pontificia Universidad
      Javeriana, Hospital Universitario San Ignacio. Bogota, Colombia.
FAU - Winskill, Peter
AU  - Winskill P
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Ghani, Azra C
AU  - Ghani AC
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Walker, Patrick G T
AU  - Walker PGT
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
FAU - Hallett, Timothy B
AU  - Hallett TB
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, United Kingdom.
LA  - eng
GR  - MC_UU_00004/04/MRC_/Medical Research Council/United Kingdom
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S019510/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20210921
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
SB  - IM
EDAT- 2021/09/23 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/09/22 07:15
PHST- 2021/06/24 00:00 [received]
PHST- 2021/09/22 07:15 [entrez]
PHST- 2021/09/23 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - 6373521 [pii]
AID - 10.1093/cid/ciab837 [doi]
PST - aheadofprint
SO  - Clin Infect Dis. 2021 Sep 21. pii: 6373521. doi: 10.1093/cid/ciab837.

PMID- 34527281
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220405
IS  - 2057-1577 (Print)
IS  - 2057-1577 (Linking)
VI  - 7
IP  - 2
DP  - 2021
TI  - Genomic epidemiology of SARS-CoV-2 transmission lineages in Ecuador.
PG  - veab051
LID - 10.1093/ve/veab051 [doi]
AB  - Characterisation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 
      genetic diversity through space and time can reveal trends in virus importation
      and domestic circulation and permit the exploration of questions regarding the
      early transmission dynamics. Here, we present a detailed description of
      SARS-CoV-2 genomic epidemiology in Ecuador, one of the hardest hit countries
      during the early stages of the coronavirus-19 pandemic. We generated and analysed
      160 whole genome sequences sampled from all provinces of Ecuador in 2020.
      Molecular clock and phylogeographic analysis of these sequences in the context of
      global SARS-CoV-2 diversity enable us to identify and characterise individual
      transmission lineages within Ecuador, explore their spatiotemporal distributions,
      and consider their introduction and domestic circulation. Our results reveal a
      pattern of multiple international importations across the country, with apparent 
      differences between key provinces. Transmission lineages were mostly introduced
      before the implementation of non-pharmaceutical interventions, with differential 
      degrees of persistence and national dissemination.
CI  - (c) The Author(s) 2021. Published by Oxford University Press.
FAU - Gutierrez, Bernardo
AU  - Gutierrez B
AUID- ORCID: https://orcid.org/0000-0002-9220-2739
AD  - Department of Zoology, University of Oxford, Oxford, Oxfordshire OX1 3SY, UK.
FAU - Marquez, Sully
AU  - Marquez S
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito 170901,
      Ecuador.
FAU - Prado-Vivar, Belen
AU  - Prado-Vivar B
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito 170901,
      Ecuador.
FAU - Becerra-Wong, Monica
AU  - Becerra-Wong M
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito 170901,
      Ecuador.
FAU - Guadalupe, Juan Jose
AU  - Guadalupe JJ
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito, Quito
      170901, Ecuador.
FAU - Candido, Darlan Da Silva
AU  - Candido DDS
AD  - Department of Zoology, University of Oxford, Oxford, Oxfordshire OX1 3SY, UK.
FAU - Fernandez-Cadena, Juan Carlos
AU  - Fernandez-Cadena JC
AD  - Omics Sciences Laboratory, Faculty of Medical Sciences, Universidad de
      Especialidades Espiritu Santo, Samborondon 092301, Ecuador.
FAU - Morey-Leon, Gabriel
AU  - Morey-Leon G
AD  - Faculty of Medical Sciences, Universidad de Guayaquil, Guayaquil 090613, Ecuador.
FAU - Armas-Gonzalez, Ruben
AU  - Armas-Gonzalez R
AD  - Faculty of Sciences, Escuela Superior Politecnica del Litoral, Guayaquil 090112, 
      Ecuador.
FAU - Andrade-Molina, Derly Madeleiny
AU  - Andrade-Molina DM
AD  - Omics Sciences Laboratory, Faculty of Medical Sciences, Universidad de
      Especialidades Espiritu Santo, Samborondon 092301, Ecuador.
FAU - Bruno, Alfredo
AU  - Bruno A
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil 3961, Ecuador.
FAU - De Mora, Domenica
AU  - De Mora D
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil 3961, Ecuador.
FAU - Olmedo, Maritza
AU  - Olmedo M
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil 3961, Ecuador.
FAU - Portugal, Denisse
AU  - Portugal D
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil 3961, Ecuador.
FAU - Gonzalez, Manuel
AU  - Gonzalez M
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil 3961, Ecuador.
FAU - Orlando, Alberto
AU  - Orlando A
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil 3961, Ecuador.
FAU - Drexler, Jan Felix
AU  - Drexler JF
AUID- ORCID: https://orcid.org/0000-0002-3509-0232
AD  - Institute of Virology, Charite-Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin 10117, Germany.
FAU - Moreira-Soto, Andres
AU  - Moreira-Soto A
AD  - Institute of Virology, Charite-Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin 10117, Germany.
FAU - Sander, Anna-Lena
AU  - Sander AL
AD  - Institute of Virology, Charite-Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin 10117, Germany.
FAU - Brunink, Sebastian
AU  - Brunink S
AD  - Institute of Virology, Charite-Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin 10117, Germany.
FAU - Kuhne, Arne
AU  - Kuhne A
AD  - Institute of Virology, Charite-Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin 10117, Germany.
FAU - Patino, Leandro
AU  - Patino L
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil 3961, Ecuador.
FAU - Carrazco-Montalvo, Andres
AU  - Carrazco-Montalvo A
AD  - Instituto Nacional de Investigacion en Salud Publica, Quito 170403, Ecuador.
FAU - Mestanza, Orson
AU  - Mestanza O
AUID- ORCID: https://orcid.org/0000-0001-7268-0496
AD  - Servicio de Genetica, Instituto Nacional de Salud del Nino San Borja, Lima 15037,
      Peru.
FAU - Zurita, Jeannete
AU  - Zurita J
AD  - Facultad de Medicina, Pontificia Universidad Catolica del Ecuador, Quito 170143, 
      Ecuador.
FAU - Sevillano, Gabriela
AU  - Sevillano G
AD  - Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito
      170104, Ecuador.
FAU - Du Plessis, Louis
AU  - Du Plessis L
AD  - Department of Zoology, University of Oxford, Oxford, Oxfordshire OX1 3SY, UK.
FAU - McCrone, John T
AU  - McCrone JT
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3JW,
      UK.
FAU - Coloma, Josefina
AU  - Coloma J
AD  - School of Public Health, University of California, Berkeley CA 94704, USA.
FAU - Trueba, Gabriel
AU  - Trueba G
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito 170901,
      Ecuador.
FAU - Barragan, Veronica
AU  - Barragan V
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito 170901,
      Ecuador.
FAU - Rojas-Silva, Patricio
AU  - Rojas-Silva P
AUID- ORCID: https://orcid.org/0000-0002-9611-3661
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito 170901,
      Ecuador.
FAU - Grunauer, Michelle
AU  - Grunauer M
AD  - Escuela de Medicina, Universidad San Francisco de Quito, Quito 170901, Ecuador.
FAU - Kraemer, Moritz U G
AU  - Kraemer MUG
AD  - Department of Zoology, University of Oxford, Oxford, Oxfordshire OX1 3SY, UK.
FAU - Faria, Nuno R
AU  - Faria NR
AD  - Department of Zoology, University of Oxford, Oxford, Oxfordshire OX1 3SY, UK.
FAU - Escalera-Zamudio, Marina
AU  - Escalera-Zamudio M
AD  - Department of Zoology, University of Oxford, Oxford, Oxfordshire OX1 3SY, UK.
FAU - Pybus, Oliver G
AU  - Pybus OG
AUID- ORCID: https://orcid.org/0000-0002-8797-2667
AD  - Department of Zoology, University of Oxford, Oxford, Oxfordshire OX1 3SY, UK.
FAU - Cardenas, Paul
AU  - Cardenas P
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito 170901,
      Ecuador.
LA  - eng
GR  - D43 TW010540/TW/FIC NIH HHS/United States
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S019510/1/MRC_/Medical Research Council/United Kingdom
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20210604
PL  - England
TA  - Virus Evol
JT  - Virus evolution
JID - 101664675
UOF - medRxiv. 2021 Apr 05;:. PMID: 33851177
PMC - PMC8244811
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - molecular epidemiology
OT  - phylogenetics
OT  - phylogeography
OT  - transmission lineages
EDAT- 2021/09/17 06:00
MHDA- 2021/09/17 06:01
CRDT- 2021/09/16 07:09
PHST- 2021/04/01 00:00 [received]
PHST- 2021/05/12 00:00 [revised]
PHST- 2021/06/03 00:00 [accepted]
PHST- 2021/09/16 07:09 [entrez]
PHST- 2021/09/17 06:00 [pubmed]
PHST- 2021/09/17 06:01 [medline]
AID - 10.1093/ve/veab051 [doi]
AID - veab051 [pii]
PST - epublish
SO  - Virus Evol. 2021 Jun 4;7(2):veab051. doi: 10.1093/ve/veab051. eCollection 2021.

PMID- 34428682
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1873-4200 (Electronic)
IS  - 0301-4622 (Linking)
VI  - 278
DP  - 2021 Nov
TI  - Comparative study of the interaction of ivermectin with proteins of interest
      associated with SARS-CoV-2: A computational and biophysical approach.
PG  - 106677
LID - S0301-4622(21)00159-9 [pii]
LID - 10.1016/j.bpc.2021.106677 [doi]
AB  - The SARS-CoV-2 pandemic has accelerated the study of existing drugs. The mixture 
      of homologs called ivermectin (avermectin-B1a [HB1a] + avermectin-B1b [HB1b]) has
      shown antiviral activity against SARS-CoV-2 in vitro. However, there are few
      reports on the behavior of each homolog. We investigated the interaction of each 
      homolog with promising targets of interest associated with SARS-CoV-2 infection
      from a biophysical and computational-chemistry perspective using docking and
      molecular dynamics. We observed a differential behavior for each homolog, with an
      affinity of HB1b for viral structures, and of HB1a for host structures
      considered. The induced disturbances were differential and influenced by the
      hydrophobicity of each homolog and of the binding pockets. We present the first
      comparative analysis of the potential theoretical inhibitory effect of both
      avermectins on biomolecules associated with COVID-19, and suggest that ivermectin
      through its homologs, has a multiobjective behavior.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Gonzalez-Paz, Lenin
AU  - Gonzalez-Paz L
AD  - Universidad del Zulia (LUZ), Facultad Experimental de Ciencias (FEC),
      Departamento de Biologia, Laboratorio de Genetica y Biologia Molecular (LGBM),
      4001 Maracaibo, Venezuela; Instituto Venezolano de Investigaciones Cientificas
      (IVIC), Centro de Estudios Botanicos y Agroforestales (CEBA), Laboratorio de
      Proteccion Vegetal (LPV), 4001 Maracaibo, Venezuela. Electronic address:
      lgonzalezpaz@gmail.com.
FAU - Hurtado-Leon, Maria Laura
AU  - Hurtado-Leon ML
AD  - Universidad del Zulia (LUZ), Facultad Experimental de Ciencias (FEC),
      Departamento de Biologia, Laboratorio de Genetica y Biologia Molecular (LGBM),
      4001 Maracaibo, Venezuela.
FAU - Lossada, Carla
AU  - Lossada C
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Centro de
      Investigacion y Tecnologia de Materiales (CITeMA), Laboratorio de Caracterizacion
      Molecular y Biomolecular, 4001 Maracaibo, Venezuela.
FAU - Fernandez-Materan, Francelys V
AU  - Fernandez-Materan FV
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Centro de
      Investigacion y Tecnologia de Materiales (CITeMA), Laboratorio de Caracterizacion
      Molecular y Biomolecular, 4001 Maracaibo, Venezuela.
FAU - Vera-Villalobos, Joan
AU  - Vera-Villalobos J
AD  - Facultad de Ciencias Naturales y Matematicas, Departamento de Quimica y Ciencias 
      Ambientales, Laboratorio de Analisis Quimico Instrumental (LAQUINS), Escuela
      Superior Politecnica del Litoral, Guayaquil, Ecuador.
FAU - Lorono, Marcos
AU  - Lorono M
AD  - Departamento Academico de Quimica Analitica e Instrumental, Facultad de Quimica e
      Ingenieria Quimica, Universidad Nacional Mayor de San Marcos, Lima, Peru.
FAU - Paz, J L
AU  - Paz JL
AD  - Departamento Academico de Quimica Inorganica, Facultad de Quimica e Ingenieria
      Quimica, Universidad Nacional Mayor de San Marcos, Lima, Peru.
FAU - Jeffreys, Laura
AU  - Jeffreys L
AD  - Centre for Drugs and Diagnostics, Department of Tropical Disease Biology,
      Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
FAU - Alvarado, Ysaias J
AU  - Alvarado YJ
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Centro de
      Investigacion y Tecnologia de Materiales (CITeMA), Laboratorio de Caracterizacion
      Molecular y Biomolecular, 4001 Maracaibo, Venezuela. Electronic address:
      alvaradoysaias@gmail.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20210819
PL  - Netherlands
TA  - Biophys Chem
JT  - Biophysical chemistry
JID - 0403171
RN  - 0 (Antiviral Agents)
RN  - 0 (KPNB1 protein, human)
RN  - 0 (alpha Karyopherins)
RN  - 0 (beta Karyopherins)
RN  - 0 (karyopherin alpha 2)
RN  - 70288-86-7 (Ivermectin)
RN  - 73989-17-0 (avermectin)
RN  - EC 3.4.22.28 (Coronavirus 3C Proteases)
RN  - EC 3.6.4.- (DNA Helicases)
SB  - IM
MH  - Animals
MH  - Antiviral Agents/*chemistry/pharmacology
MH  - Binding Sites
MH  - COVID-19/drug therapy/virology
MH  - Coronavirus 3C Proteases/*antagonists & inhibitors/chemistry/metabolism
MH  - DNA Helicases/*antagonists & inhibitors/chemistry/metabolism
MH  - Humans
MH  - Ivermectin/*analogs & derivatives/chemistry/pharmacology
MH  - Kinetics
MH  - Mice
MH  - Molecular Docking Simulation
MH  - Molecular Dynamics Simulation
MH  - Protein Binding
MH  - Protein Conformation
MH  - Protein Interaction Domains and Motifs
MH  - SARS-CoV-2/chemistry/drug effects/enzymology
MH  - Thermodynamics
MH  - alpha Karyopherins/*antagonists & inhibitors/chemistry/metabolism
MH  - beta Karyopherins/*antagonists & inhibitors/chemistry/metabolism
PMC - PMC8373590
OTO - NOTNLM
OT  - *Avermectin
OT  - *COVID-19
OT  - *Ivermectin
OT  - *Molecular docking
OT  - *Molecular dynamic
OT  - *SARS-CoV-2
EDAT- 2021/08/25 06:00
MHDA- 2021/10/08 06:00
CRDT- 2021/08/24 20:20
PHST- 2021/04/29 00:00 [received]
PHST- 2021/08/13 00:00 [revised]
PHST- 2021/08/15 00:00 [accepted]
PHST- 2021/08/25 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2021/08/24 20:20 [entrez]
AID - S0301-4622(21)00159-9 [pii]
AID - 10.1016/j.bpc.2021.106677 [doi]
PST - ppublish
SO  - Biophys Chem. 2021 Nov;278:106677. doi: 10.1016/j.bpc.2021.106677. Epub 2021 Aug 
      19.

PMID- 34343704
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211012
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 111
DP  - 2021 Oct
TI  - Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 
      seropositive individuals may need just one vaccine dose.
PG  - 261-266
LID - S1201-9712(21)00626-3 [pii]
LID - 10.1016/j.ijid.2021.07.070 [doi]
AB  - INTRODUCTION: We evaluated the immunoglobulin (Ig) G antibody response against
      the nucleocapsid protein (NP) and the receptor-binding domain (RBD) of the spike 
      protein of SARS-CoV-2 in a cohort of 86 individuals in Venezuela, before and
      after receiving the Sputnik V vaccine. METHODS: Antibody responses against NP and
      RBD were determined with an enzyme-linked immunosorbent assay just before, 3
      weeks after the first, and 6 weeks after the second dose of the vaccine. RESULTS:
      Before vaccination, 59 individuals were seronegative, and 27 seropositive for NP 
      and/or RBD. Of the seronegative cohort, 42% did not develop an IgG immune
      response against RBD after the first vaccine dose, but 100% had a strong IgG
      response after 2 doses. All seropositive individuals developed a strong IgG
      antibody response against RBD after the first vaccine dose, with antibody levels 
      approximately 40% higher than seronegative individuals who had received 2 doses. 
      Previously seropositive subjects showed no significant increase in IgG antibody
      response against RBD after the second vaccine dose. CONCLUSIONS: We demonstrate
      that 2 doses of the Sputnik V vaccine triggered antibody response in all study
      individuals. The second Sputnik V dose had no impact on IgG response for those
      seropositive for SARS-CoV-2 antigens before vaccination.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Claro, Franklin
AU  - Claro F
AD  - Servicio Autonomo Instituto de Biomedicina, Universidad Central de Venezuela,
      Caracas, Venezuela.
FAU - Silva, Douglas
AU  - Silva D
AD  - Servicio Autonomo Instituto de Biomedicina, Universidad Central de Venezuela,
      Caracas, Venezuela.
FAU - Rodriguez, Melissa
AU  - Rodriguez M
AD  - Servicio Autonomo Instituto de Biomedicina, Universidad Central de Venezuela,
      Caracas, Venezuela.
FAU - Rangel, Hector Rafael
AU  - Rangel HR
AD  - Instituto Venezolano de Investigaciones Cientificas (IVIC), Los Teques,
      Venezuela.
FAU - de Waard, Jacobus H
AU  - de Waard JH
AD  - Servicio Autonomo Instituto de Biomedicina, Universidad Central de Venezuela,
      Caracas, Venezuela; Facultad de Ciencias de la Salud, Universidad de Las Americas
      (UDLA), Quito, Ecuador. Electronic address: jacobus.dewaard@udla.edu.ec.
LA  - eng
PT  - Journal Article
DEP - 20210731
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines)
SB  - IM
MH  - Antibodies, Viral
MH  - Antibody Formation
MH  - *COVID-19
MH  - Humans
MH  - Immunoglobulin G
MH  - SARS-CoV-2
MH  - *Vaccines
PMC - PMC8325383
OTO - NOTNLM
OT  - IgG antibodies
OT  - S/P ratio
OT  - Sputnik V vaccine
OT  - nucleocapsid protein (NP)
OT  - receptor-binding domain (RBD)
OT  - vaccine booster dose
EDAT- 2021/08/04 06:00
MHDA- 2021/10/08 06:00
CRDT- 2021/08/03 20:15
PHST- 2021/06/08 00:00 [received]
PHST- 2021/07/27 00:00 [revised]
PHST- 2021/07/28 00:00 [accepted]
PHST- 2021/08/04 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2021/08/03 20:15 [entrez]
AID - S1201-9712(21)00626-3 [pii]
AID - 10.1016/j.ijid.2021.07.070 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Oct;111:261-266. doi: 10.1016/j.ijid.2021.07.070. Epub
      2021 Jul 31.

PMID- 34305903
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - ROS/RNS Balancing, Aerobic Fermentation Regulation and Cell Cycle Control - a
      Complex Early Trait ('CoV-MAC-TED') for Combating SARS-CoV-2-Induced Cell
      Reprogramming.
PG  - 673692
LID - 10.3389/fimmu.2021.673692 [doi]
AB  - In a perspective entitled 'From plant survival under severe stress to anti-viral 
      human defense' we raised and justified the hypothesis that transcript level
      profiles of justified target genes established from in vitro somatic
      embryogenesis (SE) induction in plants as a reference compared to virus-induced
      profiles can identify differential virus signatures that link to harmful
      reprogramming. A standard profile of selected genes named 'ReprogVirus' was
      proposed for in vitro-scanning of early virus-induced reprogramming in critical
      primary infected cells/tissues as target trait. For data collection, the
      'ReprogVirus platform' was initiated. This initiative aims to identify in a
      common effort across scientific boundaries critical virus footprints from diverse
      virus origins and variants as a basis for anti-viral strategy design. This
      approach is open for validation and extension. In the present study, we initiated
      validation by experimental transcriptome data available in public domain combined
      with advancing plant wet lab research. We compared plant-adapted transcriptomes
      according to 'RegroVirus' complemented by alternative oxidase (AOX) genes during 
      de novo programming under SE-inducing conditions with in vitro corona
      virus-induced transcriptome profiles. This approach enabled identifying a major
      complex trait for early de novo programming during SARS-CoV-2 infection, called
      'CoV-MAC-TED'. It consists of unbalanced ROS/RNS levels, which are connected to
      increased aerobic fermentation that links to alpha-tubulin-based cell
      restructuration and progression of cell cycle. We conclude that
      anti-viral/anti-SARS-CoV-2 strategies need to rigorously target 'CoV-MAC-TED' in 
      primary infected nose and mouth cells through prophylactic and very early
      therapeutic strategies. We also discuss potential strategies in the view of the
      beneficial role of AOX for resilient behavior in plants. Furthermore, following
      the general observation that ROS/RNS equilibration/redox homeostasis is of utmost
      importance at the very beginning of viral infection, we highlight that
      'de-stressing' disease and social handling should be seen as essential part of
      anti-viral/anti-SARS-CoV-2 strategies.
CI  - Copyright (c) 2021 Costa, Mohanapriya, Bharadwaj, Noceda, Thiers, Aziz,
      Srivastava, Oliveira, Gupta, Kumari, Sircar, Kumar, Achra, Sathishkumar, Adholeya
      and Arnholdt-Schmitt.
FAU - Costa, Jose Helio
AU  - Costa JH
AD  - Functional Genomics and Bioinformatics Group, Department of Biochemistry and
      Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
FAU - Mohanapriya, Gunasekaran
AU  - Mohanapriya G
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Plant Genetic Engineering Laboratory, Department of Biotechnology, Bharathiar
      University, Coimbatore, India.
FAU - Bharadwaj, Revuru
AU  - Bharadwaj R
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Plant Genetic Engineering Laboratory, Department of Biotechnology, Bharathiar
      University, Coimbatore, India.
FAU - Noceda, Carlos
AU  - Noceda C
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Cell and Molecular Biotechnology of Plants (BIOCEMP)/Industrial Biotechnology and
      Bioproducts, Departamento de Ciencias de la Vida y de la Agricultura, Universidad
      de las Fuerzas Armadas-ESPE, Sangolqui, Ecuador.
FAU - Thiers, Karine Leitao Lima
AU  - Thiers KLL
AD  - Functional Genomics and Bioinformatics Group, Department of Biochemistry and
      Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
FAU - Aziz, Shahid
AU  - Aziz S
AD  - Functional Genomics and Bioinformatics Group, Department of Biochemistry and
      Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
FAU - Srivastava, Shivani
AU  - Srivastava S
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Centre for Mycorrhizal Research, Sustainable Agriculture Division, The Energy and
      Resources, Institute (TERI), TERI Gram, Gurugram, India.
FAU - Oliveira, Manuela
AU  - Oliveira M
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Department of Mathematics and CIMA - Center for Research on Mathematics and Its
      Applications, Universidade de Evora, Evora, Portugal.
FAU - Gupta, Kapuganti Jagadis
AU  - Gupta KJ
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi,
      India.
FAU - Kumari, Aprajita
AU  - Kumari A
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi,
      India.
FAU - Sircar, Debabrata
AU  - Sircar D
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Department of Biotechnology, Indian Institute of Technology Roorkee, Uttarakhand,
      India.
FAU - Kumar, Sarma Rajeev
AU  - Kumar SR
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Plant Genetic Engineering Laboratory, Department of Biotechnology, Bharathiar
      University, Coimbatore, India.
FAU - Achra, Arvind
AU  - Achra A
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Department of Microbiology, Atal Bihari Vajpayee Institute of Medical Sciences & 
      Dr Ram Manohar Lohia Hospital, New Delhi, India.
FAU - Sathishkumar, Ramalingam
AU  - Sathishkumar R
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Plant Genetic Engineering Laboratory, Department of Biotechnology, Bharathiar
      University, Coimbatore, India.
FAU - Adholeya, Alok
AU  - Adholeya A
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
AD  - Centre for Mycorrhizal Research, Sustainable Agriculture Division, The Energy and
      Resources, Institute (TERI), TERI Gram, Gurugram, India.
FAU - Arnholdt-Schmitt, Birgit
AU  - Arnholdt-Schmitt B
AD  - Functional Genomics and Bioinformatics Group, Department of Biochemistry and
      Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
AD  - Non-Institutional Competence Focus (NICFocus) 'Functional Cell Reprogramming and 
      Organism Plasticity' (FunCROP), coordinated from Foros de Vale de Figueira,
      Alentejo, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210707
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (Plant Proteins)
RN  - 0 (Reactive Nitrogen Species)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Tubulin)
RN  - EC 1.- (Oxidoreductases)
RN  - EC 1.- (alternative oxidase)
RN  - EC 2.1.1.4 (ASMT protein, human)
RN  - EC 2.1.1.4 (Acetylserotonin O-Methyltransferase)
SB  - IM
MH  - Acetylserotonin O-Methyltransferase/genetics
MH  - Arabidopsis/genetics/growth & development
MH  - Cell Cycle/genetics
MH  - Cellular Reprogramming/*genetics
MH  - Databases, Genetic
MH  - Daucus carota/genetics/growth & development
MH  - Fermentation
MH  - Gene Expression Profiling
MH  - Humans
MH  - Mitochondrial Proteins/genetics/metabolism
MH  - Multifactorial Inheritance/*genetics
MH  - Oxidoreductases/genetics/metabolism
MH  - Plant Proteins/genetics/metabolism
MH  - Reactive Nitrogen Species/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - SARS-CoV-2/*pathogenicity
MH  - Tubulin/genetics
MH  - Viruses/pathogenicity
PMC - PMC8293103
OTO - NOTNLM
OT  - *SARS-CoV-2
OT  - *alternative oxidase
OT  - *mTOR
OT  - *melatonin
OT  - *redox biology
OT  - *repurposing drugs
OT  - *tubulin
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/07/27 06:00
MHDA- 2021/08/06 06:00
CRDT- 2021/07/26 06:24
PHST- 2021/02/28 00:00 [received]
PHST- 2021/06/17 00:00 [accepted]
PHST- 2021/07/26 06:24 [entrez]
PHST- 2021/07/27 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
AID - 10.3389/fimmu.2021.673692 [doi]
PST - epublish
SO  - Front Immunol. 2021 Jul 7;12:673692. doi: 10.3389/fimmu.2021.673692. eCollection 
      2021.

PMID- 34279439
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20210723
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 13
DP  - 2021 Jul 5
TI  - Plants and Natural Products with Activity against Various Types of Coronaviruses:
      A Review with Focus on SARS-CoV-2.
LID - 4099 [pii]
LID - 10.3390/molecules26134099 [doi]
AB  - COVID-19 is a pandemic disease caused by the SARS-CoV-2 virus, which is
      potentially fatal for vulnerable individuals. Disease management represents a
      challenge for many countries, given the shortage of medicines and hospital
      resources. The objective of this work was to review the medicinal plants, foods
      and natural products showing scientific evidence for host protection against
      various types of coronaviruses, with a focus on SARS-CoV-2. Natural products that
      mitigate the symptoms caused by various coronaviruses are also presented.
      Particular attention was placed on natural products that stabilize the
      Renin-Angiotensin-Aldosterone System (RAAS), which has been associated with the
      entry of the SARS-CoV-2 into human cells.
FAU - Llivisaca-Contreras, Susana A
AU  - Llivisaca-Contreras SA
AUID- ORCID: 0000-0001-9982-2634
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Centro de Agua y Desarrollo
      Sustentable, CADS, Campus Gustavo Galindo Km. 30.5 via Perimetral, Guayaquil
      EC090112, Ecuador.
FAU - Naranjo-Moran, Jaime
AU  - Naranjo-Moran J
AUID- ORCID: 0000-0002-4410-9337
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Centro de Investigaciones
      Biotecnologicas del Ecuador, CIBE, Campus Gustavo Galindo Km. 30.5 via
      Perimetral, Guayaquil EC090112, Ecuador.
FAU - Pino-Acosta, Andrea
AU  - Pino-Acosta A
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Facultad de Arte, Diseno y
      Comunicacion Audiovisual, FADCOM, Bosque Protector La Prosperina, Campus Gustavo 
      Galindo Km. 30.5 via Perimetral, Guayaquil EC090112, Ecuador.
FAU - Pieters, Luc
AU  - Pieters L
AUID- ORCID: 0000-0002-8288-4254
AD  - Natural Products & Food Research and Analysis (NatuRA), Department of
      Pharmaceutical Sciences, University of Antwerp, 2610 Antwerp, Belgium.
FAU - Vanden Berghe, Wim
AU  - Vanden Berghe W
AUID- ORCID: 0000-0003-0161-7355
AD  - Natural Products & Food Research and Analysis (NatuRA), Department of
      Pharmaceutical Sciences, University of Antwerp, 2610 Antwerp, Belgium.
AD  - Red Universitaria Para la Investigacion y Posgrados Vlir Network, Km. 30.5 via
      Perimetral, Edificio Principal, Vicerrectorado Academico (2 masculine Piso),
      Guayaquil EC090112, Ecuador.
FAU - Manzano, Patricia
AU  - Manzano P
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Centro de Investigaciones
      Biotecnologicas del Ecuador, CIBE, Campus Gustavo Galindo Km. 30.5 via
      Perimetral, Guayaquil EC090112, Ecuador.
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Facultad de Ciencias de la Vida,
      FCV, Centro de Investigaciones Biotecnologicas del Ecuador, CIBE, Campus Gustavo 
      Galindo Km. 30.5 via Perimetral, Guayaquil EC090608, Ecuador.
FAU - Vargas-Perez, Jeffrey
AU  - Vargas-Perez J
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Centro de Investigaciones
      Biotecnologicas del Ecuador, CIBE, Campus Gustavo Galindo Km. 30.5 via
      Perimetral, Guayaquil EC090112, Ecuador.
FAU - Leon-Tamariz, Fabian
AU  - Leon-Tamariz F
AD  - Red Universitaria Para la Investigacion y Posgrados Vlir Network, Km. 30.5 via
      Perimetral, Edificio Principal, Vicerrectorado Academico (2 masculine Piso),
      Guayaquil EC090112, Ecuador.
AD  - Grupo de Plantas Medicinales y Productos Naturales, Departamento de Biociencias, 
      Facultad de Ciencias Quimicas, Universidad de Cuenca, Av. 12 de Abril, Cuenca
      EC010107, Ecuador.
FAU - Cevallos-Cevallos, Juan M
AU  - Cevallos-Cevallos JM
AUID- ORCID: 0000-0003-4609-7998
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Centro de Investigaciones
      Biotecnologicas del Ecuador, CIBE, Campus Gustavo Galindo Km. 30.5 via
      Perimetral, Guayaquil EC090112, Ecuador.
AD  - Red Universitaria Para la Investigacion y Posgrados Vlir Network, Km. 30.5 via
      Perimetral, Edificio Principal, Vicerrectorado Academico (2 masculine Piso),
      Guayaquil EC090112, Ecuador.
AD  - Escuela Superior Politecnica del Litoral, ESPOL, Facultad de Ciencias de la Vida,
      FCV, Centro de Investigaciones Biotecnologicas del Ecuador, CIBE, Campus Gustavo 
      Galindo Km. 30.5 via Perimetral, Guayaquil EC090608, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210705
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antiviral Agents)
RN  - 0 (Biological Products)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Antiviral Agents/metabolism/pharmacology
MH  - Biological Products/metabolism/*pharmacology
MH  - COVID-19/drug therapy/virology
MH  - Coronavirus/*drug effects
MH  - Humans
MH  - Pandemics
MH  - Phytotherapy/*methods
MH  - Plant Extracts/metabolism/*pharmacology
MH  - Plants/chemistry
MH  - Renin-Angiotensin System/drug effects
MH  - SARS-CoV-2/*drug effects
PMC - PMC8271932
OTO - NOTNLM
OT  - angiotensin-converting enzyme inhibitors (ACEi)
OT  - antiviral
OT  - biomolecules
OT  - coronavirus disease of 2019 (COVID-19)
OT  - medicinal plants
OT  - middle east respiratory syndrome (MERS)
OT  - renin-angiotensin-aldosterone system (RAAS)
OT  - severe acute respiratory syndrome coronavirus (SARS-CoV)
OT  - viral entry inhibitors
EDAT- 2021/07/20 06:00
MHDA- 2021/07/24 06:00
CRDT- 2021/07/19 12:52
PHST- 2021/05/22 00:00 [received]
PHST- 2021/06/14 00:00 [revised]
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/07/19 12:52 [entrez]
PHST- 2021/07/20 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
AID - molecules26134099 [pii]
AID - 10.3390/molecules26134099 [doi]
PST - epublish
SO  - Molecules. 2021 Jul 5;26(13). pii: molecules26134099. doi:
      10.3390/molecules26134099.

PMID- 34178716
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 11
DP  - 2021
TI  - Analytical and Clinical Evaluation of "AccuPower SARS-CoV-2 Multiplex RT-PCR kit 
      (Bioneer, South Korea)" and "Allplex 2019-nCoV Assay (Seegene, South Korea)" for 
      SARS-CoV-2 RT-PCR Diagnosis: Korean CDC EUA as a Quality Control Proxy for
      Developing Countries.
PG  - 630552
LID - 10.3389/fcimb.2021.630552 [doi]
AB  - Background: Multiple RT-qPCR kits are available in the market for SARS-CoV-2
      diagnosis, some of them with Emergency Use Authorization (EUA) by FDA or their
      country of origin agency, but many of them lack of proper clinical evaluation.
      Objective: We evaluated the clinical performance of two Korean SARS-CoV-2 RT-PCR 
      kits available in South America, AccuPower SARS-CoV-2 Multiplex RT-PCR kit
      (Bioneer, South Korea) and Allplex 2019-nCoV Assay (Seegene, South Korea), for
      RT-qPCR SARS-CoV-2 diagnosis using the CDC protocol as a gold standard. Results: 
      We found strong differences among both kits clinical performance and analytical
      sensitivity; while the Allplex 2019-nCoV Assay has sensitivity of 96.5% and an
      estimated limit of detection of 4,000 copies/ml, the AccuPower SARS-CoV-2
      Multiplex RT-PCR kit has a sensitivity of 75.5% and limit of detection estimated 
      to be bigger than 20,000 copies/ml. Conclusions: AccuPower SARS-CoV-2 Multiplex
      RT-PCR kit and Allplex 2019-nCoV Assay are both made in South Korea but EUA by
      Korean CDC was only granted to the later. Our results support that Korean CDC EUA
      should be considered as a quality control proxy for Korean SARS-CoV-2 RT-PCR kits
      prior to importation by developing countries to guarantee high sensitivity
      diagnosis.
CI  - Copyright (c) 2021 Freire-Paspuel and Garcia-Bereguiain.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210610
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - *COVID-19
MH  - COVID-19 Testing
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Developing Countries
MH  - Humans
MH  - Quality Control
MH  - Reagent Kits, Diagnostic
MH  - Republic of Korea
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *SARS-CoV-2
MH  - Sensitivity and Specificity
MH  - United States
PMC - PMC8223252
OTO - NOTNLM
OT  - *Bioneer
OT  - *RT-PCR
OT  - *SARS-CoV-2
OT  - *Seegene
OT  - *developing countries
COIS- The authors declare that their affiliation institution "Universidad de Las
      Americas" is involved in the commercialization of "ECUGEN SARS-CoV-2 RT-qPCR
      kit". However, that kit was not used in the present study.
EDAT- 2021/06/29 06:00
MHDA- 2021/07/01 06:00
CRDT- 2021/06/28 06:04
PHST- 2020/11/17 00:00 [received]
PHST- 2021/02/10 00:00 [accepted]
PHST- 2021/06/28 06:04 [entrez]
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - 10.3389/fcimb.2021.630552 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2021 Jun 10;11:630552. doi:
      10.3389/fcimb.2021.630552. eCollection 2021.

PMID- 34166793
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20220317
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 109
DP  - 2021 Aug
TI  - Analytical and clinical evaluation of a heat shock SARS-CoV-2 detection method
      without RNA extraction for N and E genes RT-qPCR.
PG  - 315-320
LID - S1201-9712(21)00526-9 [pii]
LID - 10.1016/j.ijid.2021.06.038 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has caused significant supply shortages
      worldwide for SARS-CoV-2 molecular diagnosis, like RNA extraction kits.
      OBJECTIVE: The aim of our study was to evaluate the clinical performance and
      analytical sensitivity of a simple SARS-CoV-2 diagnosis protocol based on heat
      shock without RNA extraction using both "CDC" (N gene) and "Charite" (E gene)
      RT-qPCR protocols. RESULTS: 1,036 nasopharyngeal samples, 543 of them SARS-CoV-2 
      positive, were analyzed. The heat shock method correctly identified 68.8%
      (232/337) and 89.4% (202/226) of SARS-CoV-2 positive samples for N gene and E
      gene, respectively. Analytical sensitivity was assessed for heat shock method
      using the CDC RT-qPCR protocol, obtaining sensitivity values of 98.6%, 93.3% and 
      84.8% for limit of detection of 100.000, 50.000 and 20.000 viral RNA copies/mL of
      sample. CONCLUSIONS: Our findings show that a simple heat shock SARS-CoV-2
      RT-qPCR diagnosis method without RNA extraction is a reliable alternative for
      potentially infectious SARS-CoV-2 positive patients at the time of testing. This 
      affordable protocol can help overcome the cost and supply shortages for
      SARS-CoV-2 diagnosis, especially in developing countries. In Ecuador, it has been
      used already by laboratories in the public health system for more than 100.000
      specimens.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Bruno, Alfredo
AU  - Bruno A
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador; Universidad Agraria del Ecuador, Guayaquil, Ecuador.
FAU - de Mora, Domenica
AU  - de Mora D
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Rodriguez, Angel S
AU  - Rodriguez AS
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Paredes-Espinosa, Maria Belen
AU  - Paredes-Espinosa MB
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Olmedo, Maritza
AU  - Olmedo M
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador.
FAU - Sanchez, Martha
AU  - Sanchez M
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador.
FAU - Romero, Jennifer
AU  - Romero J
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador.
FAU - Paez, Michelle
AU  - Paez M
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador.
FAU - Gonzalez, Manuel
AU  - Gonzalez M
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador; Universidad de Guayaquil, Guayaquil, Ecuador.
FAU - Orlando, Alberto
AU  - Orlando A
AD  - Instituto Nacional de Salud Publica e Investigacion "Leopoldo Izquieta Perez",
      Guayaquil, Ecuador; Universidad Agraria del Ecuador, Guayaquil, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
      Electronic address: magbereguiain@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20210621
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (RNA, Viral)
SB  - IM
MH  - *COVID-19
MH  - COVID-19 Testing
MH  - Heat-Shock Response
MH  - Humans
MH  - Pandemics
MH  - RNA, Viral/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - *SARS-CoV-2
MH  - Sensitivity and Specificity
PMC - PMC8215877
OTO - NOTNLM
OT  - COVID-19
OT  - Heat shock
OT  - RNA extraction free
OT  - RT-qPCR
OT  - SARS-CoV-2
COIS- Declaration of Competing Interest All authors have no conflict of interest to
      declare.
EDAT- 2021/06/25 06:00
MHDA- 2021/09/01 06:00
CRDT- 2021/06/24 20:12
PHST- 2020/11/04 00:00 [received]
PHST- 2021/06/13 00:00 [revised]
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2021/06/24 20:12 [entrez]
AID - S1201-9712(21)00526-9 [pii]
AID - 10.1016/j.ijid.2021.06.038 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Aug;109:315-320. doi: 10.1016/j.ijid.2021.06.038. Epub
      2021 Jun 21.

PMID- 34149065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210911
IS  - 0022-2860 (Print)
IS  - 0022-2860 (Linking)
VI  - 1244
DP  - 2021 Nov 15
TI  - COVID-19: In silico identification of potent alpha-ketoamide inhibitors targeting
      the main protease of the SARS-CoV-2.
PG  - 130897
LID - 10.1016/j.molstruc.2021.130897 [doi]
AB  - The COVID-19 has been creating a global crisis, causing countless deaths and
      unbearable panic. Despite the progress made in the development of the vaccine,
      there is an urge need for the discovery of antivirals that may better work at
      different stages of SARS-CoV-2 reproduction. The main protease (M(pro)) of the
      SARS-CoV-2 is a crucial therapeutic target due to its critical function in virus 
      replication. The alpha-ketoamide derivatives represent an important class of
      inhibitors against the M(pro) of the SARS-CoV. While there is 99% sequence
      similarity between SARS-CoV and SARS-CoV-2 main proteases, anti-SARS-CoV
      compounds may have a huge demonstration's prospect of their effectiveness against
      the SARS-CoV-2. In this study, we applied various computational approaches to
      investigate the inhibition potency of novel designed alpha-ketoamide-based
      compounds. In this regard, a set of 21 alpha-ketoamides was employed to construct
      a QSAR model, using the genetic algorithm-multiple linear regression (GA-MLR), as
      well as a pharmacophore fit model. Based on the GA-MLR model, 713 new designed
      molecules were reduced to 150 promising hits, which were later subject to the
      established pharmacophore fit model. Among the 150 compounds, the best selected
      compounds (3 hits) with greater pharmacophore fit score were further studied via 
      molecular docking, molecular dynamic simulations along with the Absorption,
      distribution, metabolism, excretion, and toxicity (ADMET) analysis. Our approach 
      revealed that the three hit compounds could serve as potential inhibitors against
      the SARS-CoV-2 M(pro) target.
CI  - (c) 2021 Elsevier B.V. All rights reserved.
FAU - Oubahmane, Mehdi
AU  - Oubahmane M
AD  - Department of Chemistry, Faculty of Sciences Semlalia, BP, 2390 Marrakech,
      Morocco.
FAU - Hdoufane, Ismail
AU  - Hdoufane I
AD  - Department of Chemistry, Faculty of Sciences Semlalia, BP, 2390 Marrakech,
      Morocco.
FAU - Bjij, Imane
AU  - Bjij I
AD  - Department of Chemistry, Faculty of Sciences Semlalia, BP, 2390 Marrakech,
      Morocco.
FAU - Jerves, Carola
AU  - Jerves C
AD  - Departamento de Quimica, Faculdade de Ciencias da Universidade do Porto, Rua do
      Campo Alegre 687, 4169-007 Porto, Portugal.
AD  - Facultad de Ciencias Quimicas, Universidad de Cuenca, Cuenca, Ecuador.
FAU - Villemin, Didier
AU  - Villemin D
AD  - Ecole Nationale Superieure d'Ingenieurs (ENSICAEN) Laboratoire de Chimie
      Moleculaire et Thioorganique. UMR 6507 CNRS, INC3M, FR3038, Labex EMC3, Labex
      SynOrg ENSICAEN & Universite de Caen, France.
FAU - Cherqaoui, Driss
AU  - Cherqaoui D
AD  - Department of Chemistry, Faculty of Sciences Semlalia, BP, 2390 Marrakech,
      Morocco.
LA  - eng
PT  - Journal Article
DEP - 20210616
PL  - Netherlands
TA  - J Mol Struct
JT  - Journal of molecular structure
JID - 0141747
PMC - PMC8205609
OTO - NOTNLM
OT  - Main protease (Mpro)
OT  - Molecular docking
OT  - Molecular dynamics simulations
OT  - Pharmacophore modeling
OT  - QSAR
OT  - SARS-CoV-2
OT  - alpha-Ketoamide
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2021/06/22 06:00
MHDA- 2021/06/22 06:01
CRDT- 2021/06/21 05:43
PHST- 2021/03/25 00:00 [received]
PHST- 2021/06/09 00:00 [revised]
PHST- 2021/06/11 00:00 [accepted]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/06/22 06:01 [medline]
PHST- 2021/06/21 05:43 [entrez]
AID - 10.1016/j.molstruc.2021.130897 [doi]
AID - S0022-2860(21)01030-9 [pii]
PST - ppublish
SO  - J Mol Struct. 2021 Nov 15;1244:130897. doi: 10.1016/j.molstruc.2021.130897. Epub 
      2021 Jun 16.

PMID- 34137643
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 2047-7163 (Electronic)
IS  - 0036-8504 (Linking)
VI  - 104
IP  - 2
DP  - 2021 Apr-Jun
TI  - History of contact with the SARS-COV-2 virus and the sense of coherence in the
      development of psychological distress in the occupational health professionals in
      Spain.
PG  - 368504211026121
LID - 10.1177/00368504211026121 [doi]
AB  - The COVID-19 pandemic has affected the psychological well-being of healthcare
      professionals, among them, on medical and nursing occupational specialists. This 
      study describes the psychological distress that this group has suffered,
      analyzing the effect that the sense of coherence related with the history of
      contact with infected people has generated in their mental health.
      Cross-sectional descriptive study using online questionnaires. Data were
      collected on a sample of 499 subjects, representing 42.0% and 38.8% of the
      associations of specialists in Occupational Medicine and Nursing, respectively. A
      univariate data analysis, independence test, and the CHAID multivariate method
      were carried out. The percentage of workers with high psychological distress was 
      higher among women than among men; this was also higher in public sector workers 
      than in the private sector. No differences have been observed regarding
      psychological distress and educational level, coexistence, having children,
      working away from home, having a pet, or between being a physician or nurse. The 
      most efficient measure to prevent psychological distress was acting regarding the
      comprehensibility dimension of the sense of coherence. Sex, contact with any
      infected person, age, living as a couple, working in public or private centers,
      the availability of diagnostic tests, and the correlation with the manageability 
      dimension were modulating factors. Sense of coherence is an effective measure to 
      prevent psychological distress due to contact with people affected by COVID-19 in
      Occupational Health professionals.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AUID- ORCID: 0000-0001-9053-7730
AD  - Department of Sociology, Social Work and Public Health, Faculty of Labour
      Sciences, University of Huelva, Huelva, Spain.
AD  - Safety and Health Postgraduate Programme, Universidad Espiritu Santo, Guayaquil, 
      Ecuador.
FAU - Ortega-Moreno, Monica
AU  - Ortega-Moreno M
AD  - Department of Economy, Faculty of Labour Sciences, University of Huelva, Huelva, 
      Spain.
FAU - Soriano, Guillermo
AU  - Soriano G
AD  - Spanish Association of Specialists in Occupational Medicine, Madrid, Spain.
FAU - Fagundo-Rivera, Javier
AU  - Fagundo-Rivera J
AD  - Health Sciences Doctorate School, University of Huelva, Huelva, Spain.
AD  - Nursing Department, Atlantica Health School, Barcarena, Portugal.
FAU - Allande-Cusso, Regina
AU  - Allande-Cusso R
AUID- ORCID: 0000-0001-8325-0838
AD  - Nursing Department, University of Seville, Seville, Spain.
FAU - Ruiz-Frutos, Carlos
AU  - Ruiz-Frutos C
AUID- ORCID: 0000-0003-3715-1382
AD  - Department of Sociology, Social Work and Public Health, Faculty of Labour
      Sciences, University of Huelva, Huelva, Spain.
AD  - Safety and Health Postgraduate Programme, Universidad Espiritu Santo, Guayaquil, 
      Ecuador.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Prog
JT  - Science progress
JID - 0411361
SB  - IM
MH  - Adult
MH  - Anxiety/*epidemiology/physiopathology/psychology
MH  - COVID-19/*epidemiology/psychology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Male
MH  - Mental Health/statistics & numerical data
MH  - Middle Aged
MH  - Occupational Health/statistics & numerical data
MH  - *Pandemics
MH  - *Psychological Distress
MH  - SARS-CoV-2/pathogenicity
MH  - *Sense of Coherence
MH  - Spain/epidemiology
MH  - Stress, Psychological/*epidemiology/physiopathology
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *COVID-19
OT  - *Occupational practice
OT  - *occupational health professionals
OT  - *psychological distress
OT  - *sense of coherence
EDAT- 2021/06/18 06:00
MHDA- 2021/07/08 06:00
CRDT- 2021/06/17 12:20
PHST- 2021/06/17 12:20 [entrez]
PHST- 2021/06/18 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
AID - 10.1177/00368504211026121 [doi]
PST - ppublish
SO  - Sci Prog. 2021 Apr-Jun;104(2):368504211026121. doi: 10.1177/00368504211026121.

PMID- 34136351
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 2214-2509 (Print)
IS  - 2214-2509 (Linking)
VI  - 25
DP  - 2021
TI  - SARS-CoV-2 detection and sequencing in heart tissue associated with myocarditis
      and persistent arrhythmia: A case report.
PG  - e01187
LID - 10.1016/j.idcr.2021.e01187 [doi]
AB  - BACKGROUND: SARS-CoV-2 uses the human cell receptor angiotensin-converting enzyme
      (ACE2). ACE2 is widely present in the cardiovascular system including the
      myocardium and the conduction system. COVID-19 patients that present severe
      symptoms have been reported to have complications involving myocardial injuries
      caused by the virus. Here we report the detection of SARS-CoV-2 by whole genome
      sequencing in the endocardium of a patient with severe bradycardia. CASE
      PRESENTATION: We report a case of a 34-year-old male patient with COVID-19 tested
      by PCR, he started with gastrointestinal symptoms, however, he quickly
      deteriorated his hemodynamic state by means of myocarditis and bradycardia. After
      performing an endocardium biopsy, it was possible to identify the presence of
      SARS-CoV-2 in the heart tissue and to sequence its whole genome using the
      ARTIC-Network protocol and a modified tissue RNA extraction method. The patient's
      outcome was improved after a permanent pacemaker was implanted. CONCLUSIONS: It
      was possible to identify a SARS-CoV-2 clade 20A in the endocardium of the
      reported patient.
CI  - (c) 2021 The Author(s).
FAU - Egas, Diego
AU  - Egas D
AD  - Hospital Quito N degrees 1 de la Policia Nacional, Quito, Ecuador.
FAU - Guadalupe, Juan Jose
AU  - Guadalupe JJ
AD  - Universidad San Francisco de Quito, COCIBA, Laboratorio de Biotecnologia Vegetal,
      Quito, Ecuador.
FAU - Prado-Vivar, Belen
AU  - Prado-Vivar B
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Quito,
      Ecuador.
AD  - Universidad San Francisco de Quito, Centro de Bioinformatica, Quito, Ecuador.
FAU - Becerra-Wong, Monica
AU  - Becerra-Wong M
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Quito,
      Ecuador.
FAU - Marquez, Sully
AU  - Marquez S
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Quito,
      Ecuador.
FAU - Castillo, Stalin
AU  - Castillo S
AD  - Hospital Quito N degrees 1 de la Policia Nacional, Quito, Ecuador.
FAU - Latta, Johanna
AU  - Latta J
AD  - Hospital Quito N degrees 1 de la Policia Nacional, Quito, Ecuador.
FAU - Rodriguez, Francisco
AU  - Rodriguez F
AD  - Hospital Metropolitano, Quito, Ecuador.
FAU - Escorza, Giovanni
AU  - Escorza G
AD  - Hospital Metropolitano, Quito, Ecuador.
FAU - Trueba, Gabriel
AU  - Trueba G
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Quito,
      Ecuador.
FAU - Grunauer, Michelle
AU  - Grunauer M
AD  - Universidad San Francisco de Quito, Escuela de Medicina, Quito, Ecuador.
FAU - Barragan, Veronica
AU  - Barragan V
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Quito,
      Ecuador.
FAU - Rojas-Silva, Patricio
AU  - Rojas-Silva P
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Quito,
      Ecuador.
FAU - Cardenas, Paul
AU  - Cardenas P
AD  - Universidad San Francisco de Quito, COCIBA, Instituto de Microbiologia, Quito,
      Ecuador.
AD  - Universidad San Francisco de Quito, Centro de Bioinformatica, Quito, Ecuador.
LA  - eng
GR  - D43 TW010540/TW/FIC NIH HHS/United States
PT  - Case Reports
DEP - 20210611
PL  - Netherlands
TA  - IDCases
JT  - IDCases
JID - 101634540
PMC - PMC8192838
OTO - NOTNLM
OT  - Arrhythmia
OT  - COVID-19
OT  - MinION
OT  - Myocarditis
OT  - Pacemaker
OT  - SARS-CoV-2
COIS- The authors report no declarations of interest.
EDAT- 2021/06/18 06:00
MHDA- 2021/06/18 06:01
CRDT- 2021/06/17 06:46
PHST- 2020/10/21 00:00 [received]
PHST- 2021/06/10 00:00 [accepted]
PHST- 2021/06/17 06:46 [entrez]
PHST- 2021/06/18 06:00 [pubmed]
PHST- 2021/06/18 06:01 [medline]
AID - 10.1016/j.idcr.2021.e01187 [doi]
AID - S2214-2509(21)00143-8 [pii]
PST - ppublish
SO  - IDCases. 2021;25:e01187. doi: 10.1016/j.idcr.2021.e01187. Epub 2021 Jun 11.

PMID- 34124775
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 69
IP  - 10
DP  - 2021 Oct
TI  - Hand grip strength before and after SARS-CoV-2 infection in community-dwelling
      older adults.
PG  - 2722-2731
LID - 10.1111/jgs.17335 [doi]
AB  - OBJECTIVE: To assess the association between SARS-CoV-2 infection and decreased
      hand grip strength (HGS). DESIGN: Longitudinal population-based study. SETTING:
      Community-dwelling older adults (aged >/=60 years) living in a rural Ecuadorian
      village struck by the SARS-CoV-2 pandemic. PARTICIPANTS: Of 282 enrolled
      individuals, 254 (90%) finished the study. MEASUREMENTS: HGS was measured 3
      months before (January 2020) and 9 months after the introduction of the virus
      into the population (January 2021). SARS-CoV-2 antibody testing was performed in 
      two rounds: in May-June (early) and September-November (late), 2020. An
      independent association between SARS-CoV-2 infection and HGS decline was assessed
      by fitting linear mixed models for longitudinal data. Changes in HGS scores in
      SARS-CoV-2 seropositive subjects, according to the time elapsed since
      seroconversion, were compared with those who remained seronegative. RESULTS:
      Overall, 149 (59%) individuals became seropositive for SARS-CoV-2. The mean HGS
      (in kg) was 25.3 +/- 8.3 at baseline and 23.7 +/- 8.1 at follow-up (p = 0.028),
      with 140 individuals having >5% HGS decline between both measurements. The
      follow-up HGS measurement decreased by 1.72 kg in seropositive individuals, and
      by 0.57 kg in their seronegative counterparts (p < 0.001). SARS-CoV-2
      seropositive individuals were 2.27 times more likely (95% CI: 1.33-3.87) to have 
      a lower HGS measurement at the time of follow-up than those who remained
      seronegative. When compared with seronegative subjects, seropositive patients
      with early seroconversion were 3.41 times (95% CI: 1.73-6.74) more likely to have
      >5% HGS decline at the time of the follow-up than those with later, i.e., more
      recent, infections. CONCLUSIONS: This study shows an independent deleterious
      impact of SARS-CoV-2 on HGS that is more marked among individuals with infections
      that occurred more than 8 months before follow-up HGS. Results suggest the
      possibility of chronic damage to skeletal muscles by SARS-CoV-2.
CI  - (c) 2021 The American Geriatrics Society.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador, Samborondon, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc., Foster City, California, USA.
FAU - Perez, Pedro
AU  - Perez P
AD  - Department of Psychiatry, Mount Sinai Morningside, New York, New York, USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Department of Neurology, Hospital Universitario Reina Sofia, Cordoba, Spain.
FAU - Sedler, Mark J
AU  - Sedler MJ
AD  - Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
LA  - eng
GR  - Renaissance School of Medicine, Stony Brook University, New York, NY, USA
GR  - Universidad Espiritu Santo - Ecuador
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210619
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - post-acute COVID-19 syndrome
SB  - IM
MH  - Aftercare/methods/statistics & numerical data
MH  - Aged
MH  - COVID-19/*complications/diagnosis/epidemiology/physiopathology
MH  - COVID-19 Serological Testing/methods
MH  - Ecuador/epidemiology
MH  - Female
MH  - *Geriatric Assessment/methods/statistics & numerical data
MH  - *Hand Strength
MH  - Health Services for the Aged/statistics & numerical data
MH  - Humans
MH  - Independent Living/statistics & numerical data
MH  - Longitudinal Studies
MH  - Male
MH  - Rural Population
MH  - SARS-CoV-2/*isolation & purification
PMC - PMC8447376
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *hand grip
OT  - *older adults
OT  - *rural communities
EDAT- 2021/06/15 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/06/14 10:01
PHST- 2021/06/02 00:00 [revised]
PHST- 2021/02/28 00:00 [received]
PHST- 2021/06/07 00:00 [accepted]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/06/14 10:01 [entrez]
AID - 10.1111/jgs.17335 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2021 Oct;69(10):2722-2731. doi: 10.1111/jgs.17335. Epub 2021
      Jun 19.

PMID- 34118895
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210618
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jun 12
TI  - Comparison between RT-qPCR for SARS-CoV-2 and expanded triage in sputum of
      symptomatic and asymptomatic COVID-19 subjects in Ecuador.
PG  - 558
LID - 10.1186/s12879-021-06272-8 [doi]
AB  - BACKGROUND: The quantitative reverse transcriptase-polymerase chain reaction
      (RT-qPCR) effectively detects the SARS-COV-2 virus. SARS-CoV-2 Nevertheless, some
      critical gaps remain in the identification and monitoring of asymptomatic people.
      METHODS: This retrospective study included 733 asymptomatic and symptomatic
      COVID-19 subjects, who were submitted to the RT-qPCR test. The objective was to
      assess the efficacy of an expanded triage of subjects undergoing the RT-qPCR test
      for SARS-COV-2 to identify the largest possible number of COVID-19 cases in a
      hospital setting in Ecuador. SARS-CoV-2 Firstly, the sensitivity and specificity 
      as well as the predictive values of an expanded triage method were calculated. In
      addition, the Kappa coefficient was also determined to assess the concordance
      between laboratory test results and the expanded triage. RESULTS: Of a total of
      733 sputum samples; 229 were RT-qPCR-positive (31.2%) and mortality rate reached 
      1.2%. Overall sensitivity and specificity were 86.0% (95% confidence interval:
      81.0-90.0%) and 37.0% (95% confidence interval: 32.0-41.0%) respectively, with a 
      diagnostic accuracy of 52.0% and a Kappa coefficient of 0.73. An association
      between the positivity of the test and its performance before 10 days was found. 
      CONCLUSIONS: The clinical sensitivity for COVID-19 detection was within
      acceptable standards, but the specificity still fell below the values of
      reference. The lack of symptoms did not always mean to have a negative SARS-COV-2
      RT-qPCR test. The expanded triage identified a still unnoticed percentage of
      asymptomatic subjects showing positive results for the SARS-COV-2 RT-qPCR test.
      The study also revealed a significant relationship between the number of
      RT-qPCR-positive cases and the performance of the molecular diagnosis within the 
      first 10 days of COVID-19 in the symptomatic group.
FAU - Torres, Ariel
AU  - Torres A
AD  - Medicina General Integral, Master en Enfermedades Infecciosas, Hospital
      Gineco-obstetrico Nueva Aurora Luz Elena Arismendi, Quito, Ecuador.
FAU - Fors, Martha
AU  - Fors M
AD  - Escuela de Medicina, Facultad de Ciencias de la Salud, Redondel del Ciclista,
      Antigua Via a Nayon, Universidad de las Americas, 170125, Quito, Ecuador.
      martha.fors@udla.edu.ec.
FAU - Rivero, Tamaris
AU  - Rivero T
AD  - Medicina General Integral, Hospital General Santo Domingo de los Tsachilas, Santo
      Domingo, Ecuador.
FAU - Pantoja, Karina
AU  - Pantoja K
AD  - Enfermeria, Hospital General Santo Domingo de los Tsachilas, Santo Domingo,
      Ecuador.
FAU - Ballaz, Santiago
AU  - Ballaz S
AD  - Escuela de Ciencias Biologicas e Ingenieria, Universidad Yachay Tech, Hacienda
      San Jose s/n, San Miguel de Urcuqui, Ibarra, Ecuador.
AD  - Facultad de Ciencias Medicas Enrique Ortega Moreira, Universidad Espiritu Santo, 
      Samborondon, Ecuador.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20210612
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
SB  - IM
MH  - COVID-19/*diagnosis
MH  - *COVID-19 Testing
MH  - Ecuador
MH  - Humans
MH  - *Real-Time Polymerase Chain Reaction
MH  - Retrospective Studies
MH  - *SARS-CoV-2/genetics/isolation & purification
MH  - Sensitivity and Specificity
MH  - Sputum/*virology
MH  - Triage
PMC - PMC8195713
OTO - NOTNLM
OT  - COVID-19
OT  - RT-qPCR
OT  - SARS-CoV-2;sensitivity
OT  - Specificity
EDAT- 2021/06/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/06/13 20:21
PHST- 2020/12/02 00:00 [received]
PHST- 2021/05/06 00:00 [accepted]
PHST- 2021/06/13 20:21 [entrez]
PHST- 2021/06/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s12879-021-06272-8 [doi]
AID - 10.1186/s12879-021-06272-8 [pii]
PST - epublish
SO  - BMC Infect Dis. 2021 Jun 12;21(1):558. doi: 10.1186/s12879-021-06272-8.

PMID- 34084248
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210605
IS  - 1841-0987 (Print)
IS  - 1841-0987 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Oct-Dec
TI  - Sexual dimorphism in SARS-COV-2 infection.
PG  - 522-523
LID - 10.4183/aeb.2020.522 [doi]
AB  - Previous studies have demonstrated that female patients with coronavirus disease 
      2019 (COVID-19) demonstrate more favorable prognosis relative to male patients.
      In this article, we elaborate the possible role of estrogen in the modulation of 
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection severity. 
      The potential interplay between several factors, including inherently lower
      estradiol (E2) and slightly higher estrogen receptor beta (ERbeta) levels in
      males, with inflammatory mediators are described. Altogether, there seems to be a
      sexually dimorphic response towards SARS-CoV-2 infection, and a possibility that 
      COVID-19 severity is dependent on both E2 levels and ERalpha:ERbeta expression
      ratio in lymphoid and lung cells.
CI  - (c)by Acta Endocrinologica Foundation.
FAU - Ulhaq, Z S
AU  - Ulhaq ZS
AD  - Maulana Malik Ibrahim State Islamic University of Malang - Faculty of Medicine
      and Health Sciences, Malang, East Java, Indonesia, United Kingdom of Great
      Britain and Northern Ireland.
FAU - Soraya, G V
AU  - Soraya GV
AD  - Hasanuddin University - Faculty of Medicine, Makassar, South Sulawesi, Indonesia,
      United Kingdom of Great Britain and Northern Ireland.
FAU - Zambrano, L E A
AU  - Zambrano LEA
AD  - Technical University of Manabi, Faculty of Health Sciences, Portoviejo, Manabi,
      Ecuador, United Kingdom of Great Britain and Northern Ireland.
FAU - Garcia, C P
AU  - Garcia CP
AD  - Weston General Hospital, Weston-super-Mare, North Somerset, United Kingdom of
      Great Britain and Northern Ireland.
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Acta Endocrinol (Buchar)
JT  - Acta endocrinologica (Bucharest, Romania : 2005)
JID - 101269720
PMC - PMC8126387
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - Sexual dimorphism
OT  - estrogen
OT  - estrogen receptor
OT  - inflammatory mediator
EDAT- 2021/06/05 06:00
MHDA- 2021/06/05 06:01
CRDT- 2021/06/04 07:03
PHST- 2021/06/04 07:03 [entrez]
PHST- 2021/06/05 06:00 [pubmed]
PHST- 2021/06/05 06:01 [medline]
AID - 10.4183/aeb.2020.522 [doi]
AID - aeb.2020.522 [pii]
PST - ppublish
SO  - Acta Endocrinol (Buchar). 2020 Oct-Dec;16(4):522-523. doi: 10.4183/aeb.2020.522.

PMID- 34056057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210604
IS  - 2352-7714 (Print)
IS  - 2352-7714 (Linking)
VI  - 13
DP  - 2021 Dec
TI  - Crucial contribution of the universities to SARS-CoV-2 surveillance in Ecuador:
      Lessons for developing countries.
PG  - 100267
LID - 10.1016/j.onehlt.2021.100267 [doi]
AB  - COVID-19 pandemic has challenged public health systems worldwide, particularly
      affecting developing countries in Latin America like Ecuador. In this report, we 
      exposed the fundamental role of the Ecuadorian universities to improve COVID-19
      surveillance in the country, with an overall contribution over 15% of the total
      SARS-CoV-2 RT-PCR tests done. We highlight the role of our university during the 
      first semester of the COVID-19 pandemic, contributing to a massive free
      SARS-CoV-2 testing up to almost 10% of the total diagnosis completed in the
      country, mainly focus on underserved urban, rural and indigenous communities.
      Finally, we described our contribution to a high quality and low-cost SARS-CoV-2 
      RT-PCR diagnostic in Ecuador.
CI  - (c) 2021 The Author(s).
FAU - Santander-Gordon, Daniela
AU  - Santander-Gordon D
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Iturralde, Gabriel A
AU  - Iturralde GA
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Zambrano-Mila, Marlon S
AU  - Zambrano-Mila MS
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Morales-Jadan, Diana
AU  - Morales-Jadan D
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Vallejo-Janeta, Paolo A
AU  - Vallejo-Janeta PA
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Coronel, Barbara
AU  - Coronel B
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Galvis, Heberson
AU  - Galvis H
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Jaramillo-Vivanco, Tatiana
AU  - Jaramillo-Vivanco T
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Bilvao, Christian D
AU  - Bilvao CD
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Paredes-Espinosa, Maria Belen
AU  - Paredes-Espinosa MB
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Rodriguez, Angel S
AU  - Rodriguez AS
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Laglaguano, Juan C
AU  - Laglaguano JC
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Herrera, Henry
AU  - Herrera H
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Tito-Alvarez, Ana M
AU  - Tito-Alvarez AM
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
AD  - Carrera de Enfermeria, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Rivera-Olivero, Ismar A
AU  - Rivera-Olivero IA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Henriquez-Trujillo, Aquiles R
AU  - Henriquez-Trujillo AR
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Lozada, Tannya
AU  - Lozada T
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - Laboratorio de Diagnostico de SARS-CoV-2, Direccion General de Investigacion,
      Universidad de Las Americas, Quito, Ecuador.
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
CN  - "The UDLA-COVID-19 Team"
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210525
PL  - Netherlands
TA  - One Health
JT  - One health (Amsterdam, Netherlands)
JID - 101660501
PMC - PMC8146272
OTO - NOTNLM
OT  - Ecuador
OT  - Neglected communities
OT  - RT-PCR
OT  - SARS-CoV-2
OT  - Surveillance
COIS- The authors declare no conflict of interest.
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:20
PHST- 2021/02/14 00:00 [received]
PHST- 2021/05/13 00:00 [revised]
PHST- 2021/05/17 00:00 [accepted]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
PHST- 2021/05/31 06:20 [entrez]
AID - 10.1016/j.onehlt.2021.100267 [doi]
AID - S2352-7714(21)00057-4 [pii]
PST - ppublish
SO  - One Health. 2021 Dec;13:100267. doi: 10.1016/j.onehlt.2021.100267. Epub 2021 May 
      25.

PMID- 34022333
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220716
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 117
DP  - 2022 Apr
TI  - A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected
      symptomatic patients and confirmed close contacts (asymptomatic): A consensus of 
      Latin American experts.
PG  - 130-136
LID - S1201-9712(21)00412-4 [pii]
LID - 10.1016/j.ijid.2021.05.011 [doi]
AB  - INTRODUCTION: Latin America accounts for one-quarter of global COVID-19 cases and
      one-third of deaths. Inequalities in the region lead to barriers to the best use 
      of diagnostic tests during the pandemic. There is a need for simplified
      guidelines that consider the region's limited health resources, international
      guidelines, medical literature, and local expertise. METHODS: Using a modified
      Delphi method, 9 experts from Latin American countries developed a simplified
      algorithm for COVID-19 diagnosis on the basis of their answers to 24 questions
      related to diagnostic settings, and discussion of the literature and their
      experiences. RESULTS: The algorithm considers 3 timeframes (</=7 days, 8-13 days,
      and >/=14 days) and presents diagnostic options for each. SARS-CoV-2 real- time
      reverse transcription-polymerase chain reaction is the test of choice from day 1 
      to 14 after symptom onset or close contact, although antigen testing may be used 
      in specific circumstances, from day 5 to 7. Antibody assays may be used for
      confirmation, usually after day 14; however, if clinical suspicion is very high, 
      but other tests are negative, these assays may be used as an adjunct to
      decision-making from day 8 to 13. CONCLUSION: The proposed algorithm aims to
      support COVID-19 diagnosis decision-making in Latin America.
CI  - Copyright (c) 2021. Published by Elsevier Ltd.
FAU - Fay, Fabian F
AU  - Fay FF
AD  - Cibic Laboratories, Rosario, Argentina.
FAU - Alvarez-Moreno, Carlos Arturo
AU  - Alvarez-Moreno CA
AD  - Facultad de Medicina, Universidad Nacional de Colombia, Clinica Universitaria
      Colombia, Clinica Colsanitas, Bogota, Colombia.
FAU - Bonvehi, Pablo E
AU  - Bonvehi PE
AD  - Infectious Diseases Unit, Clinical Investigation and Medical Education Center,
      Buenos Aires, Argentina.
FAU - Espinoza, Carolina Cucho
AU  - Espinoza CC
AD  - School of Medicine, National University of San Marcos, Dos de Mayo Hospital,
      Lima, Peru.
FAU - Hidalgo, Marco Luis Herrera
AU  - Hidalgo MLH
AD  - Universidad de Ciencias Medicas, San Jose, Costa Rica.
FAU - Marcano-Lozada, Marcel
AU  - Marcano-Lozada M
AD  - Angios Vascular Center and Wound Clinic, Caracas, Venezuela; Juan Pablo II
      University, San Jose, Costa Rica.
FAU - Perez, Carlos M
AU  - Perez CM
AD  - Faculty of Medicine and Science, Universidad San Sebastian, Clinica Universidad
      de los Andes, Santiago, Chile.
FAU - Pulchinelli, Alvaro Jr
AU  - Pulchinelli A Jr
AD  - Federal University of Sao Paulo, Brazilian Society of Clinical Pathology, Fleury 
      Medicina e Saude Laboratory, Sao Paulo, Brazil.
FAU - Saenz-Flor, Klever Vinicio
AU  - Saenz-Flor KV
AD  - School of Medicine, Central University of Equator, Quito, Ecuador; Synlab
      Laboratories, Quito, Ecuador. Electronic address: kleversaenz@synlab.com.
FAU - Condino-Neto, Antonio
AU  - Condino-Neto A
AD  - Department of Immunology, Institute of Biomedical Sciences, University of Sao
      Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20210520
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
MH  - Algorithms
MH  - *COVID-19/diagnosis
MH  - COVID-19 Testing
MH  - Consensus
MH  - Humans
MH  - Latin America/epidemiology
MH  - *SARS-CoV-2
PMC - PMC8133827
OTO - NOTNLM
OT  - Algorithm
OT  - COVID-19
OT  - Diagnosis
OT  - Latin America
OT  - SARS-CoV- 2
EDAT- 2021/05/23 06:00
MHDA- 2022/03/31 06:00
CRDT- 2021/05/22 20:11
PHST- 2020/12/16 00:00 [received]
PHST- 2021/05/06 00:00 [revised]
PHST- 2021/05/07 00:00 [accepted]
PHST- 2021/05/23 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2021/05/22 20:11 [entrez]
AID - S1201-9712(21)00412-4 [pii]
AID - 10.1016/j.ijid.2021.05.011 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2022 Apr;117:130-136. doi: 10.1016/j.ijid.2021.05.011. Epub
      2021 May 20.

PMID- 34006342
OWN - NLM
STAT- Publisher
LR  - 20210803
IS  - 1938-744X (Electronic)
IS  - 1935-7893 (Linking)
DP  - 2021 May 19
TI  - Volcanic Ash as a Precursor for SARS-CoV-2 Infection Among Susceptible
      Populations in Ecuador: A Satellite Imaging and Excess Mortality-Based Analysis.
PG  - 1-13
LID - 10.1017/dmp.2021.154 [doi]
AB  - The global coronavirus disease 2019 (COVID-19) pandemic has altered entire
      nations and their health systems. The greatest impact of the pandemic has been
      seen among vulnerable populations, such as those with comorbidities like heart
      diseases, kidney failure, obesity, or those with worse health determinants such
      as unemployment and poverty. In the current study, we are proposing previous
      exposure to fine-grained volcanic ashes as a risk factor for developing COVID-19.
      Based on several previous studies it has been known since the mid 1980s of the
      past century that volcanic ash is most likely an accelerating factor to suffer
      from different types of cancer, including lung or thyroid cancer. Our study
      postulates, that people who are most likely to be infected during a severe acute 
      respiratory syndrome coronavirus 2 (SARS-CoV-2) widespread wave will be those
      with comorbidities that are related to previous exposure to volcanic ashes. We
      have explored 8703 satellite images from the past 21 y of available data from the
      National Oceanic and Atmospheric Administration (NOAA) database and correlated
      them with the data from the national institute of health statistics in Ecuador.
      Additionally, we provide more realistic numbers of fatalities due to the virus
      based on excess mortality data of 2020-2021, when compared with previous years.
      This study would be a very first of its kind combining social and spatial
      distribution of COVID-19 infections and volcanic ash distribution. The results
      and implications of our study will also help countries to identify such
      aforementioned vulnerable parts of the society, if the given geodynamic and
      volcanic settings are similar.
FAU - Toulkeridis, Theofilos
AU  - Toulkeridis T
AUID- ORCID: https://orcid.org/0000-0003-1903-7914
AD  - Universidad de las Fuerzas Armadas ESPE, Sangolqui, Ecuador.
AD  - Universidad de Especialidades Turisticas, Quito, Ecuador.
FAU - Seqqat, Rachid
AU  - Seqqat R
AD  - Universidad de las Fuerzas Armadas ESPE, Sangolqui, Ecuador.
FAU - Torres Arias, Marbel
AU  - Torres Arias M
AD  - Universidad de las Fuerzas Armadas ESPE, Sangolqui, Ecuador.
FAU - Salazar-Martinez, Rodolfo
AU  - Salazar-Martinez R
AD  - Universidad de las Fuerzas Armadas ESPE, Sangolqui, Ecuador.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - OneHealth Global Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Chunga, Scarlet
AU  - Chunga S
AD  - Universita degli studi dell'Insubria, Italia.
FAU - Vizuete, Karla
AU  - Vizuete K
AD  - Universidad de las Fuerzas Armadas ESPE, Sangolqui, Ecuador.
FAU - Heredia-R, Marco
AU  - Heredia-R M
AD  - Centro de Innovacion en Tecnologia para el Desarrollo, Universidad Politecnica de
      Madrid (UPM), Madrid, Spain.
FAU - Debut, Alexis
AU  - Debut A
AD  - Universidad de las Fuerzas Armadas ESPE, Sangolqui, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20210519
PL  - United States
TA  - Disaster Med Public Health Prep
JT  - Disaster medicine and public health preparedness
JID - 101297401
SB  - IM
PMC - PMC8314306
OTO - NOTNLM
OT  - COVID-19
OT  - excess mortality
OT  - pulmonary and thyroid vulnerability
OT  - spatial spreading wave of infection
OT  - volcanic ash
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:00
CRDT- 2021/05/19 05:43
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2021/05/19 05:43 [entrez]
AID - S1935789321001543 [pii]
AID - 10.1017/dmp.2021.154 [doi]
PST - aheadofprint
SO  - Disaster Med Public Health Prep. 2021 May 19:1-13. doi: 10.1017/dmp.2021.154.

PMID- 33971576
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1876-035X (Electronic)
IS  - 1876-0341 (Linking)
VI  - 14
IP  - 6
DP  - 2021 Jun
TI  - Re-infection of SARS-CoV-2: A case in a young dental healthcare worker.
PG  - 685-688
LID - S1876-0341(21)00056-3 [pii]
LID - 10.1016/j.jiph.2021.02.012 [doi]
AB  - Reinfection with SARS-CoV-2 is a rare phenomenon. To date, there has been some
      cases reported from countries such as United States, Ecuador, Hong Kong, the
      Netherlands and Belgium. This case report presents the first case of reinfection 
      from Saudi Arabia, and probably the first dental student to have been re-infected
      with COVID-19. A 24-year-old male dental student presents with reinfection after 
      a period of three months since he was first infected with COVID-19. The signs and
      symptoms reported by the patient were similar in both instances, except that he
      developed fever only at the time of reinfection. The infection and reinfection
      were confirmed with a RT-PCR test reports. This report highlights how it is
      necessary to continue to observe all the prescriptions recently indicated in the 
      literature in order to avoid new contagion for all health workers after healed
      from covid-19 or asymptomatic positive, since as seen sometimes the infection
      does not ensures complete immunity in 100% of cases.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Fageeh, Hytham
AU  - Fageeh H
AD  - Department of Preventive Dental Sciences, Jazan University, Jazan, Saudi Arabia.
FAU - Alshehri, Abdulrahman
AU  - Alshehri A
AD  - Department of Preventive Dental Sciences, College of Dentistry, Jazan University,
      Jazan, Saudi Arabia.
FAU - Fageeh, Hammam
AU  - Fageeh H
AD  - Department of Preventive Dental Sciences, College of Dentistry, Jazan University,
      Jazan, Saudi Arabia.
FAU - Bizzoca, Maria E
AU  - Bizzoca ME
AD  - Department of Clinical and Experimental Medicine, University of Foggia, Foggia,
      Italy. Electronic address: marielebizzoca@gmail.com.
FAU - Lo Muzio, Lorenzo
AU  - Lo Muzio L
AD  - Department of Clinical and Experimental Medicine, University of Foggia, Foggia,
      Italy; C.I.N.B.O. (Consorzio Interuniversitario Nazionale per la Bio-Oncologia), 
      Chieti, Italy. Electronic address: lorenzo.lomuzio@unifg.it.
FAU - Quadri, Mir F A
AU  - Quadri MFA
AD  - Department of Preventive Dental Sciences, College of Dentistry, Jazan University,
      Jazan, Saudi Arabia. Electronic address: dr.faeq.quadri@gmail.com.
LA  - eng
PT  - Case Reports
DEP - 20210306
PL  - England
TA  - J Infect Public Health
JT  - Journal of infection and public health
JID - 101487384
SB  - IM
MH  - Adult
MH  - Belgium
MH  - *COVID-19
MH  - Ecuador
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - Netherlands
MH  - Reinfection
MH  - *SARS-CoV-2
MH  - Saudi Arabia
MH  - Young Adult
PMC - PMC7936729
OTO - NOTNLM
OT  - COVID-19
OT  - Case-report
OT  - Coronavirus
OT  - Dental healthcare worker
OT  - Reinfection
OT  - SARS-CoV-2
EDAT- 2021/05/11 06:00
MHDA- 2021/06/09 06:00
CRDT- 2021/05/10 20:26
PHST- 2020/12/30 00:00 [received]
PHST- 2021/02/23 00:00 [revised]
PHST- 2021/02/25 00:00 [accepted]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2021/05/10 20:26 [entrez]
AID - S1876-0341(21)00056-3 [pii]
AID - 10.1016/j.jiph.2021.02.012 [doi]
PST - ppublish
SO  - J Infect Public Health. 2021 Jun;14(6):685-688. doi: 10.1016/j.jiph.2021.02.012. 
      Epub 2021 Mar 6.

PMID- 33970560
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2192-6506 (Electronic)
IS  - 2192-6506 (Linking)
VI  - 86
IP  - 7
DP  - 2021 Jul
TI  - An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking
      Simulations with SARS-Cov-2.
PG  - 970-971
LID - 10.1002/cplu.202100133 [doi]
AB  - Invited for this month's cover are the collaborating groups of Dr. Margarita
      Suarez at Universidad de La Habana, Cuba, and Dr. Nazario Martin at Universidad
      Complutense de Madrid, Spain, together with groups at other institutions
      worldwide. The Front Cover shows a representation of the H2 @C60 hybrid molecule 
      with a dehydroepiandrosterone moiety interacting with the active site of the SARS
      Cov-2. Read the full text of the article at 10.1002/cplu.202000770.
CI  - (c) 2021 Wiley-VCH GmbH.
FAU - Suarez, Margarita
AU  - Suarez M
AUID- ORCID: 0000-0002-3138-4364
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Makowski, Kamil
AU  - Makowski K
AUID- ORCID: 0000-0001-5806-550X
AD  - Departament of Surfactants and Nanobiotechnology, Institute for Advanced
      Chemistry of Catalonia (IQAC-CSIC), and CIBER-BBN, Barcelona, Spain.
FAU - Lemos, Reinier
AU  - Lemos R
AUID- ORCID: 0000-0001-7325-1810
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Almagro, Luis
AU  - Almagro L
AUID- ORCID: 0000-0001-5186-670X
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Rodriguez, Hortensia
AU  - Rodriguez H
AUID- ORCID: 0000-0001-6910-5685
AD  - Yachay Tech University, School of Chemical Sciences and Engineering, 100119-,
      Urququi, Ecuador.
FAU - Herranz, Maria Angeles
AU  - Herranz MA
AUID- ORCID: 0000-0001-9155-134X
AD  - Departamento de Quimica Organica, Facultad de Ciencias Quimicas, Universidad
      Complutense de Madrid, 28040-, Madrid, Spain.
FAU - Molero, Dolores
AU  - Molero D
AUID- ORCID: 0000-0001-6198-1330
AD  - CAI RMN Universidad Complutense de Madrid, 28040, Madrid, Spain.
FAU - Ortiz, Orlando
AU  - Ortiz O
AUID- ORCID: 0000-0002-6845-6851
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Maroto, Enrique
AU  - Maroto E
AUID- ORCID: 0000-0002-3485-1335
AD  - Departamento de Quimica Organica, Facultad de Ciencias Quimicas, Universidad
      Complutense de Madrid, 28040-, Madrid, Spain.
FAU - Albericio, Fernando
AU  - Albericio F
AUID- ORCID: 0000-0002-8946-0462
AD  - School of Chemistry and Physics, University of KwaZul-Natal, Durban, South
      Africa.
FAU - Murata, Yasujiro
AU  - Murata Y
AUID- ORCID: 0000-0003-0287-0299
AD  - Institute for Chemical Research, Kyoto University, Uji, Kyoto, 611-0011, Japan.
FAU - Martin, Nazario
AU  - Martin N
AUID- ORCID: 0000-0002-5355-1477
AD  - Departamento de Quimica Organica, Facultad de Ciencias Quimicas, Universidad
      Complutense de Madrid, 28040-, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20210510
PL  - Germany
TA  - Chempluschem
JT  - ChemPlusChem
JID - 101580948
SB  - IM
EDAT- 2021/05/11 06:00
MHDA- 2021/05/11 06:01
CRDT- 2021/05/10 12:41
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/11 06:01 [medline]
PHST- 2021/05/10 12:41 [entrez]
AID - 10.1002/cplu.202100133 [doi]
PST - ppublish
SO  - Chempluschem. 2021 Jul;86(7):970-971. doi: 10.1002/cplu.202100133. Epub 2021 May 
      10.

PMID- 33930542
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20210819
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 108
DP  - 2021 Jul
TI  - Evidence of SARS-CoV-2 reinfection within the same clade in Ecuador: A case
      study.
PG  - 53-56
LID - S1201-9712(21)00385-4 [pii]
LID - 10.1016/j.ijid.2021.04.073 [doi]
AB  - OBJECTIVES: To date, reported SARS-CoV-2 reinfection cases are mainly from
      strains belonging to different clades. As the pandemic advances, a few lineages
      have become dominant in certain areas leading to reinfections by similar strains.
      Here, we report a reinfection case within the same clade of the initial infection
      in a symptomatic 28-year-old-male in Quito-Ecuador. METHODS: Infection was
      detected by reverse transcription-polymerase chain reaction, and immune response 
      evaluated by antibody testing. Whole-genome sequencing was performed and
      phylogenetic analysis conducted to determine relatedness. RESULTS: Both the
      infection and the reinfection strains were assigned as Nextstrain 20B, Pangolin
      lineage B.1.1 and GISAID clade O. Our analysis indicated 4-6 fold more nucleotide
      changes than are expected for reactivation or persistence compared with the
      natural rate of SARS-CoV-2 mutation ( approximately 2-3 nucleotide changes per
      month), thus supporting reinfection. Furthermore, approximately 3 months after
      the second infection, COVID-19 antibodies were not detectable in the patient,
      suggesting potential vulnerability to a third infection. CONCLUSIONS: Our results
      showed evidence of SARS-CoV-2 reinfection within the same clade in Ecuador,
      indicating that previous exposure to SARS-CoV-2 does not guarantee immunity in
      all cases.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Sevillano, Gabriela
AU  - Sevillano G
AD  - Unidad de Investigaciones en Biomedicina, Zurita and Zurita Laboratorios, Quito, 
      Ecuador.
FAU - Ortega-Paredes, David
AU  - Ortega-Paredes D
AD  - Unidad de Investigacion en Enfermedades Transmitidas por Alimentos y Resistencia 
      a los Antimicrobianos (UNIETAR), Facultad de Veterinaria, Universidad Central del
      Ecuador, Quito, Ecuador.
FAU - Loaiza, Karen
AU  - Loaiza K
AD  - Research Unit, Life Science Initiative, Quito, Ecuador.
FAU - Zurita-Salinas, Camilo
AU  - Zurita-Salinas C
AD  - Unidad de Investigaciones en Biomedicina, Zurita and Zurita Laboratorios, Quito, 
      Ecuador.
FAU - Zurita, Jeannete
AU  - Zurita J
AD  - Unidad de Investigaciones en Biomedicina, Zurita and Zurita Laboratorios, Quito, 
      Ecuador; Facultad de Medicina, Pontificia Universidad Catolica del Ecuador,
      Quito, Ecuador. Electronic address: jzurita@zuritalaboratorios.com.
LA  - eng
PT  - Journal Article
DEP - 20210427
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Male
MH  - Phylogeny
MH  - Reinfection
MH  - *SARS-CoV-2
PMC - PMC8078048
OTO - NOTNLM
OT  - COVID-19
OT  - Ecuador
OT  - Reinfection
OT  - SARS-CoV-2
EDAT- 2021/05/01 06:00
MHDA- 2021/08/20 06:00
CRDT- 2021/04/30 20:21
PHST- 2021/04/01 00:00 [received]
PHST- 2021/04/21 00:00 [revised]
PHST- 2021/04/23 00:00 [accepted]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2021/04/30 20:21 [entrez]
AID - S1201-9712(21)00385-4 [pii]
AID - 10.1016/j.ijid.2021.04.073 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Jul;108:53-56. doi: 10.1016/j.ijid.2021.04.073. Epub 2021 
      Apr 27.

PMID- 33925680
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210518
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 9
DP  - 2021 Apr 27
TI  - Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in
      Cuenca, Ecuador, October 2020, a Cross-Sectional Study.
LID - 4657 [pii]
LID - 10.3390/ijerph18094657 [doi]
AB  - A door-to-door survey was organised in Cuenca, Ecuador, to determine the
      prevalence of COVID-19 infection and adherence of the population to COVID-19
      preventive measures. A total of 2457 persons participated in the study; 584
      (23.7%) reported having experienced at least one flu-like symptom since the onset
      of the pandemic. The maximum SARS-CoV-2 seroprevalence in Cuenca was 13.2% (CI:
      12-14.6%) (IgM or IgG positive). Considering PCR confirmed infections, the
      prevalence was 11% (CI: 10-12.4%). There was no significant difference in
      seroprevalence between rural and urban areas. Participants aged 35-49 years old, 
      living with a COVID-19 positive person, at least six people in a household,
      physical contact with someone outside the household, a contact with a person
      outside the home with flu-like symptoms, using public transport, and not having
      enough resources for living, significantly increased the odds for SARS-CoV-2
      seropositivity. Overall, there was good adherence to COVID-19 preventive
      measures. Having known someone who tested positive for COVID-19, having a primary
      or secondary level of education, and having enough resources for living,
      significantly increased the odds for higher adherence. In conclusion, despite
      good overall adherence of the population of Cuenca with COVID-19 preventive
      measures, our study suggests high ongoing COVID-19 transmission in Cuenca,
      particularly in certain parishes. Prevention should not only focus on behavioural
      change, but on intensified testing strategies in demographical risk groups.
FAU - Acurio-Paez, David
AU  - Acurio-Paez D
AUID- ORCID: 0000-0003-3258-2837
AD  - Faculty of Medical Science: Universidad de Cuenca, 010202 Cuenca, Ecuador.
FAU - Vega, Bernardo
AU  - Vega B
AUID- ORCID: 0000-0002-2545-4733
AD  - Faculty of Medical Science: Universidad de Cuenca, 010202 Cuenca, Ecuador.
FAU - Orellana, Daniel
AU  - Orellana D
AD  - Grupo de Investigacion LlactaLAB-Ciudades Sustentables, Universidad de Cuenca,
      010203 Cuenca, Ecuador.
FAU - Charry, Ricardo
AU  - Charry R
AD  - Faculty of Medical Science: Universidad de Cuenca, 010202 Cuenca, Ecuador.
FAU - Gomez, Andrea
AU  - Gomez A
AD  - Escuela de Salud Publica Universidad de Chile, 8380453 Santiago, Chile.
FAU - Obimpeh, Michael
AU  - Obimpeh M
AUID- ORCID: 0000-0001-7140-4932
AD  - Family Medicine and Population Health, University of Antwerp, 2610 Antwerp,
      Belgium.
FAU - Verhoeven, Veronique
AU  - Verhoeven V
AUID- ORCID: 0000-0002-3708-6501
AD  - Family Medicine and Population Health, University of Antwerp, 2610 Antwerp,
      Belgium.
FAU - Colebunders, Robert
AU  - Colebunders R
AUID- ORCID: 0000-0002-1919-1340
AD  - Family Medicine and Population Health, University of Antwerp, 2610 Antwerp,
      Belgium.
LA  - eng
GR  - NAP/VLIRUOS (Flemish Interuniversity Council for University Development
      Cooperation)
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210427
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - Cross-Sectional Studies
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Middle Aged
MH  - *SARS-CoV-2
MH  - Seroepidemiologic Studies
PMC - PMC8124135
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ecuador
OT  - *IgG antibodies
OT  - *IgM antibodies
OT  - *PCR test
OT  - *adherence
OT  - *prevalence
OT  - *preventive measures
EDAT- 2021/05/01 06:00
MHDA- 2021/05/05 06:00
CRDT- 2021/04/30 01:32
PHST- 2021/03/04 00:00 [received]
PHST- 2021/04/19 00:00 [revised]
PHST- 2021/04/23 00:00 [accepted]
PHST- 2021/04/30 01:32 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - ijerph18094657 [pii]
AID - 10.3390/ijerph18094657 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2021 Apr 27;18(9). pii: ijerph18094657. doi:
      10.3390/ijerph18094657.

PMID- 33901750
OWN - NLM
STAT- Publisher
LR  - 20210524
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 205
DP  - 2021 Apr 12
TI  - Previously diagnosed obstructive sleep apnea is not associated with increased
      risk of SARS-CoV-2 infection in community-dwelling older adults living in a
      highly endemic setting.
PG  - 106639
LID - S0303-8467(21)00166-9 [pii]
LID - 10.1016/j.clineuro.2021.106639 [doi]
AB  - OBJECTIVE: In view of the high prevalence of obstructive sleep apnea (OSA) and
      the increasing global pandemic of SARS-CoV-2 infection, it is likely that many
      patients with OSA get exposed to this virus. Besides theoretical assumptions,
      there is no evidence that OSA may favor SARS-CoV-2 acquisition or may lead to a
      more severe disease. Taking the opportunity of the Atahualpa Project cohort, we
      aimed to assess the relationship between previously diagnosed OSA and SARS-CoV-2 
      infection in older adults living in rural Ecuador. PATIENTS AND METHODS:
      SARS-CoV-2 antibodies were determined in 180 individuals aged > 60 years that
      underwent polysomnography previously to this novel pandemic. Those with OSA
      remained untreated due to income limitations. Exposure-effect models were fitted 
      with OSA as the exposure, SARS-CoV-2 seropositivity and symptomatology as the
      outcomes, and confounders - age, gender, obesity, arterial hypertension, diabetes
      mellitus, hypercholesterolemia, individuals per house, home confinement - as
      independent variables. RESULTS: A total of 87 (48%) individuals were seropositive
      to SARS-CoV-2, 77% of whom were symptomatic. The mean apnea/hypopnea index was
      11.1 +/- 11.7 episodes per hour, with 83 (46%) individuals having mild, and 38
      (21%) moderate-to-severe OSA. Exposure-effect models demonstrated lack of
      relationship between OSA and SARS-CoV-2 seropositivity and symptomatology.
      CONCLUSIONS: This study shows no relationship between history of OSA and
      SARS-CoV-2 seropositivity or symptomatology, opposing previous suggestions that
      persons with OSA are more prone to acquire the infection and have a more severe
      disease.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador, Guayaquil, Ecuador.
      Electronic address: oscardelbrutto@hotmail.com.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc., Foster City, CA, USA.
FAU - Castillo, Pablo R
AU  - Castillo PR
AD  - Sleep Disorders Center, Mayo Clinic College of Medicine, Jacksonville, Florida,
      USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, the Atahualpa Project, Atahualpa, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Community Center, the Atahualpa Project, Atahualpa, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20210412
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
SB  - IM
PMC - PMC8040321
OTO - NOTNLM
OT  - Apnea hipopnea index
OT  - Coronavirus-19
OT  - Obstructive sleep apnea
OT  - Population study
OT  - SARS-CoV-2
EDAT- 2021/04/27 06:00
MHDA- 2021/04/27 06:00
CRDT- 2021/04/26 20:17
PHST- 2020/07/01 00:00 [received]
PHST- 2021/04/07 00:00 [accepted]
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2021/04/26 20:17 [entrez]
AID - S0303-8467(21)00166-9 [pii]
AID - 10.1016/j.clineuro.2021.106639 [doi]
PST - aheadofprint
SO  - Clin Neurol Neurosurg. 2021 Apr 12;205:106639. doi:
      10.1016/j.clineuro.2021.106639.

PMID- 33887602
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 1578-1275 (Electronic)
IS  - 0212-6567 (Linking)
VI  - 53
IP  - 5
DP  - 2021 May
TI  - [Proposal for territorial analysis to face the SARS-CoV-2 pandemic based on the
      Profile of pneumonia and Influenza in Ecuador 2016-2018].
PG  - 102021
LID - S0212-6567(21)00055-X [pii]
LID - 10.1016/j.aprim.2021.102021 [doi]
AB  - OBJECTIVE: The present study seeks to analyse sociodemographic determinants
      related to severe acute respiratory infections (SARI) and calculate the
      priorization index in the cantons of Ecuador to identify areas probably most
      vulnerable to COVID-19 transmission. DESIGN: This descriptive ecological
      observational study. SETTING: 224 cantons (geographical area) of Ecuador with
      secondary data sources of hospital information. PARTICIPANTS: The unit of
      measurement was 224 cantons of Ecuador, in which analysed morbidity and lethality
      rates for SARI using hospital release data (2016-2018). MAIN MEASUREMENTS: Eight 
      sociodemographic indicators were structuralized, and correlation tests applied
      for a multiple regression model. The priorization index was created with criteria
      of efficiency, efficacy, effect size (IRR) and equity. Using the sum of the index
      for each indicator, the priorization score was calculated and localized in a
      territorial map. RESULTS: Morbidity associated factors where: school attendance
      years, urbanization and population density; for mortality resulted: school
      attendance and ethnics (indigenous) IRR: 1.09 (IC95%:1.06-1.15) and IRR: 1.024
      (IC95%:102-1.03) respectively. With lethality where related cantons, with
      population older than 60 years, IRR: 1.049 (IC95%: 1.03-1.07); 87 cantons had
      high priority mostly localized in the mountain region and the Morona Santiago
      Province. CONCLUSIONS: Morbidity and mortality of SARI in Ecuador are associated 
      to social and demographic factors. Priorization exercises considering these
      factors permit the identification of vulnerable territories facing respiratory
      disease propagation. The social determinants characteristic for each territory
      should be added to known individual factors to analyse the risk and vulnerability
      for COVID in the population.
CI  - Copyright (c) 2021 The Authors. Publicado por Elsevier Espana, S.L.U. All rights 
      reserved.
FAU - Rios Quituizaca, Paulina
AU  - Rios Quituizaca P
AD  - Universidad Central del Ecuador, Facultad de Ciencias Medicas, Quito, Ecuador;
      Universidad de Sao Paulo, Facultad de Medicina de Ribeirao Preto, Sao Paulo,
      Brasil. Electronic address: paulina.riosq@gmail.com.
FAU - Calderon, Lilian
AU  - Calderon L
AD  - Universidad de Sao Paulo, Facultad de Medicina de Ribeirao Preto, Sao Paulo,
      Brasil.
FAU - Piedra, Santiago
AU  - Piedra S
AD  - Hospital de Especialidades Carlos Andrade Marin. Quito, Ecuador.
FAU - Guerrero, Jhon
AU  - Guerrero J
AD  - Universidad Central del Ecuador, Facultad de Ciencias Medicas, Quito, Ecuador.
FAU - Narvaez, Alberto
AU  - Narvaez A
AD  - Universidad Central del Ecuador, Facultad de Ciencias Medicas, Quito, Ecuador.
LA  - spa
PT  - Journal Article
PT  - Observational Study
TT  - Propuesta de analisis territorial para enfrentar la pandemia por SARS-CoV-2
      basado en el perfil de neumonia e influenza en Ecuador 2016-2018.
DEP - 20210223
PL  - Spain
TA  - Aten Primaria
JT  - Atencion primaria
JID - 9111075
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/epidemiology/*etiology/*prevention & control/transmission
MH  - Child
MH  - Child, Preschool
MH  - Ecuador/epidemiology
MH  - Environment
MH  - Female
MH  - Geographic Mapping
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Influenza, Human/epidemiology/etiology/prevention & control/transmission
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - *Social Determinants of Health
MH  - Socioeconomic Factors
MH  - Vulnerable Populations
MH  - Young Adult
PMC - PMC7901493
OTO - NOTNLM
OT  - COVID-19
OT  - Neumonia
OT  - Pandemia
OT  - Pandemics
OT  - Pblacion vulnerable
OT  - Pneumonia
OT  - Riesgo
OT  - Risk
OT  - SARS virus
OT  - Vulnerable population
OT  - virus SARS
EDAT- 2021/04/23 06:00
MHDA- 2021/06/01 06:00
CRDT- 2021/04/22 20:22
PHST- 2020/06/20 00:00 [received]
PHST- 2020/10/28 00:00 [revised]
PHST- 2021/01/07 00:00 [accepted]
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
PHST- 2021/04/22 20:22 [entrez]
AID - S0212-6567(21)00055-X [pii]
AID - 10.1016/j.aprim.2021.102021 [doi]
PST - ppublish
SO  - Aten Primaria. 2021 May;53(5):102021. doi: 10.1016/j.aprim.2021.102021. Epub 2021
      Feb 23.

PMID- 33864948
OWN - NLM
STAT- MEDLINE
DCOM- 20211223
LR  - 20211225
IS  - 1665-2681 (Print)
IS  - 1665-2681 (Linking)
VI  - 25
DP  - 2021 Nov-Dec
TI  - Comparison of different prognostic scores for patients with cirrhosis
      hospitalized with SARS-CoV-2 infection.
PG  - 100350
LID - S1665-2681(21)00049-1 [pii]
LID - 10.1016/j.aohep.2021.100350 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Viral infections have been described to increase the
      risk of decompensation in patients with cirrhosis. We aimed to determine the
      effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis
      and to compare the performance of different prognostic models for predicting
      mortality. PATIENTS: We performed a prospective cohort study including 2211
      hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020
      through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We
      registered clinical and laboratory parameters of patients with and without
      cirrhosis. All patients were followed until discharge or death. We evaluated the 
      prognostic performance of different scoring systems to predict mortality in
      patients with cirrhosis using ROC curves. RESULTS: Overall, 4.6% (CI 3.7-5.6)
      subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was
      assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19
      (IQR 14-25). Mortality was 47% in patients with cirrhosis and 16% in patients
      without cirrhosis (P < .0001). Cirrhosis was independently associated with death 
      [OR 3.1 (CI 1.9-4.8); P < .0001], adjusted by age, gender, and body mass index
      >30. The areas under the ROC curves for performance evaluation in predicting
      28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American
      Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and
      MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). CONCLUSIONS:
      SARS-CoV-2 infection is associated with elevated mortality in patients with
      cirrhosis. CLIF-C had better performance in predicting mortality than NACSELD,
      CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection.
      Clinicaltrials.gov:NCT04358380.
CI  - Copyright (c) 2021 Fundacion Clinica Medica Sur, A.C. Published by Elsevier
      Espana, S.L.U. All rights reserved.
FAU - Mendizabal, Manuel
AU  - Mendizabal M
AD  - Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Universidad
      Austral, Pilar, Argentina; Latin American Liver Research Educational and
      Awareness Network (LALREAN). Electronic address: mmendiza@hospitalaustral.edu.ar.
FAU - Ridruejo, Ezequiel
AU  - Ridruejo E
AD  - Latin American Liver Research Educational and Awareness Network (LALREAN); Liver 
      Section, Centro de Educacion Medica e Investigaciones Clinicas, Buenos Aires,
      Argentina.
FAU - Pinero, Federico
AU  - Pinero F
AD  - Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Universidad
      Austral, Pilar, Argentina; Latin American Liver Research Educational and
      Awareness Network (LALREAN).
FAU - Anders, Margarita
AU  - Anders M
AD  - Latin American Liver Research Educational and Awareness Network (LALREAN);
      Hepatology and Liver Transplant Unit, Hospital Aleman, Buenos Aires, Argentina.
FAU - Padilla, Martin
AU  - Padilla M
AD  - Gastroenterology Unit, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.
FAU - Toro, Luis G
AU  - Toro LG
AD  - Hepatology and Liver Transplant Unit, Hospitales de San Vicente Fundacion de
      Medellin y Rionegro, Medellin, Colombia.
FAU - Torre, Aldo
AU  - Torre A
AD  - Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y
      Nutricion, Ciudad de Mexico, Mexico.
FAU - Montes, Pedro
AU  - Montes P
AD  - Gastroenterology Unit, Hospital Nacional Daniel A. Carrion, Callao, Peru.
FAU - Urzua, Alvaro
AU  - Urzua A
AD  - Gastroenterology Section, Internal Medicine Department, Hospital Clinico de la
      Universidad de Chile, Santiago, Chile.
FAU - Gonzalez Ballerga, Esteban
AU  - Gonzalez Ballerga E
AD  - Department of Gastroenterology, Hospital de Clinicas Jose de San Martin,
      Universidad de Buenos Aires, Buenos Aires, Argentina.
FAU - Silveyra, Maria Dolores
AU  - Silveyra MD
AD  - Department of Internal Medicine, Sanatorio Anchorena, Buenos Aires, Argentina.
FAU - Michelato, Douglas
AU  - Michelato D
AD  - Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia, Salvador
      de Bahia, Brazil.
FAU - Diaz, Javier
AU  - Diaz J
AD  - Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
FAU - Peralta, Mirta
AU  - Peralta M
AD  - Latin American Liver Research Educational and Awareness Network (LALREAN);
      Intensive Care Unit, Hospital de Infecciosas Francisco J Muniz, Buenos Aires,
      Argentina.
FAU - Pages, Josefina
AU  - Pages J
AD  - Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Universidad
      Austral, Pilar, Argentina; Latin American Liver Research Educational and
      Awareness Network (LALREAN).
FAU - Garcia, Sandro Ruiz
AU  - Garcia SR
AD  - Gastroenterology Unit, Hospital de Victor Lazarte Echegaray, Trujillo, Peru.
FAU - Gutierrez Lozano, Isabel
AU  - Gutierrez Lozano I
AD  - Department of Internal Medicine, Centro Medico ABC, Ciudad de Mexico, Mexico.
FAU - Macias, Yuridia
AU  - Macias Y
AD  - Department of Medicine, IMSS Hospital General Regional No. 1 "Dr. Carlos Mc
      Gregor Sanchez", Ciudad de Mexico, Mexico.
FAU - Cocozzella, Daniel
AU  - Cocozzella D
AD  - Latin American Liver Research Educational and Awareness Network (LALREAN);
      Department of Gastroenterology, Hospital Italiano de La Plata, La Plata,
      Argentina.
FAU - Chavez-Tapia, Norberto
AU  - Chavez-Tapia N
AD  - Medica Sur Clinic & Foundation, Ciudad de Mexico, Mexico.
FAU - Tagle, Martin
AU  - Tagle M
AD  - Gastroenterology Unit, Clinica Anglo-Americana, Lima, Peru.
FAU - Dominguez, Alejandra
AU  - Dominguez A
AD  - Department of Gastroenterology, Hospital Padre Hurtado, Santiago, Chile.
FAU - Varon, Adriana
AU  - Varon A
AD  - Latin American Liver Research Educational and Awareness Network (LALREAN); Liver 
      Unit, Fundacion Cardio-Infantil, Bogota, Colombia.
FAU - Vera Pozo, Emilia
AU  - Vera Pozo E
AD  - Hospital Regional Dr. Teodoro Maldonado Carbo del IESS, Guayaquil, Ecuador.
FAU - Higuera-de la Tijera, Fatima
AU  - Higuera-de la Tijera F
AD  - Department of Gastroenterology and Hepatology, Hospital General de Mexico "Dr.
      Eduardo Liceaga", Ciudad de Mexico, Mexico.
FAU - Bustios, Carla
AU  - Bustios C
AD  - Gastroenterology Unit, Clinica Delgado, Lima, Peru.
FAU - Conte, Damian
AU  - Conte D
AD  - Unidad de Higado, Hospital Privado de Cordoba, Cordoba, Argentina.
FAU - Escajadillo, Nataly
AU  - Escajadillo N
AD  - Gastroenterology Unit, Hospital Nacional Almanzor Aguinaga Asenjo, Chiclayo,
      Peru.
FAU - Gomez, Andres J
AU  - Gomez AJ
AD  - Endoscopy and Transplant Service, Hospital Universitario Fundacion Santa Fe de
      Bogota, Bogota, Colombia.
FAU - Tenorio, Laura
AU  - Tenorio L
AD  - Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
FAU - Castillo Barradas, Mauricio
AU  - Castillo Barradas M
AD  - Gastroenterology Unit, Hospital de Especialidades del Centro Medico Nacional La
      Raza IMSS, Ciudad de Mexico, Mexico.
FAU - Schinoni, Maria Isabel
AU  - Schinoni MI
AD  - Latin American Liver Research Educational and Awareness Network (LALREAN);
      Department of Gastroenterology, Hospital Alianza, Bahia, Brazil.
FAU - Bessone, Fernando
AU  - Bessone F
AD  - Department of Gastroenterology, Hospital Provincial del Centenario, Rosario,
      Argentina.
FAU - Contreras, Fernando
AU  - Contreras F
AD  - Department of Gastroenterology, CEDIMAT, Santo Domingo, Dominican Republic.
FAU - Nazal, Leyla
AU  - Nazal L
AD  - Department of Gastroenterology, Clinica Las Condes, Santiago, Chile.
FAU - Sanchez, Abel
AU  - Sanchez A
AD  - Department of Gastroenterology, Hospital Roosevelt, Ciudad de Guatemala,
      Guatemala.
FAU - Garcia, Matias
AU  - Garcia M
AD  - Liver Section, Centro de Educacion Medica e Investigaciones Clinicas, Buenos
      Aires, Argentina.
FAU - Brutti, Julia
AU  - Brutti J
AD  - Department of Internal Medicine, Sanatorio Anchorena, Buenos Aires, Argentina.
FAU - Cabrera, Maria Cecilia
AU  - Cabrera MC
AD  - Gastroenterology Unit, Hospital Nacional Daniel A. Carrion, Callao, Peru.
FAU - Miranda-Zazueta, Godolfino
AU  - Miranda-Zazueta G
AD  - Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y
      Nutricion, Ciudad de Mexico, Mexico.
FAU - Rojas, German
AU  - Rojas G
AD  - Department of Gastroenterology, Hospital de Clinicas Jose de San Martin,
      Universidad de Buenos Aires, Buenos Aires, Argentina.
FAU - Cattaneo, Maximo
AU  - Cattaneo M
AD  - Gastroenterology Section, Internal Medicine Department, Hospital Clinico de la
      Universidad de Chile, Santiago, Chile.
FAU - Castro-Narro, Graciela
AU  - Castro-Narro G
AD  - Medica Sur Clinic & Foundation, Ciudad de Mexico, Mexico.
FAU - Rubinstein, Fernando
AU  - Rubinstein F
AD  - Instituto de Efectividad Clinica y Sanitaria, Buenos Aires, Argentina.
FAU - Silva, Marcelo O
AU  - Silva MO
AD  - Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Universidad
      Austral, Pilar, Argentina; Latin American Liver Research Educational and
      Awareness Network (LALREAN).
LA  - eng
SI  - ClinicalTrials.gov/NCT04358380
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210414
PL  - Mexico
TA  - Ann Hepatol
JT  - Annals of hepatology
JID - 101155885
SB  - IM
CIN - Ann Hepatol. 2021 Nov-Dec;25:100360. PMID: 34119682
MH  - Body Mass Index
MH  - COVID-19/*epidemiology
MH  - Comorbidity
MH  - Female
MH  - Follow-Up Studies
MH  - *Hospitalization
MH  - Humans
MH  - Liver Cirrhosis/diagnosis/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - SARS-CoV-2
MH  - South America/epidemiology
MH  - Survival Rate/trends
PMC - PMC8045426
OTO - NOTNLM
OT  - *Acute-on-chronic liver failure
OT  - *COVID-19
OT  - *Cirrhosis
OT  - *Coronavirus
OT  - *Death
OT  - *Pandemic
EDAT- 2021/04/18 06:00
MHDA- 2021/12/24 06:00
CRDT- 2021/04/17 20:10
PHST- 2021/01/11 00:00 [received]
PHST- 2021/03/01 00:00 [revised]
PHST- 2021/03/05 00:00 [accepted]
PHST- 2021/04/18 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/04/17 20:10 [entrez]
AID - S1665-2681(21)00049-1 [pii]
AID - 10.1016/j.aohep.2021.100350 [doi]
PST - ppublish
SO  - Ann Hepatol. 2021 Nov-Dec;25:100350. doi: 10.1016/j.aohep.2021.100350. Epub 2021 
      Apr 14.

PMID- 33851177
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211117
DP  - 2021 Apr 5
TI  - Genomic epidemiology of SARS-CoV-2 transmission lineages in Ecuador.
LID - 2021.03.31.21254685 [pii]
LID - 10.1101/2021.03.31.21254685 [doi]
AB  - Characterisation of SARS-CoV-2 genetic diversity through space and time can
      reveal trends in virus importation and domestic circulation, and permit the
      exploration of questions regarding the early transmission dynamics. Here we
      present a detailed description of SARS-CoV-2 genomic epidemiology in Ecuador, one
      of the hardest hit countries during the early stages of the COVID-19 pandemic. We
      generate and analyse 160 whole genome sequences sampled from all provinces of
      Ecuador in 2020. Molecular clock and phylgeographic analysis of these sequences
      in the context of global SARS-CoV-2 diversity enable us to identify and
      characterise individual transmission lineages within Ecuador, explore their
      spatiotemporal distributions, and consider their introduction and domestic
      circulation. Our results reveal a pattern of multiple international importations 
      across the country, with apparent differences between key provinces. Transmission
      lineages were mostly introduced before the implementation of non-pharmaceutical
      interventions (NPIs), with differential degrees of persistence and national
      dissemination.
FAU - Gutierrez, Bernardo
AU  - Gutierrez B
AD  - Department of Zoology, University of Oxford, Oxford, UK.
AD  - Colegio de Ciencias Biologicas y Ambientales, Universidad San Francisco de Quito,
      Quito, Ecuador.
FAU - Marquez, Sully
AU  - Marquez S
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Prado-Vivar, Belen
AU  - Prado-Vivar B
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Becerra-Wong, Monica
AU  - Becerra-Wong M
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Guadalupe, Juan Jose
AU  - Guadalupe JJ
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito, Quito, 
      Ecuador.
FAU - da Silva Candido, Darlan
AU  - da Silva Candido D
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Fernandez-Cadena, Juan Carlos
AU  - Fernandez-Cadena JC
AD  - Omics Sciences Laboratory, Faculty of Medical Sciences, Universidad de
      Especialidades Espiritu Santo, Samborondon, Ecuador.
FAU - Morey-Leon, Gabriel
AU  - Morey-Leon G
AD  - Faculty of Medical Sciences, Universidad de Guayaquil, Guayaquil, Ecuador.
FAU - Armas-Gonzalez, Ruben
AU  - Armas-Gonzalez R
AD  - Faculty of Sciences, Escuela Superior Politecnica del Litoral, Guayaquil,
      Ecuador.
FAU - Andrade-Molina, Derly Madeleiny
AU  - Andrade-Molina DM
AD  - Omics Sciences Laboratory, Faculty of Medical Sciences, Universidad de
      Especialidades Espiritu Santo, Samborondon, Ecuador.
FAU - Bruno, Alfredo
AU  - Bruno A
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
AD  - Universidad Agraria del Ecuador.
FAU - de Mora, Domenica
AU  - de Mora D
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
FAU - Olmedo, Maritza
AU  - Olmedo M
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
FAU - Portugal, Denisse
AU  - Portugal D
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
FAU - Gonzalez, Manuel
AU  - Gonzalez M
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
FAU - Orlando, Alberto
AU  - Orlando A
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
FAU - Drexler, Jan Felix
AU  - Drexler JF
AD  - Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Institute of
      Virology, Berlin, Germany.
FAU - Moreira-Soto, Andres
AU  - Moreira-Soto A
AD  - Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Institute of
      Virology, Berlin, Germany.
FAU - Sander, Anna-Lena
AU  - Sander AL
AD  - Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Institute of
      Virology, Berlin, Germany.
FAU - Brunink, Sebastian
AU  - Brunink S
AD  - Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Institute of
      Virology, Berlin, Germany.
FAU - Kuhne, Arne
AU  - Kuhne A
AD  - Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Institute of
      Virology, Berlin, Germany.
FAU - Patino, Leandro
AU  - Patino L
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
FAU - Carrazco-Montalvo, Andres
AU  - Carrazco-Montalvo A
AD  - Instituto Nacional de Investigacion en Salud Publica, Quito, Ecuador.
FAU - Mestanza, Orson
AU  - Mestanza O
AD  - Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador.
FAU - Zurita, Jeannete
AU  - Zurita J
AD  - Facultad de Medicina, Pontificia Universidad Catolica del Ecuador, Quito,
      Ecuador.
AD  - Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito,
      Ecuador.
FAU - Sevillano, Gabriela
AU  - Sevillano G
AD  - Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito,
      Ecuador.
FAU - du Plessis, Louis
AU  - du Plessis L
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - McCrone, John T
AU  - McCrone JT
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Coloma, Josefina
AU  - Coloma J
AD  - School of Public Health, University of California, Berkeley, USA.
FAU - Trueba, Gabriel
AU  - Trueba G
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Barragan, Veronica
AU  - Barragan V
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Rojas-Silva, Patricio
AU  - Rojas-Silva P
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Grunauer, Michelle
AU  - Grunauer M
AD  - Escuela de Medicina, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Kraemer, Moritz U G
AU  - Kraemer MUG
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Faria, Nuno R
AU  - Faria NR
AD  - Department of Zoology, University of Oxford, Oxford, UK.
AD  - MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College
      London, London, UK.
FAU - Escalera-Zamudio, Marina
AU  - Escalera-Zamudio M
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Pybus, Oliver G
AU  - Pybus OG
AD  - Department of Zoology, University of Oxford, Oxford, UK.
AD  - Department of Pathobiology and Population Sciences, Royal Veterinary College
      London, London, UK.
FAU - Cardenas, Paul
AU  - Cardenas P
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
LA  - eng
GR  - D43 TW010540/TW/FIC NIH HHS/United States
GR  - MR/S019510/1/MRC_/Medical Research Council/United Kingdom
PT  - Preprint
DEP - 20210405
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Virus Evol. 2021 Jun 04;7(2):veab051. PMID: 34527281
PMC - PMC8043474
EDAT- 2021/04/15 06:00
MHDA- 2021/04/15 06:01
CRDT- 2021/04/14 06:38
PHST- 2021/04/14 06:38 [entrez]
PHST- 2021/04/15 06:00 [pubmed]
PHST- 2021/04/15 06:01 [medline]
AID - 10.1101/2021.03.31.21254685 [doi]
PST - epublish
SO  - medRxiv. 2021 Apr 5. doi: 10.1101/2021.03.31.21254685.

PMID- 33848092
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 104
IP  - 5
DP  - 2021 Mar 5
TI  - Analytical and Clinical Evaluation of Two RT-qPCR SARS-CoV-2 Diagnostic Tests
      with Emergency Use Authorization in Ecuador.
PG  - 1672-1675
LID - 10.4269/ajtmh.20-1439 [doi]
LID - tpmd201439 [pii]
AB  - Dozens of RT-qPCR kits are available in the market for SARS-CoV-2 diagnosis, some
      of them with Emergency Use Authorization (EUA) by the Food and Drug
      Administration (FDA) or at least by a responsible agency of their country of
      origin, but many of them lack proper evaluation studies because of COVID-19
      pandemic emergency. We evaluated the clinical performance of two commercially
      available kits in South America, the 2019-nCoV kit (Da An Gene, Guangzhou, China)
      and GenomeCoV19 kit (ABM, Richmond, Canada), for RT-qPCR SARS-CoV-2 diagnosis
      using the FDA EUA 2019-nCoV CDC kit (IDT, Coralville, IA) as gold standard. We
      found striking differences among clinical performance and analytical sensitivity 
      in both kits; whereas the 2019-nCoV kit (Da An Gene) has a limit of detection of 
      2,000 copies/mL and 100% of sensitivity, the GenomeCoV19 kit (ABM) has a poor
      sensitivity of 75% and a limit of detection estimated to be over 8.000 copies/mL.
      The GenomeCoV19 kit (ABM) lacks clinical use authorization in Canada; however,
      the 2019-nCoV kit (Da An Gene) is authorized by the Chinese CDC. Our results
      support that only SARS-CoV-2 diagnosis kits with clinical use authorization from 
      their country of origin should be exported to developing countries lacking proper
      evaluation agencies to avoid a deep impact of the COVID-19 pandemic due to
      unreliable diagnosis.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - 1One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Bruno, Alfredo
AU  - Bruno A
AD  - 2Instituto Nacional de Salud Publica e Investigacion Leopoldo Izquieta Perez,
      Guayaquil, Ecuador.
AD  - 3Universidad Agraria del Ecuador, Guayaquil, Ecuador.
FAU - Orlando, Alberto
AU  - Orlando A
AD  - 2Instituto Nacional de Salud Publica e Investigacion Leopoldo Izquieta Perez,
      Guayaquil, Ecuador.
AD  - 3Universidad Agraria del Ecuador, Guayaquil, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - 1One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20210305
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - COVID-19/*diagnosis
MH  - COVID-19 Nucleic Acid Testing/*methods
MH  - Ecuador/epidemiology
MH  - Humans
MH  - *Reagent Kits, Diagnostic
MH  - SARS-CoV-2/*genetics
MH  - Sensitivity and Specificity
PMC - PMC8103494
EDAT- 2021/04/14 06:00
MHDA- 2022/02/03 06:00
CRDT- 2021/04/13 14:29
PHST- 2020/11/09 00:00 [received]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/04/14 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2021/04/13 14:29 [entrez]
AID - tpmd201439 [pii]
AID - 10.4269/ajtmh.20-1439 [doi]
PST - epublish
SO  - Am J Trop Med Hyg. 2021 Mar 5;104(5):1672-1675. doi: 10.4269/ajtmh.20-1439.

PMID- 33824608
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 1179-1594 (Print)
IS  - 1179-1594 (Linking)
VI  - 14
DP  - 2021
TI  - Cycle Threshold Values in the Context of Multiple RT-PCR Testing for SARS-CoV-2.
PG  - 1311-1317
LID - 10.2147/RMHP.S282962 [doi]
AB  - PURPOSE: Discharge or follow up of confirmed coronavirus disease 2019 (COVID-19) 
      cases depend on accurate interpretation of RT-PCR. Currently, positive/negative
      interpretations are based on amplification instead of quantification of cycle
      threshold (Ct) values, which could be used as proxies of patient infectiousness. 
      Here, we measured Ct values in hospitalized confirmed COVID-19 patients at
      different times and its implications in diagnosis and follow up. PATIENTS AND
      METHODS: Observational study between March 17th-May 12th, 2020 using multiple
      RT-PCR testing. A cohort of 118 Hispanic hospitalized patients with confirmed
      COVID-19 diagnosis in a reference hospital in Quito, Ecuador. Multiple RT-PCR
      tests were performed using deep nasal swab samples and the assessment of
      SARS-CoV-2 genes N, RdRP, and E. RESULTS: Patients' median age was of 49 years
      (range: 24-91) with a male majority (62.7%). We found increasing levels of Ct
      values in time, with a mean Ct value of 29.13 (n = 61, standard deviation (sd) = 
      5.55) for the first test and 34.38 (n = 60, sd = 4), 35.52 (n = 20, sd = 2.85),
      and 36.12 (n = 6, sd = 3.28), for the second, third, and fourth tests,
      respectively. Time to RT-PCR lack of amplification for all tests was of 34 days
      while time to RT-PCR Ct values >33 was of 30 days. CONCLUSION: Cycle thresholds
      can potentially be used to improve diagnosis, management and control. We found
      that turnover time for negativity can be large for hospitalized patients and that
      11% cases persisted with infectious Ct values for more time than the current
      isolation recommendations.
CI  - (c) 2021 Romero-Alvarez et al.
FAU - Romero-Alvarez, Daniel
AU  - Romero-Alvarez D
AUID- ORCID: 0000-0002-6762-6046
AD  - Biodiversity Institute and Department of Ecology & Evolutionary Biology,
      University of Kansas, Lawrence, KS, USA.
FAU - Garzon-Chavez, Daniel
AU  - Garzon-Chavez D
AUID- ORCID: 0000-0002-8024-3509
AD  - Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito,
      Ecuador.
FAU - Espinosa, Franklin
AU  - Espinosa F
AUID- ORCID: 0000-0002-9905-1785
AD  - Departamento Microbiologia Medica, Hospital IESS Quito Sur, Quito, Ecuador.
FAU - Ligna, Edison
AU  - Ligna E
AUID- ORCID: 0000-0002-5830-1418
AD  - Departamento Microbiologia Medica, Hospital IESS Quito Sur, Quito, Ecuador.
FAU - Teran, Enrique
AU  - Teran E
AUID- ORCID: 0000-0001-6979-5655
AD  - Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito,
      Ecuador.
FAU - Mora, Francisco
AU  - Mora F
AD  - Departamento Microbiologia Medica, Hospital IESS Quito Sur, Quito, Ecuador.
FAU - Espin, Emilia
AU  - Espin E
AUID- ORCID: 0000-0003-1704-0159
AD  - Hospital IESS Carlos Andrade Marin, Quito, Ecuador.
FAU - Alban, Cristina
AU  - Alban C
AD  - Hospital IESS Carlos Andrade Marin, Quito, Ecuador.
FAU - Galarza, Juan Miguel
AU  - Galarza JM
AUID- ORCID: 0000-0002-1797-937X
AD  - Hospital IESS Carlos Andrade Marin, Quito, Ecuador.
FAU - Reyes, Jorge
AU  - Reyes J
AUID- ORCID: 0000-0002-5215-164X
AD  - Departamento Microbiologia Medica, Hospital IESS Quito Sur, Quito, Ecuador.
AD  - Universidad Central del Ecuador, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20210329
PL  - England
TA  - Risk Manag Healthc Policy
JT  - Risk management and healthcare policy
JID - 101566264
PMC - PMC8018360
OTO - NOTNLM
OT  - COVID-19
OT  - RT-PCR
OT  - SARS-CoV-2
OT  - coronavirus
OT  - cycle thresholds
OT  - diagnosis
OT  - pandemic
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/04/08 06:00
MHDA- 2021/04/08 06:01
CRDT- 2021/04/07 06:23
PHST- 2020/09/20 00:00 [received]
PHST- 2020/12/28 00:00 [accepted]
PHST- 2021/04/07 06:23 [entrez]
PHST- 2021/04/08 06:00 [pubmed]
PHST- 2021/04/08 06:01 [medline]
AID - 10.2147/RMHP.S282962 [doi]
AID - 282962 [pii]
PST - epublish
SO  - Risk Manag Healthc Policy. 2021 Mar 29;14:1311-1317. doi: 10.2147/RMHP.S282962.
      eCollection 2021.

PMID- 33791722
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
DP  - 2021 Mar 24
TI  - SARS-CoV-2 genome sequencing from COVID-19 in Ecuadorian patients: a whole
      country analysis.
LID - 2021.03.19.21253620 [pii]
LID - 10.1101/2021.03.19.21253620 [doi]
AB  - SARS-CoV-2, the etiological agent of COVID-19, was first described in Wuhan,
      China in December 2019 and has now spread globally. Ecuador was the second
      country in South America to confirm cases and Guayaquil was one of the first
      cities in the world to experience high mortality due to COVID-19. The aim of this
      study was to describe the lineages circulating throughout the country and to
      compare the mutations in local variants, to the reference strain. In this work we
      used the MinION platform (Oxford Nanopore Technologies) to sequence the whole
      SARS-CoV-2 genomes of 119 patients from all provinces of Ecuador, using the ARTIC
      network protocols. Our data from lineage assignment of the one hundred and
      nineteen whole genomes revealed twenty different lineages. All genomes presented 
      differences in the S gene compared to the Wuhan reference strain, being the D614G
      amino acid replacement the most common change. The B.1.1.119 lineage was the most
      frequent and was found in several locations in the Coast and Andean region. Three
      sequences were assigned to the new B.1.1.7 lineage. Our work is an important
      contribution to the understanding of the epidemiology of SARS-CoV-2 in Ecuador
      and South America. HIGHLIGHTS: All 119 genomes showed mutations compared to the
      reference strain, which could be important to understand the virulence, severity 
      and transmissibility of the virus.Until January 17, three sequences were assigned
      to the new B.1.1.7 lineage.Our findings suggest that there were at least twenty
      independent introductions of SARS-CoV-2 to Ecuador. ARTICLE SUMMARY LINE: We
      report 119 sequences of SARS-CoV-2 across all Ecuadorian provinces, 20 different 
      lineages were found until January 17 (th) , including B.1.1.7.
FAU - Marquez, Sully
AU  - Marquez S
FAU - Prado-Vivar, Belen
AU  - Prado-Vivar B
FAU - Jose Guadalupe, Juan
AU  - Jose Guadalupe J
FAU - Becerra-Wong, Monica
AU  - Becerra-Wong M
FAU - Gutierrez, Bernardo
AU  - Gutierrez B
CN  - Clinical COVID-19 Ecuador Consortium
FAU - Fernandez-Cadena, Juan Carlos
AU  - Fernandez-Cadena JC
FAU - Andrade-Molina, Derly
AU  - Andrade-Molina D
FAU - Morey-Leon, Gabriel
AU  - Morey-Leon G
FAU - Moncayo, Miguel
AU  - Moncayo M
FAU - Guevara, Rommel
AU  - Guevara R
FAU - Coloma, Josefina
AU  - Coloma J
FAU - Trueba, Gabriel
AU  - Trueba G
FAU - Grunauer, Michelle
AU  - Grunauer M
FAU - Barragan, Veronica
AU  - Barragan V
FAU - Rojas-Silva, Patricio
AU  - Rojas-Silva P
FAU - Cardenas, Paul
AU  - Cardenas P
AUID- ORCID: 0000-0001-9626-4489
LA  - eng
GR  - D43 TW010540/TW/FIC NIH HHS/United States
PT  - Preprint
DEP - 20210324
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
PMC - PMC8010754
EDAT- 2021/04/02 06:00
MHDA- 2021/04/02 06:01
CRDT- 2021/04/01 06:35
PHST- 2021/04/01 06:35 [entrez]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/04/02 06:01 [medline]
AID - 10.1101/2021.03.19.21253620 [doi]
PST - epublish
SO  - medRxiv. 2021 Mar 24. doi: 10.1101/2021.03.19.21253620.

PMID- 33764553
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210703
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 93
IP  - 7
DP  - 2021 Jul
TI  - Dissemination and evolution of SARS-CoV-2 in the early pandemic phase in South
      America.
PG  - 4496-4507
LID - 10.1002/jmv.26967 [doi]
AB  - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic spread
      rapidly and this scenario is concerning in South America, mainly in Brazil with
      more than seven million cases of infection. Three major pandemic lineages/clades 
      could be identified along with SARS-CoV-2 dissemination (G, GR, and GH) in the
      Americas. These clades differ according to their genomic characteristics,
      virulence, and spreading times. The present study describes the main clades and
      the respective temporal spreading analyses based on SARS-CoV-2 whole-genome
      sequences (WGS) from South America, obtained in the early pandemic phase (from
      March 1 to May 31 in 2020). SARS-CoV-2 WGSs with available information from
      country and year of sampling were obtained from different countries and the main 
      clades were identified and analyzed independently with a Bayesian approach. The
      results demonstrated the prevalence of clades GR (n = 842; 54.6%), G (n = 529;
      34.3%), and GH (n = 171; 11.1%). The frequencies of the clades were significantly
      different between South American countries. Clade G was the most prevalent in
      Ecuador, Suriname, and Uruguay, clade GR in Argentina, Brazil, and Peru, and
      clade GH in Colombia. The phylodynamic analysis indicated that all these main
      lineages increased viral spreading from February to early March and after an
      evolutionary stationary phase was observed. The decrease observed in the virus
      dissemination was directly associated to the reduction of social movement after
      March. In conclusion, these data demonstrated the current predominance of clades 
      G, GR, and GH in South America because of the early dissemination of them in the 
      first pandemic phase in South America.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Wolf, Jonas Michel
AU  - Wolf JM
AUID- ORCID: 0000-0001-7577-464X
AD  - Programa de Pos-Graduacao em Biologia Celular e Molecular Aplicada a Saude,
      Universidade Luterana do Brasil, ULBRA, Canoas, Rio Grande do Sul, Brazil.
AD  - Laboratorio de Diagnostico Molecular, Universidade Luterana do Brasil, Canoas,
      Rio Grande do Sul, Brazil.
FAU - Streck, Andre Felipe
AU  - Streck AF
AUID- ORCID: 0000-0002-4798-0777
AD  - Universidade de Caxias do Sul, UCS, Caxias do Sul, Rio Grande do Sul, Brazil.
FAU - Fonseca, Andre
AU  - Fonseca A
AUID- ORCID: 0000-0001-6381-4210
AD  - Simbios Biotecnologia, Cachoeirinha, Rio Grande do Sul, Brazil.
FAU - Ikuta, Nilo
AU  - Ikuta N
AUID- ORCID: 0000-0002-5598-5340
AD  - Simbios Biotecnologia, Cachoeirinha, Rio Grande do Sul, Brazil.
FAU - Simon, Daniel
AU  - Simon D
AUID- ORCID: 0000-0003-1122-8468
AD  - Programa de Pos-Graduacao em Biologia Celular e Molecular Aplicada a Saude,
      Universidade Luterana do Brasil, ULBRA, Canoas, Rio Grande do Sul, Brazil.
FAU - Lunge, Vagner Ricardo
AU  - Lunge VR
AUID- ORCID: 0000-0003-4012-8650
AD  - Programa de Pos-Graduacao em Biologia Celular e Molecular Aplicada a Saude,
      Universidade Luterana do Brasil, ULBRA, Canoas, Rio Grande do Sul, Brazil.
AD  - Laboratorio de Diagnostico Molecular, Universidade Luterana do Brasil, Canoas,
      Rio Grande do Sul, Brazil.
AD  - Simbios Biotecnologia, Cachoeirinha, Rio Grande do Sul, Brazil.
LA  - eng
GR  - Grant/Award Number: 48080.599.26791.12062020/FINEP, Financiadora de Estudos e
      Projetos
GR  - Grant/Award Number: 313564/2014-0; 313304/2014-9/Conselho Nacional de
      Desenvolvimento Cientifico e Tecnologico
GR  - Grant/Award Number: 001/Coordenacao de Aperfeicoamento de Pessoal de Nivel
      Superior
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210408
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
SB  - IM
MH  - Base Sequence
MH  - COVID-19/pathology/*transmission/virology
MH  - Evolution, Molecular
MH  - Genome, Viral/*genetics
MH  - Humans
MH  - Phylogeography
MH  - SARS-CoV-2/*classification/*genetics/isolation & purification
MH  - Sequence Alignment
MH  - South America
MH  - Whole Genome Sequencing
PMC - PMC8250755
OTO - NOTNLM
OT  - *SARS coronavirus
OT  - *dissemination
OT  - *pandemic
EDAT- 2021/03/26 06:00
MHDA- 2021/06/09 06:00
CRDT- 2021/03/25 12:58
PHST- 2021/03/18 00:00 [revised]
PHST- 2020/12/30 00:00 [received]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/03/26 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2021/03/25 12:58 [entrez]
AID - 10.1002/jmv.26967 [doi]
PST - ppublish
SO  - J Med Virol. 2021 Jul;93(7):4496-4507. doi: 10.1002/jmv.26967. Epub 2021 Apr 8.

PMID- 33751241
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20220218
IS  - 1432-8798 (Electronic)
IS  - 0304-8608 (Linking)
VI  - 166
IP  - 6
DP  - 2021 Jun
TI  - SARS-CoV-2 infection represents a high risk for the elderly: analysis of
      pathogenesis.
PG  - 1565-1574
LID - 10.1007/s00705-021-05042-w [doi]
AB  - As people get older, age-related alterations occur that lead to increased
      susceptibility to disease. In the current COVID-19 pandemic, older people are
      particularly susceptible to a SARS-CoV-2 infection developing into severe
      disease. The objective of this review was to examine the literature regarding
      factors that may explain the tendency of this population to develop severe
      COVID-19. Research articles considered in this review were searched for in
      EMBASE, PubMed, and Web of Science from December 2019 to December 2020. Citations
      were screened by two independent reviewers. Studies of the immune system in older
      individuals found alterations in both the adaptive and innate immune systems. The
      adaptive system is depressed in its functions, and the innate system is in a
      pro-inflammatory state that can lead to chronic disease. This pro-inflammatory
      state may be related to a severe course of disease in COVID-19. This review shows
      that the level of evidence supporting an association between immune alterations
      in the elderly and susceptibly to severe progression of SARS-CoV-2 infection is
      generally consistent. Preventive measures such as early antiviral treatment are
      of key importance for prevention of severe progression of COVID19.
FAU - Pedreanez, Adriana
AU  - Pedreanez A
AUID- ORCID: http://orcid.org/0000-0002-3937-0469
AD  - Escuela de Bioanalisis, Departamento de Microbiologia, Catedra de Inmunologia,
      Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela.
      apedreanez@gmail.com.
FAU - Mosquera-Sulbaran, Jesus
AU  - Mosquera-Sulbaran J
AUID- ORCID: http://orcid.org/0000-0002-1496-5511
AD  - Instituto de Investigaciones Clinicas "Dr. Americo Negrette". Facultad de
      Medicina, Universidad del Zulia,, Maracaibo, Venezuela.
FAU - Munoz, Nelson
AU  - Munoz N
AUID- ORCID: http://orcid.org/0000-0002-6873-0021
AD  - Facultad de Ciencias de la Salud, Universidad Nacional del Chimborazo, Riobamba, 
      Ecuador.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210322
PL  - Austria
TA  - Arch Virol
JT  - Archives of virology
JID - 7506870
SB  - IM
MH  - Aged
MH  - Aging/*immunology
MH  - COVID-19/epidemiology/*etiology/*immunology
MH  - Humans
MH  - Inflammation/etiology/immunology
MH  - Risk Factors
MH  - *SARS-CoV-2
PMC - PMC7982908
EDAT- 2021/03/23 06:00
MHDA- 2021/06/05 06:00
CRDT- 2021/03/22 19:06
PHST- 2020/12/20 00:00 [received]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2021/03/22 19:06 [entrez]
AID - 10.1007/s00705-021-05042-w [doi]
AID - 10.1007/s00705-021-05042-w [pii]
PST - ppublish
SO  - Arch Virol. 2021 Jun;166(6):1565-1574. doi: 10.1007/s00705-021-05042-w. Epub 2021
      Mar 22.

PMID- 33727235
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20220426
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Linking)
VI  - 38
IP  - 5
DP  - 2021 May
TI  - Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis 
      from the HOPE COVID-19 registry.
PG  - 359-365
LID - 10.1136/emermed-2020-210411 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has seriously challenged worldwide healthcare
      systems and limited intensive care facilities, leading to physicians considering 
      the use of non-invasive ventilation (NIV) for managing SARS-CoV-2-related acute
      respiratory failure (ARF). METHODS: We conducted an interim analysis of the
      international, multicentre HOPE COVID-19 registry including patients admitted for
      a confirmed or highly suspected SARS-CoV-2 infection until 18 April 2020. Those
      treated with NIV were considered. The primary endpoint was a composite of death
      or need for intubation. The components of the composite endpoint were the
      secondary outcomes. Unadjusted and adjusted predictors of the primary endpoint
      within those initially treated with NIV were investigated. RESULTS: 1933 patients
      who were included in the registry during the study period had data on oxygen
      support type. Among them, 390 patients (20%) were treated with NIV. Compared with
      those receiving other non-invasive oxygen strategy, patients receiving NIV showed
      significantly worse clinical and laboratory signs of ARF at presentation. Of the 
      390 patients treated with NIV, 173 patients (44.4%) met the composite endpoint.
      In-hospital death was the main determinant (147, 37.7%), while 62 patients
      (15.9%) needed invasive ventilation. Those requiring invasive ventilation had the
      lowest survival rate (41.9%). After adjustment, age (adjusted OR (adj(OR)) for
      5-year increase: 1.37, 95% CI 1.15 to 1.63, p<0.001), hypertension (adj(OR) 2.95,
      95% CI 1.14 to 7.61, p=0.03), room air O2 saturation <92% at presentation
      (adj(OR) 3.05, 95% CI 1.28 to 7.28, p=0.01), lymphocytopenia (adj(OR) 3.55, 95%
      CI 1.16 to 10.85, p=0.03) and in-hospital use of antibiotic therapy (adj(OR)
      4.91, 95% CI 1.69 to 14.26, p=0.003) were independently associated with the
      composite endpoint. CONCLUSION: NIV was used in a significant proportion of
      patients within our cohort, and more than half of these patients survived without
      the need for intubation. NIV may represent a viable strategy particularly in case
      of overcrowded and limited intensive care resources, but prompt identification of
      failure is mandatory to avoid harm. Further studies are required to better
      clarify our hypothesis. TRIAL REGISTRATION NUMBERS: NCT04334291/EUPAS34399.
CI  - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Bertaina, Maurizio
AU  - Bertaina M
AUID- ORCID: http://orcid.org/0000-0001-5727-4107
AD  - Department of Cardiology, San Giovanni Bosco Hospital, Turin, Piemonte, Italy
      maurizio.bertaina@gmail.com.
AD  - Emergency Medicine Department, Martini Hospital Centre, Torino, Piemonte, Italy.
FAU - Nunez-Gil, Ivan J
AU  - Nunez-Gil IJ
AD  - Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Community of
      Madrid, Spain.
FAU - Franchin, Luca
AU  - Franchin L
AD  - Emergency Medicine Department, Martini Hospital Centre, Torino, Piemonte, Italy.
AD  - Division of Cardiology, Cardiovascular and Thoracic Department, University
      Hospital Citta della Salute e della Scienza, Turin, Italy.
FAU - Fernandez Rozas, Inmaculada
AU  - Fernandez Rozas I
AD  - Cardiology Department, Severo Ochoa University Hospital, Leganes, Madrid, Spain.
FAU - Arroyo-Espliguero, Ramon
AU  - Arroyo-Espliguero R
AD  - Department of Cardiology, General University Hospital of Guadalajara,
      Guadalajara, Castilla-La Mancha, Spain.
FAU - Viana-Llamas, Maria C
AU  - Viana-Llamas MC
AD  - Department of Cardiology, General University Hospital of Guadalajara,
      Guadalajara, Castilla-La Mancha, Spain.
FAU - Romero, Rodolfo
AU  - Romero R
AD  - Servicio de Urgencias, Getafe University Hospital, Getafe, Community of Madrid,
      Spain.
FAU - Maroun Eid, Charbel
AU  - Maroun Eid C
AD  - Emergency Department, La Paz University Hospital, Madrid, Spain.
FAU - Uribarri, Aitor
AU  - Uribarri A
AD  - Division of Cardiology, Valladolid University Clinical Hospital, Valladolid,
      Castilla y Leon, Spain.
FAU - Becerra-Munoz, Victor Manuel
AU  - Becerra-Munoz VM
AD  - Division of Cardiology, Virgen de la Victoria University Hospital, Malaga,
      Andalucia, Spain.
FAU - Huang, Jia
AU  - Huang J
AD  - Department of Critical Care Medicine, Shenzhen Second People's Hospital,
      Shenzhen, Guangdong, China.
FAU - Alfonso, Emilio
AU  - Alfonso E
AD  - Division of Cardiology, Institute of Cardiology and Cardiovascular Surgery,
      Havana, Cuba.
FAU - Marmol-Mosquera, Fernando
AU  - Marmol-Mosquera F
AD  - Internal Medicine Department, Hospital General del norte de Guayaquil IESS Los
      Ceibos, Guayaquil, Ecuador.
FAU - Ugo, Fabrizio
AU  - Ugo F
AD  - Division of Cardiology, Sant'Andrea di Vercelli Hospital, Vercelli, Piedmont,
      Italy.
FAU - Cerrato, Enrico
AU  - Cerrato E
AD  - Division of Cardiology, San Luigi Gonzaga University Hospital, Orbassano, Italy.
FAU - Fernandez-Presa, Lucia
AU  - Fernandez-Presa L
AD  - Pulmonary Department, Hospital Clinico, Valencia, Spain.
FAU - Raposeiras Roubin, Sergio
AU  - Raposeiras Roubin S
AD  - Division of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Galicia,
      Spain.
FAU - Feltes Guzman, Gisela
AU  - Feltes Guzman G
AD  - Division of Cardiology, Hospital Nuestra Senora de America Madrid, Madrid, Spain.
FAU - Gonzalez, Adelina
AU  - Gonzalez A
AD  - Infanta Sofia University Hospital, San Sebastian de los Reyes, Community of
      Madrid, Spain.
FAU - Abumayyaleh, Mohammad
AU  - Abumayyaleh M
AD  - University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Fernandez-Ortiz, Antonio
AU  - Fernandez-Ortiz A
AD  - Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Community of
      Madrid, Spain.
FAU - Macaya, Carlos
AU  - Macaya C
AD  - Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Community of
      Madrid, Spain.
FAU - Estrada, Vicente
AU  - Estrada V
AD  - Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Community of
      Madrid, Spain.
CN  - HOPE COVID-19 investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT04334291
PT  - Journal Article
DEP - 20210316
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/complications/*mortality/*therapy
MH  - Female
MH  - Hospital Mortality/trends
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Noninvasive Ventilation/*mortality
MH  - Pandemics
MH  - Registries
MH  - Respiration, Artificial/mortality
MH  - Respiratory Insufficiency/etiology/*mortality/*therapy
MH  - SARS-CoV-2
PMC - PMC7970657
OTO - NOTNLM
OT  - COVID-19
OT  - acute care
OT  - non-invasive
OT  - respiratory
OT  - ventilation
COIS- Competing interests: None declared.
EDAT- 2021/03/18 06:00
MHDA- 2021/09/09 06:00
CRDT- 2021/03/17 06:09
PHST- 2020/07/15 00:00 [received]
PHST- 2021/01/26 00:00 [revised]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/03/18 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2021/03/17 06:09 [entrez]
AID - emermed-2020-210411 [pii]
AID - 10.1136/emermed-2020-210411 [doi]
PST - ppublish
SO  - Emerg Med J. 2021 May;38(5):359-365. doi: 10.1136/emermed-2020-210411. Epub 2021 
      Mar 16.

PMID- 33680867
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220110
IS  - 2214-7853 (Print)
IS  - 2214-7853 (Linking)
VI  - 48
DP  - 2022
TI  - COVID-19 outbreak in Malaysia: Decoding D614G mutation of SARS-CoV-2 virus
      isolated from an asymptomatic case in Pahang.
PG  - 828-836
LID - 10.1016/j.matpr.2021.02.387 [doi]
AB  - SARS-CoV-2 is a very transmissible and pathogenic coronavirus which detected in
      Malaysia in January 2020. Nevertheless, the sample from Malaysia is still
      under-sequenced. Hence lacking clarity of the circulating strain in Malaysia
      leads to a deadlock in understanding the virus infectivity. This study aimed to
      investigate the genome identity of circulating COVID-19 strains in Pahang and
      understand disease epidemiology during the pandemic. This study leveraged
      high-throughput sequencing analysis for the whole genome sequencing and
      implemented bioinformatic technique for the analysis. Here we reported that the
      virus with D614G mutation in Spike protein circulates in a few Malaysia states
      before the Sivagangga cluster announced in Kedah in July 2020. This mutated virus
      includes our virus sample isolated in April 2020 from an asymptomatic patient in 
      Pahang. Based on the phylogenetic analysis, we discovered the origin of our
      sample Pahang/IIUM91 was not related to Sivagangga cluster. Here, we have
      generated 3D structure model of Pahang/IIUM91 Spike protein. D614G mutation in
      Pahang/IIUM91 Spike protein increases viral stability and flexibility, hence
      render higher infectivity. Collectively, our results suggest for the
      establishment of a complete SARS-CoV-2 genome database in Malaysia. Hence, more
      research should be established to learn the behaviour of this virus.
CI  - (c) 2021 Elsevier Ltd. All rights reserved. Selection and peer-review under
      responsibility of the scientific committee of the 2nd International Conference on
      Innovative Technology and Sciences (iCITES 2020).
FAU - Mat Yassim, Aini Syahida
AU  - Mat Yassim AS
AD  - Faculty Industrial Sciences and Technology, Lebuhraya Tun Razak, 26300 Gambang,
      Pahang, Malaysia.
FAU - Asras, Mohd Fazli Farida
AU  - Asras MFF
AD  - Faculty Industrial Sciences and Technology, Lebuhraya Tun Razak, 26300 Gambang,
      Pahang, Malaysia.
FAU - Gazali, Ahmad Mahfuz
AU  - Gazali AM
AD  - Faculty Industrial Sciences and Technology, Lebuhraya Tun Razak, 26300 Gambang,
      Pahang, Malaysia.
AD  - Centre for Research in Advanced Tropical Bioscience (Biotropic Centre), Lebuhraya
      Tun Razak, 26300 Gambang, Pahang, Malaysia.
FAU - Marcial-Coba, Martin S
AU  - Marcial-Coba MS
AD  - Pontifical Catholic University of Ecuador, 170143 Quito, Ecuador.
FAU - Zainulabid, Ummu Afeera
AU  - Zainulabid UA
AD  - Kulliyyah of Medicine, International Islamic University Malaysia, 25200 Kuantan, 
      Pahang, Malaysia.
FAU - Ahmad, Hajar Fauzan
AU  - Ahmad HF
AD  - Faculty Industrial Sciences and Technology, Lebuhraya Tun Razak, 26300 Gambang,
      Pahang, Malaysia.
AD  - Centre for Research in Advanced Tropical Bioscience (Biotropic Centre), Lebuhraya
      Tun Razak, 26300 Gambang, Pahang, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20210227
PL  - England
TA  - Mater Today Proc
JT  - Materials today. Proceedings
JID - 101668762
PMC - PMC7914017
OTO - NOTNLM
OT  - D614G
OT  - Malaysia
OT  - Mutation
OT  - Pahang
OT  - SARS-CoV-2
OT  - Spike protein
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2021/03/09 06:00
MHDA- 2021/03/09 06:01
CRDT- 2021/03/08 05:54
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/03/09 06:01 [medline]
PHST- 2021/03/08 05:54 [entrez]
AID - 10.1016/j.matpr.2021.02.387 [doi]
AID - S2214-7853(21)01504-2 [pii]
PST - ppublish
SO  - Mater Today Proc. 2022;48:828-836. doi: 10.1016/j.matpr.2021.02.387. Epub 2021
      Feb 27.

PMID- 33669720
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 4
DP  - 2021 Feb 19
TI  - In Silico Screening of the DrugBank Database to Search for Possible Drugs against
      SARS-CoV-2.
LID - 1100 [pii]
LID - 10.3390/molecules26041100 [doi]
AB  - Coronavirus desease 2019 (COVID-19) is responsible for more than 1.80 M deaths
      worldwide. A Quantitative Structure-Activity Relationships (QSAR) model is
      developed based on experimental pIC50 values reported for a structurally diverse 
      dataset. A robust model with only five descriptors is found, with values of R(2) 
      = 0.897, Q(2)LOO = 0.854, and Q(2)ext = 0.876 and complying with all the
      parameters established in the validation Tropsha's test. The analysis of the
      applicability domain (AD) reveals coverage of about 90% for the external test
      set. Docking and molecular dynamic analysis are performed on the three most
      relevant biological targets for SARS-CoV-2: main protease, papain-like protease, 
      and RNA-dependent RNA polymerase. A screening of the DrugBank database is
      executed, predicting the pIC50 value of 6664 drugs, which are IN the AD of the
      model (coverage = 79%). Fifty-seven possible potent anti-COVID-19 candidates with
      pIC50 values > 6.6 are identified, and based on a pharmacophore modelling
      analysis, four compounds of this set can be suggested as potent candidates to be 
      potential inhibitors of SARS-CoV-2. Finally, the biological activity of the
      compounds was related to the frontier molecular orbitals shapes.
FAU - Cuesta, Sebastian A
AU  - Cuesta SA
AD  - Grupo de Quimica Computacional y Teorica (QCT-USFQ), Departamento de Ingenieria
      Quimica, Colegio Politecnico, Universidad San Francisco de Quito, Diego de Robles
      y Via Interoceanica, Quito 170901, Ecuador.
FAU - Mora, Jose R
AU  - Mora JR
AUID- ORCID: 0000-0001-6128-9504
AD  - Grupo de Quimica Computacional y Teorica (QCT-USFQ), Departamento de Ingenieria
      Quimica, Colegio Politecnico, Universidad San Francisco de Quito, Diego de Robles
      y Via Interoceanica, Quito 170901, Ecuador.
FAU - Marquez, Edgar A
AU  - Marquez EA
AUID- ORCID: 0000-0002-7503-1528
AD  - Grupo de Investigaciones en Quimica y Biologia, Departamento de Quimica y
      Biologia, Facultad de Ciencias Exactas, Universidad del Norte, Carrera 51B, Km 5,
      via Puerto Colombia, Barranquilla 081007, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20210219
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antiviral Agents)
RN  - 0 (Cysteine Proteinase Inhibitors)
RN  - EC 2.7.7.48 (RNA-Dependent RNA Polymerase)
RN  - EC 3.4.22.28 (Coronavirus 3C Proteases)
SB  - IM
MH  - Antiviral Agents/*chemistry/therapeutic use
MH  - COVID-19/drug therapy/*enzymology
MH  - *Coronavirus 3C Proteases/antagonists & inhibitors/chemistry
MH  - Cysteine Proteinase Inhibitors/*chemistry/therapeutic use
MH  - *Databases, Chemical
MH  - Drug Evaluation, Preclinical
MH  - *Molecular Docking Simulation
MH  - *Molecular Dynamics Simulation
MH  - Quantitative Structure-Activity Relationship
MH  - *RNA-Dependent RNA Polymerase/antagonists & inhibitors/chemistry
MH  - SARS-CoV-2/*enzymology
PMC - PMC7923184
OTO - NOTNLM
OT  - DrugBank
OT  - QSAR
OT  - SARS-CoV-2
OT  - docking analysis
OT  - molecular dynamics
EDAT- 2021/03/07 06:00
MHDA- 2021/03/16 06:00
CRDT- 2021/03/06 01:05
PHST- 2021/01/13 00:00 [received]
PHST- 2021/02/11 00:00 [revised]
PHST- 2021/02/16 00:00 [accepted]
PHST- 2021/03/06 01:05 [entrez]
PHST- 2021/03/07 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - molecules26041100 [pii]
AID - 10.3390/molecules26041100 [doi]
PST - epublish
SO  - Molecules. 2021 Feb 19;26(4). pii: molecules26041100. doi:
      10.3390/molecules26041100.

PMID- 33638618
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20220716
IS  - 1939-0041 (Electronic)
IS  - 1939-0041 (Linking)
VI  - 13
IP  - 5
DP  - 2021 Sep
TI  - Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.
PG  - e1707
LID - 10.1002/wnan.1707 [doi]
AB  - Several human coronaviruses (HCoVs) are distinguished by the ability to generate 
      epidemics or pandemics, with their corresponding diseases characterized by severe
      respiratory illness, such as that which occurs in severe acute respiratory
      syndrome (SARS-CoV), Middle East respiratory syndrome (MERS-CoV), and, today, in 
      SARS-CoV-2, an outbreak that has struck explosively and uncontrollably beginning 
      in December 2019 and has claimed the lives of more than 1.9 M people worldwide as
      of January 2021. The development of vaccines has taken one year, which is why it 
      is necessary to investigate whether some already-existing alternatives that have 
      been successfully developed in recent years can mitigate the pandemic's advance. 
      Silver nanoparticles (AgNPs) have proved effective in antiviral action. Thus, in 
      this review, several in vitro and in vivo studies of the effect of AgNPs on
      viruses that cause respiratory diseases are analyzed and discussed to promote an 
      understanding of the possible interaction of AgNPs with SARS-CoV-2. The study
      focuses on several in vivo toxicological studies of AgNPs and a dose
      extrapolation to humans to determine the chief avenue of exposure. It can be
      concluded that the use of AgNPs as a possible treatment for SARS-CoV-2 could be
      viable, based on comparing the virus' behavior to that of similar viruses in in
      vivo studies, and that the suggested route of administration in terms of least
      degree of adverse effects is inhalation. This article is categorized under:
      Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic
      Approaches and Drug Discovery > Nanomedicine for Respiratory Disease Toxicology
      and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Pilaquinga, Fernanda
AU  - Pilaquinga F
AUID- ORCID: 0000-0002-0841-6313
AD  - School of Chemistry Sciences, Pontificia Universidad Catolica del Ecuador, Quito,
      Ecuador.
AD  - Department of Chemistry, University of the Balearic Islands, Palma de Mallorca,
      Spain.
FAU - Morey, Jeroni
AU  - Morey J
AUID- ORCID: 0000-0002-9483-5433
AD  - Department of Chemistry, University of the Balearic Islands, Palma de Mallorca,
      Spain.
FAU - Torres, Marbel
AU  - Torres M
AD  - Immunology and Virology Laboratory, Nanoscience and Nanotechnology Center,
      Universidad de las Fuerzas Armadas, ESPE, Sangolqui, Ecuador.
FAU - Seqqat, Rachid
AU  - Seqqat R
AD  - Immunology and Virology Laboratory, Nanoscience and Nanotechnology Center,
      Universidad de las Fuerzas Armadas, ESPE, Sangolqui, Ecuador.
FAU - Pina, Maria de Las Nieves
AU  - Pina MLN
AD  - Department of Chemistry, University of the Balearic Islands, Palma de Mallorca,
      Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210227
PL  - United States
TA  - Wiley Interdiscip Rev Nanomed Nanobiotechnol
JT  - Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
JID - 101508311
RN  - 3M4G523W1G (Silver)
SB  - IM
MH  - *COVID-19/therapy
MH  - Humans
MH  - *Metal Nanoparticles/therapeutic use
MH  - Pandemics
MH  - SARS-CoV-2/drug effects
MH  - Silver
PMC - PMC7995207
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *Silver Nanoparticles
OT  - *in vitro studies
OT  - *in vivo studies
EDAT- 2021/02/28 06:00
MHDA- 2021/10/08 06:00
CRDT- 2021/02/27 08:36
PHST- 2021/01/26 00:00 [revised]
PHST- 2020/07/03 00:00 [received]
PHST- 2021/01/29 00:00 [accepted]
PHST- 2021/02/28 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2021/02/27 08:36 [entrez]
AID - 10.1002/wnan.1707 [doi]
PST - ppublish
SO  - Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Sep;13(5):e1707. doi:
      10.1002/wnan.1707. Epub 2021 Feb 27.

PMID- 33635827
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 104
IP  - 4
DP  - 2021 Feb 26
TI  - Clinical Performance and Analytical Sensitivity of Three SARS-CoV-2 Nucleic Acid 
      Diagnostic Tests.
PG  - 1516-1518
LID - 10.4269/ajtmh.20-1484 [doi]
LID - tpmd201484 [pii]
AB  - Hundreds of RT-qPCR kits are available in the market for SARS-CoV-2 diagnosis,
      some of them with emergency use authorization (EUA) by the Food Drug
      Administration (FDA) or their country of origin agency, but also many of them
      without any independent clinical performance evaluation. We performed a clinical 
      evaluation for two Chinese SARS-CoV-2 RT-PCR kits available in South America,
      COVID-19 Nucleic Acid Test Kit (eDiagnosis Biomedicine, Wuhan, China) and
      2019-nCoV Nucleic Acid Diagnostic Kit (Sansure Biotech, Changsha, China), for
      RT-qPCR SARS-CoV-2 diagnosis using the FDA EUA 2019-nCoV CDC kit (IDT,
      Coralville, IA) as gold standard. We found an excellent clinical performance and 
      analytical sensitivity for both kits with sensitivity values of 100% and 95.3%
      and estimated limit of detection of 500 copies/mL and 1,000 copies/mL, for
      eDiagnosis and Sansure Biotech kits, respectively. COVID-19 Nucleic Acid Test Kit
      (eDiagnosis) and 2019-nCoV Nucleic Acid Diagnostic Kit (Sansure Biotech) are both
      made in China and hold EUA by the Chinese CDC. Also, Sansure Biotech kit has EUA 
      by the FDA. In conclusion, our results endorse the use of these two commercially 
      available kits imported to Ecuador for SARS-CoV-2 diagnosis, as they had the
      similar clinical performance as the gold standard from the CDC.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
LA  - eng
PT  - Journal Article
DEP - 20210226
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - COVID-19/*diagnosis
MH  - COVID-19 Nucleic Acid Testing/*methods
MH  - Humans
MH  - *Reagent Kits, Diagnostic
MH  - SARS-CoV-2/*genetics
MH  - Sensitivity and Specificity
PMC - PMC8045661
EDAT- 2021/02/27 06:00
MHDA- 2022/02/03 06:00
CRDT- 2021/02/26 17:08
PHST- 2020/11/18 00:00 [received]
PHST- 2021/01/24 00:00 [accepted]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2021/02/26 17:08 [entrez]
AID - 10.4269/ajtmh.20-1484 [doi]
AID - tpmd201484 [pii]
PST - epublish
SO  - Am J Trop Med Hyg. 2021 Feb 26;104(4):1516-1518. doi: 10.4269/ajtmh.20-1484.

PMID- 33630751
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 104
IP  - 4
DP  - 2021 Feb 25
TI  - A Low-Cost SARS-CoV-2 rRBD ELISA to Detect Serostatus in Ecuadorian Population
      with COVID-19.
PG  - 1513-1515
LID - 10.4269/ajtmh.20-1420 [doi]
LID - tpmd201420 [pii]
AB  - Laboratory diagnosis of the COVID-19 relies on RT-PCR to amplify specific
      fragments of SARS-CoV-2 genome. However, serological tests are required to
      determine the immune response elicited after infection. Here, we analyzed
      convalescent sera collected from positive individuals by RT-PCR to SARS-CoV-2 (n 
      = 78), Zika (n = 20), dengue (n = 20), chikungunya (n = 54), intestinal parasites
      (n = 11), and HIV (n = 1), from different areas of Ecuador, with an in-house
      ELISA using a SARS-CoV-2 receptor binding domain recombinant (rRBD) antigen to
      detect IgG antibodies elicited by SARS-CoV-2 infection. Of the 78 samples
      positive for SARS-CoV-2 by RT-PCR, 73 showed high absorbance value compared with 
      the cutoff and five were negative. All tested sera from other infections showed
      no reactivity. Sensitivity, specificity, positive predictive value, and negative 
      predictive value were 93.6%, 100%, 100%, and 95.4%, respectively. This in-house
      anti-IgG rRBD ELISA offers an economic and simple alternative to determine IgG
      immune responses after SARS-CoV-2 infection.
FAU - Guevara, Angel
AU  - Guevara A
AD  - 1Instituto de Biomedicina, Carrera de Medicina, Universidad Central, Quito,
      Ecuador.
FAU - Vivero, Sandra
AU  - Vivero S
AD  - 1Instituto de Biomedicina, Carrera de Medicina, Universidad Central, Quito,
      Ecuador.
FAU - Nipaz, Victoria
AU  - Nipaz V
AD  - 1Instituto de Biomedicina, Carrera de Medicina, Universidad Central, Quito,
      Ecuador.
FAU - Guaraca, Victor
AU  - Guaraca V
AD  - 2Distrito de Salud 09D13, Ministerio de Salud Publica del Ecuador, Balzar,
      Ecuador.
FAU - Coloma, Josefina
AU  - Coloma J
AD  - 3Division of Infectious Diseases and Vaccinology, School of Public Health,
      University of California, Berkeley, Berkeley, California.
LA  - eng
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20210225
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
SB  - IM
MH  - Antibodies, Viral/blood
MH  - COVID-19/*diagnosis/epidemiology
MH  - COVID-19 Serological Testing/economics/*methods
MH  - Ecuador/epidemiology
MH  - Enzyme-Linked Immunosorbent Assay/economics/*methods
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Protein Binding
MH  - Protein Domains
MH  - Recombinant Proteins/immunology
MH  - SARS-CoV-2/*immunology
MH  - Spike Glycoprotein, Coronavirus/chemistry/*immunology
PMC - PMC8045656
EDAT- 2021/02/26 06:00
MHDA- 2022/02/03 06:00
CRDT- 2021/02/25 17:15
PHST- 2020/11/02 00:00 [received]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2021/02/25 17:15 [entrez]
AID - 10.4269/ajtmh.20-1420 [doi]
AID - tpmd201420 [pii]
PST - epublish
SO  - Am J Trop Med Hyg. 2021 Feb 25;104(4):1513-1515. doi: 10.4269/ajtmh.20-1420.

PMID- 33619260
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210306
IS  - 2059-0105 (Electronic)
IS  - 2059-0105 (Linking)
VI  - 6
IP  - 1
DP  - 2021 Feb 22
TI  - SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.
PG  - 28
LID - 10.1038/s41541-021-00292-w [doi]
AB  - The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family
      and causes COVID-19 disease. The newly sequenced virus appears to originate in
      China and rapidly spread throughout the world, becoming a pandemic that, until
      January 5th, 2021, has caused more than 1,866,000 deaths. Hence, laboratories
      worldwide are developing an effective vaccine against this disease, which will be
      essential to reduce morbidity and mortality. Currently, there more than 64
      vaccine candidates, most of them aiming to induce neutralizing antibodies against
      the spike protein (S). These antibodies will prevent uptake through the human
      ACE-2 receptor, thereby limiting viral entrance. Different vaccine platforms are 
      being used for vaccine development, each one presenting several advantages and
      disadvantages. Thus far, thirteen vaccine candidates are being tested in Phase 3 
      clinical trials; therefore, it is closer to receiving approval or authorization
      for large-scale immunizations.
FAU - Kyriakidis, Nikolaos C
AU  - Kyriakidis NC
AD  - One Health Research Group, Universidad de Las Americas (UDLA), Quito, Ecuador.
      nickyriakidis82@yahoo.gr.
FAU - Lopez-Cortes, Andres
AU  - Lopez-Cortes A
AD  - Centro de Investigacion Genetica y Genomica, Facultad de Ciencias de la Salud
      Eugenio Espejo, Universidad UTE, Quito, Ecuador.
AD  - Latin American Network for the Implementation and Validation of Clinical
      Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain.
FAU - Gonzalez, Eduardo Vasconez
AU  - Gonzalez EV
AD  - One Health Research Group, Universidad de Las Americas (UDLA), Quito, Ecuador.
FAU - Grimaldos, Alejandra Barreto
AU  - Grimaldos AB
AUID- ORCID: http://orcid.org/0000-0001-7477-9721
AD  - One Health Research Group, Universidad de Las Americas (UDLA), Quito, Ecuador.
FAU - Prado, Esteban Ortiz
AU  - Prado EO
AUID- ORCID: http://orcid.org/0000-0002-1895-7498
AD  - One Health Research Group, Universidad de Las Americas (UDLA), Quito, Ecuador.
      e.ortizprado@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210222
PL  - England
TA  - NPJ Vaccines
JT  - NPJ vaccines
JID - 101699863
PMC - PMC7900244
EDAT- 2021/02/24 06:00
MHDA- 2021/02/24 06:01
CRDT- 2021/02/23 06:10
PHST- 2020/10/19 00:00 [received]
PHST- 2021/01/13 00:00 [accepted]
PHST- 2021/02/23 06:10 [entrez]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2021/02/24 06:01 [medline]
AID - 10.1038/s41541-021-00292-w [doi]
AID - 10.1038/s41541-021-00292-w [pii]
PST - epublish
SO  - NPJ Vaccines. 2021 Feb 22;6(1):28. doi: 10.1038/s41541-021-00292-w.

PMID- 33608714
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20220531
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Linking)
VI  - 44
IP  - 8
DP  - 2021 Aug 13
TI  - Sleep quality deterioration in middle-aged and older adults living in a rural
      Ecuadorian village severely struck by the SARS-CoV-2 pandemic. A population-based
      longitudinal prospective study.
LID - zsab041 [pii]
LID - 10.1093/sleep/zsab041 [doi]
AB  - STUDY OBJECTIVES: This study assessed changes in sleep quality before and after
      the peak of the SARS-CoV-2 pandemic in community dwellers enrolled in the
      Atahualpa Project. METHODS: Atahualpa residents aged >/=40 years were eligible if
      they had a Pittsburgh Sleep Quality Index (PSQI) 9 months before the pandemic and
      a lateral flow-based test for identification of SARS-CoV-2 antibodies during the 
      peak of the pandemic. Six months later, individuals completed a follow-up PSQI.
      The independent relationship between SARS-CoV-2 infection and deterioration in
      sleep quality was assessed by fitting logistic mixed models for longitudinal
      data. RESULTS: Of 639 participants (mean age at baseline: 59 +/- 12.8 years), 325
      (51%) had SARS-CoV-2 antibodies. A total of 185 (29%) individuals at baseline and
      311 (49%) at follow-up were poor sleepers (p < 0.001). Mixed logistic regression 
      models demonstrated a significant increase in poor sleepers at follow-up (odds
      ratio [OR]: 2.85; 95% CI: 2.16 to 3.75), which was more marked among SARS-CoV-2
      seropositive subjects (OR: 3.8; 95% CI: 2.48 to 5.81). The adjusted proportion of
      poor sleepers increased from 29% to 56.2% (95% CI: 50.9% to 61.6%) among
      SARS-CoV-2 seropositive individuals, but only to 40.7% (95% CI: 35.3% to 46.1%)
      in their seronegative counterparts (p < 0.001). Likewise, progression from a good
      to a poor sleeper status was higher among seropositive individuals than in their 
      seronegative counterparts (38.1% vs 22.3%; p < 0.001), after adjusting for
      relevant covariates. CONCLUSIONS: This study shows a deleterious effect of
      SARS-CoV-2 in sleep quality. An effect of SARS-CoV-2 in disrupting sleep-related 
      pathways cannot be ruled out. TRIAL REGISTRATION: The Atahualpa Project has been 
      registered at ClinicalTrials.gov; the identifier number is NCT01627600, and the
      date was: 10/02/2012
      (https://clinicaltrials.gov/ct2/show/NCT01627600?cond=Atahualpa&draw=2&rank=1).
      The Sleep Disorders substudy has been registered at ClinicalTrials.gov; the
      identifier number is NCT01877616, and the date was: 06/13/2013
      (https://clinicaltrials.gov/ct2/show/NCT01877616?cond=Atahualpa&draw=2&rank=4).
CI  - (c) Sleep Research Society 2021. Published by Oxford University Press on behalf
      of the Sleep Research Society. All rights reserved. For permissions, please
      email: journals.permissions@oup.com.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador, Samborondon, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc., Foster City, CA, USA.
FAU - Costa, Aldo F
AU  - Costa AF
AUID- ORCID: 0000-0002-2075-5289
AD  - Department of Neurology, Hospital Universitario Reina Sofia, Cordoba, Spain.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, the Atahualpa Project, Atahualpa, Ecuador.
FAU - Castillo, Pablo R
AU  - Castillo PR
AD  - Sleep Disorders Center, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01627600
SI  - ClinicalTrials.gov/NCT01877616
GR  - Universidad Espiritu Santo - Ecuador
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
SB  - IM
MH  - Aged
MH  - *COVID-19
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Middle Aged
MH  - Pandemics
MH  - Prospective Studies
MH  - *SARS-CoV-2
MH  - Sleep
PMC - PMC7928566
OTO - NOTNLM
OT  - *COVID-19
OT  - *Coronavirus-19
OT  - *Pittsburgh Sleep Quality Index
OT  - *SARS-CoV-2
OT  - *sleep quality
EDAT- 2021/02/21 06:00
MHDA- 2021/09/21 06:00
CRDT- 2021/02/20 05:36
PHST- 2020/11/03 00:00 [received]
PHST- 2021/01/09 00:00 [revised]
PHST- 2021/02/21 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/02/20 05:36 [entrez]
AID - 6145160 [pii]
AID - 10.1093/sleep/zsab041 [doi]
PST - ppublish
SO  - Sleep. 2021 Aug 13;44(8). pii: 6145160. doi: 10.1093/sleep/zsab041.

PMID- 33592341
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 105
DP  - 2021 Apr
TI  - Testing for SARS-CoV-2 at the core of voluntary collective isolation: Lessons
      from the indigenous populations living in the Amazon region in Ecuador.
PG  - 234-235
LID - S1201-9712(21)00125-9 [pii]
LID - 10.1016/j.ijid.2021.02.039 [doi]
AB  - Voluntary collective isolation has been proposed to be the best response to
      COVID-19 for indigenous populations. While the potential value of voluntary
      collective isolation is appealing, the feasibility of this approach needs
      empirical evidence to support it as the best response to protect indigenous
      communities from COVID-19. This paper describes our experience during SARS-CoV-2 
      surveillance among Waorani communities in the Ecuadorian Amazonian region, from
      June to September 2020. We found that self-isolation strategies failed to contain
      the spread of SARS-CoV-2 from main urban areas to remote and isolated comunities.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito, Ecuador. Electronic address: e.ortizprado@gmail.com.
FAU - Rivera-Olivero, Ismar A
AU  - Rivera-Olivero IA
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito, Ecuador.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito, Ecuador.
FAU - Lowe, Rachel
AU  - Lowe R
AD  - Centre for Mathematical Modelling of Infectious Diseases and Centre on Climate
      Change and Planetary Health, London School of Hygiene & Tropical Medicine,
      London, United Kingdom.
FAU - Lozada, Tannya
AU  - Lozada T
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito, Ecuador.
FAU - Henriquez-Trujillo, Aquiles R
AU  - Henriquez-Trujillo AR
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Faculty of Medicine, Universidad de las Americas,
      Quito, Ecuador. Electronic address: magbereguiain@gmail.com.
CN  - UDLA COVID-19 Team
LA  - eng
PT  - Journal Article
DEP - 20210213
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
MH  - COVID-19/diagnosis/epidemiology/*prevention & control
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Population Groups
MH  - *SARS-CoV-2
MH  - *Social Isolation
OTO - NOTNLM
OT  - Amazonia
OT  - COVID-19
OT  - Ecuador
OT  - Indigenous people
OT  - SARS-CoV-2
EDAT- 2021/02/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2021/02/16 20:10
PHST- 2020/12/29 00:00 [received]
PHST- 2021/01/29 00:00 [revised]
PHST- 2021/02/10 00:00 [accepted]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
PHST- 2021/02/16 20:10 [entrez]
AID - S1201-9712(21)00125-9 [pii]
AID - 10.1016/j.ijid.2021.02.039 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Apr;105:234-235. doi: 10.1016/j.ijid.2021.02.039. Epub
      2021 Feb 13.

PMID- 33582369
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210518
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 105
DP  - 2021 Apr
TI  - Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in
      Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay.
PG  - 21-25
LID - S1201-9712(21)00120-X [pii]
LID - 10.1016/j.ijid.2021.02.034 [doi]
AB  - BACKGROUND: Studies of T-cell immune responses against SARS-CoV-2 are important
      in understanding the immune status of individuals or populations. Here, we use a 
      simple, cheap, and rapid whole blood stimulation assay - an Interferon-Gamma
      Release Assay (IGRA) - to study T-cell immunity to SARS-CoV-2 in convalescent
      COVID-19 patients and in unexposed healthy contacts from Quito, Ecuador. METHODS:
      Interferon-gamma (INF-gamma) production was measured in the heparinized blood of 
      convalescent and unexposed subjects after stimulation for 24 h with the
      SARS-CoV-2 Spike S1 protein, the Receptor Binding Domain (RBD) protein or the
      Nucleocapsid (NP) protein, respectively. The presence of IgG-RBD protein
      antibodies in both study groups was determined with an "in-house" ELISA. RESULTS:
      As measured with INF-gamma production, 80% of the convalescent COVID-19 patients,
      all IgG-RBD seropositive, had a strong T-cell response. However, unexpectedly,
      44% of unexposed healthy controls, all IgG-RBD seronegative, had a strong
      virus-specific T-cell response with the COVID-19 IGRA, probably because of prior 
      exposure to common cold-causing coronaviruses or other viral or microbial
      antigens. CONCLUSION AND DISCUSSION: The high percentage of unexposed healthy
      subjects with a pre-existing immunity suggests that a part of the Ecuadorian
      population is likely to have SARS-CoV-2 reactive T-cells. Given that the IGRA
      technique is simple and can be easily scaled up for investigations where high
      numbers of patients are needed, this COVID-19 IGRA may serve to determine if the 
      T-cell only response represents protective immunity to SARS-CoV-2 infection in a 
      population-based study.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Echeverria, Gustavo
AU  - Echeverria G
AD  - Instituto de Investigacion en Zoonosis-CIZ, Universidad Central del Ecuador,
      Ecuador.
FAU - Guevara, Angel
AU  - Guevara A
AD  - Instituto de Biomedicina, carrera de Medicina, Universidad Central, Quito,
      Ecuador.
FAU - Coloma, Josefina
AU  - Coloma J
AD  - Division of Infectious Diseases and Vaccinology, School of Public Health,
      University of California, Berkeley, CA, USA.
FAU - Ruiz, Alison Mera
AU  - Ruiz AM
AD  - BioGENA, Division Investigacion y Desarrollo, Quito, Ecuador.
FAU - Vasquez, Maria Mercedes
AU  - Vasquez MM
AD  - One Health Research Group. Facultad de Ciencias de la Salud, Universidad de Las
      Americas (UDLA), Quito, Ecuador.
FAU - Tejera, Eduardo
AU  - Tejera E
AD  - One Health Research Group. Facultad de Ciencias de la Salud, Universidad de Las
      Americas (UDLA), Quito, Ecuador.
FAU - de Waard, Jacobus H
AU  - de Waard JH
AD  - One Health Research Group. Facultad de Ciencias de la Salud, Universidad de Las
      Americas (UDLA), Quito, Ecuador. Electronic address: jacobusdeward@gmail.com.
LA  - eng
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20210212
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
MH  - Adult
MH  - COVID-19/*immunology
MH  - Female
MH  - Humans
MH  - *Interferon-gamma Release Tests
MH  - Male
MH  - Middle Aged
MH  - SARS-CoV-2/*immunology
MH  - T-Lymphocytes/*immunology
PMC - PMC7879022
OTO - NOTNLM
OT  - COVID-19
OT  - ELISPOT
OT  - Interferon-Gamma (IFN-gamma) release assay (IGRA)
OT  - Nucleocapsid protein
OT  - Pre-existing immunity
OT  - SARS-CoV-2
OT  - Spike protein
OT  - T cells
EDAT- 2021/02/15 06:00
MHDA- 2021/05/13 06:00
CRDT- 2021/02/14 20:28
PHST- 2021/01/03 00:00 [received]
PHST- 2021/02/01 00:00 [revised]
PHST- 2021/02/07 00:00 [accepted]
PHST- 2021/02/15 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2021/02/14 20:28 [entrez]
AID - S1201-9712(21)00120-X [pii]
AID - 10.1016/j.ijid.2021.02.034 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Apr;105:21-25. doi: 10.1016/j.ijid.2021.02.034. Epub 2021 
      Feb 12.

PMID- 33578745
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210303
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 4
DP  - 2021 Feb 10
TI  - An On-Line Cross-Sectional Questionnaire to Assess Knowledge of COVID-19 Pandemic
      among Citizens Tested for the SARS-CoV-2 Virus in Quito and Ibarra, Ecuador.
LID - 1691 [pii]
LID - 10.3390/ijerph18041691 [doi]
AB  - Several public health measures have been implemented to contain the SARS-CoV-2
      outbreak. The adherence to control measures is known to be influenced by people's
      knowledge, attitudes and practices with regard to the disease. This study aimed
      at assessing COVID-19 knowledge in individuals who were tested for the virus. An 
      online cross-sectional survey of 32 items, adapted to the national context, was
      conducted among 1656 Ecuadorians. The mean knowledge score was 22.5 +/- 3 out of 
      28, with significant differences being observed with regard to educational
      attainment. People with postgraduate training scored higher than those with
      college, secondary and elementary instruction. Indeed, multiple linear regression
      revealed that lower scores were associated significantly with the latter three
      levels of education. Interviewees were knowledgeable about the symptoms,
      detection, transmission and prevention of the disease. However, they were less
      assertive regarding the characteristics of the virus as well as the usefulness of
      traditional and unproven treatments. These outcomes indicated a lack of knowledge
      in fundamental aspects of virus biology, which may limit the effectiveness of
      further prevention campaigns. Conclusively, educational and communicational
      programs must place emphasis on explaining the basic molecular characteristics of
      SARS-CoV-2; such information will certainly contribute to improve the public's
      adherence to control measures.
FAU - Ortega-Paredes, David
AU  - Ortega-Paredes D
AD  - Unidad de Investigacion en Enfermedades Transmitidas por Alimentos y Resistencia 
      a los Antimicrobianos (UNIETAR), Facultad de Veterinaria, Universidad Central del
      Ecuador, Quito 170129, Ecuador.
AD  - Education Unit, Life Science Initiative, Quito 170607, Ecuador.
FAU - Zurita, Jeannete
AU  - Zurita J
AD  - Zurita & Zurita Laboratorios, Biomedical Research Unit, Quito 170104, Ecuador.
FAU - Zurita, Camilo
AU  - Zurita C
AD  - Zurita & Zurita Laboratorios, Biomedical Research Unit, Quito 170104, Ecuador.
FAU - Leoro-Garzon, Paula
AU  - Leoro-Garzon P
AD  - Departamento de Biologia Molecular, Laboratorio Clinico e Inmunologico Inmunolab,
      Quito 170403, Ecuador.
FAU - Leoro-Monroy, Galo
AU  - Leoro-Monroy G
AD  - Departamento de Biologia Molecular, Laboratorio Clinico e Inmunologico Inmunolab,
      Quito 170403, Ecuador.
FAU - Larrea-Alvarez, Cesar Marcelo
AU  - Larrea-Alvarez CM
AD  - Education Unit, Life Science Initiative, Quito 170607, Ecuador.
FAU - Loaiza, Karen
AU  - Loaiza K
AUID- ORCID: 0000-0002-4282-1152
AD  - Education Unit, Life Science Initiative, Quito 170607, Ecuador.
FAU - Fernandez-Moreira, Esteban
AU  - Fernandez-Moreira E
AUID- ORCID: 0000-0003-1892-5370
AD  - Facultad de Ciencias de la Salud, Escuela de Medicina, Universidad de las
      Americas, Quito 170517, Ecuador.
FAU - Molina-Cuasapaz, Gabriel
AU  - Molina-Cuasapaz G
AUID- ORCID: 0000-0002-1597-5957
AD  - Facultad de Ciencias Agropecuarias y Recursos Naturales, Carrera de Medicina
      Veterinaria, Universidad Tecnica de Cotopaxi , Latacunga-Cotopaxi 050101,
      Ecuador.
FAU - Larrea-Alvarez, Marco
AU  - Larrea-Alvarez M
AD  - School of Biological Science and Engineering, Yachay-Tech University, Hacienda
      San Jose, Urcuqui-Imbabura 100650, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20210210
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *COVID-19
MH  - Cross-Sectional Studies
MH  - Ecuador/epidemiology
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Pandemics
MH  - Surveys and Questionnaires
PMC - PMC7916451
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ecuador
OT  - *SARS-CoV-2
OT  - *knowledge
OT  - *private laboratory
OT  - *survey
EDAT- 2021/02/14 06:00
MHDA- 2021/02/18 06:00
CRDT- 2021/02/13 01:01
PHST- 2020/12/29 00:00 [received]
PHST- 2021/02/02 00:00 [revised]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/02/13 01:01 [entrez]
PHST- 2021/02/14 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - ijerph18041691 [pii]
AID - 10.3390/ijerph18041691 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2021 Feb 10;18(4). pii: ijerph18041691. doi:
      10.3390/ijerph18041691.

PMID- 33576150
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20210921
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 28
IP  - 10
DP  - 2021 Oct
TI  - Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2
      infection: A longitudinal prospective study nested to a population cohort.
PG  - 3245-3253
LID - 10.1111/ene.14775 [doi]
AB  - BACKGROUND AND PURPOSE: Neurological complications of SARS-CoV-2 infection are
      noticed among critically ill patients soon after disease onset. Information on
      delayed neurological sequelae of SARS-CoV-2 infection is nil. Following a
      longitudinal study design, the occurrence of cognitive decline among individuals 
      with a history of mild symptomatic SARS-CoV-2 infection was assessed. METHODS:
      Stroke- and seizure-free Atahualpa residents aged >/=40 years, who had
      pre-pandemic cognitive assessments as well as normal brain magnetic resonance
      imaging and electroencephalogram recordings, underwent repeated evaluations 6
      months after a SARS-CoV-2 outbreak infection in Atahualpa. Patients requiring
      oxygen therapy, hospitalization, and those who had initial neurological
      manifestations were excluded. Cognitive decline was defined as a reduction in the
      Montreal Cognitive Assessment (MoCA) score between the post-pandemic and
      pre-pandemic assessments that was >/=4 points greater than the reduction observed
      between two pre-pandemic MoCAs. The relationship between SARS-CoV-2 infection and
      cognitive decline was assessed by fitting logistic mixed models for longitudinal 
      data as well as exposure-effect models. RESULTS: Of 93 included individuals (mean
      age 62.6 +/- 11 years), 52 (56%) had a history of mild symptomatic SARS-CoV-2
      infection. Post-pandemic MoCA decay was worse in seropositive individuals.
      Cognitive decline was recognized in 11/52 (21%) seropositive and 1/41 (2%)
      seronegative individuals. In multivariate analyses, the odds for developing
      cognitive decline were 18.1 times higher among SARS-CoV-2 seropositive
      individuals (95% confidence interval 1.75-188; p = 0.015). Exposure-effect models
      confirmed this association (beta = 0.24; 95% confidence interval 0.07-0.41; p =
      0.006). CONCLUSIONS: This study provides evidence of cognitive decline among
      individuals with mild symptomatic SARS-CoV-2 infection. The pathogenesis of this 
      complication remains unknown.
CI  - (c) 2021 European Academy of Neurology.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - School of Medicine, Universidad Espiritu Santo-Ecuador, Samborondon, Ecuador.
FAU - Wu, Shasha
AU  - Wu S
AD  - Department of Neurology, University of Chicago, Chicago, IL, USA.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc, Foster City, CA, USA.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Department of Neurology, Hospital Universitario Reina Sofia, Cordoba, Spain.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, the Atahualpa Project, Atahualpa, Ecuador.
FAU - Issa, Naoum P
AU  - Issa NP
AD  - Department of Neurology, University of Chicago, Chicago, IL, USA.
LA  - eng
GR  - Universidad Espiritu Santo, Ecuador
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210301
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Aged
MH  - *COVID-19
MH  - *Cognitive Dysfunction/epidemiology/etiology
MH  - Humans
MH  - Longitudinal Studies
MH  - Middle Aged
MH  - Prospective Studies
MH  - SARS-CoV-2
PMC - PMC8014083
OTO - NOTNLM
OT  - *COVID-19
OT  - *Montreal Cognitive Assessment
OT  - *SARS-CoV-2
OT  - *cognitive decline
OT  - *coronavirus-19
EDAT- 2021/02/13 06:00
MHDA- 2021/09/22 06:00
CRDT- 2021/02/12 06:16
PHST- 2021/02/07 00:00 [revised]
PHST- 2020/11/29 00:00 [received]
PHST- 2021/02/09 00:00 [accepted]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
PHST- 2021/02/12 06:16 [entrez]
AID - 10.1111/ene.14775 [doi]
PST - ppublish
SO  - Eur J Neurol. 2021 Oct;28(10):3245-3253. doi: 10.1111/ene.14775. Epub 2021 Mar 1.

PMID- 33572702
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210316
IS  - 2076-393X (Print)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 2
DP  - 2021 Jan 29
TI  - Immune Response to SARS-CoV-2 Infection in Obesity and T2D: Literature Review.
LID - 102 [pii]
LID - 10.3390/vaccines9020102 [doi]
AB  - In December 2019, a novel coronavirus known as SARS-CoV-2 was first detected in
      Wuhan, China, causing outbreaks of the coronavirus disease COVID-19 that has now 
      spread globally. For this reason, The World Health Organization (WHO) declared
      COVID-19 a public health emergency in March 2020. People living with pre-existing
      conditions such as obesity, cardiovascular diseases, type 2 diabetes (T2D), and
      chronic kidney and lung diseases, are prone to develop severe forms of disease
      with fatal outcomes. Metabolic diseases such as obesity and T2D alter the balance
      of innate and adaptive responses. Both diseases share common features
      characterized by augmented adiposity associated with a chronic systemic low-grade
      inflammation, senescence, immunoglobulin glycation, and abnormalities in the
      number and function of adaptive immune cells. In obese and T2D patients infected 
      by SARS-CoV-2, where immune cells are already hampered, this response appears to 
      be stronger. In this review, we describe the abnormalities of the immune system, 
      and summarize clinical findings of COVID-19 patients with pre-existing conditions
      such as obesity and T2D as this group is at greater risk of suffering severe and 
      fatal clinical outcomes.
FAU - Perez-Galarza, Jorge
AU  - Perez-Galarza J
AD  - Research Institute of Biomedicine, Central University of Ecuador, Quito 170201,
      Ecuador.
AD  - Faculty of Medicine, Central University of Ecuador, Quito 170403, Ecuador.
FAU - Procel, Cesar
AU  - Procel C
AD  - Hospital Metropolitano, Quito 170509, Ecuador.
FAU - Canadas, Cristina
AU  - Canadas C
AD  - Research Institute of Biomedicine, Central University of Ecuador, Quito 170201,
      Ecuador.
FAU - Aguirre, Diana
AU  - Aguirre D
AD  - Research Institute of Biomedicine, Central University of Ecuador, Quito 170201,
      Ecuador.
FAU - Pibaque, Ronny
AU  - Pibaque R
AUID- ORCID: 0000-0002-2639-4584
AD  - Research Institute of Biomedicine, Central University of Ecuador, Quito 170201,
      Ecuador.
FAU - Bedon, Ricardo
AU  - Bedon R
AUID- ORCID: 0000-0003-2293-8879
AD  - Faculty of Medicine, Central University of Ecuador, Quito 170403, Ecuador.
AD  - Hospital General Docente de Calderon, Quito 170201, Ecuador.
FAU - Sempertegui, Fernando
AU  - Sempertegui F
AD  - Faculty of Medicine, Central University of Ecuador, Quito 170403, Ecuador.
FAU - Drexhage, Hemmo
AU  - Drexhage H
AD  - Immunology Department, Erasmus Medical Center, 3015 Rotterdam, The Netherlands.
FAU - Baldeon, Lucy
AU  - Baldeon L
AUID- ORCID: 0000-0002-0447-0136
AD  - Research Institute of Biomedicine, Central University of Ecuador, Quito 170201,
      Ecuador.
AD  - Faculty of Medicine, Central University of Ecuador, Quito 170403, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210129
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC7911386
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - T2D
OT  - adaptive
OT  - immunity
OT  - innate
OT  - obesity
EDAT- 2021/02/13 06:00
MHDA- 2021/02/13 06:01
CRDT- 2021/02/12 01:02
PHST- 2020/11/30 00:00 [received]
PHST- 2021/01/09 00:00 [revised]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2021/02/12 01:02 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/02/13 06:01 [medline]
AID - vaccines9020102 [pii]
AID - 10.3390/vaccines9020102 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 Jan 29;9(2). pii: vaccines9020102. doi:
      10.3390/vaccines9020102.

PMID- 33556041
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 104
IP  - 4
DP  - 2021 Feb 8
TI  - Massive SARS-CoV-2 RT-PCR Testing on Rural Communities in Manabi Province
      (Ecuador) Reveals Severe COVID-19 Outbreaks.
PG  - 1493-1494
LID - 10.4269/ajtmh.20-1208 [doi]
LID - tpmd201208 [pii]
AB  - Rural communities from Latin America are particularly susceptible to develop
      serious outbreaks of infectious diseases. Inadequate diagnosis and poor health
      infrastructure jeopardize proper contact tracing and other actions to reduce the 
      impact of COVID-19 in the region. We herein describe the preliminary data of our 
      ongoing fieldwork of massive testing among nonhospitalized rural population in
      Manabi Province of the coastal region of Ecuador. A total of 1,479 people from
      six different rural communities were tested for SARS-CoV-2 by RT-qPCR following
      the CDC protocol; 350 individuals tested positive, resulting in an overall attack
      rate of 23.7% for SARS-CoV-2 infection. This ultrahigh prevalence must urge to
      the public health authorities from Ecuador to take immediate actions to
      counteract this dramatic scenario in Manabi Province and to improve SARS-CoV-2
      testing countrywide.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
FAU - Henriquez-Trujillo, Aquiles R
AU  - Henriquez-Trujillo AR
FAU - Rivera-Olivero, Ismar A
AU  - Rivera-Olivero IA
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
FAU - Vallejo-Janeta, Alexander Paolo
AU  - Vallejo-Janeta AP
FAU - Lozada, Tannya
AU  - Lozada T
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
CN  - UDLA COVID-19 Team
LA  - eng
PT  - Journal Article
DEP - 20210208
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
SB  - IM
MH  - COVID-19/*diagnosis/epidemiology
MH  - *COVID-19 Nucleic Acid Testing
MH  - Ecuador/epidemiology
MH  - Humans
MH  - *Mass Screening
MH  - Rural Population
MH  - *SARS-CoV-2
PMC - PMC8045655
EDAT- 2021/02/09 06:00
MHDA- 2022/02/03 06:00
CRDT- 2021/02/08 17:10
PHST- 2020/09/16 00:00 [received]
PHST- 2021/01/12 00:00 [accepted]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2021/02/08 17:10 [entrez]
AID - 10.4269/ajtmh.20-1208 [doi]
AID - tpmd201208 [pii]
PST - epublish
SO  - Am J Trop Med Hyg. 2021 Feb 8;104(4):1493-1494. doi: 10.4269/ajtmh.20-1208.

PMID- 33540487
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20220716
IS  - 2192-6506 (Electronic)
IS  - 2192-6506 (Linking)
VI  - 86
IP  - 7
DP  - 2021 Jul
TI  - An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking
      Simulations with SARS-Cov-2.
PG  - 972-981
LID - 10.1002/cplu.202000770 [doi]
AB  - We report the synthesis and characterization of a fullerene-steroid hybrid that
      contains H2 @C60 and a dehydroepiandrosterone moiety synthesized by a
      cyclopropanation reaction with 76 % yield. Theoretical calculations at the
      DFT-D3(BJ)/PBE 6-311G(d,p) level predict the most stable conformation and that
      the saturation of a double bond is the main factor causing the upfield shielding 
      of the signal appearing at -3.13 ppm, which corresponds to the H2 located inside 
      the fullerene cage. Relevant stereoelectronic parameters were also investigated
      and reinforce the idea that electronic interactions must be considered to develop
      studies on chemical-biological interactions. A molecular docking simulation
      predicted that the binding energy values for the protease-hybrid complexes were
      -9.9 kcal/mol and -13.5 kcal/mol for PL(pro) and 3CL(pro) respectively,
      indicating the potential use of the synthesized steroid-H2 @C60 as
      anti-SARS-Cov-2 agent.
CI  - (c) 2021 Wiley-VCH GmbH.
FAU - Suarez, Margarita
AU  - Suarez M
AUID- ORCID: 0000-0002-3138-4364
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Makowski, Kamil
AU  - Makowski K
AUID- ORCID: 0000-0001-5806-550X
AD  - Departament of Surfactants and Nanobiotechnology, Institute for Advanced
      Chemistry of Catalonia (IQAC-CSIC) and CIBER-BBN, Barcelona, Spain.
FAU - Lemos, Reinier
AU  - Lemos R
AUID- ORCID: 0000-0001-7325-1810
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Almagro, Luis
AU  - Almagro L
AUID- ORCID: 0000-0001-5186-670X
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Rodriguez, Hortensia
AU  - Rodriguez H
AUID- ORCID: 0000-0001-6910-5685
AD  - Yachay Tech University, School of Chemical Sciences and Engineering, 100119-,
      Urququi, Ecuador.
FAU - Herranz, Maria Angeles
AU  - Herranz MA
AUID- ORCID: 0000-0001-9155-134X
AD  - Departamento de Quimica Organica, Facultad de Ciencias Quimicas, Universidad
      Complutense de Madrid, 28040-, Madrid, Spain.
FAU - Molero, Dolores
AU  - Molero D
AUID- ORCID: 0000-0001-6198-1330
AD  - CAI RMN Universidad Complutense de Madrid 28040 Madrid (Spain).
FAU - Ortiz, Orlando
AU  - Ortiz O
AUID- ORCID: 0000-0002-6845-6851
AD  - Laboratorio de Sintesis Organica, Facultad de Quimica, Universidad de la Habana, 
      10400, La Habana, Cuba.
FAU - Maroto, Enrique
AU  - Maroto E
AUID- ORCID: 0000-0002-3485-1335
AD  - Departamento de Quimica Organica, Facultad de Ciencias Quimicas, Universidad
      Complutense de Madrid, 28040-, Madrid, Spain.
FAU - Albericio, Fernando
AU  - Albericio F
AUID- ORCID: 0000-0002-8946-0462
AD  - School of Chemistry and Physics, University of KwaZul-Natal, Durban, South
      Africa.
FAU - Murata, Yasujiro
AU  - Murata Y
AUID- ORCID: 0000-0003-0287-0299
AD  - Institute for Chemical Research, Kyoto University Uji, Kyoto, 611-0011, Japan.
FAU - Martin, Nazario
AU  - Martin N
AUID- ORCID: 0000-0002-5355-1477
AD  - Departamento de Quimica Organica, Facultad de Ciencias Quimicas, Universidad
      Complutense de Madrid, 28040-, Madrid, Spain.
LA  - eng
GR  - CTQ2017-83531-R/Ministerio de Economia y Competitividad (MINECO) of Spain
GR  - P223LH-001-059/PNCB of MES, Cuba
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210204
PL  - Germany
TA  - Chempluschem
JT  - ChemPlusChem
JID - 101580948
RN  - 0 (Antiviral Agents)
RN  - 0 (Fullerenes)
RN  - C24W7J5D5R (Androsterone)
RN  - EC 3.4.22.- (3C-like protease, SARS coronavirus)
RN  - EC 3.4.22.2 (Coronavirus Papain-Like Proteases)
RN  - EC 3.4.22.2 (papain-like protease, SARS-CoV-2)
RN  - EC 3.4.22.28 (Coronavirus 3C Proteases)
RN  - NP9U26B839 (fullerene C60)
SB  - IM
MH  - Androsterone/*chemistry
MH  - Antiviral Agents/*chemistry/metabolism
MH  - Binding Sites
MH  - COVID-19/pathology/virology
MH  - Coronavirus 3C Proteases/chemistry/metabolism
MH  - Coronavirus Papain-Like Proteases/chemistry/metabolism
MH  - Density Functional Theory
MH  - Fullerenes/*chemistry
MH  - Humans
MH  - *Molecular Docking Simulation
MH  - Protein Binding
MH  - SARS-CoV-2/isolation & purification/*metabolism
MH  - Static Electricity
MH  - Thermodynamics
PMC - PMC8014820
OTO - NOTNLM
OT  - *SARS-Cov-2
OT  - *cyclopropanation
OT  - *fullerenes
OT  - *molecular docking
OT  - *steroid hybrids
EDAT- 2021/02/05 06:00
MHDA- 2021/07/15 06:00
CRDT- 2021/02/04 20:22
PHST- 2021/01/21 00:00 [revised]
PHST- 2020/12/02 00:00 [received]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2021/02/04 20:22 [entrez]
AID - 10.1002/cplu.202000770 [doi]
PST - ppublish
SO  - Chempluschem. 2021 Jul;86(7):972-981. doi: 10.1002/cplu.202000770. Epub 2021 Feb 
      4.

PMID- 33534773
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 104
IP  - 3
DP  - 2021 Jan 13
TI  - SARS-CoV-2 RNA in Swabbed Samples from Latrines and Flushing Toilets: A
      Case-Control Study in a Rural Latin American Setting.
PG  - 1045-1047
LID - 10.4269/ajtmh.20-1380 [doi]
LID - tpmd201380 [pii]
AB  - Information about factors potentially favoring the spread of SARS-CoV-2 in rural 
      settings is limited. Following a case-control study design in a rural Ecuadorian 
      village that was severely struck by the pandemic, SARS-CoV-2 RNA were detected by
      real-time PCR in swabs obtained from inner and upper walls in 24/48 randomly
      selected latrines from case-houses and in 12/48 flushing toilets from paired
      control-houses (P = 0.014; McNemar's test). This association persisted in a
      conditional logistic regression model adjusted for relevant covariates (OR: 4.82;
      95% CI: 1.38-16.8; P = 0.014). In addition, SARS-CoV-2-seropositive subjects were
      more often identified among those living in houses with a latrine (P = 0.002).
      Latrines have almost five times the odds of containing SARS-CoV-2 RNA than their 
      paired flushing toilets. Latrines are reservoirs of SARS-CoV-2 RNA, and it cannot
      be ruled out that latrines could contribute to viral transmission in rural
      settings. Frequent disinfection of latrines should be recommended to reduce the
      likelihood of fecal contamination.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AD  - 1School of Medicine, Universidad Espiritu Santo - Ecuador, Samborondon, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - 2Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - 3Department of Epidemiology, Gilead Sciences, Inc., Foster City, California.
FAU - Andrade-Molina, Derly
AU  - Andrade-Molina D
AD  - 4Omics Sciences Laboratory, Universidad Espiritu Santo - Ecuador, Samborondon,
      Ecuador.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - 2Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Garcia, Hector H
AU  - Garcia HH
AD  - 5Department of Microbiology, Center for Global Health, Instituto Nacional de
      Ciencias Neurologicas, Universidad Peruana Cayetano Heredia, Lima, Peru.
FAU - Fernandez-Cadena, Juan C
AU  - Fernandez-Cadena JC
AD  - 4Omics Sciences Laboratory, Universidad Espiritu Santo - Ecuador, Samborondon,
      Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20210113
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Bathroom Equipment/*virology
MH  - COVID-19/epidemiology/immunology/*virology
MH  - Case-Control Studies
MH  - Family Characteristics
MH  - Humans
MH  - Latin America/epidemiology
MH  - RNA, Viral/*analysis/*genetics
MH  - Rural Population/*statistics & numerical data
MH  - SARS-CoV-2/*genetics/immunology/isolation & purification
MH  - Serologic Tests
MH  - Toilet Facilities
MH  - Young Adult
PMC - PMC7941810
EDAT- 2021/02/04 06:00
MHDA- 2022/02/02 06:00
CRDT- 2021/02/03 17:11
PHST- 2020/10/22 00:00 [received]
PHST- 2020/12/29 00:00 [accepted]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/02/03 17:11 [entrez]
AID - 10.4269/ajtmh.20-1380 [doi]
AID - tpmd201380 [pii]
PST - epublish
SO  - Am J Trop Med Hyg. 2021 Jan 13;104(3):1045-1047. doi: 10.4269/ajtmh.20-1380.

PMID- 33513511
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20211231
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 770
DP  - 2021 May 20
TI  - High prevalence of SARS-CoV-2 infection among food delivery riders. A case study 
      from Quito, Ecuador.
PG  - 145225
LID - S0048-9697(21)00291-6 [pii]
LID - 10.1016/j.scitotenv.2021.145225 [doi]
AB  - AIM: COVID-19 pandemic has posed an unprecedented pressure on health systems and 
      economies worldwide. Delivery services have grown as an alternative source of
      revenue for many people. Consumers generally perceive that delivery services are 
      safer than going into a restaurant, because they reduce exposure to other people 
      and their risk of SARS-CoV-2 contagion. There are no studies analyzing viral load
      or the burden of COID-19 within this population. This study aims to describe the 
      presence of SARS-CoV-2 among food delivery riders in the city of Quito, Ecuador. 
      STUDY DESIGN: From July and August 2020, bike and motorbike riders self-employed 
      in two of the main online delivery services in Quito, Ecuador, were invited for
      RT-PCR testing for SARS-CoV-2 detection during the compulsory lockdown due to the
      COVID-19 pandemic. The Center for Disease Control (CDC) 2019-Novel Coronavirus
      (2019-nCoV) RT-qPCR Diagnostic Panel was used to identify the presence of
      SARS-CoV-2 in nasopharyngeal swabs. All samples were processed in the BSL2
      certified molecular biology laboratory at Universidad de Las Americas. RESULTS: A
      total of 22 out of 145 delivery workers (15.2%) tested positive for SARS-CoV-2.
      The majority of workers were men (n = 138), the average age of male workers was
      32 years-old (+/-7.3) and 38 years-old (+/- 10.6) for females. The presence of
      mild symptoms was reported in only 9 subjects (6%). The calculated viral load was
      higher among males with 1.31E+08 copies/mL vs 2.30E+06 in females, although this 
      difference was not statistically significant (p value: 0.68, [CI: -53 to -79]).
      CONCLUSIONS: The self-employed food delivery riders have a high incidence rate of
      SARS-CoV-2 infection in relation to the national average. It is important to
      point out that this is the first study of its kind in Latin-American and probably
      one of the very few in the world. The results emphasize the need for policy
      makers to look at the pandemic from as many population's sub-groups as possible. 
      Delivery riders are a highly moving population that offer their services to a
      wide range of clients, including vulnerable populations such as the elderly or
      those less likely to leave their house for basic needs stoking.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador. Electronic address: e.ortizprado@gmail.com.
FAU - Henriquez-Trujillo, Aquiles R
AU  - Henriquez-Trujillo AR
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Rivera-Olivero, Ismar A
AU  - Rivera-Olivero IA
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Lozada, Tannya
AU  - Lozada T
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador. Electronic address: magbereguiain@gmail.com.
CN  - UDLA-COVID-19 team
AD  - One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20210117
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
SB  - IM
MH  - Adult
MH  - Aged
MH  - *COVID-19
MH  - Communicable Disease Control
MH  - Ecuador/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Pandemics
MH  - Prevalence
MH  - *SARS-CoV-2
PMC - PMC7813502
OTO - NOTNLM
OT  - COVID-19
OT  - Food delivery
OT  - Riders
OT  - SARS-CoV-2
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/01/30 06:00
MHDA- 2021/03/19 06:00
CRDT- 2021/01/29 20:08
PHST- 2020/11/13 00:00 [received]
PHST- 2020/12/26 00:00 [revised]
PHST- 2021/01/13 00:00 [accepted]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
PHST- 2021/01/29 20:08 [entrez]
AID - S0048-9697(21)00291-6 [pii]
AID - 10.1016/j.scitotenv.2021.145225 [doi]
PST - ppublish
SO  - Sci Total Environ. 2021 May 20;770:145225. doi: 10.1016/j.scitotenv.2021.145225. 
      Epub 2021 Jan 17.

PMID- 33434671
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210612
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 104
DP  - 2021 Mar
TI  - Low clinical performance of the Isopollo COVID-19 detection kit (M Monitor, South
      Korea) for RT-LAMP SARS-CoV-2 diagnosis: A call for action against low quality
      products for developing countries.
PG  - 303-305
LID - S1201-9712(21)00017-5 [pii]
LID - 10.1016/j.ijid.2020.12.088 [doi]
AB  - BACKGROUND: Multiple molecular kits are available for the diagnosis of severe
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, with many
      lacking proper clinical evaluation due to the emergency caused by the coronavirus
      disease 2019 (COVID-19) pandemic, particularly in developing countries. METHODS: 
      This study was conducted to evaluate the clinical performance of the Isopollo
      COVID-19 detection kit (M Monitor, South Korea) for reverse transcription
      loop-mediated isothermal amplification (RT-LAMP) SARS-CoV-2 diagnosis, using the 
      SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) protocol as
      the gold standard. RESULTS: A total of 220 clinical samples were included in the 
      study; 168 samples were SARS-CoV-2-positive and 52 samples were
      SARS-CoV-2-negative according to the SARS-CoV-2 RT-PCR protocol. For the Isopollo
      COVID-19 detection kit, only 104 out of 168 samples were SARS-CoV-2-positive.
      This result shows a low clinical performance, with sensitivity of 61.9% for the
      evaluated RT-LAMP assay. CONCLUSIONS: Proper clinical performance evaluation
      studies by regulatory agencies in developing countries such as Ecuador should be 
      mandatory prior to clinical use authorization of SARS-CoV-2 diagnosis kits,
      particularly when those kits lack either US Food and Drug Administration or
      country of origin clinical use authorization.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
      Electronic address: magbereguiain@gmail.com.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20210109
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (Reagent Kits, Diagnostic)
RN  - LAMP assay
SB  - IM
MH  - COVID-19/*diagnosis/epidemiology/virology
MH  - COVID-19 Testing
MH  - Developing Countries
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Molecular Diagnostic Techniques
MH  - Nucleic Acid Amplification Techniques
MH  - *Pandemics
MH  - Reagent Kits, Diagnostic/*standards
MH  - Reverse Transcription
MH  - SARS-CoV-2/genetics/*isolation & purification
PMC - PMC7834296
OTO - NOTNLM
OT  - Isopollo COVID-19
OT  - RT-LAMP
OT  - RT-PCR
OT  - SARS-CoV-2
EDAT- 2021/01/13 06:00
MHDA- 2021/05/05 06:00
CRDT- 2021/01/12 20:08
PHST- 2020/10/05 00:00 [received]
PHST- 2020/12/27 00:00 [revised]
PHST- 2020/12/29 00:00 [accepted]
PHST- 2021/01/13 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
PHST- 2021/01/12 20:08 [entrez]
AID - S1201-9712(21)00017-5 [pii]
AID - 10.1016/j.ijid.2020.12.088 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Mar;104:303-305. doi: 10.1016/j.ijid.2020.12.088. Epub
      2021 Jan 9.

PMID- 33430299
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210218
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jan 7
TI  - Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases
      Inhibitors from Molecular Modeling Studies.
LID - 74 [pii]
LID - 10.3390/biom11010074 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic is caused by a novel
      coronavirus; the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
      Millions of cases and deaths to date have resulted in a global challenge for
      healthcare systems. COVID-19 has a high mortality rate, especially in elderly
      individuals with pre-existing chronic comorbidities. There are currently no
      effective therapeutic approaches for the prevention and treatment of COVID-19.
      Therefore, the identification of effective therapeutics is a necessity. Terpenes 
      are the largest class of natural products that could serve as a source of new
      drugs or as prototypes for the development of effective pharmacotherapeutic
      agents. In the present study, we discuss the antiviral activity of these natural 
      products and we perform simulations against the M(pro) and PL(pro) enzymes of
      SARS-CoV-2. Our results strongly suggest the potential of these compounds against
      human coronaviruses, including SARS-CoV-2.
FAU - Diniz, Lucio Ricardo Leite
AU  - Diniz LRL
AD  - College of Nordeste da Bahia, Coronel Joao Sa 48590-000, Brazil.
FAU - Perez-Castillo, Yunierkis
AU  - Perez-Castillo Y
AUID- ORCID: 0000-0002-3710-0035
AD  - Bio-Cheminformatics Research Group and Escuela de Ciencias Fisicas y Matematicas,
      Universidad de Las Americas, Quito 170125, Ecuador.
FAU - Elshabrawy, Hatem A
AU  - Elshabrawy HA
AD  - Department of Molecular and Cellular Biology, College of Osteopathic Medicine,
      Sam Houston State University, Conroe, TX 77304, USA.
FAU - Filho, Carlos da Silva Maia Bezerra
AU  - Filho CDSMB
AUID- ORCID: 0000-0003-0628-5783
AD  - Department of Pharmaceutical Sciences, Federal University of Paraiba, Joao Pessoa
      58051-900, Brazil.
FAU - de Sousa, Damiao Pergentino
AU  - de Sousa DP
AUID- ORCID: 0000-0002-7180-4896
AD  - Department of Pharmaceutical Sciences, Federal University of Paraiba, Joao Pessoa
      58051-900, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210107
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - 0 (Antiviral Agents)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Terpenes)
RN  - EC 3.4.22.- (3C-like proteinase, SARS-CoV-2)
RN  - EC 3.4.22.28 (Coronavirus 3C Proteases)
SB  - IM
MH  - Antiviral Agents/chemistry/*pharmacology
MH  - COVID-19/drug therapy/virology
MH  - Coronavirus 3C Proteases/*antagonists & inhibitors/metabolism
MH  - *Drug Discovery
MH  - Humans
MH  - Molecular Docking Simulation
MH  - Protease Inhibitors/chemistry/*pharmacology
MH  - SARS-CoV-2/*drug effects/enzymology
MH  - Terpenes/chemistry/*pharmacology
PMC - PMC7825698
OTO - NOTNLM
OT  - *COVID-19
OT  - *MERS-CoV
OT  - *Middle East Respiratory Syndrome Virus
OT  - *SARS-CoV
OT  - *SARS-CoV-2
OT  - *natural products
OT  - *plants
OT  - *saponins
OT  - *terpenoid
OT  - *viruses
EDAT- 2021/01/13 06:00
MHDA- 2021/01/22 06:00
CRDT- 2021/01/12 01:16
PHST- 2020/11/26 00:00 [received]
PHST- 2020/12/23 00:00 [revised]
PHST- 2020/12/29 00:00 [accepted]
PHST- 2021/01/12 01:16 [entrez]
PHST- 2021/01/13 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - biom11010074 [pii]
AID - 10.3390/biom11010074 [doi]
PST - epublish
SO  - Biomolecules. 2021 Jan 7;11(1). pii: biom11010074. doi: 10.3390/biom11010074.

PMID- 33419936
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20220323
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 371
IP  - 6530
DP  - 2021 Feb 12
TI  - Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK.
PG  - 708-712
LID - 10.1126/science.abf2946 [doi]
AB  - The United Kingdom's COVID-19 epidemic during early 2020 was one of world's
      largest and was unusually well represented by virus genomic sampling. We
      determined the fine-scale genetic lineage structure of this epidemic through
      analysis of 50,887 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
      genomes, including 26,181 from the UK sampled throughout the country's first wave
      of infection. Using large-scale phylogenetic analyses combined with
      epidemiological and travel data, we quantified the size, spatiotemporal origins, 
      and persistence of genetically distinct UK transmission lineages. Rapid
      fluctuations in virus importation rates resulted in >1000 lineages; those
      introduced prior to national lockdown tended to be larger and more dispersed.
      Lineage importation and regional lineage diversity declined after lockdown,
      whereas lineage elimination was size-dependent. We discuss the implications of
      our genetic perspective on transmission dynamics for COVID-19 epidemiology and
      control.
CI  - Copyright (c) 2021 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - du Plessis, Louis
AU  - du Plessis L
AUID- ORCID: https://orcid.org/0000-0003-0352-6289
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - McCrone, John T
AU  - McCrone JT
AUID- ORCID: https://orcid.org/0000-0002-9846-8917
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Zarebski, Alexander E
AU  - Zarebski AE
AUID- ORCID: https://orcid.org/0000-0003-1824-7653
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Hill, Verity
AU  - Hill V
AUID- ORCID: https://orcid.org/0000-0002-3509-8146
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Ruis, Christopher
AU  - Ruis C
AUID- ORCID: https://orcid.org/0000-0003-0977-5534
AD  - Molecular Immunity Unit, Department of Medicine, University of Cambridge,
      Cambridge, UK.
AD  - Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
FAU - Gutierrez, Bernardo
AU  - Gutierrez B
AUID- ORCID: https://orcid.org/0000-0002-9220-2739
AD  - Department of Zoology, University of Oxford, Oxford, UK.
AD  - School of Biological and Environmental Sciences, Universidad San Francisco de
      Quito, Quito, Ecuador.
FAU - Raghwani, Jayna
AU  - Raghwani J
AUID- ORCID: https://orcid.org/0000-0001-8538-4995
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Ashworth, Jordan
AU  - Ashworth J
AUID- ORCID: https://orcid.org/0000-0003-1740-7475
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Colquhoun, Rachel
AU  - Colquhoun R
AUID- ORCID: https://orcid.org/0000-0002-5577-9897
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Connor, Thomas R
AU  - Connor TR
AUID- ORCID: https://orcid.org/0000-0003-2394-6504
AD  - School of Biosciences, Cardiff University, Cardiff, UK.
AD  - Pathogen Genomics Unit, Public Health Wales NHS Trust, Cardiff, UK.
FAU - Faria, Nuno R
AU  - Faria NR
AUID- ORCID: https://orcid.org/0000-0001-8839-2798
AD  - Department of Zoology, University of Oxford, Oxford, UK.
AD  - MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College
      London, London, UK.
FAU - Jackson, Ben
AU  - Jackson B
AUID- ORCID: https://orcid.org/0000-0002-9981-0649
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Loman, Nicholas J
AU  - Loman NJ
AUID- ORCID: https://orcid.org/0000-0002-9843-8988
AD  - Institute of Microbiology and Infection, University of Birmingham, Birmingham,
      UK.
FAU - O'Toole, Aine
AU  - O'Toole A
AUID- ORCID: https://orcid.org/0000-0001-8083-474X
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Nicholls, Samuel M
AU  - Nicholls SM
AUID- ORCID: https://orcid.org/0000-0003-4081-065X
AD  - Institute of Microbiology and Infection, University of Birmingham, Birmingham,
      UK.
FAU - Parag, Kris V
AU  - Parag KV
AUID- ORCID: https://orcid.org/0000-0002-7806-3605
AD  - MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College
      London, London, UK.
FAU - Scher, Emily
AU  - Scher E
AUID- ORCID: https://orcid.org/0000-0002-5401-5879
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
FAU - Vasylyeva, Tetyana I
AU  - Vasylyeva TI
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Volz, Erik M
AU  - Volz EM
AUID- ORCID: https://orcid.org/0000-0001-6268-8937
AD  - MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College
      London, London, UK.
FAU - Watts, Alexander
AU  - Watts A
AUID- ORCID: https://orcid.org/0000-0002-2675-3460
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
AD  - BlueDot, Toronto, Canada.
FAU - Bogoch, Isaac I
AU  - Bogoch II
AD  - Department of Medicine, University of Toronto, Toronto, Canada.
AD  - Divisions of General Internal Medicine and Infectious Diseases, University Health
      Network, Toronto, Canada.
FAU - Khan, Kamran
AU  - Khan K
AUID- ORCID: https://orcid.org/0000-0003-4367-960X
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
AD  - BlueDot, Toronto, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Canada.
CN  - COVID-19 Genomics UK (COG-UK) Consortium
FAU - Aanensen, David M
AU  - Aanensen DM
AUID- ORCID: https://orcid.org/0000-0001-6688-0854
AD  - Centre for Genomic Pathogen Surveillance, Wellcome Genome Campus, Hinxton, UK.
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Kraemer, Moritz U G
AU  - Kraemer MUG
AUID- ORCID: https://orcid.org/0000-0001-8838-7147
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Rambaut, Andrew
AU  - Rambaut A
AUID- ORCID: https://orcid.org/0000-0003-4337-3707
AD  - Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.
      a.rambaut@ed.ac.uk oliver.pybus@zoo.ox.ac.uk.
FAU - Pybus, Oliver G
AU  - Pybus OG
AUID- ORCID: https://orcid.org/0000-0002-8797-2667
AD  - Department of Zoology, University of Oxford, Oxford, UK. a.rambaut@ed.ac.uk
      oliver.pybus@zoo.ox.ac.uk.
AD  - Department of Pathobiology and Population Sciences, Royal Veterinary College
      London, London, UK.
LA  - eng
GR  - MC_PC_19012/MRC_/Medical Research Council/United Kingdom
GR  - MR/S019510/1/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_19027/MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
GR  - MR/J014370/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/T030062/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/L015080/1/MRC_/Medical Research Council/United Kingdom
GR  - RP-PG-0514-20018/DH_/Department of Health/United Kingdom
GR  - MR/M501621/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210108
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
SB  - IM
CIN - Science. 2021 Feb 12;371(6530):680-681. PMID: 33574202
MH  - COVID-19/*epidemiology/prevention & control/transmission/*virology
MH  - Chain of Infection
MH  - Communicable Disease Control
MH  - Communicable Diseases, Imported/epidemiology/virology
MH  - Epidemics
MH  - *Genome, Viral
MH  - Humans
MH  - Phylogeny
MH  - SARS-CoV-2/*genetics
MH  - Travel
MH  - United Kingdom/epidemiology
PMC - PMC7877493
EDAT- 2021/01/10 06:00
MHDA- 2021/02/25 06:00
CRDT- 2021/01/09 05:31
PHST- 2020/10/22 00:00 [received]
PHST- 2020/12/18 00:00 [accepted]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2021/01/09 05:31 [entrez]
AID - science.abf2946 [pii]
AID - 10.1126/science.abf2946 [doi]
PST - ppublish
SO  - Science. 2021 Feb 12;371(6530):708-712. doi: 10.1126/science.abf2946. Epub 2021
      Jan 8.

PMID- 33408209
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20211008
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jan 6
TI  - Recommendations for SARS-CoV-2/COVID-19 testing: a scoping review of current
      guidance.
PG  - e043004
LID - 10.1136/bmjopen-2020-043004 [doi]
AB  - BACKGROUND: Testing used in screening, diagnosis and follow-up of COVID-19 has
      been a subject of debate. Several organisations have developed formal advice
      about testing for COVID-19 to assist in the control of the disease. We collated, 
      delineated and appraised current worldwide recommendations about the role and
      applications of tests to control SARS-CoV-2/COVID-19. METHODS: We searched for
      documents providing recommendations for COVID-19 testing in PubMed, EMBASE,
      LILACS, the Coronavirus Open Access Project living evidence database and relevant
      websites such as TRIP database, ECRI Guidelines Trust, the GIN database, from
      inception to 21 September 2020. Two reviewers applied the eligibility criteria to
      potentially relevant citations without language or geographical restrictions. We 
      extracted data in duplicate, including assessment of methodological quality using
      the Appraisal of Guidelines for Research and Evaluation-II tool. RESULTS: We
      included 47 relevant documents and 327 recommendations about testing. Regarding
      the quality of the documents, we found that the domains with the lowest scores
      were 'Editorial independence' (Median=4%) and 'Applicability' (Median=6%). Only
      six documents obtained at least 50% score for the 'Rigour of development' domain.
      An important number of recommendations focused on the diagnosis of suspected
      cases (48%) and deisolation measures (11%). The most frequently recommended test 
      was the reverse transcription-PCR (RT-PCR) assay (87 recommendations) and the
      chest CT (38 recommendations). There were 22 areas of agreement among guidance
      developers, including the use of RT-PCR for SARS-Cov-2 confirmation, the limited 
      role of bronchoscopy, the use chest CT and chest X-rays for grading severity and 
      the co-assessment for other respiratory pathogens. CONCLUSION: This first scoping
      review of recommendations for COVID-19 testing showed many limitations in the
      methodological quality of included guidance documents that could affect the
      confidence of clinicians in their implementation. Future guidance documents
      should incorporate a minimum set of key methodological characteristics to enhance
      their applicability for decision making.
CI  - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arevalo-Rodriguez, Ingrid
AU  - Arevalo-Rodriguez I
AUID- ORCID: 0000-0002-7326-4504
AD  - Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, IRYCIS, CIBER 
      of Epidemiology and Public Health, Madrid, Spain.
FAU - Seron, Pamela
AU  - Seron P
AD  - Department of Internal Medicine, Faculty of Medicine, Universidad de La Frontera,
      Temuco, Chile.
FAU - Buitrago-Garcia, Diana
AU  - Buitrago-Garcia D
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern,
      Switzerland, Bern, Switzerland.
FAU - Ciapponi, Agustin
AU  - Ciapponi A
AD  - Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires,
      Argentina.
FAU - Muriel, Alfonso
AU  - Muriel A
AUID- ORCID: 0000-0002-4805-4011
AD  - Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, CIBER of
      Epidemiology and Public Health, Madrid, Spain.
FAU - Zambrano-Achig, Paula
AU  - Zambrano-Achig P
AD  - Centro de investigacion en Salud Publica y Epidemiologia Clinica (CISPEC).
      Facultad de Ciencias de la Salud "Eugenio Espejo", Universidad UTE, Quito,
      Ecuador.
FAU - Del Campo, Rosa
AU  - Del Campo R
AD  - Department of Microbiology, Ramon y Cajal University Hospital, Ramon y Cajal
      Health Research Institute (IRYCIS), Madrid, Spain.
FAU - Galan-Montemayor, Juan Carlos
AU  - Galan-Montemayor JC
AD  - Department of Microbiology, Ramon y Cajal University Hospital. Ramon y Cajal
      Health Research Institute (IRYCIS), CIBER of Epidemiology and Public Health
      (CIBERESP), Madrid, Spain.
FAU - Simancas-Racines, Daniel
AU  - Simancas-Racines D
AD  - Centro de investigacion en Salud Publica y Epidemiologia Clinica (CISPEC).
      Facultad de Ciencias de la Salud "Eugenio Espejo", Universidad UTE, Quito,
      Ecuador.
FAU - Perez-Molina, Jose A
AU  - Perez-Molina JA
AD  - Infectious Diseases Department, National Referral Centre for Tropical Diseases,
      Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.
FAU - Khan, Khalid Saeed
AU  - Khan KS
AD  - Department of Preventive Medicine and Public Health, Faculty of Medicine,
      University of Granada, CIBER of Epidemiology and Public Health, Granada, Spain.
FAU - Zamora, Javier
AU  - Zamora J
AUID- ORCID: 0000-0003-4901-588X
AD  - Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, CIBER of
      Epidemiology and Public Health, Madrid, Spain j.zamora.1@bham.ac.uk.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/*diagnosis/epidemiology
MH  - COVID-19 Testing/*standards
MH  - Humans
MH  - Pandemics
MH  - *Practice Guidelines as Topic
MH  - *SARS-CoV-2
MH  - Tomography, X-Ray Computed/*methods
PMC - PMC7789202
OTO - NOTNLM
OT  - *diagnostic microbiology
OT  - *epidemiology
OT  - *protocols & guidelines
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation
      for the submitted work; KSK has been paid for developing and delivering
      educational presentations for Ferring Pharmaceuticals and Olympus company; KSK
      has been an editor of medical Journals including BJOG, EBM-BMJ, BMC Med Edu; no
      other relationships or activities that could appear to have influenced the
      submitted work.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/14 06:00
CRDT- 2021/01/07 06:00
PHST- 2021/01/07 06:00 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - bmjopen-2020-043004 [pii]
AID - 10.1136/bmjopen-2020-043004 [doi]
PST - epublish
SO  - BMJ Open. 2021 Jan 6;11(1):e043004. doi: 10.1136/bmjopen-2020-043004.

PMID- 33283036
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 2352-8737 (Electronic)
IS  - 2352-8737 (Linking)
VI  - 6
IP  - 1
DP  - 2020
TI  - The impact of SARS-CoV-2 in dementia across Latin America: A call for an urgent
      regional plan and coordinated response.
PG  - e12092
LID - 10.1002/trc2.12092 [doi]
AB  - The SARS-CoV-2 global pandemic will disproportionately impact countries with weak
      economies and vulnerable populations including people with dementia. Latin
      American and Caribbean countries (LACs) are burdened with unstable economic
      development, fragile health systems, massive economic disparities, and a high
      prevalence of dementia. Here, we underscore the selective impact of SARS-CoV-2 on
      dementia among LACs, the specific strain on health systems devoted to dementia,
      and the subsequent effect of increasing inequalities among those with dementia in
      the region. Implementation of best practices for mitigation and containment faces
      particularly steep challenges in LACs. Based upon our consideration of these
      issues, we urgently call for a coordinated action plan, including the development
      of inexpensive mass testing and multilevel regional coordination for dementia
      care and related actions. Brain health diplomacy should lead to a shared and
      escalated response across the region, coordinating leadership, and triangulation 
      between governments and international multilateral networks.
CI  - (c) 2020 The Authors. Alzheimer's & Dementia: Translational Research & Clinical
      Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's
      Association.
FAU - Ibanez, Agustin
AU  - Ibanez A
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Cognitive Neuroscience Center (CNC) Universidad de San Andres Buenos Aires
      Argentina.
AD  - National Scientific and Technical Research Council (CONICET) Buenos Aires
      Argentina.
AD  - Center for Social and Cognitive Neuroscience (CSCN) Universidad Adolfo Ibanez,
      School of Psychology, Adolfo Ibanez University Santiago Chile.
AD  - Universidad Autonoma del Caribe Barranquilla Colombia.
FAU - Santamaria-Garcia, Hernando
AU  - Santamaria-Garcia H
AD  - Pontificia Universidad Javeriana, Bogota, Departamentos de Psiquiatria, Instituto
      de Envejecimiento, Centro de Memoria y Cognicion Intellectus Hospital
      Universitario San Ignacio Bogota Colombia.
FAU - Guerrero Barragan, Alejandra
AU  - Guerrero Barragan A
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Servicio de Neurologia Subred de Servicios de Salud Suroccidente Bogota Colombia.
FAU - Kornhuber, Alexander
AU  - Kornhuber A
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
FAU - Ton, Alyne Mendonca Marques
AU  - Ton AMM
AD  - Laboratory of Translational Physiology and Pharmacology Pharmaceutical Sciences
      Graduate Program, Vila Velha University Vila Velha Espirito Santo Brazil.
FAU - Slachevsky, Andrea
AU  - Slachevsky A
AD  - Memory and Neuropsychiatric Clinic (CMYN), Neurology Department Del Salvador
      Hospital and University of Chile Faculty of Medicine Santiago Chile.
AD  - Geroscience Center for Brain Health and Metabolism (GERO), Faculty of Medicine
      University of Chile Santiago Chile.
AD  - Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology
      Department - ICBM, Neuroscience and East Neuroscience Departments, Faculty of
      Medicine University of Chile Santiago Chile.
AD  - Department of Neurology and Psychiatry Clinica Alemana-Universidad del Desa
      Concepcion Chile.
FAU - Teixeira, Antonio Lucio
AU  - Teixeira AL
AD  - Instituto de Ensino e Pesquisa Santa Casa BH Belo Horizonte Brazil.
AD  - UT Health Houston Texas USA.
FAU - Mar Meza, Beatriz Marcela
AU  - Mar Meza BM
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
FAU - Serrano, Cecilia M
AU  - Serrano CM
AD  - Cognitive Neurology, Department of Neurology Cesar Milstein Hospital, ALMA
      (Asociacion de Lucha contra el Mal de Alzheimer y alteraciones semejantes de la
      Republica Argentina), Research Ethics Committee, Ministry of Health of Buenos
      Aires Buenos Aires Argentina.
FAU - Cano, Carlos
AU  - Cano C
AD  - Pontificia Universidad Javeriana, Bogota, Departamentos de Psiquiatria, Instituto
      de Envejecimiento, Centro de Memoria y Cognicion Intellectus Hospital
      Universitario San Ignacio Bogota Colombia.
FAU - Arias Gonzalez, Carolina
AU  - Arias Gonzalez C
AD  - Neuroscience Research Institute and Department of Molecular Cellular and
      Developmental Biology University of California Santa Barbara Santa Barbara
      California USA.
FAU - Gonzalez-Billault, Christian
AU  - Gonzalez-Billault C
AD  - Geroscience Center for Brain Health and Metabolism (GERO), Faculty of Medicine
      University of Chile Santiago Chile.
FAU - Butler, Christopher
AU  - Butler C
AD  - Department of Brain Sciences Imperial College London UK.
AD  - Nuffield Department of Clinical Neurosciences University of Oxford Oxford UK.
AD  - Department of Neurology Pontificia Universidad Catolica de Chile Santiago Chile.
FAU - Bustin, Julian
AU  - Bustin J
AD  - Instituto de Neurologia Cognitiva INCYT Buenos Aires Argentina.
FAU - Duran-Aniotz, Claudia
AU  - Duran-Aniotz C
AD  - Center for Social and Cognitive Neuroscience (CSCN) Universidad Adolfo Ibanez,
      School of Psychology, Adolfo Ibanez University Santiago Chile.
AD  - Geroscience Center for Brain Health and Metabolism (GERO), Faculty of Medicine
      University of Chile Santiago Chile.
AD  - Biomedical Neuroscience Institute, Faculty of Medicine University of Chile
      Santiago Chile.
FAU - Acosta, Daisy
AU  - Acosta D
AD  - Universidad Nacional Pedro Henriquez Urena (UNPHU), Internal Medicine Department 
      Geriatric Section Santo Domingo Dominican Republic.
FAU - Matallana, Diana L
AU  - Matallana DL
AD  - Pontificia Universidad Javeriana, Bogota, Departamentos de Psiquiatria, Instituto
      de Envejecimiento, Centro de Memoria y Cognicion Intellectus Hospital
      Universitario San Ignacio Bogota Colombia.
FAU - Acosta-Alvear, Diego
AU  - Acosta-Alvear D
AD  - Neuroscience Research Institute and Department of Molecular Cellular and
      Developmental Biology University of California Santa Barbara Santa Barbara
      California USA.
FAU - Trepel, Dominic
AU  - Trepel D
AD  - Global Brain Health Institute Trinity College Dublin Dublin Ireland.
FAU - Resende, Elisa De Paula Franca
AU  - Resende EPF
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Instituto de Ensino e Pesquisa Santa Casa BH Belo Horizonte Brazil.
AD  - Federal University of Rio de Janeiro Rio de Janeiro Brazil.
FAU - de Oliveira, Fabricio Ferreira
AU  - de Oliveira FF
AD  - Department of Neurology and Neurosurgery, Escola Paulista de Medicina Federal
      University of Sao Paulo - UNIFESP Sao Paulo Brazil.
FAU - Ibanez, Francisco
AU  - Ibanez F
AD  - FCEFyN, Universidad Nacional de San Juan San Juan Argentina.
FAU - De Felice, Fernanda G
AU  - De Felice FG
AD  - Federal University of Rio de Janeiro Rio de Janeiro Brazil.
AD  - Queen's University Kingston Ontario Canada.
FAU - Navarrete, Gorka
AU  - Navarrete G
AD  - Center for Social and Cognitive Neuroscience (CSCN) Universidad Adolfo Ibanez,
      School of Psychology, Adolfo Ibanez University Santiago Chile.
FAU - Tarnanas, Ioannis
AU  - Tarnanas I
AD  - Altoida Inc. Houston Texas USA.
AD  - Swiss National Task Force for Dementia Geneva Switzerland.
FAU - Meier, Irene B
AU  - Meier IB
AD  - Altoida Inc. Houston Texas USA.
AD  - Swiss National Task Force for Dementia Geneva Switzerland.
FAU - Smid, Jerusa
AU  - Smid J
AD  - Department of Neurology University of Sao Paulo; Institute of Infectious Diseases
      Emilio Ribas Sao Paulo Brazil.
FAU - Llibre-Guerra, Jorge
AU  - Llibre-Guerra J
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Department of Neurology Washington University School of Medicine St Louis USA.
FAU - Llibre-Rodriguez, Juan J
AU  - Llibre-Rodriguez JJ
AD  - Finlay-Albarran Medicine Faculty Universidad de Ciencias Medicas La Havana Cuba.
FAU - Fajersztajn, Lais
AU  - Fajersztajn L
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Department of Pathology, Laboratory of Experimental Air Pollution University of
      Sao Paulo School of Medicine Sao Paulo Brazil.
FAU - Takada, Leonel Tadao
AU  - Takada LT
AD  - Hospital das Clinicas University of Sao Paulo Medical School Sao Paulo Brazil.
FAU - Duque, Lissette
AU  - Duque L
AD  - Cognitive Disorders Unit, Neuromedicenter National Commission in Bioethics Quito 
      Ecuador.
FAU - Okada de Oliveira, Maira
AU  - Okada de Oliveira M
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Hospital das Clinicas University of Sao Paulo Medical School Sao Paulo Brazil.
AD  - Hospital Santa Marcelina Sao Paulo Brazil.
FAU - Bicalho, Maria Aparecida Camargos
AU  - Bicalho MAC
AD  - Federal University of Minas Gerais Belo Horizonte Brazil.
FAU - Behrens, Maria Isabel
AU  - Behrens MI
AD  - Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology
      Department - ICBM, Neuroscience and East Neuroscience Departments, Faculty of
      Medicine University of Chile Santiago Chile.
AD  - FCEFyN Universidad Nacional de San Juan San Juan Argentina.
AD  - Departamento de Neurologia and Neurocirugia Hospital Clinico, Departamento de
      Neurociencias Centro de Investigacion Clinica Avanzada (CICA) Facultad de
      Medicina, Hospital Clinico, Universidad de Chile Santiago Chile.
FAU - Pintado-Caipa, Maritza
AU  - Pintado-Caipa M
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Unit Cognitive Impairment and Dementia Prevention Cognitive Neurology Center,
      Peruvian Institute of Neurosciences Lima Peru.
FAU - Parra, Mario
AU  - Parra M
AD  - University of Strathclyde Glasgow UK.
FAU - Wilson, Maxwell Z
AU  - Wilson MZ
AD  - Neuroscience Research Institute and Department of Molecular Cellular and
      Developmental Biology University of California Santa Barbara Santa Barbara
      California USA.
FAU - De La Cruz Puebla, Myriam
AU  - De La Cruz Puebla M
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Vall d'Hebron Research Institute (VHIR) Autonome University of Barcelona
      Barcelona Spain.
FAU - Custodio, Nilton
AU  - Custodio N
AD  - Unit Cognitive Impairment and Dementia Prevention Cognitive Neurology Center,
      Peruvian Institute of Neurosciences Lima Peru.
FAU - Santibanez, Rodrigo
AU  - Santibanez R
AD  - Department of Neurology Pontificia Universidad Catolica de Chile Santiago Chile.
AD  - Neurology Service Complejo Asistencial Dr. Sotero del Rio Santiago Chile.
FAU - Serafim, Rodrigo Bernardo
AU  - Serafim RB
AD  - Behavioral Neurology Clinic Santa Casa de Belo Horizonte MG Brazil.
FAU - Tavares, Ronnielly Melo
AU  - Tavares RM
AD  - Federal University of Rio de Janeiro Rio de Janeiro Brazil.
AD  - Behavioral Neurology Clinic Santa Casa de Belo Horizonte MG Brazil.
FAU - Pina Escudero, Stefanie Danielle
AU  - Pina Escudero SD
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
FAU - Leon Rodriguez, Tomas
AU  - Leon Rodriguez T
AD  - Memory and Neuropsychiatric Clinic (CMYN), Neurology Department Del Salvador
      Hospital and University of Chile Faculty of Medicine Santiago Chile.
FAU - Dawson, Walter
AU  - Dawson W
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
AD  - Department of Neurology School of Medicine, Oregon Health and Science University 
      Portland Oregon USA.
AD  - Institute on Aging College of Urban and Public Affairs, Portland State University
      Portland Oregon USA.
FAU - Miller, Bruce L
AU  - Miller BL
AD  - Global Brain Health Institute (GBHI) University of California San Francisco
      (UCSF) San Francisco California USA.
FAU - Kosik, Kenneth S
AU  - Kosik KS
AD  - Neuroscience Research Institute and Department of Molecular Cellular and
      Developmental Biology University of California Santa Barbara Santa Barbara
      California USA.
LA  - eng
GR  - MR/K010395/1/MRC_/Medical Research Council/United Kingdom
GR  - R01 AG057234/AG/NIA NIH HHS/United States
PT  - Journal Article
DEP - 20201123
PL  - United States
TA  - Alzheimers Dement (N Y)
JT  - Alzheimer's & dementia (New York, N. Y.)
JID - 101650118
PMC - PMC7683959
OTO - NOTNLM
OT  - Latin American and Caribbean countries
OT  - SARS-CoV-2
OT  - coronavirus
OT  - dementia
OT  - health system
COIS- Agustin Ibanez is partially supported by grants from CONICET, FONCyT-PICT
      2017-1818, FONCyT-PICT 2017 1820, ANID/FONDAP/15150012, INECO Foundation, the
      Interamerican Development Bank (IDB), GBHI ALZ UK-20-639295, and the
      MULTI-PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat,
      supported by National Institutes of Health, National Institutes of Aging [R01
      AG057234], Alzheimer's Association [SG-20-725707], Tau Consortium, and Global
      Brain Health Institute). Fabricio Ferreira de Oliveira has contributed by way of 
      a grant from FAPESP - The State of Sao Paulo Research Foundation (grant
      #2015/10109-5). Alzheimer's Society Canada and the Weston Brain Institute (to
      FGF), National Institute for Translational Neuroscience (INNT/Brazil) (to FGF),
      the Brazilian funding agencies Conselho Nacional de Desenvolvimento Cientifico e 
      Tecnologico (CNPq) and Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro 
      (FAPERJ) (to FGF). Elisa De Paula Franca Resende received funding from the
      Alzheimer's Association. Alzheimer's Association Research Grant 2018-AARG-591107 
      and REDI170583 (CDA). Maria Isabel Behrens is supported by grants from FONDECYT
      (Fondo de Desarrollo Cientifico y Tecnologico) Grant 1190958, FONDEF (Fondo de
      Fomento al Desarrollo Cientifico y Tecnologico Grant ID19I10302, and URedes
      URC-036/17. Andrea Slachevsky is partially supported by grants from
      ANID/FONDAP/15150012, ANID / Fondecyt/ 1141279. Kenneth S. Kosik has support from
      the Alzheimer's Association and Tau Consortium. The contents of this publication 
      are solely the responsibility of the authors and do not represent the official
      views of these Institutions. The other authors declare no conflicts of interest.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:36
PHST- 2020/09/02 00:00 [received]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/12/07 05:36 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.1002/trc2.12092 [doi]
AID - TRC212092 [pii]
PST - epublish
SO  - Alzheimers Dement (N Y). 2020 Nov 23;6(1):e12092. doi: 10.1002/trc2.12092.
      eCollection 2020.

PMID- 33252294
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20201214
IS  - 1473-0804 (Electronic)
IS  - 1369-7137 (Linking)
VI  - 23
IP  - 6
DP  - 2020 Dec
TI  - The severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection
      and the climacteric woman.
PG  - 525-527
LID - 10.1080/13697137.2020.1837547 [doi]
AB  - The severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection
      has affected millions of individuals worldwide, causing high mortality rates and 
      severe physical sequelae, with a negative impact on society, economy, health
      care, lifestyle and personal relationships. Studies have confirmed this infection
      has sex and age differences in terms of disease severity and immune response,
      with a particular relationship with the anti-Mullerian hormone, a marker of
      aging, and estradiol, a marker of ovarian function. Postmenopausal women seem to 
      present a more severe infection as compared to premenopausal ones. Estradiol
      protects the vascular system, mediating with the renin-angiotensin-aldosterone
      system, whereas testosterone enhances the levels of angiotensin-converting enzyme
      and the transmembrane protease serine-type 2, thus delaying viral clearance in
      men as compared to women. This new infection will stay among us, transforming our
      social, economic and daily lifestyle, and hence medical and health care as well
      as the use of menopause hormone therapy will need redefining, considering both
      preventive and curative perspectives.
FAU - Chedraui, Peter
AU  - Chedraui P
AUID- ORCID: 0000-0002-1556-3979
AD  - Instituto de Investigacion e Innovacion en Salud Integral, Facultad de Ciencias
      Medicas, Universidad Catolica de Santiago de Guayaquil, Guayaquil, Ecuador.
FAU - Perez-Lopez, Faustino R
AU  - Perez-Lopez FR
AUID- ORCID: 0000-0002-2801-416X
AD  - Department of Obstetrics and Gynecology, University of Zaragoza, Faculty of
      Medicine, and Aragon Health Research Institute, Zaragoza, Spain.
LA  - eng
PT  - Editorial
PL  - England
TA  - Climacteric
JT  - Climacteric : the journal of the International Menopause Society
JID - 9810959
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
SB  - IM
MH  - COVID-19/epidemiology/*metabolism
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Middle Aged
MH  - Peptidyl-Dipeptidase A/metabolism
MH  - Postmenopause/*metabolism
MH  - SARS-CoV-2/*metabolism
MH  - *Women's Health
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *climacteric
OT  - *lockdown
OT  - *menopause
OT  - *mortality
OT  - *ovarian hormones
OT  - *sex difference
EDAT- 2020/12/01 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/30 12:08
PHST- 2020/11/30 12:08 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1080/13697137.2020.1837547 [doi]
PST - ppublish
SO  - Climacteric. 2020 Dec;23(6):525-527. doi: 10.1080/13697137.2020.1837547.

PMID- 33242475
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20220401
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 21
IP  - 6
DP  - 2021 Jun
TI  - A case of SARS-CoV-2 reinfection in Ecuador.
PG  - e142
LID - S1473-3099(20)30910-5 [pii]
LID - 10.1016/S1473-3099(20)30910-5 [doi]
FAU - Prado-Vivar, Belen
AU  - Prado-Vivar B
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador;
      Colegio de Ciencias Biologicas y Ambientales, and Centro de Bioinformatica,
      Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Becerra-Wong, Monica
AU  - Becerra-Wong M
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Guadalupe, Juan Jose
AU  - Guadalupe JJ
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito, Quito, 
      Ecuador.
FAU - Marquez, Sully
AU  - Marquez S
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Gutierrez, Bernardo
AU  - Gutierrez B
AD  - Laboratorio de Biotecnologia Vegetal, Universidad San Francisco de Quito, Quito, 
      Ecuador; Department of Zoology, University of Oxford, Oxford, UK.
FAU - Rojas-Silva, Patricio
AU  - Rojas-Silva P
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Grunauer, Michelle
AU  - Grunauer M
AD  - Escuela de Medicina, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Trueba, Gabriel
AU  - Trueba G
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Barragan, Veronica
AU  - Barragan V
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador.
FAU - Cardenas, Paul
AU  - Cardenas P
AD  - Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador;
      Colegio de Ciencias Biologicas y Ambientales, and Centro de Bioinformatica,
      Universidad San Francisco de Quito, Quito, Ecuador. Electronic address:
      pacardenas@usfq.edu.ec.
LA  - eng
GR  - U01 AI151788/AI/NIAID NIH HHS/United States
PT  - Letter
DEP - 20201123
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
RN  - 0 (Antibodies, Viral)
SB  - IM
CIN - Lancet Infect Dis. 2021 Jan 20;:. PMID: 33484647
MH  - Antibodies, Viral
MH  - *COVID-19/immunology/virology
MH  - Ecuador
MH  - Humans
MH  - Mutation
MH  - *Reinfection
MH  - SARS-CoV-2/genetics/immunology
PMC - PMC7833993
EDAT- 2020/11/27 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/11/26 20:07
PHST- 2020/10/13 00:00 [received]
PHST- 2020/11/10 00:00 [revised]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2020/11/26 20:07 [entrez]
AID - S1473-3099(20)30910-5 [pii]
AID - 10.1016/S1473-3099(20)30910-5 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2021 Jun;21(6):e142. doi: 10.1016/S1473-3099(20)30910-5. Epub 
      2020 Nov 23.

PMID- 33189137
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20210506
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 17
IP  - 1
DP  - 2020 Nov 14
TI  - Poor sensitivity of "AccuPower SARS-CoV-2 real time RT-PCR kit (Bioneer, South
      Korea)".
PG  - 178
LID - 10.1186/s12985-020-01445-4 [doi]
AB  - BACKGROUND: Several molecular kits are available for SARS-CoV-2 diagnosis, mostly
      lacking of proper clinical evaluation due to the emergency caused by COVID19
      pandemia, particularly at developing countries like Ecuador. OBJECTIVE: We
      carried out an evaluation of the clinical performance of "AccuPower SARS-CoV-2
      Real Time RT-PCR kit" (Bioneer, South Korea) for SARS-CoV-2 diagnosis using
      2019-nCoV CDC EUA kit (IDT, USA) as a gold standard. RESULTS: 48 clinical
      specimens were included on the study, 38 tested SARS-CoV-2 positive and 10
      SARS-CoV-2 negative for 2019-nCoV CDC EUA kit. For "AccuPower SARS-CoV-2 Real
      Time RT-PCR kit", only 30 were SARS-CoV-2 positive, indicating a low clinical
      performance with sensitivity of 78.9%. Moreover, the limit of detection for
      "AccuPower SARS-CoV-2 Real Time RT-PCR kit" was estimated to be higher than
      40,000 viral RNA copies/mL of sample. CONCLUSIONS: Proper clinical performance
      evaluation studies from government agencies at developing countries should be
      mandatory prior to clinical use authorization of SARS-CoV-2 diagnosis kits,
      particularly when those kits lack of either FDA or its country of origin clinical
      use authorization, to prevent the distribution of low quality products that may
      have a negative impact of COVID19 surveillance at developing countries.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
      magbereguiain@gmail.com.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
EIN - Virol J. 2021 Feb 18;18(1):41. PMID: 33602239
MH  - COVID-19/*diagnosis
MH  - *COVID-19 Nucleic Acid Testing/standards
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Limit of Detection
MH  - Molecular Diagnostic Techniques
MH  - Reagent Kits, Diagnostic
MH  - SARS-CoV-2/genetics/*isolation & purification
MH  - Sensitivity and Specificity
PMC - PMC7666399
OTO - NOTNLM
OT  - *Bioneer
OT  - *CDC
OT  - *RT-PCR
OT  - *SARS-CoV-2
EDAT- 2020/11/16 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/15 20:18
PHST- 2020/09/14 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/11/15 20:18 [entrez]
PHST- 2020/11/16 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12985-020-01445-4 [doi]
AID - 10.1186/s12985-020-01445-4 [pii]
PST - epublish
SO  - Virol J. 2020 Nov 14;17(1):178. doi: 10.1186/s12985-020-01445-4.

PMID- 33172092
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 21
DP  - 2020 Nov 6
TI  - Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible
      Inhibitors of the SARS-CoV-2 M(pro) Protease.
LID - E5172 [pii]
LID - 10.3390/molecules25215172 [doi]
AB  - Wuhan, China was the epicenter of the first zoonotic transmission of the severe
      acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) in December 2019 and 
      it is the causative agent of the novel human coronavirus disease 2019 (COVID-19).
      Almost from the beginning of the COVID-19 outbreak several attempts were made to 
      predict possible drugs capable of inhibiting the virus replication. In the
      present work a drug repurposing study is performed to identify potential
      SARS-CoV-2 protease inhibitors. We created a Quantitative Structure-Activity
      Relationship (QSAR) model based on a machine learning strategy using hundreds of 
      inhibitor molecules of the main protease (M(pro)) of the SARS-CoV coronavirus.
      The QSAR model was used for virtual screening of a large list of drugs from the
      DrugBank database. The best 20 candidates were then evaluated in-silico against
      the M(pro) of SARS-CoV-2 by using docking and molecular dynamics analyses.
      Docking was done by using the Gold software, and the free energies of binding
      were predicted with the MM-PBSA method as implemented in AMBER. Our results
      indicate that levothyroxine, amobarbital and ABP-700 are the best potential
      inhibitors of the SARS-CoV-2 virus through their binding to the M(pro) enzyme.
      Five other compounds showed also a negative but small free energy of binding:
      nikethamide, nifurtimox, rebimastat, apomine and rebastinib.
FAU - Tejera, Eduardo
AU  - Tejera E
AD  - Grupo de Bio-Quimioinformatica, Universidad de Las Americas, Quito 170513,
      Ecuador.
AD  - Facultad de Ingenieria y Ciencias Aplicadas, Universidad de Las Americas, Quito
      170513, Ecuador.
FAU - Munteanu, Cristian R
AU  - Munteanu CR
AUID- ORCID: 0000-0002-5628-2268
AD  - Faculty of Computer Science, Centre for Information and Communications Technology
      Research (CITIC), University of A Coruna, 15007 A Coruna, Spain.
AD  - Biomedical Research Institute of A Coruna (INIBIC), University Hospital Complex
      of A Coruna (CHUAC), 15006 A Coruna, Spain.
FAU - Lopez-Cortes, Andres
AU  - Lopez-Cortes A
AUID- ORCID: 0000-0003-1503-1929
AD  - Centro de Investigacion Genetica y Genomica, Facultad de Ciencias de la Salud
      Eugenio Espejo, Universidad UTE, Quito 170129, Ecuador.
AD  - Latin American Network for Implementation and Validation of Clinical
      Pharmacogenomics Guidelines (RELIVAF-CYTED), 28029 Madrid, Spain.
FAU - Cabrera-Andrade, Alejandro
AU  - Cabrera-Andrade A
AUID- ORCID: 0000-0001-9702-6618
AD  - Grupo de Bio-Quimioinformatica, Universidad de Las Americas, Quito 170513,
      Ecuador.
AD  - Carrera de Enfermeria, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito 170513, Ecuador.
FAU - Perez-Castillo, Yunierkis
AU  - Perez-Castillo Y
AUID- ORCID: 0000-0002-3710-0035
AD  - Grupo de Bio-Quimioinformatica, Universidad de Las Americas, Quito 170513,
      Ecuador.
AD  - Escuela de Ciencias Fisicas y Matematicas, Universidad de Las Americas, Quito
      170513, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20201106
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antiviral Agents)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Small Molecule Libraries)
RN  - EC 3.4.22.- (3C-like protease, SARS coronavirus)
RN  - EC 3.4.22.28 (Coronavirus 3C Proteases)
RN  - GWH6IJ239E (Amobarbital)
RN  - Q51BO43MG4 (Thyroxine)
SB  - IM
MH  - Amobarbital/pharmacology
MH  - Antiviral Agents/chemistry/*pharmacology
MH  - Binding Sites
MH  - COVID-19/*drug therapy
MH  - Computer Simulation
MH  - Coronavirus 3C Proteases/*antagonists & inhibitors
MH  - Drug Discovery/*methods
MH  - Drug Repositioning/*methods
MH  - Humans
MH  - Machine Learning
MH  - Molecular Docking Simulation
MH  - Molecular Dynamics Simulation
MH  - Pandemics
MH  - Protease Inhibitors/chemistry/*pharmacology
MH  - Protein Binding
MH  - Quantitative Structure-Activity Relationship
MH  - SARS-CoV-2/drug effects/*enzymology
MH  - Small Molecule Libraries/chemistry
MH  - Software
MH  - Thermodynamics
MH  - Thyroxine/pharmacology
PMC - PMC7664330
OTO - NOTNLM
OT  - COVID-19
OT  - QSAR
OT  - SARS-CoV-2
OT  - drugs repurposing
OT  - molecular dynamics
EDAT- 2020/11/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/11 01:02
PHST- 2020/09/26 00:00 [received]
PHST- 2020/10/28 00:00 [revised]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/11/11 01:02 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - molecules25215172 [pii]
AID - 10.3390/molecules25215172 [doi]
PST - epublish
SO  - Molecules. 2020 Nov 6;25(21). pii: molecules25215172. doi:
      10.3390/molecules25215172.

PMID- 33169096
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2196-3045 (Print)
VI  - 7
IP  - 4
DP  - 2020
TI  - The SARS-CoV-2 Pandemic in Latin America: the Need for Multidisciplinary
      Approaches.
PG  - 120-125
LID - 10.1007/s40475-020-00219-w [doi]
AB  - Purpose of Review: Acute respiratory infections of viral etiology (ARIVE)
      constitute one of the most frequent infectious processes among humans. They cause
      significant morbidity and mortality every year in all age groups and regions of
      the world. Their etiology is diverse, and seasonal viruses began their journey,
      at some point, with an episode of expansion before their annual circulation as
      seasonal agents. The coronavirus disease 2019 (COVID-19) pandemic is a challenge 
      for Latin America. Understanding dynamics is essential for decision making, to
      reduce the health, economic, and social impacts of the pandemic. Recent Findings:
      Currently, governments in Latin America have taken measures to mitigate the
      spread of COVID-19 primarily based on World Health Organization recommendations. 
      However, the potential impact of the virus in Latin America is still unknown.
      Given the urgency, governments need more accurate estimates of what could happen 
      in Latin America in order to make informed decisions, At the September 20, 2020, 
      cumulative cases 2295 of COVID-19 per 1 million population has been registered in
      Latin America and the Caribbean. Brazil, Peru, and Chile are the most countries
      affected by this pandemic, registering a total of cumulative cases per million
      inhabitants of 21,148, 22,941, and 23,262 respectively. Peru has shown the
      highest death numbers with 949 per million inhabitants. Summary: The Latin
      American health authorities should make the most beneficial decisions based in
      scientific facts for the health and life of citizens, both understood in the
      broadest and most inclusive sense.Once the epidemic is over, Latin America should
      begin a profound health reform, at a single and universal health system,
      integrated and coordinated, where the leading role of the Ministry of Health is
      resumed, to have a national network of modern, integrated, and excellent quality 
      laboratories for the benefit of the entire society.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Callejas, Diana
AU  - Callejas D
AUID- ORCID: https://orcid.org/0000-0002-7864-5357
AD  - Facultad de Ciencias de la Salud, Universidad Tecnica de Manabi, Portoviejo,
      Manabi Ecuador.grid.442241.50000 0001 0580 871X
FAU - Echevarria, Jose M
AU  - Echevarria JM
AD  - Facultad de Biologia, Universidad Complutense, Madrid, Spain.grid.4795.f0000 0001
      2157 7667
FAU - Carrero, Yenddy
AU  - Carrero Y
AD  - Facultad de Ciencias de la Salud, Carrera de Medicina, Universidad Tecnica de
      Ambato, Ambato, Ecuador.grid.442092.90000 0001 2186 6637
FAU - Rodriguez-Morales, Alfonso J
AU  - Rodriguez-Morales AJ
AD  - Grupo de Investigacion en Salud Publica e Infecciones, Facultad de Ciencias de la
      Salud, Universidad Tecnologica de Pereira, Risaralda, Colombia.grid.412256.60000 
      0001 2176 1069
AD  - Grupo de Investigacion en Biomedicina, Facultad de Medicina, Fundacion
      Universitaria Autonoma de las Americas, Pereira, Risaralda
      Colombia.grid.441853.f0000 0004 0418 3510
FAU - Moreira, Ruth
AU  - Moreira R
AD  - Facultad de Ciencias Medicas, Carrera de Medicina, Universidad Laica Eloy Alfaro 
      de Manabi, Manta, Manabi Ecuador.grid.442235.60000 0001 0744 6732
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201103
PL  - Switzerland
TA  - Curr Trop Med Rep
JT  - Current tropical medicine reports
JID - 101625249
PMC - PMC7609365
OTO - NOTNLM
OT  - Acute respiratory infection
OT  - And Latin America
OT  - COVID-19
OT  - Coronavirus
OT  - Pandemic
OT  - Pneumonia
OT  - SARS-CoV-2
EDAT- 2020/11/11 06:00
MHDA- 2020/11/11 06:01
CRDT- 2020/11/10 05:45
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2020/11/11 06:01 [medline]
PHST- 2020/11/10 05:45 [entrez]
AID - 10.1007/s40475-020-00219-w [doi]
AID - 219 [pii]
PST - ppublish
SO  - Curr Trop Med Rep. 2020;7(4):120-125. doi: 10.1007/s40475-020-00219-w. Epub 2020 
      Nov 3.

PMID- 33149153
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201218
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Nov 4
TI  - Optimized and scalable synthesis of magnetic nanoparticles for RNA extraction in 
      response to developing countries' needs in the detection and control of
      SARS-CoV-2.
PG  - 19004
LID - 10.1038/s41598-020-75798-9 [doi]
AB  - Ecuador is one of the most affected countries, with the coronavirus disease 2019 
      (COVID-19) infection, in Latin America derived from an ongoing economic crisis.
      One of the most important methods for COVID-19 detection is the use of techniques
      such as real time RT-PCR based on a previous extraction/purification of RNA
      procedure from nasopharyngeal cells using functionalized magnetic nanoparticles
      (MNP). This technique allows the processing of ~ 10,000 tests per day in private 
      companies and around hundreds per day at local Universities guaranteeing to reach
      a wide range of the population. However, the main drawback of this method is the 
      need for specialized MNP with a strong negative charge for the viral RNA
      extraction to detect the existence of the SARS-CoV-2 virus. Here we present a
      simplified low cost method to produce 10 g of nanoparticles in 100 mL of solution
      that was scaled to one litter by parallelizing the process 10 times in just two
      days and allowing for the possibility of making ~ 50,000 COVID-19 tests. This
      communication helps in reducing the cost of acquiring MNP for diverse
      biomolecular applications supporting developing country budgets constraints and
      chemical availability specially during the COVID-19 International Health
      Emergency.
FAU - Chacon-Torres, Julio C
AU  - Chacon-Torres JC
AD  - School of Physical Sciences and Nanotechnology, Yachay Tech University, 100119,
      Urcuqui, Ecuador. jchacon@yachaytech.edu.ec.
FAU - Reinoso, C
AU  - Reinoso C
AD  - School of Physical Sciences and Nanotechnology, Yachay Tech University, 100119,
      Urcuqui, Ecuador.
FAU - Navas-Leon, Daniela G
AU  - Navas-Leon DG
AD  - School of Chemical Sciences and Engineering, Yachay Tech University, 100119,
      Urcuqui, Ecuador.
FAU - Briceno, Sarah
AU  - Briceno S
AD  - School of Physical Sciences and Nanotechnology, Yachay Tech University, 100119,
      Urcuqui, Ecuador.
FAU - Gonzalez, Gema
AU  - Gonzalez G
AD  - School of Physical Sciences and Nanotechnology, Yachay Tech University, 100119,
      Urcuqui, Ecuador. ggonzalez@yachaytech.edu.ec.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Covid-19 aAPC vaccine)
RN  - 0 (Magnetite Nanoparticles)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - COVID-19 Testing
MH  - COVID-19 Vaccines
MH  - Clinical Laboratory Techniques/*methods
MH  - Coronavirus Infections/diagnosis
MH  - *Costs and Cost Analysis
MH  - Developing Countries
MH  - Humans
MH  - Magnetite Nanoparticles/*chemistry/economics
MH  - RNA, Viral/chemistry
MH  - Reverse Transcriptase Polymerase Chain Reaction/economics/*methods
PMC - PMC7642403
EDAT- 2020/11/06 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/11/05 06:01
PHST- 2020/05/01 00:00 [received]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/11/05 06:01 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - 10.1038/s41598-020-75798-9 [doi]
AID - 10.1038/s41598-020-75798-9 [pii]
PST - epublish
SO  - Sci Rep. 2020 Nov 4;10(1):19004. doi: 10.1038/s41598-020-75798-9.

PMID- 33119616
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20210209
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Linking)
VI  - 14
IP  - 10
DP  - 2020 Oct
TI  - SARS-CoV-2 in the Amazon region: A harbinger of doom for Amerindians.
PG  - e0008686
LID - 10.1371/journal.pntd.0008686 [doi]
AB  - As the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic
      continues to expand, healthcare resources globally have been spread thin. Now,
      the disease is rapidly spreading across South America, with deadly consequences
      in areas with already weakened public health systems. The Amazon region is
      particularly susceptible to the widespread devastation from Coronavirus disease
      2019 (COVID-19) because of its immunologically fragile native Amerindian
      inhabitants and epidemiologic vulnerabilities. Herein, we discuss the current
      situation and potential impact of COVID-19 in the Amazon region and how further
      spread of the epidemic wave could prove devastating for many Amerindian people
      living in the Amazon rainforest.
FAU - Ramirez, Juan David
AU  - Ramirez JD
AD  - Grupo de Investigaciones Microbiologicas - UR (GIMUR), Departamento de Biologia, 
      Facultad de Ciencias Naturales, Universidad del Rosario. Bogota, Colombia.
FAU - Sordillo, Emilia Mia
AU  - Sordillo EM
AUID- ORCID: 0000-0001-7787-3051
AD  - Icahn School of Medicine at Mount Sinai, New York, United States.
FAU - Gotuzzo, Eduardo
AU  - Gotuzzo E
AD  - Universidad Peruana Cayetano Heredia. Lima, Peru.
FAU - Zavaleta, Carol
AU  - Zavaleta C
AD  - Universidad Peruana Cayetano Heredia. Lima, Peru.
FAU - Caplivski, Daniel
AU  - Caplivski D
AD  - Icahn School of Medicine at Mount Sinai, New York, United States.
FAU - Navarro, Juan Carlos
AU  - Navarro JC
AUID- ORCID: 0000-0002-7692-4248
AD  - Universidad Internacional SEK, Quito, Ecuador.
FAU - Crainey, James Lee
AU  - Crainey JL
AUID- ORCID: 0000-0001-6812-9327
AD  - Instituto Leonidas e Maria Deane/ILMD/FIOCRUZ, Manaus, Brasil.
FAU - Bessa Luz, Sergio Luiz
AU  - Bessa Luz SL
AD  - Instituto Leonidas e Maria Deane/ILMD/FIOCRUZ, Manaus, Brasil.
FAU - Noguera, Lourdes A Delgado
AU  - Noguera LAD
AUID- ORCID: 0000-0003-0910-5434
AD  - Instituto de Investigaciones Biomedicas IDB / Emerging Pathogens
      Network-Incubadora Venezolana de la Ciencia, Cabudare, Venezuela.
FAU - Schaub, Roxane
AU  - Schaub R
AUID- ORCID: 0000-0001-5742-3280
AD  - CIC AG/Inserm 1424, Centre Hospitalier de Cayenne Andree Rosemon, Cayenne, French
      Guiana.
AD  - Laboratoire des Ecosystemes Amazoniens et Pathologie Tropicale (EPaT) EA 3593,
      Universite de Guyane, Labex CEBA, DFR Sante, Cayenne, French Guiana.
FAU - Rousseau, Cyril
AU  - Rousseau C
AUID- ORCID: 0000-0003-1538-9621
AD  - Sante publique France. French National Public Health Agency. Regional unit.
      French Guiana. France.
FAU - Herrera, Giovanny
AU  - Herrera G
AD  - Grupo de Investigaciones Microbiologicas - UR (GIMUR), Departamento de Biologia, 
      Facultad de Ciencias Naturales, Universidad del Rosario. Bogota, Colombia.
FAU - Oliveira-Miranda, Maria A
AU  - Oliveira-Miranda MA
AUID- ORCID: 0000-0002-4889-3130
AD  - Wataniba Amazon Social Workgroup, Caracas, Venezuela.
FAU - Quispe-Vargas, Maria Teresa
AU  - Quispe-Vargas MT
AD  - Wataniba Amazon Social Workgroup, Caracas, Venezuela.
FAU - Hotez, Peter J
AU  - Hotez PJ
AD  - National School of Tropical Medicine, Baylor College of Medicine, Houston, United
      States.
FAU - Paniz Mondolfi, Alberto
AU  - Paniz Mondolfi A
AUID- ORCID: 0000-0003-1259-1736
AD  - Icahn School of Medicine at Mount Sinai, New York, United States.
AD  - Instituto de Investigaciones Biomedicas IDB / Emerging Pathogens
      Network-Incubadora Venezolana de la Ciencia, Cabudare, Venezuela.
AD  - Academia Nacional de Medicina de Venezuela, Caracas, Venezuela.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201029
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
SB  - IM
EIN - PLoS Negl Trop Dis. 2021 Feb 9;15(2):e0009118. PMID: 33561162
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*ethnology/mortality
MH  - Humans
MH  - *Indians, South American
MH  - Pandemics
MH  - Pneumonia, Viral/*ethnology/mortality
MH  - Rainforest
MH  - SARS-CoV-2
MH  - South America/epidemiology
PMC - PMC7595282
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/30 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/10/29 17:14
PHST- 2020/10/29 17:14 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 10.1371/journal.pntd.0008686 [doi]
AID - PNTD-D-20-01025 [pii]
PST - epublish
SO  - PLoS Negl Trop Dis. 2020 Oct 29;14(10):e0008686. doi:
      10.1371/journal.pntd.0008686. eCollection 2020 Oct.

PMID- 33115681
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210414
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 102
DP  - 2021 Jan
TI  - Analytical sensitivity and clinical performance of a triplex RT-qPCR assay using 
      CDC N1, N2, and RP targets for SARS-CoV-2 diagnosis.
PG  - 14-16
LID - S1201-9712(20)32250-5 [pii]
LID - 10.1016/j.ijid.2020.10.047 [doi]
AB  - BACKGROUND: Several RT-qPCR kits are available for SARS-CoV-2 diagnosis and some 
      have emergency use authorization from the US Food and Drug Administration. In
      particular, the nCoV19 CDC kit includes two targets for detecting SARS-CoV-2 (N1 
      and N2) and an RNaseP (RP) target for RNA extraction quality control, all of
      which are labeled with FAM, and thus three PCR reactions are required per sample.
      METHODS: We designed a triplex RT-qPCR assay based on nCoV19 primers and probes
      where N1, N2, and RP are labeled with FAM, HEX, and Cy5, respectively, so only a 
      single PCR reaction is required for each sample for SARS-CoV-2 diagnosis.
      RESULTS: In total, 172 samples were analyzed in both singleplex and triplex
      assays, where 86 samples tested SARS-CoV-2 negative with both assays, so the
      triplex assay specificity was 100%. In addition, 86 samples tested SARS-Co-V 2
      positive with the singleplex assay and 84 with the triplex assay, so the
      sensitivity was 97.7%. The limit of detection for the triplex assay was
      determined as 1000 copies/mL. CONCLUSIONS: This new triplex RT-qPCR assay based
      on primers and probes from the CDC protocol is highly reliable for SARS-CoV-2
      diagnosis, and it could speed up detection and save reagents during the current
      SARS-CoV-2 testing supplies shortage.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
      Electronic address: magbereguiain@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201025
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (DNA Primers)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - COVID-19/diagnosis/virology
MH  - COVID-19 Nucleic Acid Testing/*methods
MH  - COVID-19 Testing
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Clinical Laboratory Techniques/methods
MH  - DNA Primers/genetics
MH  - Humans
MH  - RNA, Viral/genetics
MH  - SARS-CoV-2/genetics/*isolation & purification
MH  - Sensitivity and Specificity
MH  - United States
PMC - PMC7585718
EDAT- 2020/10/30 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/10/29 05:32
PHST- 2020/09/15 00:00 [received]
PHST- 2020/10/08 00:00 [revised]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/10/29 05:32 [entrez]
AID - S1201-9712(20)32250-5 [pii]
AID - 10.1016/j.ijid.2020.10.047 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Jan;102:14-16. doi: 10.1016/j.ijid.2020.10.047. Epub 2020 
      Oct 25.

PMID- 33102678
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211115
IS  - 2352-7714 (Print)
IS  - 2352-7714 (Linking)
VI  - 11
DP  - 2020 Dec 20
TI  - "One health" inspired SARS-CoV-2 surveillance: The Galapagos Islands experience.
PG  - 100185
LID - 10.1016/j.onehlt.2020.100185 [doi]
AB  - The COVID-19 pandemic has spread worldwide since the outbreak in Wuhan (China) in
      December 2019, currently infecting over 25 million people and causing more than
      800.000 deaths. In Ecuador, up to the 30th of August 2020, overall 113.648
      confirmed cases and 6.555 deaths have been declared. Besides overloading of
      hospital, capacity for molecular diagnosis of SARS-CoV-2 by the Ministry of
      Public Health was quickly overwhelmed. In this context, emergency authorization
      for SARS-CoV-2 RT-qPCR diagnosis was granted to other institutions, like the
      "Agencia de Regulacion y Control para la Bioseguridad y Cuarentena de Galapagos" 
      (ABG), that implemented "LabGal" with support of One Health Research Group from
      "Universidad de Las Americas" (UDLA). The previous experience of ABG and the One 
      Health Research Group in conducting massive surveillance of zoonotic diseases on 
      livestock was crucial to the success on the control of COVID-19 outbreak at
      Galapagos Islands by the end of May 2020, when Latin American countries were
      leading the spread of the pandemic.
CI  - (c) 2020 The Authors.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Vega-Marino, Patricio
AU  - Vega-Marino P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Velez, Alberto
AU  - Velez A
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Castillo, Paulina
AU  - Castillo P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Masaquiza, Carlos
AU  - Masaquiza C
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Cedeno-Vega, Ronald
AU  - Cedeno-Vega R
AD  - Pan American Health Organization, Quito, Ecuador.
FAU - Lozada, Tannya
AU  - Lozada T
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Cruz, Marilyn
AU  - Cruz M
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - Netherlands
TA  - One Health
JT  - One health (Amsterdam, Netherlands)
JID - 101660501
EIN - One Health. 2021 Dec;13:100345. PMID: 34778508
PMC - PMC7574858
COIS- The authors declare no conflict of interest.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:27
PHST- 2020/08/30 00:00 [received]
PHST- 2020/10/12 00:00 [revised]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
PHST- 2020/10/26 05:27 [entrez]
AID - 10.1016/j.onehlt.2020.100185 [doi]
AID - S2352-7714(20)30286-X [pii]
PST - ppublish
SO  - One Health. 2020 Dec 20;11:100185. doi: 10.1016/j.onehlt.2020.100185. Epub 2020
      Oct 20.

PMID- 33084512
OWN - NLM
STAT- MEDLINE
DCOM- 20220302
LR  - 20220302
IS  - 1538-0254 (Electronic)
IS  - 0739-1102 (Linking)
VI  - 40
IP  - 5
DP  - 2022 Mar
TI  - Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal
      plants of the Andean Region: molecular docking and molecular dynamics
      simulations.
PG  - 2010-2023
LID - 10.1080/07391102.2020.1835716 [doi]
AB  - Given the highly contagious nature of SARS-CoV-2, it has resulted in an
      unprecedented number of COVID-19 infected and dead people worldwide. Since there 
      is currently no vaccine available in the market, the identification of potential 
      drugs is urgently needed to control the pandemic. In this study, 92
      phytochemicals from medicinal plants growing in the Andean region were screened
      against SARS-CoV-2 3 C-like protease (3CLpro) and RNA-dependent RNA polymerase
      (RdRp) in their active sites through molecular docking. The cutoff values were
      set from the lowest docking scores of the FDA-approved drugs that are being used 
      to treat COVID-19 patients (remdesivir, lopinavir, and ritonavir). Compounds with
      docking scores that were lower than cutoff values were validated by molecular
      dynamics simulation with GROMACS, using root mean square deviation (RMSD), root
      mean square fluctuation (RMSF), radius of gyration (Rg), and intermolecular
      hydrogen bonds (H-bonds). Furthermore, binding free energies were estimated using
      the MM-PBSA method, and ADMET profiles of potential inhibitors were assessed.
      Computational analyses revealed that the interaction with hesperidin (theoretical
      binding energies, DeltaGbind = -15.18 kcal/mol to 3CLpro and DeltaGbind = -9.46
      kcal/mol to RdRp) remained stable in both enzymes, unveiling its remarkable
      potential as a possible multitarget antiviral agent to treat COVID-19.
      Importantly, lupinifolin with an estimated binding affinity to 3CLpro higher than
      hesperidin (DeltaGbind = -20.93 kcal/mol) is also a potential inhibitor of the
      3CLpro. These two compounds displayed suitable pharmacological and structural
      properties to be drug candidates, demonstrating to be worthy of further
      research.Communicated by Ramaswamy H. Sarma.
FAU - Mosquera-Yuqui, Francisco
AU  - Mosquera-Yuqui F
AD  - Departamento de Ciencias de La Vida y La Agricultura, Universidad de Las Fuerzas 
      Armadas-ESPE, Sangolqui, Ecuador.
AD  - Grupo de Investigacion y Desarrollo de la Biotecnologia BioSin-Biociencias,
      Quito, Ecuador.
FAU - Lopez-Guerra, Nicolas
AU  - Lopez-Guerra N
AD  - Grupo de Investigacion y Desarrollo de la Biotecnologia BioSin-Biociencias,
      Quito, Ecuador.
AD  - Oklahoma State University, Stillwater, OK, USA.
FAU - Moncayo-Palacio, Eduardo A
AU  - Moncayo-Palacio EA
AD  - Grupo de Investigacion y Desarrollo de la Biotecnologia BioSin-Biociencias,
      Quito, Ecuador.
AD  - Departamento de Quimica y Ciencias Exactas, Universidad Tecnica Particular de
      Loja, Loja, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - England
TA  - J Biomol Struct Dyn
JT  - Journal of biomolecular structure & dynamics
JID - 8404176
RN  - 0 (Phytochemicals)
RN  - EC 2.7.7.48 (RNA-Dependent RNA Polymerase)
SB  - IM
MH  - *COVID-19/drug therapy
MH  - Humans
MH  - Molecular Docking Simulation
MH  - Molecular Dynamics Simulation
MH  - Phytochemicals/pharmacology
MH  - *Plants, Medicinal
MH  - RNA-Dependent RNA Polymerase
MH  - SARS-CoV-2
PMC - PMC7657401
OTO - NOTNLM
OT  - *ADMET
OT  - *MM-PBSA
OT  - *SARS-CoV-2
OT  - *molecular docking
OT  - *molecular dynamics
EDAT- 2020/10/22 06:00
MHDA- 2022/03/03 06:00
CRDT- 2020/10/21 12:20
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
PHST- 2020/10/21 12:20 [entrez]
AID - 10.1080/07391102.2020.1835716 [doi]
PST - ppublish
SO  - J Biomol Struct Dyn. 2022 Mar;40(5):2010-2023. doi:
      10.1080/07391102.2020.1835716. Epub 2020 Oct 21.

PMID- 32988333
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20220122
IS  - 2047-7732 (Electronic)
IS  - 2047-7724 (Linking)
VI  - 114
IP  - 8
DP  - 2020 Dec
TI  - Late incidence of SARS-CoV-2 infection in a highly-endemic remote rural village. 
      A prospective population-based cohort study.
PG  - 457-462
LID - 10.1080/20477724.2020.1826152 [doi]
AB  - Data on SARS-CoV-2 transmission in rural communities is scarce or non-existent. A
      previous cross-sectional study in middle-aged and older adults enrolled in the
      Atahualpa Project Cohort demonstrated that 45% of participants had SARS-CoV-2
      antibodies, 77% of whom were symptomatic. Here, we assessed the incidence of
      SARS-CoV-2 infection in the above-mentioned rural population. One month after
      baseline testing, 362 of 370 initially seronegative individuals were re-tested to
      assess incidence of seroconversion and associated risk factors. Twenty-eight of
      them (7.7%) became seropositive. The overall incidence rate ratio was 7.4 per 100
      person months of potential virus exposure (95% C.I.: 4.7-10.2). Six seroconverted
      individuals (21.4%) developed SARS-CoV-2-related symptomatology. The only
      covariate significantly associated with seroconversion was the use of an open
      latrine. Predictive margins showed that these individuals were 2.5 times more
      likely to be infected (95% C.I.: 1.03-6.1) than those using a flushing toilet.
      Therefore, along one month, approximately 8% of seronegative individuals became
      infected, even after almost half of the population was already seropositive.
      Nevertheless, a smaller proportion of incident cases were symptomatic (21% versus
      77% of the earlier cases), and no deaths were recorded. Whether this decreased
      clinical expression resulted from a lower viral load in new infections cannot be 
      determined. Increased seroconversion in individuals using latrines is consistent 
      with a contributory role of fecal-oral transmission, although we cannot rule out 
      the possibility that latrines are acting as a proxy for poverty or other unknown 
      interacting variables.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador , Guayaquil, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AUID- ORCID: 0000-0002-2075-5289
AD  - Community Center, The Atahualpa Project , Atahualpa, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc ., Foster City, CA, USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AUID- ORCID: 0000-0002-2508-6328
AD  - Community Center, The Atahualpa Project , Atahualpa, Ecuador.
FAU - Bustos, Javier A
AU  - Bustos JA
AUID- ORCID: 0000-0002-5797-3052
AD  - Center for Global Health, Department of Microbiology, Universidad Peruana
      Cayetano Heredia , Lima, Peru.
FAU - Garcia, Hector H
AU  - Garcia HH
AD  - Center for Global Health, Department of Microbiology, Universidad Peruana
      Cayetano Heredia , Lima, Peru.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - Pathog Glob Health
JT  - Pathogens and global health
JID - 101583421
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Viral/blood
MH  - COVID-19/blood/*diagnosis/*epidemiology/virology
MH  - COVID-19 Serological Testing
MH  - Cross-Sectional Studies
MH  - Ecuador/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Rural Population/statistics & numerical data
MH  - SARS-CoV-2/genetics/*isolation & purification/physiology
MH  - Seroconversion
PMC - PMC7759268
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ecuador
OT  - *SARS-CoV-2
OT  - *cohort study
OT  - *incidence
OT  - *rural setting
EDAT- 2020/09/30 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/09/29 05:25
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/09/29 05:25 [entrez]
AID - 10.1080/20477724.2020.1826152 [doi]
PST - ppublish
SO  - Pathog Glob Health. 2020 Dec;114(8):457-462. doi: 10.1080/20477724.2020.1826152. 
      Epub 2020 Sep 29.

PMID- 32979475
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20210110
IS  - 1872-7492 (Electronic)
IS  - 0168-1702 (Linking)
VI  - 290
DP  - 2020 Dec
TI  - "Sample pooling of RNA extracts to speed up SARS-CoV-2 diagnosis using CDC FDA
      EUA RT-qPCR kit".
PG  - 198173
LID - S0168-1702(20)31080-7 [pii]
LID - 10.1016/j.virusres.2020.198173 [doi]
AB  - BACKGROUND: The CDC protocol for SARS-CoV2 RT-PCR diagnosis (2019-nCoV CDC kit)
      is considered a gold standard worldwide; based on three different FAM probes (N1 
      and N2 for viral detection; RP for RNA extraction quality control), three
      reactions per sample are needed for SARS-CoV-2 diagnosis. RESULTS: We herein
      describe a sample pooling protocol: pooling 3 RNA extractions into a single PCR
      reaction; we tested this protocol with 114 specimens grouped in 38 pools and
      found no significant differences for N1 and N2 Ct values between pool and single 
      sample PCR reaction. CONCLUSION: This pool of three protocol has a sensitivity of
      100 % compared to the standard single sample protocol. For a typical 96-well
      plate, this pool assay allows 96 samples processing, speeding up diagnosis and
      reducing cost while maintaining clinical performance, particularly useful for
      SARS-CoV-2 diagnosis at developing countries.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Vega-Marino, Patricio
AU  - Vega-Marino P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Velez, Alberto
AU  - Velez A
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Cruz, Marilyn
AU  - Cruz M
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
      Electronic address: magbereguiain@gmail.com.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200924
PL  - Netherlands
TA  - Virus Res
JT  - Virus research
JID - 8410979
RN  - 0 (RNA, Viral)
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - COVID-19/*diagnosis
MH  - *COVID-19 Nucleic Acid Testing/economics
MH  - Diagnostic Tests, Routine
MH  - Humans
MH  - Nasopharynx/virology
MH  - RNA, Viral/genetics
MH  - Reagent Kits, Diagnostic
MH  - Real-Time Polymerase Chain Reaction
MH  - SARS-CoV-2/genetics/*isolation & purification
MH  - Sensitivity and Specificity
MH  - Specimen Handling/*methods/standards
MH  - Time Factors
PMC - PMC7513759
OTO - NOTNLM
OT  - *CDC
OT  - *Pools
OT  - *RT-qPCR
OT  - *SARS-CoV-2
EDAT- 2020/09/27 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/26 20:09
PHST- 2020/05/28 00:00 [received]
PHST- 2020/09/13 00:00 [revised]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/26 20:09 [entrez]
AID - S0168-1702(20)31080-7 [pii]
AID - 10.1016/j.virusres.2020.198173 [doi]
PST - ppublish
SO  - Virus Res. 2020 Dec;290:198173. doi: 10.1016/j.virusres.2020.198173. Epub 2020
      Sep 24.

PMID- 32978364
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 21
DP  - 2020 Sep 26
TI  - SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment 
      with Hydroxychloroquine for Systemic Lupus Erythematosus.
PG  - e927304
LID - 10.12659/AJCR.927304 [doi]
AB  - BACKGROUND This case series describes 5 patients with SARS-CoV-2 infection and
      COVID-19 in Ecuador who had been treated with hydroxychloroquine for systemic
      lupus erythematosus (SLE) prior to their COVID-19 illness. CASE REPORT Case #1
      reports a 29-year-old woman who had been treated with 200 mg of
      hydroxychloroquine per day for 1 year and presented with flu-like symptoms, chest
      pain, fever, odynophagia, asthenia, dry cough, and chills. Case #2 was a
      34-year-old woman whose treatment for SLE included 200 mg of hydroxychloroquine
      per day since 2017. She arrived at the clinic with a dry cough, asthenia, and
      myalgias. Case #3 was a 24-year-old woman who had been using 200 mg of
      hydroxychloroquine per day since 2010. She presented with asthenia, myalgias,
      headaches, hypogeusia, and anosmia. Case #4 was a 39-year-old woman taking 200 mg
      of hydroxychloroquine every day for SLE who presented with dyspnea, chest pain,
      odynophagia, hypogeusia, anosmia, diarrhea, and fever. Case #5 was a 46-year-old 
      woman who had been taking 200 mg of hydroxychloroquine since 2019. She came to
      our hospital complaining of chest pain, fever, and dyspnea. In all 5 patients,
      SARS-CoV-2 infection was confirmed with a nasopharyngeal SARS-CoV-2 reverse
      transcription-polymerase chain reaction (RT-PCR) test using the Cepheid/GeneXpert
      system. CONCLUSIONS All 5 of our patients with SLE who were taking
      hydroxychloroquine presented with SARS-CoV-2 infection and symptoms of COVID-19. 
      This case series provides support for a lack of prevention of COVID-19 by
      hydroxychloroquine.
FAU - Zurita, Maria Fernanda
AU  - Zurita MF
AD  - Universidad Espiritu Santo (Holy Spirit University), School of Medicine,
      Samborondon, Ecuador.
FAU - Iglesias Arreaga, Adriana
AU  - Iglesias Arreaga A
AD  - Universidad Espiritu Santo (Holy Spirit University), School of Medicine,
      Samborondon, Ecuador.
FAU - Luzuriaga Chavez, Adriana A
AU  - Luzuriaga Chavez AA
AD  - Universidad Espiritu Santo (Holy Spirit University), School of Medicine,
      Samborondon, Ecuador.
FAU - Zurita, Luis
AU  - Zurita L
AD  - Department of Rheumatology, Unit of Rheumatology and Autoimmune Diseases (UNERA),
      Clinica Alcivar, Guayaquil, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20200926
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (RNA, Viral)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques
MH  - Coronavirus Infections/diagnosis/epidemiology/*prevention & control
MH  - Dyspnea/diagnosis/etiology
MH  - Ecuador
MH  - Emergency Service, Hospital
MH  - Female
MH  - Fever/diagnosis/etiology
MH  - Humans
MH  - Hydroxychloroquine/*administration & dosage
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Middle Aged
MH  - Pandemics/*prevention & control/statistics & numerical data
MH  - Pneumonia, Viral/diagnosis/epidemiology/*prevention & control
MH  - RNA, Viral/analysis
MH  - Real-Time Polymerase Chain Reaction/methods
MH  - Risk Assessment
MH  - Sampling Studies
MH  - Treatment Failure
MH  - Young Adult
PMC - PMC7526941
EDAT- 2020/09/27 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/26 05:25
PHST- 2020/09/26 05:25 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 927304 [pii]
AID - 10.12659/AJCR.927304 [doi]
PST - epublish
SO  - Am J Case Rep. 2020 Sep 26;21:e927304. doi: 10.12659/AJCR.927304.

PMID- 32977231
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210110
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 418
DP  - 2020 Nov 15
TI  - Frailty and SARS-CoV-2 infection. A population-based study in a highly endemic
      village.
PG  - 117136
LID - S0022-510X(20)30473-1 [pii]
LID - 10.1016/j.jns.2020.117136 [doi]
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador, Samborondon, Ecuador.
      Electronic address: odelbrutto@uees.edu.ec.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Community Center, the Atahualpa Project, Atahualpa, Ecuador.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, the Atahualpa Project, Atahualpa, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc., Foster City, CA, USA.
LA  - eng
PT  - Letter
DEP - 20200910
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
SB  - IM
MH  - Aged
MH  - COVID-19/*epidemiology
MH  - Comorbidity
MH  - Ecuador/epidemiology
MH  - Female
MH  - Frailty/*epidemiology
MH  - Humans
MH  - Independent Living/statistics & numerical data
MH  - Male
MH  - Pandemics
MH  - SARS-CoV-2
PMC - PMC7488595
OTO - NOTNLM
OT  - *Atahualpa
OT  - *COVID-19
OT  - *Community dwelling older adults
OT  - *Coronavirus-19
OT  - *Ecuador
OT  - *Edmonton frailty scale
OT  - *Frailty
OT  - *SARS-CoV-2
EDAT- 2020/09/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/25 20:17
PHST- 2020/08/10 00:00 [received]
PHST- 2020/09/05 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/25 20:17 [entrez]
AID - S0022-510X(20)30473-1 [pii]
AID - 10.1016/j.jns.2020.117136 [doi]
PST - ppublish
SO  - J Neurol Sci. 2020 Nov 15;418:117136. doi: 10.1016/j.jns.2020.117136. Epub 2020
      Sep 10.

PMID- 32950697
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210110
IS  - 1567-7257 (Electronic)
IS  - 1567-1348 (Linking)
VI  - 85
DP  - 2020 Nov
TI  - Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in
      South America.
PG  - 104557
LID - S1567-1348(20)30388-9 [pii]
LID - 10.1016/j.meegid.2020.104557 [doi]
AB  - SARS-CoV-2 is a new member of the genus Betacoronavirus, responsible for the
      COVID-19 pandemic. The virus crossed the species barrier and established in the
      human population taking advantage of the spike protein high affinity for the ACE 
      receptor to infect the lower respiratory tract. The Nucleocapsid (N) and Spike
      (S) are highly immunogenic structural proteins and most commercial COVID-19
      diagnostic assays target these proteins. In an unpredictable epidemic, it is
      essential to know about their genetic variability. The objective of this study
      was to describe the substitution frequency of the S and N proteins of SARS-CoV-2 
      in South America. A total of 504 amino acid and nucleotide sequences of the S and
      N proteins of SARS-CoV-2 from seven South American countries (Argentina, Brazil, 
      Chile, Ecuador, Peru, Uruguay, and Colombia), reported as of June 3, and
      corresponding to samples collected between March and April 2020, were compared
      through substitution matrices using the Muscle algorithm. Forty-three sequences
      from 13 Colombian departments were obtained in this study using the Oxford
      Nanopore and Illumina MiSeq technologies, following the amplicon-based ARTIC
      network protocol. The substitutions D614G in S and R203K/G204R in N were the most
      frequent in South America, observed in 83% and 34% of the sequences respectively.
      Strikingly, genomes with the conserved position D614 were almost completely
      replaced by genomes with the G614 substitution between March to April 2020. A
      similar replacement pattern was observed with R203K/G204R although more marked in
      Chile, Argentina and Brazil, suggesting similar introduction history and/or
      control strategies of SARS-CoV-2 in these countries. It is necessary to continue 
      with the genomic surveillance of S and N proteins during the SARS-CoV-2 pandemic 
      as this information can be useful for developing vaccines, therapeutics and
      diagnostic tests.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Franco-Munoz, Carlos
AU  - Franco-Munoz C
AD  - Unidad de Secuenciacion y Genomica, Grupo de Investigacion Basica y Aplicada en
      Enfermedades Emergentes, Direccion de Investigacion en Salud Publica, Instituto
      Nacional de Salud, Bogota 111321, Colombia; Grupo de Parasitologia, Direccion de 
      Investigacion en Salud Publica, Instituto Nacional de Salud, Bogota 111321,
      Colombia. Electronic address: cefrancom@unal.edu.co.
FAU - Alvarez-Diaz, Diego A
AU  - Alvarez-Diaz DA
AD  - Unidad de Secuenciacion y Genomica, Grupo de Investigacion Basica y Aplicada en
      Enfermedades Emergentes, Direccion de Investigacion en Salud Publica, Instituto
      Nacional de Salud, Bogota 111321, Colombia.
FAU - Laiton-Donato, Katherine
AU  - Laiton-Donato K
AD  - Unidad de Secuenciacion y Genomica, Grupo de Investigacion Basica y Aplicada en
      Enfermedades Emergentes, Direccion de Investigacion en Salud Publica, Instituto
      Nacional de Salud, Bogota 111321, Colombia.
FAU - Wiesner, Magdalena
AU  - Wiesner M
AD  - Grupo de Microbiologia, Direccion de Investigacion en Salud Publica, Instituto
      Nacional de Salud, Bogota, Colombia.
FAU - Escandon, Patricia
AU  - Escandon P
AD  - Grupo de Microbiologia, Direccion de Investigacion en Salud Publica, Instituto
      Nacional de Salud, Bogota, Colombia.
FAU - Usme-Ciro, Jose A
AU  - Usme-Ciro JA
AD  - Unidad de Secuenciacion y Genomica, Grupo de Investigacion Basica y Aplicada en
      Enfermedades Emergentes, Direccion de Investigacion en Salud Publica, Instituto
      Nacional de Salud, Bogota 111321, Colombia; Centro de Investigacion en Salud para
      el Tropico-CIST, Universidad Cooperativa de Colombia, Santa Marta, 470003,
      Colombia.
FAU - Franco-Sierra, Nicolas D
AU  - Franco-Sierra ND
AD  - Programa Ciencias de la Biodiversidad, Instituto de Investigacion de Recursos
      Biologicos Alexander von Humboldt, Bogota 111311, Colombia.
FAU - Florez-Sanchez, Astrid C
AU  - Florez-Sanchez AC
AD  - Direccion de Redes en Salud Publica, Instituto Nacional de Salud, Bogota 111321, 
      Colombia.
FAU - Gomez-Rangel, Sergio
AU  - Gomez-Rangel S
AD  - Grupo de Virologia, Direccion de Redes en Salud Publica, Instituto Nacional de
      Salud, Bogota 111321, Colombia.
FAU - Rodriguez-Calderon, Luz D
AU  - Rodriguez-Calderon LD
AD  - Grupo de Virologia, Direccion de Redes en Salud Publica, Instituto Nacional de
      Salud, Bogota 111321, Colombia.
FAU - Barbosa-Ramirez, Juliana
AU  - Barbosa-Ramirez J
AD  - Grupo de Virologia, Direccion de Redes en Salud Publica, Instituto Nacional de
      Salud, Bogota 111321, Colombia.
FAU - Ospitia-Baez, Erika
AU  - Ospitia-Baez E
AD  - Grupo de Virologia, Direccion de Redes en Salud Publica, Instituto Nacional de
      Salud, Bogota 111321, Colombia.
FAU - Walteros, Diana M
AU  - Walteros DM
AD  - Direccion de Vigilancia en Salud Publica, Instituto Nacional de Salud, Bogota
      111321, Colombia.
FAU - Ospina-Martinez, Martha L
AU  - Ospina-Martinez ML
AD  - Direccion General, Instituto Nacional de Salud, Bogota 111321, Colombia.
FAU - Mercado-Reyes, Marcela
AU  - Mercado-Reyes M
AD  - Unidad de Secuenciacion y Genomica, Grupo de Investigacion Basica y Aplicada en
      Enfermedades Emergentes, Direccion de Investigacion en Salud Publica, Instituto
      Nacional de Salud, Bogota 111321, Colombia; Direccion de Investigacion en Salud
      Publica, Instituto Nacional de Salud, Bogota 111321, Colombia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200917
PL  - Netherlands
TA  - Infect Genet Evol
JT  - Infection, genetics and evolution : journal of molecular epidemiology and
      evolutionary genetics in infectious diseases
JID - 101084138
RN  - 0 (Coronavirus Nucleocapsid Proteins)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (Viral Proteins)
RN  - 0 (spike protein, SARS-CoV-2)
SB  - IM
MH  - *Amino Acid Substitution
MH  - COVID-19/*diagnosis
MH  - Coronavirus Nucleocapsid Proteins/genetics
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Phylogeny
MH  - SARS-CoV-2/*classification/genetics
MH  - Sequence Analysis, RNA
MH  - South America
MH  - Spike Glycoprotein, Coronavirus/genetics
MH  - Viral Proteins/*genetics
PMC - PMC7497549
OTO - NOTNLM
OT  - *Non-synonymous substitutions
OT  - *Nucleocapsid
OT  - *SARS-CoV-2
OT  - *South America
OT  - *Spike
EDAT- 2020/09/21 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/20 20:28
PHST- 2020/06/15 00:00 [received]
PHST- 2020/08/31 00:00 [revised]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/20 20:28 [entrez]
AID - S1567-1348(20)30388-9 [pii]
AID - 10.1016/j.meegid.2020.104557 [doi]
PST - ppublish
SO  - Infect Genet Evol. 2020 Nov;85:104557. doi: 10.1016/j.meegid.2020.104557. Epub
      2020 Sep 17.

PMID- 32894259
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Sep 7
TI  - [Ethical dimensions of prevention and planning in assisted-living facilities
      during the SARS-CoV-2 pandemic (Covid-19): a public health emergency.]
LID - e202009105 [pii]
AB  - The SARS-CoV-2 pandemic (Covid-19) has had a major impact on residents of
      assisted-living facilities. While it is plausible that the characteristics of
      these patients and their special clinical fragility have contributed to their
      greater vulnerability to infection, other related factors cannot be ruled out,
      such as the quality of management at these centers and the lack of planning for
      actions taken before and during the health crisis. Both aspects pertain to the
      field of public health, where the ethics of the common good conflicts with the
      autonomy of the individual.
FAU - Coronado-Vazquez, Valle
AU  - Coronado-Vazquez V
AD  - Centro de Salud de Illescas. Toledo. Espana.
AD  - Grupo de Bioetica de la Sociedad Madrilena de Medicina de Familia y Comunitaria
      (SoMaMFyC). Madrid. Espana.
FAU - Castro-Martin, Josefa
AU  - Castro-Martin J
AD  - Grupo de Bioetica de la Sociedad Madrilena de Medicina de Familia y Comunitaria
      (SoMaMFyC). Madrid. Espana.
AD  - Centro de Salud Benita de Avila. Madrid. Espana.
FAU - Camara-Escribano, Carmen
AU  - Camara-Escribano C
AD  - Grupo de Bioetica de la Sociedad Madrilena de Medicina de Familia y Comunitaria
      (SoMaMFyC). Madrid. Espana.
AD  - Centro de Salud Dos de Mayo. Madrid. Espana.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Programa de Posgrado de Seguridad y Salud. Universidad Espiritu Santo. Guayaquil.
      Ecuador.
FAU - Martin-Lopez, Cristina
AU  - Martin-Lopez C
AD  - Unidad de Rehabilitacion. Hospital de Rio Tinto. Huelva. Espana.
FAU - Garcia-Iglesias, Juan Jesus
AU  - Garcia-Iglesias JJ
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Escuela Superior de Salud. Universidade Atlantica. Lisboa. Portugal.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Dimensiones eticas de la prevencion y planificacion en los centros
      sociosanitarios durante la pandemia por SARS-CoV-2 (Covid-19): una emergencia de 
      salud publica.
DEP - 20200907
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Assisted Living Facilities/*ethics
MH  - Betacoronavirus
MH  - COVID-19
MH  - Community Health Planning/*ethics
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health/*ethics
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Spain/epidemiology
OTO - NOTNLM
OT  - Emergency planning
OT  - Ethic
OT  - Public health
OT  - SARS-CoV-2
OT  - Social health centers
OT  - Spain
EDAT- 2020/09/08 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/07 12:11
PHST- 2020/07/10 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/07 12:11 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Sep 7;94.

PMID- 32858479
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20220531
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Linking)
VI  - 191
DP  - 2020 Dec
TI  - Spread of SARS-CoV-2 through Latin America and the Caribbean region: A look from 
      its economic conditions, climate and air pollution indicators.
PG  - 109938
LID - S0013-9351(20)30833-1 [pii]
LID - 10.1016/j.envres.2020.109938 [doi]
AB  - We have evaluated the spread of SARS-CoV-2 through Latin America and the
      Caribbean (LAC) region by means of a correlation between climate and air
      pollution indicators, namely, average temperature, minimum temperature, maximum
      temperature, rainfall, average relative humidity, wind speed, and air pollution
      indicators PM10, PM2.5, and NO2 with the COVID-19 daily new cases and deaths. The
      study focuses in the following LAC cities: Mexico City (Mexico), Santo Domingo
      (Dominican Republic), San Juan (Puerto Rico), Bogota (Colombia), Guayaquil
      (Ecuador), Manaus (Brazil), Lima (Peru), Santiago (Chile), Sao Paulo (Brazil) and
      Buenos Aires (Argentina). The results show that average temperature, minimum
      temperature, and air quality were significantly associated with the spread of
      COVID-19 in LAC. Additionally, humidity, wind speed and rainfall showed a
      significant relationship with daily cases, total cases and mortality for various 
      cities. Income inequality and poverty levels were also considered as a variable
      for qualitative analysis. Our findings suggest that and income inequality and
      poverty levels in the cities analyzed were related to the spread of COVID-19
      positive and negative, respectively. These results might help decision-makers to 
      design future strategies to tackle the spread of COVID-19 in LAC and around the
      world.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Bolano-Ortiz, Tomas R
AU  - Bolano-Ortiz TR
AD  - Mendoza Regional Faculty - National Technological University (FRM-UTN), 273
      Coronel Rodriguez St., 5500, Mendoza, Argentina; National Scientific and
      Technical Research Council (CONICET), Mendoza, Argentina. Electronic address:
      tomas.bolano@frm.utn.edu.ar.
FAU - Camargo-Caicedo, Yiniva
AU  - Camargo-Caicedo Y
AD  - Environmental Systems Modeling Research Group (GIMSA), University of Magdalena,
      Santa Marta, Colombia.
FAU - Puliafito, Salvador Enrique
AU  - Puliafito SE
AD  - Mendoza Regional Faculty - National Technological University (FRM-UTN), 273
      Coronel Rodriguez St., 5500, Mendoza, Argentina; National Scientific and
      Technical Research Council (CONICET), Mendoza, Argentina.
FAU - Ruggeri, Maria Florencia
AU  - Ruggeri MF
AD  - Centre for Environmental Technologies (CETAM), Universidad Tecnica Federico Santa
      Maria (UTFSM), Av. Espana 1680, Valparaiso, Chile.
FAU - Bolano-Diaz, Sindy
AU  - Bolano-Diaz S
AD  - Environmental Systems Modeling Research Group (GIMSA), University of Magdalena,
      Santa Marta, Colombia.
FAU - Pascual-Flores, Romina
AU  - Pascual-Flores R
AD  - Mendoza Regional Faculty - National Technological University (FRM-UTN), 273
      Coronel Rodriguez St., 5500, Mendoza, Argentina; National Scientific and
      Technical Research Council (CONICET), Mendoza, Argentina.
FAU - Saturno, Jorge
AU  - Saturno J
AD  - Independent researcher, Braunschweig, Germany.
FAU - Ibarra-Espinosa, Sergio
AU  - Ibarra-Espinosa S
AD  - University of Sao Paulo (USP), Sao Paulo, Brazil.
FAU - Mayol-Bracero, Olga L
AU  - Mayol-Bracero OL
AD  - Department of Environmental Science, University of Puerto Rico, San Juan, PR,
      USA.
FAU - Torres-Delgado, Elvis
AU  - Torres-Delgado E
AD  - Department of Environmental Science, University of Puerto Rico, San Juan, PR,
      USA.
FAU - Cereceda-Balic, Francisco
AU  - Cereceda-Balic F
AD  - Centre for Environmental Technologies (CETAM), Universidad Tecnica Federico Santa
      Maria (UTFSM), Av. Espana 1680, Valparaiso, Chile; Department of Chemistry,
      Universidad Tecnica Federico Santa Maria (UTFSM), Av. Espana 1680, Valparaiso,
      Chile.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200715
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
SB  - IM
MH  - *Air Pollution
MH  - Argentina/epidemiology
MH  - Betacoronavirus
MH  - Brazil
MH  - COVID-19
MH  - Caribbean Region
MH  - Chile
MH  - Cities
MH  - *Climate
MH  - Colombia
MH  - *Coronavirus Infections
MH  - Dominican Republic
MH  - Ecuador
MH  - Humans
MH  - Income
MH  - Latin America
MH  - Mexico
MH  - *Pandemics
MH  - Peru
MH  - *Pneumonia, Viral
MH  - *Poverty
MH  - SARS-CoV-2
PMC - PMC7361092
OTO - NOTNLM
OT  - *COVID-19
OT  - *Climate indicators
OT  - *Economic conditions
OT  - *Latin America and the Caribbean
OT  - *Pollution indicators
EDAT- 2020/08/29 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/06/07 00:00 [received]
PHST- 2020/07/03 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - S0013-9351(20)30833-1 [pii]
AID - 10.1016/j.envres.2020.109938 [doi]
PST - ppublish
SO  - Environ Res. 2020 Dec;191:109938. doi: 10.1016/j.envres.2020.109938. Epub 2020
      Jul 15.

PMID- 32837536
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220715
IS  - 1752-4571 (Print)
IS  - 1752-4571 (Linking)
VI  - 13
IP  - 9
DP  - 2020 Oct
TI  - SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals
      undiscovered amino acids necessary for complex stability.
PG  - 2168-2178
LID - 10.1111/eva.12980 [doi]
AB  - The emergence of SARS-CoV-2 has resulted in nearly 1,280,000 infections and
      73,000 deaths globally so far. This novel virus acquired the ability to infect
      human cells using the SARS-CoV cell receptor hACE2. Because of this, it is
      essential to improve our understanding of the evolutionary dynamics surrounding
      the SARS-CoV-2 hACE2 interaction. One way theory predicts selection pressures
      should shape viral evolution is to enhance binding with host cells. We first
      assessed evolutionary dynamics in select betacoronavirus spike protein genes to
      predict whether these genomic regions are under directional or purifying
      selection between divergent viral lineages, at various scales of relatedness.
      With this analysis, we determine a region inside the receptor-binding domain with
      putative sites under positive selection interspersed among highly conserved
      sites, which are implicated in structural stability of the viral spike protein
      and its union with human receptor ACE2. Next, to gain further insights into
      factors associated with recognition of the human host receptor, we performed
      modeling studies of five different betacoronaviruses and their potential binding 
      to hACE2. Modeling results indicate that interfering with the salt bridges at hot
      spot 353 could be an effective strategy for inhibiting binding, and hence for the
      prevention of SARS-CoV-2 infections. We also propose that a glycine residue at
      the receptor-binding domain of the spike glycoprotein can have a critical role in
      permitting bat SARS-related coronaviruses to infect human cells.
CI  - (c) 2020 The Authors. Evolutionary Applications published by John Wiley & Sons
      Ltd.
FAU - Armijos-Jaramillo, Vinicio
AU  - Armijos-Jaramillo V
AUID- ORCID: https://orcid.org/0000-0003-2965-2515
AD  - Grupo de Bio-Quimioinformatica Carrera de Ingenieria en Biotecnologia Facultad de
      Ingenieria y Ciencias Agropecuarias Universidad de Las Americas Quito Ecuador.
FAU - Yeager, Justin
AU  - Yeager J
AUID- ORCID: https://orcid.org/0000-0001-8692-6311
AD  - Biodiversidad Medio Ambiente y Salud (BIOMAS) Direccion General de Investigacion 
      Universidad de Las Americas Quito Ecuador.
FAU - Muslin, Claire
AU  - Muslin C
AUID- ORCID: https://orcid.org/0000-0002-2746-6914
AD  - One Health Research Group Faculty of Health Sciences Universidad de Las Americas 
      Quito Ecuador.
FAU - Perez-Castillo, Yunierkis
AU  - Perez-Castillo Y
AUID- ORCID: https://orcid.org/0000-0002-3710-0035
AD  - Grupo de Bio-Quimioinformatica y Escuela de Ciencias Fisicas y Matematicas
      Universidad de Las Americas Quito Ecuador.
LA  - eng
SI  - Dryad/10.5061/dryad.w3r2280mp
PT  - Journal Article
DEP - 20200507
PL  - England
TA  - Evol Appl
JT  - Evolutionary applications
JID - 101461828
PMC - PMC7262083
OTO - NOTNLM
OT  - ACE2
OT  - SARS-CoV-2
OT  - coronavirus
OT  - molecular dynamics
OT  - positive selection
OT  - purifying selection
OT  - spike protein
COIS- None declared.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1111/eva.12980 [doi]
AID - EVA12980 [pii]
PST - epublish
SO  - Evol Appl. 2020 May 7;13(9):2168-2178. doi: 10.1111/eva.12980. eCollection 2020
      Oct.

PMID- 32781165
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20210110
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 99
DP  - 2020 Oct
TI  - SARS-CoV-2-related mortality in a rural Latin American population.
PG  - 226-228
LID - S1201-9712(20)30630-5 [pii]
LID - 10.1016/j.ijid.2020.08.003 [doi]
AB  - A sudden increase in adult mortality associated with respiratory diseases was
      noticed in Atahualpa (a rural Ecuadorian village), coinciding with the
      introduction of SARS-CoV-2 in the region. From a total of 1,852 individuals aged 
      >/=18 years, 40 deaths occurred between January and June, 2020. In addition, a
      seroprevalence survey showed that 45% of the adult population have SARS-CoV-2
      antibodies. Verbal autopsies revealed SARS-CoV-2 as the most likely cause of
      death in 29 cases. The mean age of suspected or confirmed SARS-CoV-2 cases was
      76.9+/-12.1 years, while that of those dying from unrelated causes was
      60.3+/-20.4 years (p=0.003). The overall mortality rate was 21.6 per 1,000
      population (95% C.I.: 15.9 - 29.2), almost three-quarters of it due to SARS-CoV-2
      (15.7 per 1,000; 95% C.I.: 11 - 22.4). This configures a 266% of excess mortality
      when compared to 5.9 per 1,000 (95% C.I.: 3.3 - 10.6) deaths from other causes.
      When SARS-CoV-2 mortality rate was calculated in individuals aged >/=60 years, it
      raised up to 68.9 per 1,000 (95% C.I.: 47.8 - 98.4). After peaking in April and
      May, mortality significantly decreased. It is possible that the high proportion
      of infected individuals and the resulting herd immunity contributed to the
      observed reduction in mortality.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador, Guayaquil, Ecuador.
      Electronic address: oscardelbrutto@hotmail.com.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc., Foster City, CA, USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Bustos, Javier A
AU  - Bustos JA
AD  - Center for Global Health, Department of Microbiology, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
FAU - Garcia, Hector H
AU  - Garcia HH
AD  - Center for Global Health, Department of Microbiology, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
LA  - eng
PT  - Journal Article
DEP - 20200808
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/mortality
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/mortality
MH  - *Rural Population
MH  - SARS-CoV-2
MH  - *Seroepidemiologic Studies
PMC - PMC7414723
OTO - NOTNLM
OT  - Coronavirus-19
OT  - Ecuador
OT  - Mortality
OT  - Rural setting
OT  - SARS-CoV-2
EDAT- 2020/08/12 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/08/02 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - S1201-9712(20)30630-5 [pii]
AID - 10.1016/j.ijid.2020.08.003 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2020 Oct;99:226-228. doi: 10.1016/j.ijid.2020.08.003. Epub 2020
      Aug 8.

PMID- 32773657
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20210201
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Linking)
VI  - 39
IP  - 10
DP  - 2020 Oct
TI  - Medically Attended Outpatient Coronavirus Infections in Ecuadorean Children
      During the 20 Months Preceding Countrywide Lockdown Related to the SARS-CoV-2
      Pandemic of 2020.
PG  - e291-e296
LID - 10.1097/INF.0000000000002840 [doi]
AB  - BACKGROUND: Human coronaviruses (HCoVs) cause respiratory tract infections during
      childhood manifesting as common colds, bronchiolitis, croup and pneumonia. In
      temperate geographies, HCoV activity peaks between December and March. The
      epidemiology and manifestations of HCoV infections have not been previously
      reported from Ecuador. METHODS: Children <5 years who presented with >/=2
      symptoms consistent with an acute respiratory tract infection were eligible for
      enrollment. After obtaining informed consent, demographic data and details
      regarding the acute illness were recorded. Secretions collected with a
      nasopharyngeal swab underwent diagnostic testing using multiplex polymerase chain
      reaction. RESULTS: A total of 850 subjects were enrolled. A total of 677 (80%)
      tested positive for at least 1 pathogen, including 49 (7.2%) who tested positive 
      for >/=1 HCoV type. HCoV-NL63 was the most frequent type detected (39%), followed
      by HCoV-OC43 (27%), 229E (22%) and HKU1 (12%). Nearly all subjects who tested
      positive for HCoV had nasal congestion or secretions (47/49; 96%). The most
      frequent syndromic diagnosis was common cold (41%), followed by bronchiolitis
      (27%). We found no association between the infecting HCoV type and subject's
      syndromic diagnosis (P > 0.05) or anatomic location of infection (upper vs. lower
      respiratory tract; P > 0.05). The 2018-2019 peak HCoV activity occurred from
      October to November; the 2019-2020 peak occurred from January to February.
      CONCLUSIONS: HCoVs were detected in ~7% of outpatient Ecuadorean children <5
      years of age with symptoms of acute respiratory tract infection. The most
      frequently detected HCoV types, and the period of peak HCoV activity differed for
      the 2018-2019 and 2019-2020 seasons.
FAU - Sippy, Rachel
AU  - Sippy R
AD  - From the State University of New York Institute for Global Health and
      Translational Science, Syracuse, New York.
FAU - Prado, Esteban Ortiz
AU  - Prado EO
AD  - OneHealth Global Research Group, Universidad de las Americas, Quito, Ecuador.
FAU - Pizarro Fajardo, Freddy
AU  - Pizarro Fajardo F
AD  - Center of Investigation at Teofila Davila Hospital, State University of New York 
      Upstate Medical University, Machala, Ecuador.
FAU - Hidalgo, Ivan
AU  - Hidalgo I
AD  - Centro Medico Hidalgo Jaramillo, Quito, Ecuador.
FAU - Aguilar, Guillermo Victoriano
AU  - Aguilar GV
AD  - Centro de Salud Tipo C Velasco Ibarra, Ministerio de Salud Publica, Machala,
      Ecuador.
FAU - Bonville, Cynthia A
AU  - Bonville CA
AD  - Department of Pediatrics, State University of New York Upstate Medical
      University, Syracuse, New York.
FAU - Aponte, Cinthya Cueva
AU  - Aponte CC
AD  - Center of Investigation at Teofila Davila Hospital, State University of New York 
      Upstate Medical University, Machala, Ecuador.
FAU - Gomez, Mariuxi Salazar
AU  - Gomez MS
AD  - Center of Investigation at Teofila Davila Hospital, State University of New York 
      Upstate Medical University, Machala, Ecuador.
FAU - Aponte, Jorge Luis Carrillo
AU  - Aponte JLC
AD  - Center of Investigation at Teofila Davila Hospital, State University of New York 
      Upstate Medical University, Machala, Ecuador.
FAU - Cordova, Mercy Borbor
AU  - Cordova MB
AD  - Facultad de Ingenieria en Ciencias de la Tierra, Department of Engineering in
      Earth Sciences, Guayaquil, Ecuador.
FAU - Polo, Gladys Rincon
AU  - Polo GR
AD  - Facultad de Ingenieria en Ciencias de la Tierra, Department of Engineering in
      Earth Sciences, Guayaquil, Ecuador.
FAU - Suryadevara, Manika
AU  - Suryadevara M
AD  - Department of Pediatrics, State University of New York Upstate Medical
      University, Syracuse, New York.
FAU - Domachowske, Joseph B
AU  - Domachowske JB
AD  - From the State University of New York Institute for Global Health and
      Translational Science, Syracuse, New York.
AD  - Center of Investigation at Teofila Davila Hospital, State University of New York 
      Upstate Medical University, Machala, Ecuador.
AD  - Department of Pediatrics, State University of New York Upstate Medical
      University, Syracuse, New York.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
SB  - IM
MH  - Acute Disease
MH  - Ambulatory Care/statistics & numerical data
MH  - Child, Preschool
MH  - Coronavirus/classification/*isolation & purification
MH  - Coronavirus Infections/diagnosis/epidemiology/pathology/*virology
MH  - Ecuador/epidemiology
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Nasopharynx/virology
MH  - Respiratory Tract Infections/diagnosis/epidemiology/pathology/*virology
MH  - Seasons
EDAT- 2020/08/11 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 10.1097/INF.0000000000002840 [doi]
AID - 00006454-202010000-00001 [pii]
PST - ppublish
SO  - Pediatr Infect Dis J. 2020 Oct;39(10):e291-e296. doi:
      10.1097/INF.0000000000002840.

PMID- 32755528
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20220317
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 103
IP  - 3
DP  - 2020 Sep
TI  - Household Clustering of SARS-CoV-2 in Community Settings: A Study from Rural
      Ecuador.
PG  - 1207-1210
LID - 10.4269/ajtmh.20-0688 [doi]
LID - tpmd200688 [pii]
AB  - The SARS-CoV-2 pandemic is now expanding into the developing world with
      devastating consequences. Departing from a population-based study in rural
      Ecuador where all adult individuals (aged 40 years or older) were tested for
      SARS-CoV-2 IgG and IgM antibodies, we expanded it to include a house-based
      case-control component assessing in-house clustering and other variables
      potentially associated with infection. We selected houses where exactly two study
      participants lived and were both seropositive (case-houses), and matched 1:1 to
      control-houses where both were seronegative. Younger household members had an
      antibody test performed. Infected household members were found in 33 (92%)
      case-houses and in only six (17%) control-houses. In 28/29 discordant house
      pairs, the case-house had seropositive household members and the control-house
      did not (odds ratio: 28; 95% CI: 4.6-1,144). Our data demonstrate strong in-house
      clustering of infection in community settings, stressing the importance of early 
      case ascertainment and isolation for SARS-CoV-2 control.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AD  - 1School of Medicine, Universidad Espiritu Santo, Guayaquil, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - 2Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - 3Department of Epidemiology, Gilead Sciences, Inc., Foster City, California.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - 2Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Bustos, Javier A
AU  - Bustos JA
AD  - 4Department of Microbiology, Center for Global Health, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
FAU - Garcia, Hector H
AU  - Garcia HH
AD  - 4Department of Microbiology, Center for Global Health, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Viral/blood
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Case-Control Studies
MH  - Child
MH  - Cluster Analysis
MH  - Coronavirus Infections/*epidemiology
MH  - Ecuador/epidemiology
MH  - Family Characteristics
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Immunoglobulin M/blood
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Young Adult
PMC - PMC7470588
EDAT- 2020/08/07 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/08/07 06:00 [entrez]
AID - 10.4269/ajtmh.20-0688 [doi]
AID - tpmd200688 [pii]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Sep;103(3):1207-1210. doi: 10.4269/ajtmh.20-0688.

PMID- 32717052
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 73
IP  - 2
DP  - 2021 Jul 15
TI  - SARS-CoV-2 in Rural Latin America. A Population-based Study in Coastal Ecuador.
PG  - 314-317
LID - 10.1093/cid/ciaa1055 [doi]
AB  - Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were
      detected in 303/673 rural Ecuadorian adults (45%), 77% of whom had compatible
      clinical manifestations. Seropositivity was associated with the use of open
      latrines. Our findings support the fears of mass spread of SARS-CoV-2 in rural
      Latin America and cannot exclude a contributing role for fecal-oral transmission.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - School of Medicine, Universidad Espiritu Santo-Ecuador, Samborondon, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc, Foster City, California, USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Bustos, Javier A
AU  - Bustos JA
AD  - Center for Global Health, Department of Microbiology, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
FAU - Garcia, Hector H
AU  - Garcia HH
AD  - Center for Global Health, Department of Microbiology, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
LA  - eng
GR  - Universidad Espiritu Santo-Ecuador
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Latin America
MH  - Rural Population
MH  - *SARS-CoV-2
PMC - PMC7454322
OTO - NOTNLM
OT  - *Ecuador
OT  - *SARS-CoV-2
OT  - *coronavirus-19
OT  - *population study
OT  - *rural setting
EDAT- 2020/07/28 06:00
MHDA- 2021/07/21 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/06/17 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 5876901 [pii]
AID - 10.1093/cid/ciaa1055 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2021 Jul 15;73(2):314-317. doi: 10.1093/cid/ciaa1055.

PMID- 32702272
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20201218
IS  - 1522-1601 (Electronic)
IS  - 0161-7567 (Linking)
VI  - 129
IP  - 2
DP  - 2020 Aug 1
TI  - Geographic components of SARS-CoV-2 expansion: a hypothesis.
PG  - 257-262
LID - 10.1152/japplphysiol.00362.2020 [doi]
AB  - The emergence of COVID-19 infection (caused by the SARS-CoV-2 virus) in Wuhan,
      China in the latter part of 2019 has, within a relatively short time, led to a
      global pandemic. Amidst the initial spread of SARS-CoV-2 across Asia, an
      epidemiologic trend emerged in relation to high altitude (HA) populations.
      Compared with the rest of Asia, SARS-CoV-2 exhibited attenuated rates of
      expansion with limited COVID-19 infection severity along the Tibetan plateau.
      These characteristics were soon evident in additional HA regions across Bolivia, 
      central Ecuador, Nepal, Bhutan, and the Sichuan province of mainland China. This 
      mini-review presents a discussion surrounding attributes of the HA environment,
      aspects of HA physiology, as well as, genetic variations among HA populations
      which may provide clues for this pattern of SARS-CoV-2 expansion and COVID-19
      infection severity. Explanations are provided in the hypothetical, albeit
      relevant historical evidence is provided to create a foundation for future
      research.
FAU - Joyce, Kelsey E
AU  - Joyce KE
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Birmingham, United Kingdom.
FAU - Weaver, Samuel R
AU  - Weaver SR
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Birmingham, United Kingdom.
FAU - Lucas, Samuel J E
AU  - Lucas SJE
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Birmingham, United Kingdom.
LA  - eng
GR  - BBSRC MIBTP Studentship/International
GR  - JABBS Foundation Studentship/International
PT  - Journal Article
PT  - Review
DEP - 20200723
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
RN  - EC 3.4.17.23 (ACE2 protein, human)
RN  - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
SB  - IM
MH  - *Altitude
MH  - Angiotensin-Converting Enzyme 2
MH  - *Betacoronavirus
MH  - Bolivia/epidemiology
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/diagnosis/*epidemiology/metabolism
MH  - Humans
MH  - Nepal/epidemiology
MH  - *Pandemics/statistics & numerical data
MH  - Peptidyl-Dipeptidase A/metabolism
MH  - Pneumonia, Viral/diagnosis/*epidemiology/metabolism
MH  - SARS-CoV-2
PMC - PMC7414234
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *high altitude
OT  - *hypoxia
EDAT- 2020/07/24 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1152/japplphysiol.00362.2020 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 2020 Aug 1;129(2):257-262. doi:
      10.1152/japplphysiol.00362.2020. Epub 2020 Jul 23.

PMID- 32700665
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20220317
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 103
IP  - 3
DP  - 2020 Sep
TI  - Incident SARS-CoV-2 Infection and a Shared Latrine.
PG  - 941-942
LID - 10.4269/ajtmh.20-0793 [doi]
LID - tpmd200793 [pii]
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AD  - 1School of Medicine, Universidad Espiritu Santo, Ecuador, Samborondon, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - 2Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Garcia, Hector H
AU  - Garcia HH
AD  - 3Department of Microbiology, Center for Global Health, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*transmission
MH  - Female
MH  - Humans
MH  - *Hygiene
MH  - Male
MH  - Pandemics
MH  - Pneumonia, Viral/*transmission
MH  - SARS-CoV-2
MH  - *Toilet Facilities
PMC - PMC7470579
EDAT- 2020/07/24 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.4269/ajtmh.20-0793 [doi]
AID - tpmd200793 [pii]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Sep;103(3):941-942. doi: 10.4269/ajtmh.20-0793.

PMID- 32699204
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20220618
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Jul 23
TI  - [Impact of SARS-CoV-2 (Covid-19) on the mental health of healthcare
      professionals: a systematic review.]
LID - e202007088 [pii]
AB  - BACKGROUND: In times of this global pandemic situation, population's mental
      health is compromised, especially in those groups that are at the forefront of
      defence against the virus such as healthcare professionals. The objective of this
      study was to analyze the impact of the SARS-CoV-2 outbreak on healthcare
      professionals' mental health. METHODS: A systematic review was carried out
      following the PRISMA format in Pubmed, Scopus, Web of Science, CINAHL, PsycINFO
      and ScienceDirect electronic databases between January and May 2020.
      Methodological quality was evaluated using the Joanna Briggs Institute (JBI)
      critical appraisal tools for non-randomized studies. RESULTS: A total of 13
      studies were included in this review. Professionals' mental health and mental
      functions were compromised, being especially affected those professionals on the 
      front line of battle against the virus. However, these stats were below the
      general population data. Although there is wide variability of results,
      medium-high levels of anxiety (26,5%-44,6%), depression (8,1%-25%), concern and
      insomnia are detected (23,6%-38%). Paradoxically, stress levels were below
      expectations (3,8%-68,3%). CONCLUSIONS: The mental well-being of health
      professionals working on the front line is compromised in times of pandemic by
      presenting medium-high levels of anxiety, depression, nervousness and insomnia,
      and, to a lesser extent, stress.
FAU - Garcia-Iglesias, Juan Jesus
AU  - Garcia-Iglesias JJ
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Escuela Superior de Salud. Universidade Atlantica. Lisboa. Portugal.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Programa de Posgrado de Seguridad y Salud. Universidad Espiritu Santo. Guayaquil.
      Ecuador.
FAU - Martin-Pereira, Jorge
AU  - Martin-Pereira J
AD  - Consorcio de transporte sanitario onubense. Base en Centro de Salud de Isla
      Cristina. Huelva. Espana.
FAU - Fagundo-Rivera, Javier
AU  - Fagundo-Rivera J
AD  - Escuela Superior de Salud. Universidade Atlantica. Lisboa. Portugal.
AD  - Servicio Andaluz de Salud. Sevilla. Espana.
FAU - Ayuso-Murillo, Diego
AU  - Ayuso-Murillo D
AD  - Consejo General de Enfermeria de Espana. Madrid. Espana.
FAU - Martinez-Riera, Jose Ramon
AU  - Martinez-Riera JR
AD  - Departamento de Enfermeria Comunitaria, Medicina Preventiva y Salud Publica e
      Historia de la Ciencia. Facultad de Ciencias de la Salud. Universidad de
      Alicante. Alicante. Espana.
FAU - Ruiz-Frutos, Carlos
AU  - Ruiz-Frutos C
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Programa de Posgrado de Seguridad y Salud. Universidad Espiritu Santo. Guayaquil.
      Ecuador.
LA  - spa
PT  - Journal Article
PT  - Systematic Review
TT  - Impacto del SARS-CoV-2 (Covid-19) en la salud mental de los profesionales
      sanitarios: una revision sistematica.
DEP - 20200723
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
CIN - Isr Med Assoc J. 2022 May;24(5):342. PMID: 35598064
MH  - Anxiety
MH  - Betacoronavirus
MH  - Burnout, Professional
MH  - COVID-19
MH  - Coronavirus Infections/*psychology
MH  - Delivery of Health Care
MH  - Depression
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Mental Health
MH  - Occupational Health
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology
MH  - SARS-CoV-2
MH  - Sleep Initiation and Maintenance Disorders
MH  - Spain/epidemiology
MH  - Stress, Psychological
OTO - NOTNLM
OT  - Anxiety
OT  - Depression
OT  - Health personnel
OT  - Mental health
OT  - Pandemic
OT  - Professional burnout
OT  - Psychological stress
OT  - SARS-CoV-2
OT  - Spain
EDAT- 2020/07/24 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Jul 23;94.

PMID- 32679506
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20210219
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 743
DP  - 2020 Nov 15
TI  - SARS-CoV-2 in river water: Implications in low sanitation countries.
PG  - 140832
LID - S0048-9697(20)34356-4 [pii]
LID - 10.1016/j.scitotenv.2020.140832 [doi]
AB  - Since the beginning of COVID-19 pandemic studies on viral shedding have reported 
      that this virus is excreted in feces in most patients. High viral loads are found
      at the sewage pipeline or at the entrance of wastewater treatment plants from
      cities where the number of COVID-19 cases are significant. In Quito (Ecuador) as 
      in many other cities worldwide, wastewater is directly discharged into natural
      waters. The aim of this study was to evaluate SARS-CoV-2 presence in urban
      streams from a low sanitation context. Three river locations along the urban
      rivers of Quito were sampled on the 5th of June during a peak of COVID-19 cases. 
      River samples were evaluated for water quality parameters and afterwards,
      concentrated for viral analysis using skimmed milk flocculation method. The viral
      concentrates were quantified for SARS-CoV-2 (N1 and N2 target regions) and Human 
      Adenovirus as a human viral indicator. The results showed that SARS-CoV-2 was
      detected for both target regions in all samples analyzed in a range of 2,91E+05
      to 3,19E+06 GC/L for N1 and from 2,07E+05 to 2,22E+06 GC/L for N2. The high
      values detected in natural waters from a low sanitation region have several
      implications in health and ecology that should be further assessed.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Guerrero-Latorre, Laura
AU  - Guerrero-Latorre L
AD  - Grupo de Investigacion en Biodiversidad, Medio Ambiente y Salud, Facultad de
      Ingenierias y Ciencias Aplicadas, Universidad de Las Americas, Ecuador;
      Department of Biology, Area of Microbiology, University of Girona, Spain.
FAU - Ballesteros, Isabel
AU  - Ballesteros I
AD  - Grupo de Investigacion en Biodiversidad, Medio Ambiente y Salud, Facultad de
      Ingenierias y Ciencias Aplicadas, Universidad de Las Americas, Ecuador.
FAU - Villacres-Granda, Irina
AU  - Villacres-Granda I
AD  - Laboratorios de Investigacion, Universidad de Las Americas, Ecuador.
FAU - Granda, M Genoveva
AU  - Granda MG
AD  - Laboratorios de Investigacion, Universidad de Las Americas, Ecuador.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - Laboratorios de Investigacion, Universidad de Las Americas, Ecuador.
FAU - Rios-Touma, Blanca
AU  - Rios-Touma B
AD  - Grupo de Investigacion en Biodiversidad, Medio Ambiente y Salud, Facultad de
      Ingenierias y Ciencias Aplicadas, Universidad de Las Americas, Ecuador.
      Electronic address: blanca.rios@udla.edu.ec.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cities
MH  - *Coronavirus Infections
MH  - Ecuador
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Rivers
MH  - SARS-CoV-2
MH  - *Sanitation
PMC - PMC7343659
OTO - NOTNLM
OT  - Andean rivers
OT  - COVID-19
OT  - Ecuador
OT  - HAdV
OT  - Viral dissemination
OT  - Wastewater
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/07/18 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/06/14 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - S0048-9697(20)34356-4 [pii]
AID - 10.1016/j.scitotenv.2020.140832 [doi]
PST - ppublish
SO  - Sci Total Environ. 2020 Nov 15;743:140832. doi: 10.1016/j.scitotenv.2020.140832. 
      Epub 2020 Jul 9.

PMID- 32671516
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1573-3610 (Electronic)
IS  - 0094-5145 (Linking)
VI  - 46
IP  - 2
DP  - 2021 Apr
TI  - Social Determinants of Health and Risk of SARS-CoV-2 Infection in
      Community-Dwelling Older Adults Living in a Rural Latin American Setting.
PG  - 292-297
LID - 10.1007/s10900-020-00887-9 [doi]
AB  - High social risk, as measured by the social determinants of health (SDH), may
      increase the risk of SARS-CoV-2 infection. However, this association has not been
      studied in rural communities. Using the Atahualpa Project cohort, we aimed to
      assess the association between SDH and SARS-CoV-2 seropositivity in
      community-dwelling older adults living in rural Ecuador. SARS-CoV-2 antibodies
      were determined in 319 individuals aged >/= 60 years that completed a validated
      field instrument to assess their social risk before the introduction of this
      novel pandemic. Multivariate models were fitted to assess the independent
      association between SDH-and each of their components-and SARS-CoV-2
      seropositivity, after adjusting for relevant covariates. According to the Gijon
      scale, 102 (32%) individuals had a high social risk (>/= 10 points). A total of
      141 (44%) individuals were seropositive to SARS-CoV-2. A fully-adjusted logistic 
      regression model showed an independent) association between social risk and
      SARS-CoV-2 positivity (OR 1.15; 95% CI 1.04-1.27; p = 0.008). For every unit of
      the total SDH score, the odds of SARS-CoV-2 seropositivity increased 15% (95% CI 
      3.7-27%). In addition, multivariate models showed that the individual component
      of SDH more strongly associated with SARS-CoV-2 seropositivity was housing, which
      suggested that lack of basic home facilities may increase the risk of SARS-CoV-2 
      infection. Knowledge on the association between high social risk and SARS-CoV-2
      infection is indispensable for the development of cost-effective preventive
      strategies for controlling modifiable factors that are in the path of SARS-CoV-2 
      infection among older adults living in underserved communities.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
AUID- ORCID: 0000-0003-1917-8805
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador, Samborondon, Ecuador.
      oscardelbrutto@hotmail.com.
AD  - , Air Center 3542, PO Box 522970, Miami, FL, 33152-2970, USA.
      oscardelbrutto@hotmail.com.
FAU - Mera, Robertino M
AU  - Mera RM
AD  - Department of Epidemiology, Gilead Sciences, Inc., Foster City, CA, USA.
FAU - Recalde, Bettsy Y
AU  - Recalde BY
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
FAU - Costa, Aldo F
AU  - Costa AF
AD  - Community Center, The Atahualpa Project, Atahualpa, Ecuador.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Community Health
JT  - Journal of community health
JID - 7600747
SB  - IM
MH  - Aged
MH  - COVID-19/epidemiology/*psychology
MH  - Cohort Studies
MH  - Ecuador
MH  - Female
MH  - Humans
MH  - Independent Living/*statistics & numerical data
MH  - Latin America
MH  - Logistic Models
MH  - Male
MH  - Population Density
MH  - Prevalence
MH  - Rural Population/*statistics & numerical data
MH  - Social Determinants of Health/*statistics & numerical data
MH  - Socioeconomic Factors
PMC - PMC7363014
OTO - NOTNLM
OT  - *Older adults
OT  - *Rural communities
OT  - *SARS-CoV-2
OT  - *Social determinants of health
EDAT- 2020/07/17 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/07/17 06:00 [entrez]
AID - 10.1007/s10900-020-00887-9 [doi]
AID - 10.1007/s10900-020-00887-9 [pii]
PST - ppublish
SO  - J Community Health. 2021 Apr;46(2):292-297. doi: 10.1007/s10900-020-00887-9.

PMID- 32656101
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20201218
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 10
DP  - 2020
TI  - Cotton-Tipped Plastic Swabs for SARS-CoV-2 RT-qPCR Diagnosis to Prevent Supply
      Shortages.
PG  - 356
LID - 10.3389/fcimb.2020.00356 [doi]
AB  - CDC and WHO guidelines for severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) diagnosis only recommend synthetic fiber swabs for nasopharyngeal
      (NP) sampling. We show that cotton-tipped plastic swabs do not inhibit PCR and
      have equivalent performance to rayon swabs. Cotton-tipped plastic swabs are
      massively produced worldwide and would prevent swab supply shortages under the
      current high SARS-CoV-2 testing demands, particularly in developing countries.
CI  - Copyright (c) 2020 Freire-Paspuel, Vega-Marino, Velez, Castillo, Gomez-Santos,
      Cruz and Garcia-Bereguiain.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
FAU - Vega-Marino, Patricio
AU  - Vega-Marino P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Velez, Alberto
AU  - Velez A
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Castillo, Paulina
AU  - Castillo P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Gomez-Santos, Eliana Elizabeth
AU  - Gomez-Santos EE
AD  - Hospital Republica del Ecuador, Ministerio de Salud Publica, Puerto Ayora,
      Ecuador.
FAU - Cruz, Marilyn
AU  - Cruz M
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 0 (Plastics)
RN  - 0 (RNA, Viral)
RN  - 9004-34-6 (Cellulose)
RN  - BX81F82EWG (rayon, purified)
SB  - IM
MH  - Betacoronavirus/genetics/*isolation & purification
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Cellulose/supply & distribution
MH  - Clinical Laboratory Techniques/*instrumentation/methods
MH  - Coronavirus Infections/*diagnosis/virology
MH  - Cotton Fiber/supply & distribution
MH  - Diagnostic Equipment/*supply & distribution
MH  - Disposable Equipment/*supply & distribution
MH  - Humans
MH  - Nasopharynx
MH  - Pandemics
MH  - Plastics/supply & distribution
MH  - Pneumonia, Viral/*diagnosis/virology
MH  - RNA, Viral/analysis
MH  - Real-Time Polymerase Chain Reaction/*instrumentation/methods
MH  - SARS-CoV-2
MH  - Specimen Handling/instrumentation/methods
PMC - PMC7324669
OTO - NOTNLM
OT  - *SARS-CoV-2
OT  - *cotton swab
OT  - *rayon swab
OT  - *surveillance
OT  - *swabs
EDAT- 2020/07/14 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
AID - 10.3389/fcimb.2020.00356 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2020 Jun 23;10:356. doi: 10.3389/fcimb.2020.00356.
      eCollection 2020.

PMID- 32623267
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20201218
IS  - 1879-0070 (Electronic)
IS  - 0732-8893 (Linking)
VI  - 98
IP  - 1
DP  - 2020 Sep
TI  - Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus
      and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.
PG  - 115094
LID - S0732-8893(20)30471-5 [pii]
LID - 10.1016/j.diagmicrobio.2020.115094 [doi]
AB  - Coronaviruses are an extensive family of viruses that can cause disease in both
      animals and humans. The current classification of coronaviruses recognizes 39
      species in 27 subgenera that belong to the family Coronaviridae. From those, at
      least 7 coronaviruses are known to cause respiratory infections in humans. Four
      of these viruses can cause common cold-like symptoms. Those that infect animals
      can evolve and become infectious to humans. Three recent examples of these viral 
      jumps include SARS CoV, MERS-CoV and SARS CoV-2 virus. They are responsible for
      causing severe acute respiratory syndrome (SARS), Middle East respiratory
      syndrome (MERS) and the most recently discovered coronavirus disease during 2019 
      (COVID-19). COVID-19, a respiratory disease caused by the SARS-CoV-2 virus, was
      declared a pandemic by the World Health Organization (WHO) on 11 March 2020. The 
      rapid spread of the disease has taken the scientific and medical community by
      surprise. Latest figures from 20 May 2020 show more than 5 million people had
      been infected with the virus, causing more than 330,000 deaths in over 210
      countries worldwide. The large amount of information received daily relating to
      COVID-19 is so abundant and dynamic that medical staff, health authorities,
      academics and the media are not able to keep up with this new pandemic. In order 
      to offer a clear insight of the extensive literature available, we have conducted
      a comprehensive literature review of the SARS CoV-2 Virus and the Coronavirus
      Diseases 2019 (COVID-19).
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas
      (UDLA), Quito, Ecuador. Electronic address: e.ortizprado@gmail.com.
FAU - Simbana-Rivera, Katherine
AU  - Simbana-Rivera K
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas
      (UDLA), Quito, Ecuador. Electronic address: ksimbanarivera@gmail.com.
FAU - Gomez-Barreno, Lenin
AU  - Gomez-Barreno L
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas
      (UDLA), Quito, Ecuador. Electronic address: lsgomezbarreno@gmail.com.
FAU - Rubio-Neira, Mario
AU  - Rubio-Neira M
AD  - Hospital Baca Ortiz, Pediatric and Cardiology Department, Quito, Ecuador.
      Electronic address: drrubio24@yahoo.com.
FAU - Guaman, Linda P
AU  - Guaman LP
AD  - Centro de Investigacion Biomedica, Facultad de Ciencias de la Salud Eugenio
      Espejo, Universidad UTE, Quito, Ecuador. Electronic address:
      linda.guaman@ute.edu.ec.
FAU - Kyriakidis, Nikolaos C
AU  - Kyriakidis NC
AD  - Grupo de Investigacion en Biotecnologia Aplicada a Biomedicina (BIOMED),
      Universidad de la Americas, Quito, Ecuador. Electronic address:
      nikolaos.kyriakidis@udla.edu.ec.
FAU - Muslin, Claire
AU  - Muslin C
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas
      (UDLA), Quito, Ecuador. Electronic address: claire.muslin@udla.edu.ec.
FAU - Jaramillo, Ana Maria Gomez
AU  - Jaramillo AMG
AD  - Faculty of Medicine, Pontificia Universidad Catolica del Ecuador, Quito, Ecuador.
      Electronic address: mdanamagomez84@gmail.com.
FAU - Barba-Ostria, Carlos
AU  - Barba-Ostria C
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas
      (UDLA), Quito, Ecuador. Electronic address: carlos.barba.ostria@udla.edu.ec.
FAU - Cevallos-Robalino, Domenica
AU  - Cevallos-Robalino D
AD  - Intensive Care Unit, Hospital Quito Sur IESS, Quito, Ecuador. Electronic address:
      domecevallos.92@gmail.com.
FAU - Sanches-SanMiguel, Hugo
AU  - Sanches-SanMiguel H
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas
      (UDLA), Quito, Ecuador. Electronic address: hmssanmiguel@icloud.com.
FAU - Unigarro, Luis
AU  - Unigarro L
AD  - Intensive Care Unit, Hospital SOLCA Quito, Quito, Ecuador. Electronic address:
      luisunigarro3@gmail.com.
FAU - Zalakeviciute, Rasa
AU  - Zalakeviciute R
AD  - Grupo de Biodiversidad Medio Ambiente y Salud (BIOMAS), Universidad de Las
      Americas, Quito, Ecuador; Intelligent and Interactive Systems Lab (SI2 Lab)
      Universidad de Las Americas (UDLA), Quito, Ecuador. Electronic address:
      rasa.zalakeviciute@udla.edu.ec.
FAU - Gadian, Naomi
AU  - Gadian N
AD  - University of Southampton, Department of Public Health, Southampton, United
      Kingdome. Electronic address: naomigadian@hotmail.com.
FAU - Lopez-Cortes, Andres
AU  - Lopez-Cortes A
AD  - Centro de Investigacion Genetica y Genomica, Facultad de Ciencias de la Salud
      Eugenio Espejo, Universidad UTE, Quito, Ecuador; Red Latinoamericana de
      Implementacion y Validacion de Guias Clinicas Farmacogenomicas (RELIVAF-CYTED),
      Quito, Ecuador. Electronic address: aalc84@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200530
PL  - United States
TA  - Diagn Microbiol Infect Dis
JT  - Diagnostic microbiology and infectious disease
JID - 8305899
SB  - IM
MH  - *Betacoronavirus/genetics/immunology/physiology
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/epidemiology/immunology/*virology
MH  - Genome, Viral/genetics
MH  - HIV Infections/complications
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/epidemiology/immunology/*virology
MH  - SARS-CoV-2
MH  - Virus Replication
PMC - PMC7260568
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Pandemic
OT  - Review
OT  - SARS-CoV-2
EDAT- 2020/07/06 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - S0732-8893(20)30471-5 [pii]
AID - 10.1016/j.diagmicrobio.2020.115094 [doi]
PST - ppublish
SO  - Diagn Microbiol Infect Dis. 2020 Sep;98(1):115094. doi:
      10.1016/j.diagmicrobio.2020.115094. Epub 2020 May 30.

PMID- 32588004
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210716
DP  - 2020 Jun 14
TI  - Genome sequencing of the first SARS-CoV-2 reported from patients with COVID-19 in
      Ecuador.
LID - 2020.06.11.20128330 [pii]
LID - 10.1101/2020.06.11.20128330 [doi]
AB  - SARS-CoV-2, the etiological agent of COVID-19 was first described in Wuhan in
      December 2019 and has now spread globally. Ecuador was the second country in
      South America to report confirmed cases. The first case reported in Quito, the
      capital city of Ecuador, was a tourist who came from the Netherlands and
      presented symptoms on March 10th, 2020 (index case). In this work we used the
      MinION platform (Oxford Nanopore Technologies) to sequence the metagenome of the 
      bronchoalveolar lavage (BAL) from this case reported, and subsequently we
      sequenced the whole genome of the index case and other three patients using the
      ARTIC network protocols. Our data from the metagenomic approach confirmed the
      presence of SARS-CoV-2 coexisting with pathogenic bacteria suggesting
      coinfection. Relevant bacteria found in the BAL metagenome were Streptococcus
      pneumoniae, Mycobacterium tuberculosis, Staphylococcus aureus and Chlamydia spp. 
      Lineage assignment of the four whole genomes revealed three different origins.
      The variant HEE-01 was imported from the Netherlands and was assigned to B
      lineage, HGSQ-USFQ-018, belongs to the B.1 lineage showing nine nucleotide
      differences with the reference strain and grouped with sequences from the United 
      Kingdom, and HGSQ-USFQ-007 and HGSQ-USFQ-010 belong to the B lineage and grouped 
      with sequences from Scotland. All genomes show mutations in their genomes
      compared to the reference strain, which could be important to understand the
      virulence, severity and transmissibility of the virus. Our findings also suggest 
      that there were at least three independent introductions of SARS-CoV-2 to
      Ecuador.
FAU - Marquez, Sully
AU  - Marquez S
FAU - Prado-Vivar, Belen
AU  - Prado-Vivar B
FAU - Guadalupe, Juan Jose
AU  - Guadalupe JJ
FAU - Gutierrez Granja, Bernardo
AU  - Gutierrez Granja B
FAU - Jibaja, Manuel
AU  - Jibaja M
FAU - Tobar, Milton
AU  - Tobar M
FAU - Mora, Francisco
AU  - Mora F
FAU - Gaviria, Juan
AU  - Gaviria J
FAU - Garcia, Maria
AU  - Garcia M
FAU - Ligna, Edison
AU  - Ligna E
FAU - Espinosa, Franklin
AU  - Espinosa F
FAU - Reyes, Jorge
AU  - Reyes J
FAU - Barragan, Veronica
AU  - Barragan V
FAU - Rojas-Silva, Patricio
AU  - Rojas-Silva P
FAU - Trueba, Gabriel
AU  - Trueba G
FAU - Grunauer, Michelle
AU  - Grunauer M
FAU - Cardenas, Paul
AU  - Cardenas P
AUID- ORCID: 0000-0001-9626-4489
LA  - eng
GR  - D43 TW010540/TW/FIC NIH HHS/United States
PT  - Preprint
DEP - 20200614
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
PMC - PMC7310664
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - 10.1101/2020.06.11.20128330 [doi]
PST - epublish
SO  - medRxiv. 2020 Jun 14. doi: 10.1101/2020.06.11.20128330.

PMID- 32572019
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20220415
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Jun 23
TI  - [Digital surveillance tools for contact tracking of infected persons by
      SARS-CoV-2.]
LID - e202006067 [pii]
AB  - BACKGROUND: In times of pandemic, case management and tracking people with
      contact can be differential elements for controlling the spread. The objective of
      this review was to evaluate the digital tools used to track contacts of people
      infected with SARS-CoV-2. METHODS: A systematic exploratory review was conducted 
      in the electronic databases Pubmed, Scopus and Web of Science on May 29, 2020
      through the descriptors: coronavirus, digital surveillance and contact tracing. A
      total of 11 studies were finally selected. RESULTS: The results showed that some 
      countries are implementing digital tools for contact tracking through mobile apps
      that allow user data to be shared via the device's GPS and/or Bluetooth. The
      terms on the privacy and confidentiality of the population data are, in some
      cases, questionable. CONCLUSIONS: The use of digital surveillance tools to track 
      contacts of people infected with an infectious disease, such as SARS-CoV-2, can
      be key to reducing the number of people infected and reducing the spread of the
      virus.
FAU - Garcia-Iglesias, Juan Jesus
AU  - Garcia-Iglesias JJ
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Escuela Superior de Salud. Universidad Atlantica. Lisboa. Portugal.
FAU - Martin-Pereira, Jorge
AU  - Martin-Pereira J
AD  - Consorcio de transporte sanitario onubense. Base en Centro de Salud de Isla
      Cristina. Huelva. Espana.
FAU - Fagundo-Rivera, Javier
AU  - Fagundo-Rivera J
AD  - Escuela de Doctorado en Ciencias de la Salud. Universidad de Huelva. Huelva.
      Espana.
AD  - Servicio Andaluz de Salud. Andalucia. Espana.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Programa de Posgrado de Seguridad y Salud. Universidad Espiritu Santo. Guayaquil.
      Ecuador.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Herramientas de vigilancia digital para el rastreo de contactos de personas
      contagiadas de SARS-CoV-2.
DEP - 20200623
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Contact Tracing/*instrumentation/methods
MH  - Coronavirus Infections/*diagnosis/epidemiology/*transmission
MH  - Databases, Factual
MH  - Humans
MH  - Mobile Applications
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/epidemiology/*transmission
MH  - SARS-CoV-2
MH  - Spain
OTO - NOTNLM
OT  - Communicable disease control
OT  - Contact tracing
OT  - Covid-19
OT  - Epidemiological monitoring
OT  - Medical informatics applications
OT  - Public health
OT  - Spain
EDAT- 2020/06/24 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/05/31 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Jun 23;94.

PMID- 32485473
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20210110
IS  - 1873-5967 (Electronic)
IS  - 1386-6532 (Linking)
VI  - 128
DP  - 2020 Jul
TI  - Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR detection of SARS-CoV-2 from
      nasopharyngeal samples using CDC FDA EUA qPCR kit as a gold standard: An example 
      of the need of validation studies.
PG  - 104454
LID - S1386-6532(20)30196-7 [pii]
LID - 10.1016/j.jcv.2020.104454 [doi]
AB  - BACKGROUND: Several qPCR kits are available for SARS-CoV-2 diagnosis, mostly
      lacking of evaluation due to covid19 emergency. OBJECTIVE: We evaluated nCoV-QS
      (MiCo BioMed) kit using CDC kit as gold standard. RESULTS: We found limitations
      for nCoV-QS: 1) lower sensitivity 2) lack of RNA quality control probe.
      CONCLUSIONS: Validation studies should be implemented for any SARS-CoV-2 RT-qPCR 
      commercial kit to prevent unreliable diagnosis.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Freire-Paspuel, Byron
AU  - Freire-Paspuel B
AD  - One Health Research Group. Universidad de Las Americas. Quito, Ecuador.
FAU - Vega-Marino, Patricio
AU  - Vega-Marino P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Velez, Alberto
AU  - Velez A
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Castillo, Paulina
AU  - Castillo P
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Cruz, Marilyn
AU  - Cruz M
AD  - Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos,
      Puerto Ayora, Ecuador.
FAU - Garcia-Bereguiain, Miguel Angel
AU  - Garcia-Bereguiain MA
AD  - One Health Research Group. Universidad de Las Americas. Quito, Ecuador.
      Electronic address: magbereguiain@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - Netherlands
TA  - J Clin Virol
JT  - Journal of clinical virology : the official publication of the Pan American
      Society for Clinical Virology
JID - 9815671
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Betacoronavirus/genetics/*isolation & purification
MH  - COVID-19
MH  - Coronavirus Infections/*diagnosis/virology
MH  - Humans
MH  - Nasopharynx/virology
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/virology
MH  - Reagent Kits, Diagnostic
MH  - Real-Time Polymerase Chain Reaction/*methods
MH  - SARS-CoV-2
MH  - Sensitivity and Specificity
PMC - PMC7243755
OTO - NOTNLM
OT  - *CDC
OT  - *RT-qPCR
OT  - *SARS-CoV-2
OT  - *Validation
COIS- Declaration of Competing Interest All authors have no conflict of interest to
      declare.
EDAT- 2020/06/03 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/05/16 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - S1386-6532(20)30196-7 [pii]
AID - 10.1016/j.jcv.2020.104454 [doi]
PST - ppublish
SO  - J Clin Virol. 2020 Jul;128:104454. doi: 10.1016/j.jcv.2020.104454. Epub 2020 May 
      22.

PMID- 32333993
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20201231
IS  - 1878-1519 (Electronic)
IS  - 1569-9048 (Linking)
VI  - 277
DP  - 2020 Jun
TI  - Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude?
PG  - 103443
LID - S1569-9048(20)30101-4 [pii]
LID - 10.1016/j.resp.2020.103443 [doi]
AB  - In the present study we analyze the epidemiological data of COVID-19 of Tibet and
      high-altitude regions of Bolivia and Ecuador, and compare to lowland data, to
      test the hypothesis that high-altitude inhabitants (+2,500 m above sea-level) are
      less susceptible to develop severe adverse effects in acute SARS-CoV-2 virus
      infection. Analysis of available epidemiological data suggest that physiological 
      acclimatization/adaptation that counterbalance the hypoxic environment in
      high-altitude may protect from severe impact of acute SARS-CoV-2 virus infection.
      Potential underlying mechanisms such as: (i) a compromised half-live of the virus
      caused by the high-altitude environment, and (ii) a hypoxia mediated down
      regulation of angiotensin-converting enzyme 2 (ACE2), which is the main binding
      target of SARS-CoV-2 virus in the pulmonary epithelium are discussed.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Arias-Reyes, Christian
AU  - Arias-Reyes C
AD  - Institute Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ),
      Faculty of Medicine, Universite Laval, Quebec, QC, Canada.
FAU - Zubieta-DeUrioste, Natalia
AU  - Zubieta-DeUrioste N
AD  - High Altitude Pulmonary and Pathology Institute IPPA. La Paz, Bolivia.
FAU - Poma-Machicao, Liliana
AU  - Poma-Machicao L
AD  - Institute Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ),
      Faculty of Medicine, Universite Laval, Quebec, QC, Canada.
FAU - Aliaga-Raduan, Fernanda
AU  - Aliaga-Raduan F
AD  - Institute Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ),
      Faculty of Medicine, Universite Laval, Quebec, QC, Canada.
FAU - Carvajal-Rodriguez, Favio
AU  - Carvajal-Rodriguez F
AD  - Institute Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ),
      Faculty of Medicine, Universite Laval, Quebec, QC, Canada.
FAU - Dutschmann, Mathias
AU  - Dutschmann M
AD  - Florey Institute of Neuroscience and Mental Health, Gate 11 Royal Parade, 3052,
      University of Melbourne Victoria, Australia.
FAU - Schneider-Gasser, Edith M
AU  - Schneider-Gasser EM
AD  - Institute of Veterinary Physiology, Vetsuisse-Faculty University of Zurich,
      Winterthurerstrasse 260, Switzerland.
FAU - Zubieta-Calleja, Gustavo
AU  - Zubieta-Calleja G
AD  - High Altitude Pulmonary and Pathology Institute IPPA. La Paz, Bolivia. Electronic
      address: gzubietajr@gmail.com.
FAU - Soliz, Jorge
AU  - Soliz J
AD  - Institute Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ),
      Faculty of Medicine, Universite Laval, Quebec, QC, Canada; High Altitude
      Pulmonary and Pathology Institute IPPA. La Paz, Bolivia. Electronic address:
      jorge.soliz@crchuq.ulaval.ca.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - Netherlands
TA  - Respir Physiol Neurobiol
JT  - Respiratory physiology & neurobiology
JID - 101140022
RN  - S88TT14065 (Oxygen)
SB  - IM
CIN - Respir Physiol Neurobiol. 2020 Aug;279:103448. PMID: 32437878
CIN - Respir Physiol Neurobiol. 2020 Aug;279:103464. PMID: 32447057
CIN - Respir Physiol Neurobiol. 2020 Sep;280:103487. PMID: 32619691
CIN - High Alt Med Biol. 2020 Dec;21(4):426-427. PMID: 32803989
MH  - Altitude
MH  - Betacoronavirus/pathogenicity/*physiology
MH  - Bolivia/epidemiology
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*virology
MH  - Disease Susceptibility
MH  - Ecuador/epidemiology
MH  - Humans
MH  - Oxygen
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*virology
MH  - SARS-CoV-2
MH  - Tibet/epidemiology
MH  - Virulence
PMC - PMC7175867
OTO - NOTNLM
OT  - *COVID-19
OT  - *Hypoxia
OT  - *Lung remodeling
OT  - *UV
EDAT- 2020/04/26 06:00
MHDA- 2020/05/14 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - S1569-9048(20)30101-4 [pii]
AID - 10.1016/j.resp.2020.103443 [doi]
PST - ppublish
SO  - Respir Physiol Neurobiol. 2020 Jun;277:103443. doi: 10.1016/j.resp.2020.103443.
      Epub 2020 Apr 22.
